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Chapter 1 
General introduction

 General introduction 15
Background
The clinical presentation of infections caused by the same micro-organism is highly 
diverse. This is for example demonstrated for infections with Neisseria meningitidis 
and respiratory syncytial virus. Some patients infected with N. meningitidis develop 
meningitis, while others present with sepsis or even septic shock. Moreover, only part 
of the individuals colonized with N. meningitidis develops clinical disease indicating 
a different susceptibility between individuals to develop clinical disease. The disease 
phenotype in respiratory syncytial virus infection varies from a common cold to severe 
bronchiolitis which requires mechanical ventilation.(1) A similar variation is observed 
in autoimmune diseases: While some patients with rheumatoid arthritis (RA) have 
relatively mild disease, in others joint erosion develops rather early after diagnosis. 
Although part of these variations in susceptibility and severity of infection is explained 
by, for example, age or crowding, the reasons for this variation are not completely 
clear. Genetic heterogeneity is thought to play a role.
Genetic polymorphisms are known to contribute to the susceptibility and severity 
of infectious and autoimmune diseases and other complex diseases.(2) Currently 
in complex diseases, only 2-3 and in some maybe 5% of the heritability, which is 
the proportion of differences between individuals explained by genetic differences, is 
elucidated by genes actually found to be associated with this disease. A few examples 
of complex phenotypes related to genetic polymorphisms are listed in Table 1.
Epidemiology of genetic variation
The human genome consists of about 30,000-50,000 genes and the complete 
sequence is now available at www.ncbi.nlm.nih.gov. Multiple types of genetic variations 
have been described thus far (Table 2).(3) The research described in this thesis is 
limited to single nucleotide polymorphisms (SNPs). SNPs are present throughout 
the genome and occur about once every 100 to 300 bases, although ‘hotspots’ like 
the HLA encoding regions are present. Nearly 12 million unique reference SNPs are 
known today, of which approximately 6 million have been validated, and this number is 
still expanding on a daily basis. Little over 5 million of the SNPs are located in genes, 
of which most (3.8 million) are located in intronic regions, while 80,000 SNPs result in 
an amino acid substitution. (Database of Single Nucleotide Polymorphisms (dbSNP). 
Bethesda (MD): National Centre for Biotechnology Information, National Library of 
Medicine. (dbSNP Build ID: 128, available at www.ncbi.nlm.nih.gov/projects/SNP, 
April 1, 2008).(4) An overview of SNP location and their potential effects is listed in 
table 3.
The nature of the SNP, it being a single nucleotide substitution, and the available 
techniques enable researchers to perform high throughput analysis in terms of both 
SNPs and samples.
Each SNP, if relevant, generally is thought to have only a minor contribution to 
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Table 2. Different types of genetic variation and their definition.1
1Table modified from Feuk et al. with author permission.(3)
the phenotype. This is especially true in multifactorial traits and diseases such as 
inflammatory diseases, on which this thesis focuses. In addition to multiple genetic 
polymorphisms, other host- environmental- and microbial factors, are expected 
to influence the course of disease. However, there are prominent examples of 
apparently complex and important traits that are critically determined by genetic 
variations with modest effects (see Table 1 for examples). The textbook example 
is the T>A substitution located in codon 6 of the β-globin gene resulting in a valine 
instead of a glutamine in this molecule, known as Hemoglobin S, which is famous 
for resistance to malaria infection in heterozygous individuals. Recently a major role 
was found for genetic variation in a single gene encoding insulin-like growth factor 
(IGF) in determining the body size of dogs.(5) Although it could be argued that body 
size is not a complex trait, it certainly is a very important one in biological terms. This 
thesis covers complex diseases of which the phenotype is codetermined by multiple 
factors.
Table 3. SNP location and its possible effect.
12
Table 2. ifferent types of genetic variation and their definition.
1
Type of genetic variation Definition Reference
SNP Single base pair variation present in > 1% of chromosomes in
a certain population
(23-25)
Haplotype Combination of alleles on a single chromatid that are
statistically associated
(26)
Microsatellite Sequences with variable numbers of 1-6 bp repeats, (total <
200 bp)
(25, 27, 28)
Minisatellite and variable number of tandem
repeats (VNTRs)
Polymorphic sequence containing 20-50 copies of 6-100 bp
repeats
(29-31)
Insertion/deletion Deletion or insertion of a segment of DNA of variable size (32, 33)
Multisite variant (MSV) Single nucleotide variant with complex characteristics due to
CNV or gene conversion
(34)
Intermediate-sized structural variant (ISV) Gain or loss of a DNA sequence > 8 kb in size, also includes
inversion breakpoints
(35)
Copy number variation (CNV) DNA segments ! 1 kb, present in a variable copy number
when compared to a reference genome
(36-38)
Copy number polymorphism (CNP) As CNV with a frequency > 1%
Large scale CNV (LCV) CNV ~50 kb in size or greater
Inversion Segment of DNA present in the reverse orientation (39)
Translocation DNA fragment that is attached to a different chromosome (39, 40)
Unbalanced rearrangements Rearrangements which lead to a net gain or loss of DNA
Table odified from Feuk et al, with author permission.(3)
Table 3. SNP location and its possible effect.
SNP location Possible effect
Promoter region Increased or decreased expression
Exon Silent, no amino acid substitution
Aberrant protein synthesis
Amino acid substitution:
No effect on protein function
Altered protein function
Intron RNA splicing, RNA stability, mRNA expression level
3’ UTR RNA stability
Outside gene region Possible eff ct on mRNA expression lev l
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At the initiation of these studies we intended to use the Affymetrix micro-array 
technology to genotype multiple single nucleotide polymorphisms (SNPs) and to 
develop an immuno-array in collaboration with Affymetrix. Unfortunately, the original 
plan was ahead of its time and it was not possible to realize this within the time 
available for this project. However, over the five year period of this project, there have 
been enormous technical developments, which have now resulted in the availability 
of genome wide SNP arrays.
Selection of diseases studied
Diseases/phenotypes in our study were selected on the basis of presumed certain 
similarities in their pathogenesis. All diseases included had inflammatory components, 
thought to be elicited by common (innate) immune response pathways. These immune 
response pathways could be initiated by infection or colonization with bacteria or 
viruses, or be an effect of autoimmune response. The availability of well described, 
homogenous patients was a prerequisite for the inclusion of a cohort into the study, 
to minimize the chance of introducing bias as seen in poorly defined heterogeneous 
cohorts.
Within the (inter)national collaborations in this project we have selected the following 
diseases: meningococcal infection, chronic hepatitis C virus (HCV) infection 
and recurrent acute otitis media being infectious diseases; rheumatoid arthritis 
(RA) from the group of autoimmune diseases; and Guillain Barré syndrome (GBS) 
and Barrett oesophagus as intermediates between infectious and autoimmune 
disease. In addition we investigated S. aureus nasal carriage as being a risk factor 
for infection, and sepsis after severe multiple trauma as an inflammatory condition 
(Table 4). To determine allele frequencies in the general population, genotypes were 
also determined in a cohort of 463 healthy Caucasian blood donors.
For S. aureus nasal carriage and chronic hepatitis C virus infection, genetic variation 
in these pathogens was also included in the study, as we do recognize the importance 
of studying both host and microbe variation in the elucidation of the pathogenesis 
of infectious diseases.(6, 7) The interaction of the microbe and the host in a given 
environmental context will determine the outcome after exposure of the host to the 
microbe: asymptomatic colonization, infection, severity of infection, and outcome of 
infection.(8)
Selection of the genetic variations studied
The candidate gene approach was used to select genes of interest. This method 
starts with the assumption, or concrete knowledge from functional studies, that a 
certain gene is likely to be involved in the pathogenesis of the selected disease. 
Since we aimed to analyze several infectious and autoimmune diseases in parallel, 
we assessed what could be common denominators in inflammatory diseases. 
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Our choice was based on the literature available at that time and included genes 
involved in pro- and anti-inflammatory response, complement regulation, coagulation 
and fibrinolysis, apoptosis, pattern recognition and signalling pathways (Table 5). 
In addition, factors involved in tissue repair and integrity were included, since their 
role became more and more prominent in the past few years, as illustrated in celiac 
disease and atopic dermatitis.(9, 10)
Table 5. Genetic single nucleotide polymorphisms analyzed.
1Abbreviations: TNFA, tumour necrosis factor α; IL, interleukin; CRP, C-reactive protein; IL1RN, IL1 receptor 
antagonist; C1INH; complement component inhibitor-1; CFH, complement factor H; PAI1, plasminogen 
activator inhibitor; NOS2A, inducible nitric oxide synthase; PARP, poly (ADP-ribose) polymerase; TLR, Toll 
like receptor; DEFA4, α defensin 4; DEFB1, β defensin 1; IFNAR, interferon alpha receptor; STAT2, signal 
transducer and activator of transcription.
2Polymorphisms indicated by asterisks were excluded after initial assessment, either because they were 
not observed in our cohort, since technical problems occurred, or because of errors in prior publication.
The SNPs in these genes were selected because of their location in the promoter or 
coding region, because of their potential functional relevance. One SNP in IL8 that 
is located in an intron was included because of previously described associations 
with viral infection.(11) Fourteen of the initially 45 included SNPs were subsequently 
excluded. Three of these were excluded for technical reasons. Two SNPs appeared to 
14
Table 5. tic single nucleotide polymorphisms analyzed.
Gene SNP
Pro-inflammatory
TNFA
1
A-863C (rs1800630), T-857C (rs1799724), G-376A (rs3093659),
G-308A (rs1800629), G-238A (rs361525)
IL6 G-174C (rs1800795)
IL8 C781T intron (rs2227306)
CRP C1184T (rs1130864), C2042T (rs1205), C2911G (rs3093068)
IL1B C-511T (rs16944), C-31T (rs1143627), 3’ UTR (rs3087261)*,
promoter region C/T (rs3087258)*
Anti-inflammatory
IL4 C-524T (rs2243250) (is identical to -590)
IL10 G-1082A (rs1800896), C-819T (rs3021097)
IL1RN C2018T (rs419598)
Complement regulation
C1INH V480M (rs4926), T308S (rs1803212)*
CFH Tyr402His (rs1061170)
Tissue integrity, coagulation and fibrinolysis
PAI1 -675 4G/5G (rs1799889), insertion/deletion, G-504 A (rs2227632)*,
A15T (rs6092)*, V17I (rs6090)*,H25P (rs2227647)*, R209H
(rs2227669)*, T255N (rs2227685)*
Apoptosis
NOS2a S608L (rs2297518)
PARP V762A (rs1136410), A188T (rs1805409)*, H613Q (rs1059011)*,
C908Y (rs1059040)*
Host-pathogen interaction
TLR2 Arg753Gln (rs5743708)
TLR4 D299G (rs4986790), T399I (rs4986791), V270G (is identical to
V310G) (rs2770144)*
CD14 C-260T (rs2569190)
DEFA4 3’UTR A/G (rs736227)
DEFB1 Promoter region G/C (rs1800972)
LBP C98G*, P436L*
IFN signaling pathway
IFNAR1 L168V (rs2257167)
IFNAR2 V10F (rs7279064)
STAT2 I294M (rs2066807)
Abbreviations: TNFA, tumour necrosis factor _; IL, interleukin; CRP, C-reactive protein; IL1RN, IL1 receptor antagonist;
C1INH; complement component inhibitor-1; CFH, complement factor H; PAI1, plasminogen activator inhibitor; NOS2A,
inducible nitric oxide synthase; PARP, poly (ADP-ribose) polymerase; TLR, Toll like receptor; DEFA4, _ defensin 4;
DEFB1, _ defensin 1; IFNAR, interferon alpha receptor; STAT2, signal transducer and activator of transcription.
2
Polymorphisms indicated by asterisks were excluded after initial assessment, either because they were not observed in
our cohort, since technical problems occurred, or because of errors in prior publication.
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be incorrectly described in the initial publication, and for the other ten the rare variant 
was not observed in our Caucasian reference population.(12) For some diseases 
additional genes were included because of a special interest and collaboration with 
several research groups.
The genotyping techniques used for this thesis were Single Base Extension and 
TaqMan allelic discrimination. These methods were selected because of their 
robustness, because they can be applied in a high throughput fashion using 384-well 
plates, and because of their ready availability for our project.
During the course of this project the scientific community required increasingly sound 
evidence in SNP research. This is reflected by the demand of increasing cohort sizes, 
testing in validation cohorts, and functional support.(13)
Functional assays in meningococcal disease
We performed a pilot study comparing the transcriptional profile in severe paediatric 
meningococcal sepsis patients with that of healthy matched individuals, using 
Affymetrix expression micro-arrays (HG U133 2.0). The aim of this part of the 
study was to identify biological pathways in the complex processes involved in 
the pathogenesis of meningococcal sepsis. In addition, in collaboration with the 
Department of Haematology of the Erasmus MC and with other (inter)national 
research groups, we investigated the expression of several proteins involved in 
coagulation and fibrinolysis, and inflammation.
(Inter)national collaboration
As mentioned several times above, collaboration between different departments was 
initiated to perform the research project that has led to this thesis. Primarily eight 
departments within the Erasmus University Medical Centre Rotterdam (Erasmus MC) 
were involved: Paediatrics, Immunology, Neurology, Gastroenterology, Rheumatology, 
Dermatology, Medical Microbiology and Infectious diseases, and Virology. This 
collaboration was started because of a mutual interest in the role of genetic variation 
in disease susceptibility and pathogenesis, and because the diseases of interest 
were considered to have certain similarities in their pathogenesis. 
Additional Erasmus MC departments joined the collaboration, including the department 
of Internal Medicine, where most of the genotyping was performed, the department of 
Epidemiology and Biostatistics, and the department of Haematology and their (inter)
national partners from Groningen, the Netherlands and Leuven, Belgium. 
For specific diseases of interest, other (inter)national partners joined our 
collaboration. For RA these were the departments of Rheumatology from the Medical 
Centre Rijnmond-Zuid, and the Sint Franciscus Hospital, both in Rotterdam. These 
ensured the inclusion of large numbers of well defined RA patients. Together with 
the department of Gastroenterology and Hepatology of the Academic Medical 
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Centre Amsterdam, and their partners, we analysed a cohort of patients with 
Barrett oesophagus and other projects are still ongoing. Through the department of 
Gastroenterology of the Erasmus MC we were able to perform a genotyping study 
in a cohort of patients with HCV infection that was established in an international 
collaborative effort.
A long lasting collaboration with the department of Anaesthesiology, Intensive Care 
Medicine and Pain Therapy, University Hospital Giessen, Germany enabled us to 
perform a replication study, analysing a PAI1 polymorphism in trauma patients. 
Mutual interest in pneumococcal infections and previous collaboration resulted in the 
genotyping of children with recurrent otitis media from the OMAVAX study, based in 
Hoofddorp and Utrecht, the Netherlands.
The Netherlands Reference Laboratory for Bacterial Meningitis, Academic Medical 
Centre Amsterdam provided valuable information regarding meningococcal 
serogroups.
Together with the group of professor Thierry Calandra from the Infectious Diseases 
service, Department of Medicine from the Centre Hospitalier Universitaire Vaudois, 
Switzerland, and their USA partners, and the department of Chemical Endocrinology, 
Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, we 
combined adult and paediatric patient cohorts to provide a more complete view of the 
role of macrophage migration inhibitory factor in sepsis.
Large numbers of well defined patients with meningococcal infection were included 
together with the Department of Paediatrics, Imperial College London St. Mary’s 
Campus, London, United Kingdom and the UK Meningococcal Research group. 
Even more, international collaboration with groups in Singapore, Graz (Austria) and 
London has been initiated and a genome wide approach study is currently ongoing 
for the cohort(s) of patients with meningococcal disease.
Statistical and bioinformatics support for the genotyping studies was provided by 
the department of Medical Statistics, LUMC, Leiden University Medical Centre, the 
Netherlands, and by the Information and Communication Theory Group, Faculty 
of Electrical Engineering, Mathematics, and Computer Science, Delft University of 
Technology, Delft, the Netherlands.
The unique aspect of this collaboration was the participation of departments with 
expertise in the fields of infection, immunology, haematology, genetics, genetic 
epidemiology and bioinformatics, and the availability of well-defined patient cohorts. 
Both clinical and laboratory departments participated. The study described in this 
thesis was supported by a Revolving Fund Top Down grant of the Erasmus MC.
Outline of this thesis
The first part of the thesis elucidates several factors involved in (meningococcal) 
sepsis in children and adults. Chapter 2.1 reviews the role of genetic polymorphisms 
in meningococcal infection as known at the start of project start of this project. 
Chapter 2.2 illustrates the role of age gender and era on the outcome of 
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meningococcal sepsis patients admitted to the Paediatric Intensive Care Unit of the 
Erasmus MC-Sophia. Chapter 2.3 describes the current hypotheses and findings in 
the pathogenesis of sepsis and therapeutic trials, underscoring the importance of 
the balance between pro-inflammatory and anti-inflammatory actions. In chapters 
2.4 and 2.5 the role of genetic polymorphisms in antimicrobial peptides, cytokines 
and coagulation factors, in susceptibility to and severity of meningococcal infection 
is demonstrated. In addition, in chapters 2.5 and 2.6 the functional relevance is 
demonstrated of thrombin activatable fibrinolysis inhibitor (TAFI) and its activation 
markers and the role of von Willebrand factor (VWF) and ADAMTS13 (a disintegrin 
and metalloprotease with thrombospondin type 1 motif) in paediatric meningococcal 
infection. In chapter 2.7, the role of macrophage migration inhibitory factor (MIF) in 
adult and paediatric sepsis patients is supported by the association with severity 
and mortality. The transcriptional profiling study in meningococcal sepsis patients 
illustrating the involvement of multiple pathways is described in chapter 2.8. The role 
of plasminogen activator inhibitor-1 (PAI1) 4G/5G polymorphism in multiple trauma 
patients is described in chapter 2.9.
The second part of the thesis concerns inflammatory diseases that are now considered 
to be (partly) of autoimmune and (partly) of infectious origin. The role of SNPs in 
Guillain Barré syndrome (GBS), rheumatoid arthiritis (RA), Barrett oesophagus, 
and chronic HCV infection is assessed in chapters 3.1-3.4, suggesting a role for 
polymorphisms in genes in pro- and anti-inflammatory pathways, and in molecules 
involved in tissue integrity as well as Toll like receptors in these diseases.
In chapters 4.1 and 4.2, the third part of this thesis, the role of genetic polymorphisms 
in recurrence of acute otitis media is discussed, demonstrating, e.g., a possible role 
for impaired tissue repair in the susceptibility for recurrent otitis media.
Chapters 5.1-5.3 provide evidence for an effect of host cytokine and complement, 
and microbial genetic polymorphisms in Staphylococcus aureus nasal colonization. 
Finally, in chapter 6.1 and 6.2, the previous studies and future research perspectives 
in genetic association studies are discussed.
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2Chapter 2Genetic polymorphisms and their consequences in patients with (meningococcal) sepsis

Chapter 2.1 
Host genetic determinants of Neisseria meningitidis 
infections
M. Emonts, J.A. Hazelzet, R. de Groot, and P.W.M. Hermans
Lancet Infect Dis 3(9):565-577, 2003
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Abstract
The clinical presentation of infections caused by Neisseria meningitidis is highly 
diverse. Some patients develop meningitis, while others present with sepsis or even 
septic shock. After invasion of the bloodstream by the bacteria, three main cascade 
pathways are activated. These are the complement system, the inflammatory 
response, and the coagulation and fibrinolysis pathway. These pathways do not act 
independently but are able to interact with each other. Genetic polymorphisms among 
components of these pathways have shown to be involved in the susceptibility, 
severity and outcome of meningococcal disease. We review knowledge of genetic 
variations associated with susceptibility to and severity of meningococcal infection. 
Complement deficiencies and defects in sensing or opsonophagocytic pathways, like 
the rare Toll-like receptor 4 single nucleotide polymorphisms (SNPs) and combinations 
of inefficient variants of Fcγ-receptors, seem to have the most important role in 
genetically determined susceptibility. Effect on severity has repeatedly been found for 
FcγRIIa and Plasminogen activator inhibitor type 1 (PAI1) polymorphisms. Outcome 
effects have been confirmed for SNPs in properdin deficiencies, PAI1 and combination 
of the -511C/T SNP in IL1B and the +2018C/T SNP in ILRN. Conflicting results are 
found for the effect of the -308G/A promoter polymorphism in Tumour necrosis factor 
(TNF) A. These differences may reflect discrepancies in group definitions between 
studies or the influence of additional SNPs in the TNFA promoter, which can form 
haplotypes representing different cytokine production capacity. For several SNPs, 
the potential effect on susceptibility, severity or outcome has not yet been confirmed 
in an independent study.
Introduction
Despite ongoing improvement of treatment strategies in infections caused by 
Neisseria meningitidis the mortality rates are still very high, and range from 4-40%. 
The wide range indicates the different clinical presentations of infection. The disease 
spectrum varies from meningitis to sepsis and septic shock (Figure 1). Meningitis 
has a mortality rate of 4-6%, while in septic shock mortality rates up to 40% have 
been reported. Meningococcal lipopolysaccharide (LPS) is thought to be one of the 
major factors that induce the host response during bacterial invasion. This response 
is complex and involves, besides non-immunological clearing mechanisms such as 
cholesterol, the activation of three main cascade reactions (Figure 2). The first is the 
complement system that, apart from contribution to phagocytosis of the bacteria, 
functions as an inducer for the inflammatory reaction via C3a and C5a. The second 
cascade reaction is the coagulation and fibrinolysis pathway. Both are stimulated in 
meningococcal infection, which results in a prothrombotic stage. The third system is 
the inflammatory reaction mediated by different cytokines and chemokines among 
which Tumour necrosis factor (TNF)α and IL-1β play a central role in immunological 
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defence. One of the pathways leading to cytokine stimulation is triggered through 
interaction of bacterial molecules with Toll-like receptors (TLRs). 
Figure 1. Petechial and purpuric rash in a child with meningococcal septic shock.
At this moment ten TLRs are identified in human beings, each recognizing specific 
known or unknown microbial molecules. TLR4 and TLR2, for instance, recognize 
meningococcal LPS, while TLR9 recognizes CpG-rich bacterial DNA.(1) Stimulation of 
TLRs leads to the transcription of NFκB, which in turn activates immune response genes 
leading to activation of dendritic cells and regulation of the adaptive immune response 
(Figure 3).(2) In patients with sepsis activation of these cascades are translated into a 
sudden onset of fever and petechial or purpuric rash followed by hypotension (Figure 
1). In septic shock, disseminated coagulation and multiple organ failure develop. For 
extensive reviews of the pathophysiology see previous reports.(3, 4)
The broad range of clinical presentations of N. meningitidis infections raises the 
question of why some patients show very few clinical symptoms and others die within 
several hours after onset of symptoms. Variations in host genetic factors are known 
to contribute to differences in clinical response. Haralambous et al. quantified the 
host genetic component to meningococcal disease susceptibility, calculating the 
sibling risk ratio (λs) as the ratio of observed meningococcal disease cases among 
845 siblings of 443 cases in white people in the UK to that expected. The overall 
λs they found was 30.3. Depending on the meningococcal disease onset within set 
time points of the index case λs varied between 8.2 and 11.9, suggesting that host 
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Figure 2. Inflammatory cascade initiated during meningococcal sepsis. The three main cascades involved 
in the pathophysiology of meningococcal infection. The factors depicted in bold are discussed in the text. 
Adapted from Rich et al.(84) ARDS, acute respiratory distress syndrome; IL, interleukin; INF, interferon; 
TNF, tumour necrosis factor.
genetic factors may contribute approximately one third of the total λs.(5) 
Researchers currently focus on a wide variety of infections and other diseases. 
Genetic polymorphisms are relatively stable in the human population. It has been 
shown that these polymorphisms may affect susceptibility, severity and outcome of 
infectious disease. This review focuses on what is known of genetic variability in the 
susceptibility to and severity of meningococcal infections (Table 1).
Lipopolysaccharide, PG monomers, DNA repeats
Lipoproteins, Teichoic acid
Microbial toxins, other microbial components
Cytokine stimulation
Nitric oxide
Coagulopathy
Kinin stimulation
Prostaglandins
Leukotrienes
Platelet-activating/factor
Fibrin deposition
Disseminated intra-
vascular coagulation
TNF-A
IL-1
INF-G
IL-6,
IL-8
IL-10
Complement activation
C5a
C3a
Leukocyte chemotaxis
Inflammation
Generalized endothelial damage
Vascular leak
Tissue oedema
Vasodilatation
Leukocyte activation
Bleeding
Temperature dysregulation
Tachycardia,hyperventilation
Hypotension
Pallor, peripheral vasoconstriction
Cutaneous signs
Multiorgan failure
(ARDS, renal failure)
Altered mental status
Shock
Death
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Figure 3. Activation of cytokines through interaction of LPS with Toll-like receptor 4. IRAK, interleukin-1 
receptor-associated kinase; MyD, myeloid differentiation factor; TIR, Toll/interleukin-1 receptor; TRAF, 
TNF receptor-associated factor.
Search strategy and selection criteria
Data for this review were identified through Pub Med searches. Search terms 
were “meningococ* and polymorph*”, “meningococ* and (disease* or infection*)”, 
“meningococ*” and “meningococ* and (susceptib* or severity)”. Individual genes were 
searched for by their specific names. English language papers only were reviewed.
Innate immunity
Toll-like receptors. Innate immunity has a very important role in the first recognition 
of invading pathogens. This recognition was, until recently, believed to be non-
specific. However, elucidation of the function of TLRs has shown otherwise. TLRs 
sense different microbial molecules, covering a range of pathogens that cause 
infections in the host. C3H/HeJ mice, having a point mutation in tlr4 that abolishes 
LPS responses, are hypo-responsive to Gram-negative infections.(6, 7) The common 
Asp299Gly polymorphism in TLR4 alters the extracellular domain of the receptor, and 
airway epithelial cells of patients carrying this polymorphism are hypo responsive to 
Cytokines IKB
IKB
NFKB
IRAK
MyD88
TIR domain
Death domain
Cytokines
IL-6, TNFA, IL1B, IKB
TRAF6
TLR4
MD2
CD14
LPS
IKK
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LPS. However, no association has been seen between the Asp299Gly polymorphism 
and the susceptibility or severity of meningococcal infection.(8) Smirnova et al. 
reported an excess of rare aminoacid polymorphisms in TLR4.(9) None of these rare 
variants was individually over-represented in a UK patient population with systemic 
meningococcal disease. When the individuals with a rare variant of TLR4 were 
combined, a significant excess was seen in the patient group compared to healthy 
controls. These results suggest that a deficiency in sensing meningococcal LPS 
increases risk of disease.(10) 
No significant association was seen for polymorphisms in TLR2 and meningococcal 
infection.(10) TLR2 recognizes other bacterial components, such as lipopeptides 
and peptidoglycan.(6) So far no polymorphisms in TLR9 in relation to meningococcal 
disease have been studied. If a relation exists it is likely to contribute to a different 
extent in populations with different ethnical background considering the varying allele 
frequencies reported.(11) TLRs recognize ligands in the presence of CD14 and 
MD2 (TLR4) and activation of the diverse TLRs results in the activation of different 
pathways, leading to NFκB activation. Polymorphisms in the factors in these pathways 
might also indicate different phenotypes.
LPS binding protein and bactericidal/permeability increasing protein. Besides 
non-immunological clearing of LPS by alkaline phosphatase and cholesterol, LPS 
binds to LPS binding protein (LBP) to form a complex that binds TLR4 via CD14. 
In a recent study the Cys98Gly and Pro436Leu polymorphisms of LBP did not 
show correlation with the susceptibility or severity of bacterial sepsis in people but 
a relationship was found with the outcome of bacterial sepsis in men. It has been 
proposed that these polymorphisms might in part explain the worse outcome of 
bacterial infections reported in men. In the same study polymorphisms in bactericidal/
permeability increasing protein (BPI) have also been assessed. BPI is another 
protein binding to LPS and inhibiting LPS-induced host cell responses. The A645G, 
the G545C silent polymorphism, nor the PstI site in intron 5 was associated with 
outcome and severity of bacterial sepsis. However, in this study the limited amount 
of data prohibited the analysis of Gram-negative versus Gram-positive infections, 
which in our opinion introduces a bias with respect to LPS-related susceptibility. This 
might have limited the sensitivity in detecting an association in the latter study.(12) 
Confirmation of the findings in an independent study taking into account the nature of 
the causative bacteria is warranted.
Angiotensin converting enzyme. Angiotensin Converting Enzyme (ACE) is 
associated with proinflammatory response. The absence of a 284 base-pairs (bp) 
marker in the ACE gene (D allele) is associated with higher circulating ACE activity 
compared with presence of this marker (I allele).(13) The DD genotype has shown 
to be related to higher tissue activity and associated with venous thrombo-embolism.
(14, 15) Harding et al. have shown that in children with meningococcal disease the DD 
genotype is associated with higher Glasgow Meningococcal Septicaemia Prognostic 
Scoring, higher inotropic support and ventilation, higher predicted risk of mortality 
and longer paediatric-intensive-care-unit stay, compared with the II and ID genotype. 
The DD genotype is associated with increased disease severity, and, although not 
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significant, a twofold increase in mortality has been reported. The genotype distribution 
was demonstrated to be similar for patients and healthy controls, suggesting no effect 
of ACE polymorphism on susceptibility to meningococcal disease. The reported 
association with disease severity might be explained by an increased proinflammatory 
response in DD individuals due to increased ACE concentrations. Unfortunately, no 
data on ACE concentrations are available in this study.(16)
Complement
Mannose binding lectin. Complement activation forms a significant part of the innate 
immunity. Besides beneficial effects, harmful effects have also been attributed to 
complement activation. The severity of hypotension is in part regulated by complement 
activation. At present, three activation pathways are considered (Figure 4). First, 
the classical pathway, which is activated by antibody-antigen interactions and by 
C-reactive protein.(17) Second, the alternative pathway of innate immunity, which is 
activated through interaction of C3 with factor B and factor D to generate C3b. Third 
the additional innate activation pathway, which is activated through mannose binding 
lectin (MBL). The two pathways of the innate immunity do not require antibodies. All 
three pathways converge in a common final pathway.
Figure 4. Three pathways of complement activation leading to a common late pathway, which generates 
the membrane attack complex (MAC) and inflammatory mediators C3a and C5a. Adapted from Hibberd et 
al.(18)  MASP, mannose-binding-lectin-associated serine protease.
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MBL first forms trimers, which in turn further assemble to multimers. The MBL multimers 
bind to sugars and LPS on the bacterial surface. This complex then activates the 
MBL-associated serine proteases (MASP) 1 and MASP2. MASPs activate C4 of the 
typical pathway.
Three allelic variants of MBL have been described in codons 52, 54 and 57 of exon 1. 
In codon 54 and 57 a mutation causes the disruption of the axial glycine repeats (Gly-
Xaa-Yaa) resulting in aberrant trimers. These trimers cannot form correct multimers 
and are unstable. Via an unknown mechanism, the codon 52 mutation also results 
in unstable trimers. Heterozygotes for the variant alleles show a decrease in MBL 
serum concentrations to 10% of normal, while in people homozygous for any of the 
three mutations concentrations drop to 1% of normal.(18, 19) In children the variant 
alleles were associated with the susceptibility to meningococcal infection. Patients 
homozygous for the variant alleles showed a trend towards slightly less severe 
disease than heterozygous and wild-type individuals. This observation, however, did 
not reach statistical significance.(20) The finding that low serum MBL is associated 
with susceptibility to meningococcal infection was supported by the report of three 
cases in a single family by Bax et al.(21) Unfortunately they did not provide information 
on the genotypes.
C3. C3 has a central position in complement activation. All three complement 
pathways described lead to activation of C3, resulting in the fragments C3a and 
C3b. C3a, together with C5a, is a potent proinflammatory and chemoattractant 
molecule. C3b functions as an opsonin and, when bound to the C3 convertase, forms 
the C5 convertase that produces C5a and C5b. C5b initiates the late events in the 
complement pathway resulting in the formation of the membrane-attack complex 
(MAC). The MAC creates pores in the pathogen cell membrane causing bacterial 
death. Deficiency of C3 results in compromised opsonisation and phagocytosis of 
bacteria and, hence, in increased susceptibility to meningococcal and other bacterial 
infections.(22) However, excessive activation of the complement system was shown 
in children with septic shock related to outcome, severity of disease and capillary 
leakage.(17)
Properdin. Another important factor of the alternative complement pathway is 
properdin, also called factor P, which is coded on the short arm of the X chromosome.
(23) It is a positive regulator acting through stabilization of the C3 convertase 
C3b,Bb. Properdin deficiencies are associated with increased risk for meningococcal 
infection. Three different variants of properdin deficiency have been described. Type I 
deficiency is characterised by absence of the properdin protein in the plasma. In type 
II a low but detectable properdin plasma concentration is reported whereas in type III 
a normal concentration of a dysfunctional variant protein is found.(24) The molecular 
basis for the deficiencies is heterogeneous. Type I deficiency is caused mainly by 
a mutation resulting in a premature stop codon in exon 4-6.(25-27) In type II two 
distinct mutations have been described, C2124T (Arg/Trp) and G827A in exon 4 and 
intron 3, respectively.(26) In type III a single base substitution, T>G in exon 9 causing 
an amino acid substitution, Tyr387Asp, results in the abolishment of convertase 
stabilizing function.(28)
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All three properdin deficiency variants are associated with increased susceptibility to 
infection with N. meningitidis. The severity of disease differs between individuals with 
properdin deficiency and, in addition, depends on the serotype of the meningococcal 
strain involved. In general an increased disease severity and poor outcome is 
observed. Mortality rates of 75% and more recently 33% have been reported.(29, 30) 
Differences with respect to meningococcal disease in properdin-deficient individuals 
can also be explained by the contribution of additional genetic factors. Spath et al. 
found in their group of nine properdin-deficient individuals that those patients with a 
positive history for meningococcal disease invariably lacked the G2m(n) IgG allotype, 
while in all other individuals this allotype could clearly be detected. Lack of the G2m(n) 
allotype is known to be associated with poor antibody responses to T-independent 
antigens and possibly lower IgG2 concentrations. Meningococcal LPS can elicit an 
IgG2 response.(25) Another explanation for the clinical differences may be different 
inactivation patterns of the X chromosome in heterozygous female patients. 
Late complement deficiency and factor D. Patients having late complement 
deficiency (LCCD, C5-C9) are known to have recurrent Gram-negative bacterial 
infections. Failure to form a MAC underlies this increased susceptibility. These 
infections result in milder disease severity than reported for the total patient population, 
suggesting adverse effects of complement activation during meningococcal infections. 
Fcγ receptor polymorphisms have shown to affect disease susceptibility in LCCD 
individuals (See below).(31) Complement D deficiency was seen in members of a 
family with severe N. meningitidis infections. The alternative pathway for complement 
activation was impaired. This pathway, by contrast with the classical pathway, seems 
to be prominent in meningococcal infection.(32, 33)
The genetic variations described so far in complement factors appear to contribute 
mainly to susceptibility and not severity of meningococcal disease, underlining 
the importance of the serum bactericidal capacity in the host defence against 
meningococcal infection.
Aquired immunity
FCγ Receptors. Fcγ receptors (FcγRs) belong to a heterogeneous family of receptors 
and are grouped in three classes (FcγRI, II and III). Three subtypes of receptors 
responsible for IgG-mediated signalling (FcγRIIa, FcγRIIIa, FcγRIIIb) are thought to 
be important in host defence against meningococci. FcγRIIa is located on leukocytes 
and mononuclear macrophages and is sensitive to IgG2 and IgG3. Two alleles are 
known to differ at aminoacid position 131 because of single point mutation (SNP) 
in exon 4. The 131R (arginine) allotype confers lower interaction efficiency towards 
IgG2 and IgG3 than the 131H (histidine) allotype. Two allotypes known for FcγRIIIa, 
158Phe and 158Val, show different binding of IgG1, IgG3 and IgG4, as interaction 
with FcγRIIIa158V is stronger. FcγRIIIb is expressed on neutrophils and has the 
neutrophil antigen (NA) polymorphism representing 4 aminoacids substitutions in 
the membrane-distal loop of the receptor. FcγRIIIb-NA2 binds IgG1 and IgG3 less 
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efficiently than FcγRIIIb-NA1.(34) One can imagine that differences in the efficiency 
to bind IgGs result in different host response effectiveness and thereby variable 
susceptibility to and/or severity of disease.
A study in survivors of meningococcal disease and first-degree relatives of survivors 
and non-survivors showed no differences in FcγR distribution. The FcγRIIaR131 
allele was more often seen in meningitis patients compared with sepsis patients. The 
FcγRIIIa-V158 allelic frequency was markedly increased in relatives of meningitis 
patients compared with relatives of patients presenting with haemodynamic instability. 
The RR-FF-NA2/2 frequency that represents the least efficient FcγR combination, 
and is responsible for diminished phagocytosis, was tripled in first-degree relatives 
compared with healthy non-related controls. These data suggest an association 
between FcγR haplotype and susceptibility to and severity of meningococcal 
disease.(34) In contrast to Van der Pol et al., Domingo et al. have found the FcγRIIa-
131Arg/Arg genotype to be more common in patients with sepsis than in patients 
with meningitis with or without sepsis. Differences in genotype distribution between 
patients and controls were not reported. Meningococcal serotypes were distributed 
similarly among different genotypes. Complications were more frequent in patients 
homozygous for FcγRIIa-131Arg, but long-term sequelae were found equally in 
patients with different genotypes. A prognostic score of 1 or more, indicating severe 
disease according to the Barcelona Meningococcal Disease Surveillance Group, was 
seen more often in patients homozygous for FcγRIIa-131Arg. No mortality differences 
were reported.(35) In a retrospective study Bredius et al. saw that the R/R genotype 
is present more often in survivors of meningococcal disease than in healthy controls 
(OR 2.67). This finding suggests a role for the FcγRIIa polymorphism in susceptibility 
to meningococcal disease. Because of the retrospective nature of the study, no data 
on genotypes for non-survivors are available, hence effects on severity of disease 
remain unknown.(36) In a recent study, Smith et al. were unable to find an association 
between FcγRIIa and FcγRIIIb polymorphisms and meningococcal disease in a patient 
population in Western Norway.(37) However, the small sample size, 50 patients and 
100 healthy controls, although well defined, may have prevented them from finding 
an association. 
Additionally, Platonov et al. have studied the FcγRIIa-131 polymorphism in 29 Russian 
LCCD patients and 107 healthy geographically matched controls. Genotype distribution 
was similar for patients and controls. Patients who contracted their first meningococcal 
disease episode under the age of 10 had mainly the FcγRIIa-131His/His genotype 
while in patients with the first disease period above the age of 10 years the FcγRIIa-
131Arg/Arg genotype was more prevalent. Overall the R/R and R/H genotypes were 
associated with more severe disease as compared to the H/H genotype. This effect 
was most pronounced for the disease episodes in patients above 10 years of age.(31) 
The combination of R/R and NA2/NA2 in a group of 15 Dutch LCCD patients increased 
susceptibility to meningococcal disease (OR 13.9).(38) This relation could not be 
observed in a group of 15 properdin-deficient patients.(39)
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Coagulation
Activation of coagulation and fibrinolysis is the result of the acute inflammatory 
response as mentioned above. The prothrombotic endothelium surface results from 
cytokine activation. Subsequently, tissue factor production results in activation of the 
extrinsic pathway of coagulation and the production of platelet-activating factors. The 
fibrinolytic system is initially activated but is subsequently inhibited. This results in 
a marked imbalance in coagulation and fibrinolysis resulting in a net procoagulant 
state and ultimately disseminated intravascular coagulation. This leads to deposition 
of fibrin, the formation of microthrombi and bleeding. Multiorgan failure and death are 
the most severe clinical outcomes of this imbalance.
Tissue-type plasminogen activator. Tissue-type plasminogen activator (t-PA) is 
a serine protease that converts plasminogen into its active form plasmin, which in 
turn leads to fibrinolysis. Impaired t-PA function leads to insufficient lysis of thrombi. 
Differences in t-PA production or impaired function could therefore affect the severity 
of meningococcal disease. An insertion/deletion polymorphism of an Alu element in 
TPA considered to affect the basal levels of t-PA has been investigated in relation 
to meningococcal disease. No association could be seen between the different 
alleles, and the severity or outcome of meningococcal disease.(40) The authors 
have regarded the admission to an intensive care unit (ICU) as a criterion for severe 
meningococcal disease. In our opinion this only holds partially true, since not all 
patients admitted to the ICU actually develop septic shock. This approach might have 
prevented them from finding significant differences between the study populations. 
Although the levels of t-PA during meningococcal septic shock do not differ much 
from baseline, the 4G/5G polymorphism in plasminogen activator inhibitor type 1 
(PAI1, see below) might have prevented finding an association with t-PA.(41) Further 
research regarding polymorphisms in TPA in combination with polymorphisms in 
other factors involved in coagulation and fibrinolysis with respect to meningococcal 
disease is therefore required.
PAI-1. PAI-1 is responsible for the inhibition of fibrinolysis both directly and indirectly 
through inhibition of t-PA (Figure 5). In turn, PAI-1 is inhibited by activated protein 
C. In septic shock, laboratory findings show decreased concentrations of all 
coagulation factors especially protein C.(41) The gene encoding PAI-1 has several 
polymorphic loci, including a 3’-HindIII site, a CA(n) repeat in intron 3 and a 4G/5G 
insertion deletion polymorphism at -675 in the promoter. PAI-1 activity has shown 
to be significantly higher in control subjects homozygous for the 4G allele than in 
those homozygous for the 5G allele.(42) The production of PAI-1 mRNA after IL-1 
stimulation seemed to be greater in HepG2 cells bearing the 4G allele.(43) In patients 
with meningococcal sepsis the levels of PAI-1 are positively related to severity of 
disease, outcome, cytokine levels, acute phase proteins and coagulation parameters.
(41) In non-survivors the PAI-1 concentrations were shown to be 1.9 times higher 
for the same TNF-α concentrations than in survivors.(44) TNF-α induces PAI-1 
production. In children with meningococcal disease a relation has been observed 
between genotype, PAI-1 concentrations and outcome of disease. The patients with 
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the 4G homozygous genotype had higher PAI-1 concentrations and had an increased 
risk of death. No association was observed with severity of disease.(45)
A similar study by Westendorp et al. has shown a higher incidence of the 5G/5G 
genotype among relatives of patients with meningitis. Patients whose relatives 
were carriers of the 4G/4G genotype had a six-fold higher risk of developing septic 
shock than meningitis.(46) In a recent study including 510 UK paediatric patients, 
210 parents and 155 UK Caucasian controls, no association was seen between the 
4G/5G polymorphism and susceptibility. In patients with meningococcal sepsis the 
relative risk of death was 2.9 for the 4G homozygous patients compared with the 
combined 4G/5G and homozygous 5G genotypes. In survivors the risk of developing 
vascular complications was significantly higher in the patients homozygous for the 
4G allele.(47)
Figure 5. The action of Protein C, PAI-1 and t-PA on fibrinolysis. u-PA, urokinase-type plasminogen 
activator.
Factor V Leiden. Factor V Leiden (FVL) is associated with thrombotic events, and is 
therefore a candidate for involvement in the development of meningococcal purpura 
fulminans. A study comparing children with meningococcal disease, healthy controls, 
and parents of children with meningococcal disease did not reveal an association with 
the FVL mutation and susceptibility. Patients heterozygous for the mutation showed 
increased complications, as assessed by requirement for skin grafting, referral to 
plastic surgeon, and/or amputation. A significant effect on mortality has not been 
reported.(48)
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Protein C and thrombomodulin. To prevent hypercoagulability, anticoagulants serve 
to guard the balance between coagulation and fibrinolysis. Activated protein C, together 
with its cofactor protein S, inactivates the procoagulant factors V and VIII. PAI-1 is 
also inhibited by protein C. Protein C is initially expressed as an inactive protein and 
for activation the interaction with thrombin, thrombomodulin and endothelial protein 
C receptor is required. In severe meningococcal sepsis low concentrations especially 
of protein C are seen, and the expression of thrombomodulin is down regulated.(41, 
49) However, administration of unactivated protein C to two patients in a study by 
Faust et al. did not result in detectable concentrations of activated protein C. Low 
expression rates of thrombomodulin and protein C receptor on the intact vascular 
endothelium in skin biopsy samples of patients with meningococcal sepsis compared 
with normal controls might explain this finding, since low levels of activator molecules 
result in impaired activation of protein C. In-vitro studies using plasma spiked with 
activated protein C showed recovery of activated protein C function, which ruled 
out the presence of an inhibitory factor in the plasma.(49) Impairment of the protein 
C activation in patients with meningococcal sepsis results in a procoagulant state 
and formation of thrombotic lesions. On the other hand, a placebo-controlled study 
using protein C concentrate showed activation of protein C and a dose dependent 
effect on coagulation parameters.(50, 51) A third effect of (activated) protein C is the 
down regulation of the inflammatory response: decreased production of cytokines 
and decreased adherence of leukocytes to the endothelial wall, which makes this 
molecule extremely important during the sepsis process.(52) Until now there have 
been no studies investigating the role of protein C, thrombomodulin and thrombin 
polymorphisms in meningococcal disease, although the clinical importance of these 
molecules does warrant further investigation.
Cytokines
TNF-α. TNF-α has a central role in the activation of the inflammatory response, 
and concentrations are raised in all patients with meningococcal disease. TNF-α 
activates adhesion promoting receptors and ligands enabling leukocytes to cross the 
endothelium and reach the site of inflammation. Other inflammatory mediators such 
as INF-γ, IL-6 and IL-8 are activated by TNF-α. A procoagulant state is promoted by 
the induction of tissue factor release. TNF-α blood levels are positively associated 
with disease severity, coagulopathies and outcome.(53) Westendorp et al. have found 
higher TNF-α response in ex vivo blood samples after stimulation with endotoxin 
in patients who had experienced a moderately severe disease course compared 
to patients with a mild course. The TNF-α response was low again in survivors of 
fulminant disease. Similar experiments using blood from monozygotic twins showed 
that a 60% heritability for TNF-α production.(54) On admission for meningococcal 
disease, patients who did not survive had initial TNF-α concentrations three times 
higher than those in survivors with a clinical disease presentation of similar severity.(55) 
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The G-308A polymorphism in the TNFA promoter region has shown to be associated 
with outcome of meningococcal disease. The TNF2 allele (-308A) is associated 
with an increased risk of death in children.(56) Despite sufficient power this could 
not be confirmed in a separate older patient group.(57) Since the mortality risk in 
meningococcal disease is significantly affected by age, this might explain the reported 
differences between the two studies.(58) No association has been reported for the 
G-308A polymorphism and susceptibility of meningococcal disease.(56) Opinions 
differ on the role of this polymorphism and the severity of disease.(54, 56, 59, 
60) The G-308A and the G-238A polymorphisms did not show a relation with TNF 
production capacity.(54) Huizinga et al. reported that on ex-vivo simulation of whole 
blood with endotoxin individuals with the -238 G/A genotype had a significantly lower 
TNF-α production compared to donors with the -238 G/G genotype. No differences 
were found in TNF-α production for the different -308 and -376 promoter genotypes.
(61) In a study performed by Uglialoro et al., who identified three additional SNPs 
at positions -574(G/A), -856(C/T) and -862(C/A), no relation was seen between 
these and formerly described SNPs and TNF-α production.(62) These results were 
obtained using cloned promoters and a reporter gene. In each construct only one of 
the rare variants was present and other polymorphic sites were represented by the 
common allele. Unfortunately, the possible cumulative effect of SNPs on the TNF-α 
production was not accounted for.(63, 64) It is clear that TNF-α production is affected 
by genetic factors in meningococcal sepsis, but the relative importance of the known 
polymorphisms is still under discussion.
Interleukin 1 family. The interleukin 1 family consists of both pro-inflammatory 
and counter-inflammatory members. The genes IL1A and IL1B encode the pro-
inflammatory proteins IL-1α and IL-1β, respectively. The IL-1 receptor antagonist (IL-
1RA) represents the anti-inflammatory component. IL-1RA can bind the IL-1 receptor 
without inducing signal transduction. Several polymorphisms are known in the IL-1 
family. Five alleles of IL1RN, the gene coding IL-1RA, are known to differ by a variable 
number repeat of 86 bp in intron 2.(65) This repeat contains transcription factor 
binding sites. The IL1RNA2 allele has two repeats and is in linkage disequilibrium 
with SNP T8006, also known as T2018C.(57, 66) The A2 allele has shown to be 
associated with susceptibility to severe sepsis in patients in a surgical intensive care 
unit.(63) Carrol et al. have shown no significant correlation between the presence of 
the A2 allele and disease susceptibility, severity, or risk of dying in 144 meningococcal 
infection cases in a tertiary children’s hospital. In 70 % of cases the diagnosis was 
confirmed microbiologically. However, a trend suggesting less severe diseases in the 
presence of the A2 allele was reported.(67)
Read et al. have investigated whether variants of the IL-1 and TNF gene families are 
associated with severe manifestations of meningococcal infection. All patients included 
had microbiologically proven N. meningitidis infection. A significant association has 
been seen between the outcome and the IL1B C-511T polymorphism. Patients 
homozygous for either the common or the rare allele had increased odds ratios for 
death, compared to heterozygous individuals. The combination of heterozygosity of 
IL1B -511 together with homozygosity of the common allele of IL1RN at +2018 was 
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significantly associated with survival. This implies an interaction between the IL1B -511 
and IL1RN 2018 polymorphisms. In this study no association between the TNF -308 
genotype and fatal outcome has been shown.(57) The relationship between allelic 
variants of the IL-1 gene cluster and meningococcal disease has been confirmed in 
a second and larger study by Read et al. in England and Wales. All patients in this 
study had microbiologically confirmed meningococcal infection. Patients carrying the 
common allele at the IL1B -511 site were more likely to survive. Patients who carried 
the rare allele at IL1RN 2018 in addition to the common IL1B allele were less likely to 
survive than those who did not carry the rare allele. This association was still present 
after correction for effects of age, infecting serogroup and socio-economic status. 
No difference was found in genotype frequencies between patients and healthy 
controls.(58) These data suggest that the IL-1 genotype influences the outcome of 
meningococcal disease.
Interleukin 6. Interleukin 6 (IL-6) is a major pyrogen and is responsible for the 
induction of hepatic acute phase proteins and antibody production by B cells. IL-6 
blood concentrations are increased in meningococcal infection and IL-6 concentrations 
were seen to be significantly higher in non-survivors compared with survivors.(44) 
The G-174C polymorphism in the promoter region of IL6 is associated with poor 
outcome in meningococcal infection. Carriers of the G allele had an increased 
risk of death (OR 3.06).(68) In a second study, in which the role of the G-174C 
polymorphism in sepsis caused by different bacteria other than N. meningitidis, 
in patients admitted to a surgical ICU was investigated, the reverse relation was 
observed: the G/G genotype was associated with improved survival, while the non-
survivors did have significantly higher IL-6 plasma concentration. IL-6 concentrations 
showed no correlation with the G-174C genotype. Again no difference was seen 
between genotype distributions between patients with and without sepsis and 
between patients and healthy controls, suggesting the lack of association between 
the G-174C SNP and susceptibility to sepsis.(69) The contradictory results regarding 
the outcome of sepsis might be explained by the fact that this polymorphism is part 
of a complex haplotype associated with differences in IL-6 production. The -579G, 
-572G, -373A9/T11, -174G haplotype shows higher transcription of IL-6 in an ECV304 
cell line after IL-1 induction than the other polymorphism combinations. This study 
clearly shows that different polymorphisms can have an influence on transcription, 
but they are not functioning independently.(70) When assessing the contribution of 
the G-174C polymorphism in meningococcal disease, the complete haplotype should 
be considered. Another important matter in studying the relation of IL-6 levels and 
genotypes is the timeframe between onset of endotoxemia and measurement of IL-6 
concentrations. Il-6 and other cytokines have been shown to reach a peak level at 
different time points after controlled injection with endotoxin before concentrations 
decline. Depending on the time of sampling one will find different IL-6 concentrations, 
which makes the identification of a possible relation between genotype and cytokine 
concentration very difficult in the non-controlled setting.(71) On the other hand, IL-6 is 
one of the few cytokines, which remains elevated in non-survivors in a murine sepsis 
model.(72) Furthermore IL-6 seems to be directly related to myocardial dysfunction, 
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which makes IL-6 an important target for research.
Interleukin 10. IL-10 is an important cytokine, particularly known for its anti-
inflammatory action. It is produced by cells of the monocyte/macrophage lineage. 
It deactivates macrophages and inhibits activation of Th1 cells and expression of 
IFN-γ.
The pro-inflammatory TNF is also inhibited by IL-10. To estimate the heritability of IL-
10 and TNF production a study in first-degree relatives of survivors and non-survivors 
of meningococcal disease has been undertaken. Basal levels of neither IL-10 or TNF 
production differed between relatives of survivors and non-survivors. However, after 
ex-vivo stimulation of whole-blood samples with Escherichia coli endotoxin, the IL-
10 production in relatives of non-survivors was twofold higher than in relatives of 
survivors, while the reverse was seen for TNF production. Families with high IL-10 
production had a 20-fold increased risk for fatal disease.(54) Additionally, in a twin 
study the heritability of IL-10 in monozygotic twins was found to be 75%.(54) In this 
study no data are available on IL10 polymorphisms. Two CA-repeat microsatellites, 
IL-10.R and IL-10.G located at -4 kb and -1.2 kb upstream from the IL-10 transcription 
start site, are correlated with IL-10 production levels upon induction with LPS. 
IL-10.R3 was associated with low IL-10 production, while the IL-10.R2/IL-10.
G14 haplotype was associated with the highest secretion levels.(73) Additional 
polymorphisms in the promoter region, A-3715T, T-3575A, G-2849A, A-2776G, 
C-2763A, C-2100A, G-2050A, G-1330A, G-1082A, C-819T and C-592A, have also 
been identified.(74, 75) The -3575, -2849, -2763 haplotype A-[G/A]-A was seen more 
often in low IL-10 producers, while the T-G-C haplotype was significantly associated 
with high IL-10 production. The high IL-10 production phenotype in the individuals 
carrying the distal TGC haplotype was independent of the proximal haplotype. In 
black Americans a significant difference between normal donors and SLE patients at 
-2763 was reported. The lack of effect from the -3537 SNP in this population might 
be explained by the different allele frequencies observed between black Americans 
and whites. The -3537T allele frequency was significantly higher in the first group.
(75) In first-degree relatives of survivors and non-survivors of meningococcal disease 
Van der Pol et al. have found a non-random distribution of IL10 -1082 genotype in 
combination with the FcγRIIa, compared with a healthy control population in which 
the combination was randomly distributed.(34) No data concerning the distribution of 
the IL10 genotype in relatives of survivors versus non-survivors has been discussed. 
Hence, the role of IL10 polymorphisms in meningococcal disease needs further 
investigation.
Discussion
Meningococcal disease comprises a complex pathophysiology resulting in a spectrum 
of disease presentation in affected individuals. The contribution of host genetic factors 
to the risk of meningococcal disease as determined in a sibling study by Haralambous 
et al. was suggested to be one-third of the total risk.(5)
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Defective serum bactericidal activity has an important role in susceptibility to 
meningococcal infection. This is illustrated by the recurrent infections in complement-
deficient individuals. The presence of specific antibodies, however, is of even more 
importance in conferring resistance to infection. Increase of antibody titers upon 
nasopharyngeal colonization with meningococci has been demonstrated.(76) A study 
in military recruits revealed that all individuals that developed meningococcal disease 
in their training period showed selective deficiency of antibodies to the causative agent 
in base line sera drawn at the time of enrollement in the army. These individuals were 
capable of initiating an immune response to meningococcal antigens as shown by 
the increase in antibody titers in convalescent sera. The increase in antibody titer was 
accompanied by a rise in bactericidal activity of the serum samples.(77) Absence of 
serotype-specific antibodies in recurrent meningococcal infection has been reported.
(78) The fact that prevalence of meningococcal C disease declines after major 
vaccination campaigns in different European countries supports the importance of 
bacterial antibodies in susceptibility to disease.(79, 80)
Given the complex nature of the disease, assessing the contribution of host factors 
in infection requires a strict definition of the patient population. Patients with 
meningococcal meningitis might have different “susceptibility genotypes” than septic 
shock patients, since different pathophysiologic pathways are activated. Combining 
these study populations is therefore not advisable. Unfortunately, severity of disease 
is defined in different ways by distinct research groups. Also different subgroups 
are defined. This may in part explain the observed differences between studies 
analysing similar polymorphisms. In the analysis of the role of Fcγ receptors, for 
instance, Domingo et al. have excluded patients with complement deficiency.(35) 
This was not done by Van der Pol et al. and, hence, might have contributed to the 
differences observed between the two studies.(34) Within countries this problem is 
usually addressed by the introduction of severity scores like the Rotterdam score and 
the PRISM score for paediatric patients in the Netherlands and the United Kingdom, 
respectively.(81, 82) Although these scores do not differ essentially, subtle differences 
in clinical definitions (e.g. septic shock criteria) do occur. The same problems occur 
when comparing patients with sepsis of unknown microbiologic origin. Host response 
to Gram-positive microbes might differ from the response towards Gram-negative 
bacteria.(6). It must be noted, however, that in approximately 10% of the cases 
meningococcal infection cannot be proven with microbiological techniques, while the 
clinical presentation is typical.
In addition, it might be difficult to obtain patient groups of sufficient numbers to show an 
association between disease susceptibility, severity and outcome when investigating 
genotypes with extremely low allele frequencies. Concerning associations with 
disease susceptibility it is important to define an appropriate control cohort. The 
individuals of this cohort should be from the same geographic region as the patient 
cohort, to avoid confounding effects such as different disease prevalence, and socio 
economic status of the populations. While selecting the healthy controls it is advisable 
to obtain information on ethnical background, although we are aware that this is 
not always possible due to local guidelines of medical ethical committees. Ethnic 
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differences in the study population might interfere with the analysis of supposed 
associations. Some investigators have demonstrated that the contribution of ethnic 
differences to the variations in the human genome is limited to about 10% (between 
different continents), while the variation within a sample of individuals from the same 
region contributes 84.4% to the total variation.(83) However, it is also known that 
allele frequencies of certain polymorphisms show a different distribution among 
populations with distinct ethnical backgrounds.(11, 19, 75) Preferably, a control 
population with the same genetic and environmental background, which has also 
been exposed to meningococcal species, is considered. Studies including relatives 
of patients as controls, might overcome this problem. In such studies the reported 
and expected inheritance of the different alleles is compared. An issue that is not 
addressed in all studies is Hardy Weinberg Equilibrium (HWE). In the general 
population the genotypes should be in HWE. This means that the observed genotype 
frequencies are in accordance with those expected in Mendelian inheritance. If HWE 
is not reached this means that one of the genotypes (1/1, 1/2, or 2/2) is over- or 
underrepresented in comparison with the other genotypes. If this happens several 
problems might have raised. First, the selection of the control population is biased, 
giving a deviation of the expected genotype frequencies. Secondly, the disequilibrium 
may reveal a technical problem in the genotyping analysis in which one of the alleles 
is preferentially observed, skewing the distribution. Third, it is a coincidence, which is 
more likely to occur in small control populations.
Besides differences in host genetics, one also should consider confounders of 
microbial differences. Read et al. have found that patients infected with serogroup 
C meningococci were more likely to die of infection than those infected with 
other serotypes.(58) Such an event should be considered in a regression model. 
Unfortunately, this correction has not been implemented in all studies. In some studies 
this was not possible due to inclusion of patients with microbiologically unconfirmed 
meningococcal infection.
Another focus of investigation is the interaction of the polymorphisms and the 
cumulative effect on the course of meningococcal disease. These interactions might 
be either synergistic or counteracting. In the IL-1 family synergistic interactions have 
been observed for IL1B -511 and IL1RN 2018.(70) If SNP interactions are present 
a single polymorphism might explain only part of the differences observed, while 
in combination with an, or more than one, additional polymorphism, the relative 
contribution might be different. This might also be expected for polymorphisms in 
PAI1 and TPA. The higher levels of PAI-1 in individuals homozygous for the 4G allele 
will lead to increased inhibition of t-PA. This results in a net prothrombotic state, which 
would also be expected from a low t-PA productive allele. Although an association 
has been found between the PAI1 polymorphism and meningococcal disease, no 
relation was found for the TPA insertion-deletion polymorphism and the disease.(40, 
45-47) The functional consequences for the TPA polymorphism are not clear and lack 
of association might indicate that the insertion deletion polymorphism is not involved 
in t-PA production. On the other hand, the PAI1 4G/5G polymorphism might interact 
with the TPA polymorphism and since no correction was made for this polymorphism 
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with known interaction with meningococcal disease, an association with TPA can 
be missed. However, the increase in PAI-1 concentrations in septic shock is much 
more extensive than the slight increase in t-PA, possibly overruling the effect of 
relatively small differences in t-PA concentrations. By combining multiple genes in the 
coagulation and fibrinolysis pathway an effect on disease severity can be estimated. 
Carriers of FVL, who also have the alleles resulting in the combination of increased 
PAI-1 levels and decreased protein C, t-PA, endothelial protein C receptor, thrombin 
and thrombomodulin concentrations, will have the highest risk of developing vascular 
complications in meningococcal disease. Large patient cohorts are needed to ensure 
sufficient power for such interaction analyses. When polymorphisms are located on 
the same chromosome it is important to consider linkage disequilibrium. Linkage 
disequilibrium addresses the allelic association of pairs of polymorphic loci. If linkage 
disequilibrium is present this means that the alleles are not independently inherited, 
and it should be corrected for. Additionally, one must always consider the possibility 
that disease is not linked to the studied gene, but to another gene in linkage with the 
first. 
When an association is found it is important to look at the clinical relevance of the 
association. Is the polymorphism associated with susceptibility to or severity of 
meningococcal disease? What is the contribution of the polymorphism and might 
it affect therapy? Polymorphisms associated with susceptibility only will not likely 
contribute to changes in therapeutic strategy once an individual has contracted the 
disease, but may influence vaccination strategies. Was the association seen in one 
study or was it seen repeatedly in unrelated patient cohorts? This fact is of special 
interest, since conflicting results have been found for some of the polymorphic loci. 
On the other hand, publication bias can also occur. It can be assumed that studies 
finding no association for a given polymorphism are less likely to be published.
Since the prevalence of meningococcal disease in individual medical centres is low 
and large patient cohorts are required to study the relevance of multiple polymorphisms 
in a reliable way, we advocate collaborative efforts between centres to increase 
statistical power. Data regarding the causative microbes, age and other possible 
confounders should be included in a regression analysis to obtain the ”true” relevance 
of the studied genetic variations. Reported associations should be confirmed in an 
independent patient cohort. The development of high-throughput molecular genetic 
techniques is of great importance in our efforts to unravel the immense complexity of 
the presumed genetic interactions.
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Abstract
Objective. To gain insight into factors that might affect results of future case-control 
studies, we performed an analysis of children with sepsis and purpura admitted to 
the Paediatric Intensive Care Unit (PICU) of Erasmus MC-Sophia Children’s Hospital 
(Rotterdam, the Netherlands). 
Patients and methods. Between 1988 and 2006, all 287 children consecutively 
admitted with sepsis and purpura were included in various sepsis studies. Data 
regarding age, gender, ethnicity, serogroup of Neisseria meningitidis, severity, therapy 
and survival were collected prospectively. These data were pooled into one database 
and analyzed retrospectively. 
Results. The case fatality rate (CFR) from sepsis and purpura was 15.7%. During the 
study period survival improved significantly. Younger age was significantly associated 
with more severe disease and a higher CFR. Children under the median age of 3.0 
years had an increased risk of case fatality (odds ratio 4.3, 95% CI 2.1-9.2; p<0.001). 
Gender was not associated with CFR. However, males did have higher Paediatric 
Risk of Mortality scores, fewer PICU-free days and more presence of shock. The 
course of sepsis and purpura was not related to ethnic origin. A causative organism 
was isolated in 84.3%. N. meningitidis was the major organism (97.5%). Although N. 
meningitidis serogroup B was observed more often in younger children, serogroups 
were not associated with severity or survival. During the study period, the use of 
inotropic agents and corticosteroids changed substantially (less dopamine and more 
dobutamine, norepinephrine and corticosteroids). 
Conclusions. Age and gender are determinants of severity of paediatric sepsis and 
purpura. Survival rates have improved during the last two decades.
Introduction
Sepsis and purpura in children is a clinically distinct disease entity caused by high 
concentrations of microbes and their products. Since the introduction of a vaccine 
against Haemophilus influenzae type b more than 90% of the cases of sepsis and 
purpura in the western world are caused by Neisseria meningitidis.(1-3) The resulting 
disease entity is referred to as meningococcal sepsis. 
Meningococcal sepsis in children develops when the initial host response to the 
infection becomes inappropriately amplified and dysregulated. Clinically, the onset 
is often insidious. After the development of the first petechiae, the patient rapidly 
deteriorates and may subsequently develop shock, disseminated intravascular 
coagulation (DIC) and ultimately organ failure. The severity of these symptoms 
requires immediate therapy.(4, 5) Despite recent advances in therapy, the case 
fatality rate (CFR) remains high and ranges from 4 to 40%.(1, 6-8) The incidence 
of disease is highest among young children (age 0 to 4 years) and adolescents.(1-
3) In the Netherlands meningococcal sepsis occurs in 4.5 per 100,000 inhabitants 
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(2001). Due to the sudden increase in the incidence of meningococcal disease in 
2001 a national vaccination campaign against serogroup C meningococci (2002) was 
implemented among children from 1 to 18 years of age.(9, 10)
In recent years, many studies have focused on the elucidation of the pathogenesis of 
sepsis. However, much about the epidemiology of sepsis in children is still unknown. 
In this paper, we seek to describe the epidemiology of sepsis and purpura in children 
referred to the Paediatric Intensive Care Unit (PICU) of Erasmus MC-Sophia Children’s 
Hospital in Rotterdam, the Netherlands. The aim of this study was to analyze the 
variation in severity and survival of children with respect to age, gender, ethnicity and 
serogroup of N. meningitidis.
Methods
The study was conducted in accordance with the Declaration of Helsinki. Permission 
for the study was obtained from the medical ethics committee of Erasmus MC.
Participants. All children admitted with sepsis and purpura (and/or petechiae) to 
the PICU of the Erasmus MC-Sophia Children’s Hospital since 1988 were included. 
A vast majority of the children were previously included in Rotterdam-based sepsis 
studies.(11-16) Data regarding the remaining children with sepsis and purpura were 
derived from PICU admission records. Informed consent was obtained from parents 
or legal guardians of all children that were included in this study. Children were 
considered to have sepsis when they presented with tachycardia, tachypnea and a 
body temperature of less than 36oC or greater than 38.5oC (rectal).(17) Prospective 
data on all children were collected at various time points in the course of the disease. 
Both laboratory parameters and disease severity scoring systems, like Paediatric Risk 
of Mortality (PRISM) score and predicted death rate (PDR) based on the Rotterdam 
score, were selected as markers of severity of disease.(18-20) Additionally, presence 
of DIC and presence of shock were recorded as markers of severity.(17, 19, 21) The 
number of PICU-free days was determined on day 28 after admission using the date 
of admission and the date of discharge. A non-survivor had 0 PICU free days.
All laboratory parameters, obtained at baseline from an arterial blood sample, were 
collected within 4 hours after admission to the PICU. 
Ethnicity was determined by checking patient information, and if not specified, first 
and surname were checked and ethnicity was determined by means of the combined 
name method.(22) Ethnicity was categorized into Dutch Caucasian, Turkish, 
Moroccan, Hindustani, African descent and other. 
Serogrouping of N. meningitidis isolates was performed at the Netherlands Reference 
Laboratory for Bacterial Meningitis Amsterdam using immunodiffusion with polyclonal 
antisera.(23)
Statistical analyses. Retrospectively, severity and survival of children with sepsis 
and purpura with respect to age, gender, causative organism and ethnicity was 
analyzed using SPSS 11.01 (SPSS Inc., Chicago, IL, USA). Clinical and laboratory 
parameters were included in the analysis only if they were determined in at least 90% 
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of all children.
Mann-Whitney U test, Student’s t test, c2 test and Spearman correlation (rs) were 
used when appropriate. When necessary, variables were log-transformed to obtain 
an approximately normal distribution. For these variables, geometric mean values 
and their 95% confidence intervals (CI) are depicted in text and tables. P values of 
less than or equal to 0.05 were considered statistically significant.
Results
Between August 1988 and June 2006, 287 children with sepsis and purpura were 
admitted to the PICU of the Erasmus MC-Sophia Children’s Hospital. The overall 
CFR was 15.7% (45 children died). Median age at admission was 3.0 years (range 
0.1-17.9 years) (Figure 1). 
Figure 1. Distribution of age at admission in children with sepsis and purpura. The children are subdivided 
according to causative organism. N.f.d., not further defined.
Of the 287 children, 155 (54%) were male and 132 (46%) were female. The male-to-
female ratio was 1.2. The majority of the children were Dutch Caucasians (73.8%). 
Laboratory parameters present at baseline in more than 90% of the children were 
base excess, lactate, C-reactive protein (CRP), fibrinogen, platelet count, leukocytes, 
and glucose.
Survival. Severity of illness was significantly less in survivors when compared to 
non-survivors, both in disease severity scoring systems and laboratory parameters 
(Table 1). Survival was significantly correlated with year of admission (p=<0.05, rs 
0.128), indicating that survival has improved significantly during the study period 
(Figure 2). Gender did not differ between survivors and non-survivors (p=0.15). The 
vast majority of fatal cases died of refractory septic shock (75.6%).
Age. Age was significantly correlated with PRISM-score (p<0.001, rs -0.317), PDR 
(p<0.001, rs -0.321), presence of DIC (p<0.001, rs -0.245), base excess (p<0.001, rs 
0.313), CRP (p<0.05, rs 0.161), fibrinogen (p<0.001, rs 0.301), leukocyte count (p<0.001, 
rs 0.284), thrombocyte count (p<0.01, rs 0.184) and glucose levels (p<0.001, rs 0.296). 
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Table 1. Comparison of disease characteristics between non-survivors and survivors.
1Results represent median (min-max) unless stated otherwise
2p<0.01.
3p<0.001.
4Predicted death rate was based on the Rotterdam score. CI, confidence interval; DIC, Disseminated 
Intravascular Coagulation; PRISM, Paediatric Risk of Mortality.
This indicates that younger children had higher PRISM scores, higher PDR, more 
presence of DIC, lower base excess, lower CRP, lower fibrinogen, lower leukocyte 
count, lower thrombocyte count and lower glucose levels on admission.  
Figure 2. Case fatality rate (CFR) and CFR trend line during the study period.
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Table 1. Comparison of disease characteristics between non-survivors and survivors.
Survivors
1
Non-survivors
Total number of children (%) 242 45
(84.3) (15.7)
Male-to-female ratio 1.1 1.7
Number of children with DIC (%) 174
2
32
2
(75) (97)
N. meningitidis serogroup B (%) 147 (74.2) 28 (73.7)
C (%) 37 (18.7) 7 (18.4)
PRISM score 14
3
23
3
(1  37) (8  44)
Predicted death rate (%)
4
3.1
3
87.4
3
(0  100) (1.1 - 100.0)
Base excess (mmol/L) -7
3
-13
3
(-23  4.4) (-28 - 0.6)
Lactate (mmol/L) 3.7
3
6.6
c
   geometric mean (95% CI) (3.4 - 4.3) (5.8 - 7.4)
C-reactive protein (mg/L) 106
3
53
3
(10  334) (6  226)
Fibrinogen (g/L) 2.8
3
0.9
3
(0.3 - 6.8) (0.2 - 5.4)
Platelet count (x10 /  L)
3
126
3
47
3
(15  475) (13  202)
Leukocytes (x10 /  L)
3
10.6
3
4.7
3
   geometric mean (95% CI) (9.5  11.9) (3.7 - 6.0)
Glucose (mmol/L) 6.3
3
4.3
3
   geometric mean (95% CI) (5.9 - 6.8) (3.6 - 5.3)
1
Results represent median (min-max) unle s stated otherwise
2
p< .01.
3
p< . 01.
4
Predicted death rate was based on the Ro terdam score. CI, confidence i terval; I , i i t  
Coagulation; PRISM, Paediatric Risk of Mortality.Intr vascular
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Median age of children was 3.0 years (range 0.1-17.9 years). Children 3.0 years old 
or younger had a higher CFR (odds ratio 4.3; 95% CI 2.1-9.2, p<0.001) (Figure 3). 
Figure 3. Distribution of age at admission among survivors and non-survivors of sepsis and purpura.
Gender. The median age did not differ significantly between males (2.8 years) and 
females (3.5 years) (p=0.16). Male patients had significantly fewer PICU-free days 
(p=0.04) and higher PRISM-scores (p=0.02) than females. Shock was slightly more 
often present in males than in females (89% versus 80%, p=0.04). CFR and other 
markers of severity of disease did not differ between males and females. Since males 
had higher PRISM scores, but no increased CFR, we analyzed the different variables 
determining the PRISM score. Of these variables, only a trend for lower glucose 
levels in males compared to females was observed (p=0.06).
Ethnicity. The majority of the children were Dutch Caucasians (n = 211, 73.5%). Of 
the remaining 76 children, 12 were Turkish (4.2%), 16 were Moroccan (5.6%), 3 were 
Hindustani (1.1%), 7 were of African descent (2.5%), 7 were designated other (2.5%) 
and in 31 children ethnicity could not be determined (10.8%). No differences with respect 
to severity of disease or case fatality were found between the different ethnic groups. 
Causative organism. A causative organism could be determined in 242 children 
(84.3%), with N. meningitidis being the major causative organism (n = 236 (97.5%), 
 
Figure 4. Number of children with sepsis and purpura due to N. meningitidis per year (since 1988), admitted 
to the PICU of Erasmus MC-Sophia Children’s Hospital (Rotterdam, the Netherlands).
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Figure 4). Of these 236, 175 (74.2%) were N. meningitidis serogroup B, 44 (18.6%) 
were serogroup C, and in 17 (7.2%) the serogroup was not determined (Tables 1 
and 2). Streptococcus pneumoniae was the causative organism in 3 children, 
Staphylococcus aureus in 1 and H. influenzae in 2. Of the remaining 45 children, 43 
children had clinical features of meningococcal sepsis.(3)
Table 2. Incidence of serogroup, serotype and serosubtype of N. meningitidis.
NT, Non-typable.
For logistic reasons the causative organism could not be determined in 2 children. No 
differences with respect to survival, disease severity scoring systems and presence 
of shock were observed between N. meningitidis serogroups B and C. However, the 
median age of children with sepsis and purpura due to serogroup B was lower than 
that of the serogroup C-infected children (2.8 and 6.0 years respectively, p<0.001, 
Table 3). The distribution of serogroup, serotype and serosubtype of N. meningitidis 
in the positive cultures is depicted in Table 2.  
Meningococcal C vaccination campaign and therapy. In 2001 and 2002, a sudden 
increase was noted in the incidence of meningococcal infection in the Netherlands. 
This was caused mainly by serogroup C N. meningitidis. The implementation of the 
meningococcal C vaccination campaign in July 2002 resulted in a sharp decline of
11
Table 2. Incidence of serogroup, serotype and serosubtype of N. meningitidis.
Serogroup Serotype Serosubtype Number Percentage
B 1 P1.4 4 1.8
P1.16 4 1.8
NT 3 1.4
Other 1 0.5
2A 3 1.4
4 P1.4 57 26
P1.6 3 1.4
P1.7 3 1.4
P1.9 4 1.8
P1.10 4 1.8
P1.15 5 2.3
NT 28 12.8
Other 13 5.9
NT P1.1 6 2.7
P1.4 8 3.7
NT 8 3.7
Other 4 1.8
Other 17 7.8
C 2A P1.2 12 5.5
P1.5 9 4.1
P1.7 1 0.5
NT 7 3.2
2B P1.1 1 0.5
P1.2 7 3.2
4 P1.4 3 1.4
NT 2 0.9
Other 2 0.9
NT, Non-typable.
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Table 3. Comparison of disease characteristics based on serogroup of N. meningitidis.
1Results represent median (min-max) unless stated otherwise.
2p<0.001.
3Predicted death rate was based on the Rotterdam score.
4p<0.01.
5p<0.05.
PRISM, Paediatric Risk of Mortality; DIC, Disseminated Intravascular Coagulation; PICU, Paediatric 
Intensive Care Unit.
the number of cases caused by serogroup C (Figure 4). Since 2003, there has not 
been a case of sepsis due to N. meningitidis serogroup C in our hospital. Parallel 
to this, the incidence of serogroup B has declined and is returning to the incidence 
level of before 1989. Before the national meningococcal C vaccination, 248 children 
in our study population were admitted with sepsis and purpura, whereas since the 
vaccination campaign 39 children have been admitted. 
Remarkably, since the implementation of meningococcal C vaccination, no deaths 
have occurred in children with sepsis and purpura admitted to our PICU. The median 
age of the children did not differ significantly before and after vaccination (3.2 and 
2.5 years, respectively, p=0.23, Table 4). Glucose levels were significantly lower 
in the patient group before compared to the patient group after the vaccination 
campaign (p<0.05). Children admitted before the vaccination campaign had 
significantly fewer PICU-free days and more presence of DIC (both p<0.05). The 
PRISM score was not significantly different between patients groups before and after 
the Meningococcal C vaccination campaign. In addition, since 2002, treatment of 
children with meningococcal sepsis at our PICU has changed due to implementation 
of international guidelines.(8) After the vaccination campaign, more children were 
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Table 3. Compari  f disease characteristics based on serogroup f N. meningitidis.
N. meningitidis
1
Serogroup B Serogroup C
Total number of children 175 44
Age in years 2.8
2
6.0
2
(0.1-17.9) (0.1-16.5)
PRISM score 16 14
(1-37) (1-35)
Predicted death rate (%)
3
8.9 4.9
(0  100) (0  100)
Number of children with DIC (%) 128 32
(81) (74)
Number of PICU-free days 24 25
(0  28) (0  27)
Base excess (mmol/L) -8 -8.0
(-21 - 4.4) (-28  3)
Lactate (mmol/L) 4.2 3.5
   geometric mean (95% CI) (3.8 - 4.6) (2.9 - 4.2)
C-reactive protein (mg/L) 82
4
128
4
(6  287) (20  326)
Fibrinogen (g/L) 2.4 2.8
(0.2 - 6.8) (0.3 - 6.6)
Platelet count (x10 /  L)
3
110 113
(15  475) (13  336)
Leukocytes (x10 /  L)
3
8.8
5
12.2
5
   geometric mean (95% CI) (7.6 - 10.1) (9.9 - 15.0)
Glucose (mmol/L) 5.9 6.2
   geometric mean (95% CI) (5.4 - 6.5) (5.5 - 6.9)
1
Results represent edian (min-max) unless stated otherwise.
2
p<0.001.
3
Predicted death rate was based on the Rotterdam score.
4
p<0.01.
5
p<0.05.
PRISM, Paediatric Risk of Mortality; DIC, Disseminated Intravascular Coagulation; PICU, Paediatric Intensive 
Care Unit.
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treated with corticosteroids (18 (9.3%) before versus 15 (42.9%) after; p<0.001) and 
more children were mechanically ventilated (128 (51.8%) before versus 28 (71.8%) 
after; p<0.05) (Table 4). 
Table 4. Comparison of disease characteristics between children with sepsis and purpura before 
and after the national Meningococcal C vaccination campaign (July 2002).
1Results represent median (min-max) unless stated otherwise.
2p<0.01.
3p<0.05.
4Predicted death rate was based on the Rotterdam score.
DIC, Disseminated Intravascular Coagulation; PICU, Paediatric Intensive Care Unit; PRISM, Paediatric 
Risk of Mortality.
In addition, year of admission was significantly correlated with the use of dobutamine 
(p<0.001, rs 0.262), dopamine (p<0.001, rs -0.218), norepinephrine (p<0.001, rs 0.329) 
and corticosteroids (p<0.001, rs 0.245), but not with the use of epinephrine. This 
indicates that during the study period the use of dobutamine, norepinephrine and 
corticosteroids significantly increased in the treatment of sepsis and purpura while 
the use of dopamine significantly decreased (Figure 5).
Discussion
In this mono-centre cohort study of 287 children between 0 and 18 years with sepsis 
and purpura, we found that younger children had more severe disease and an 
increased risk of case fatality. The CFR of sepsis and purpura has improved in recent 
13
Table 4. Comparison of disease characteristics between children with sepsis and purpura before and after
the national Meningococcal C vaccination campaign (July 2002).
Before MenC vaccination
1
After MenC vaccination
Total number of children (%) 248 39
(86.4) (13.6)
Case fatality (%) 45
2
0
2
(18.1) (0)
Age in years 3.2 2.5
(0.1 - 17.9) (0.3 - 13.1)
Number of children with DIC (%) 186
3
20
3
(79.5) (62.5)
Number of PICU-free days 24
3
25
3
(0  28) (0  27)
PRISM 15 20
(1  44) (2  37)
Predicted death rate (%)
4
5.6 8.1
(0  100) (0  100)
Base excess (mmol/L) -7.7 -8
(-28 - 4.4) (-18 - -2)
Lactate (mmol/L) 4.1 4.0
   geometric mean (95% CI) (3.8 - 4.4) (3.3 - 4.8)
C-reactive protein (mg/L) 93 84
(6  326) (25  334)
Fibrinogen (g/L) 2.5 3.2
(0.2 - 6.8) (0.3 - 6.4)
Platelet count (x10 /  L)
3
110 135
(13  475) (25  227)
Leukocytes (x10
3
/ L) 8.9 12.1
   geometric mean (95% CI) (7.9 - 10.0) (9.4 - 15.6)
Glucose (mmol/L) 5.7
3
7.2
3
   geometric mean (95% CI) (5.3 - 6.2) (6.2 - 8.2)
1
Results r resent median (min-max) unless stated otherwise.
2
p<0.01.
3
p<0.05.
4
Predicted death rate was based on the Rotterdam score
DIC, Disseminated Intravascular Coagulation; PICU, Paediatric Intensive Care Unit; PRISM, Paediatric Risk of
Mortality.
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years despite comparable disease severity on admission. Male patients had higher 
PRISM scores and fewer PICU-free days. However, the CFR did not differ between 
males and females. Ethnicity did not influence disease severity and survival. The 
serogroups of N. meningitidis were not related to severity or survival. 
Figure 5. Use of inotropic agents during the study period 1988 to 2006. Some patients received more than 
one inotropic agent; therefore the number of patients in this figure exceeds the number of patients in this 
study (n = 287).
Children with sepsis and purpura admitted to the PICU of the Erasmus MC-Sophia 
Children’s Hospital account for approximately 25% of all paediatric sepsis cases 
in the Netherlands and therefore may provide a representative sample of cases in 
the Netherlands. (National PICU registry, unpublished data) In addition, Rotterdam 
covers an area in the Netherlands (that is the southwest of the Netherlands) in which 
meningococcal disease used to occur frequently. 
In this large cohort of paediatric sepsis and purpura, low age was significantly 
associated with increased severity of disease, higher incidence of DIC and increased 
CFR. Half of the children in our population were younger than 3 years of age. A 
comparison with the literature showed that incidence rates indeed drop after infancy 
and then increase again slightly during adolescence.(1, 9, 24) The increased CFR 
and the more severe disease in younger children may result from the still developing 
immune, coagulation and stress response systems in young children and therefore 
the relative inability to induce an effective immune response to a high load of micro-
organisms such as N. meningitidis.(13, 19)
The CFR due to sepsis and purpura was 15.7% over the past two decades. This is 
in accordance with other large studies reporting case fatality rates of 10.4 to 20%.(7, 
24-26) It must be noted that Jensen et al. and Sharip et al. studied meningococcal 
disease, not specifically paediatric sepsis and purpura.(7, 24)
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N. meningitidis was the causative organism of sepsis and purpura in the vast 
majority of cases. Martin et al. also found that Gram-negative bacteria were the 
predominant causative organisms of sepsis in the US between 1979 and 1987.(27) 
In our study, the incidence of disease due to serogroup B was much higher than 
that due to serogroup C. N. meningitidis and serogroup B was seen more often in 
younger children compared to serogroup C. No differences with respect to severity 
of illness scores and CFR were observed between serogroup B and C. Erickson 
and de Wals suggested a more severe course of serogroup C infections, indicated 
by increased mortality due to serogroup C (14%) compared with serogroup B (7%).
(28) Spanjaard et al. found a CFR in meningococcal sepsis caused by serogroup B 
of 8.1% compared with 7.1% in serogroup C.(29) However, Erickson and de Wals 
studied both meningitis and sepsis in all culture-proven cases of N. meningitidis, and 
Spanjaard et al. studied all culture-proven cases including adults in the Netherlands, 
whereas we studied paediatric cases of sepsis and purpura.(28, 29)
Since the implementation of the meningococcal C vaccination in July 2002, there 
has not been a fatal case of sepsis and purpura in our PICU. Because severity of 
disease before and after the implementation did not differ between the two groups, 
the increased survival may have resulted from improved treatment strategies.(8) 
International treatment guidelines were implemented at that time, health care workers 
received additional training, and public awareness increased, resulting in a decreased 
patient delay. Furthermore, we observed a change in the choice of inotropic agents 
used since 2002. It must be noted that the number of children included since 2002 is 
low. However, these observations do warrant further research in a prospective study.
Gender was not associated with CFR from sepsis and purpura, although males did 
have significantly more severe disease, based on the PRISM score and fewer PICU-
free days, compared to females. Bindl et al. found a male-to-female ratio of 1.7 in 
sepsis patients aged 1 week to 8 years with severe sepsis and septic shock, whereas 
we observed a male-to-female ratio of 1.2.(30) However, in those cases caused by N. 
meningitidis, which is the major causative organism in our study, males and females 
were equally represented among non-survivors. Watson et al. and Martin et al. also 
found a predisposition for male gender in sepsis, but they did not specify the male-to-
female ratio in sepsis caused by N. meningitidis.(26, 27)
Due to the small number of children in the different ethnic groups, we may not have 
been able to detect differences between the different ethnic groups with respect to 
severity or case fatality of sepsis and purpura as of yet. In addition, during the 18-
year study period the dynamics of the Dutch population (especially in Rotterdam) 
underwent changes, which may not be reflected in this study. Rosenstein et al. 
proposed a predisposition for sepsis in children of African descent.(1) Sharip et al. 
found an age-adjusted increased risk of case fatality in individuals of African descent 
compared to Caucasians and other ethnic groups.(24)
A possible limitation of our study may be that the serotypes of N. meningitidis 
were not determined in all children with meningococcal sepsis. Due to the rapidly 
progressive nature of this disease, it is possible that we did not include a number of 
the most severe cases because of case fatality before admission or referral to the 
Erasmus MC-Sophia. On the other hand, the fact that only children with sepsis and 
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purpura admitted to the PICU were included, this may have resulted in a skewed 
representation of all children with sepsis and purpura (that is, children with relatively 
mild disease admitted to a general ward).
Conclusion
The CFR in this study was 15.7%. Age was the most important predictor of severity 
and case fatality of sepsis and purpura. Male gender was associated with higher 
PRISM scores and fewer PICU-free days, but no differences in CFR were seen. N. 
meningitidis was the causative organism in the vast majority of cases. No differences 
between N. meningitidis serogroup B and C with respect to disease severity scores 
and case fatality were observed. Ethnicity was not associated with the course of 
sepsis and purpura. In future studies investigating effects on severity and survival 
of sepsis and purpura, age and gender should be taken into account. The possible 
effect of different choice of inotropic agents warrants further investigation. Also, other 
possible differences between male and female sepsis patients should be investigated. 
With the changing demography in the Netherlands (especially in the Rotterdam area) 
differences between ethnic groups require further examination.
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Introduction
Sepsis is a significant healthcare problem both in industrialised and developing 
countries. In the United States the incidence of disease is 56 and 240 per 100.000 
per year in children and adults respectively. In adults underlying disease is present 
in 83%. Approximately 50% of the children have underlying diseases. Annual total 
costs of sepsis in the United States are estimated at $2 billion in children and $17 
billion in adults.(1, 2) The major pathogens causing severe sepsis and septic shock 
are N. meningitidis, S. pneumoniae, Group A α- and β- haemolytic Streptococci and 
Staphylococcus aureus. Group B Streptococci play an important role in neonatal 
sepsis, while Capnocytophaga canimorsus is occasionally reported after dog bites. 
Before the vaccination era, Haemophilus influenzae was a major cause of sepsis in 
infants and young children.
Pathogenesis of sepsis
The severity of sepsis is partly dependent on virulence characteristics of the pathogen. 
Initially the innate immune system plays a key role in the recognition of microbial 
molecules. Signalling through Toll-like receptors (TLRs), of which ten different types 
have been described, each recognizing specific molecules, results in activation 
of NFκB.(3, 4) NFκB is a transcription factor that induces cytokine expression 
and activation of immune cells from both the innate and the specific lineages. In 
meningococcal infection lipopolysaccharide (LPS) of the bacterial cell wall is the 
major mediator of TLR4 and TLR2 activation (Figure 1). In addition, LPS induces 
extensive activation of the complement cascade and also, signals through the recently 
discovered TREM-1 receptor on myeloid cells.(5) This results in the recruitment of 
macrophages, opsonophagocytosis and lysis of pathogens. LPS levels in patients 
with meningococcal sepsis are associated with severity of disease and mortality. 
Another important pathway in the pathophysiology of sepsis is the tissue factor 
mediated activation of coagulation. In combination with attenuation of fibrinolysis due 
to high levels of plasminogen activator inhibitor (PAI)-1, an anti-fibrinolytic mediator, 
this results in a net procoagulant state.
In patients with sepsis the endothelium becomes activated and apoptosis is induced. 
This leads to containment of infection, when only a local inflammatory response is 
present. However, in systemic infection generalised endothelial dysfunction develops 
manifesting itself by an inappropriate vascular tone, increased vascular permeability, 
endothelial cell apoptosis and diffuse intravascular coagulation.(6-8)
Different models explaining disease
The immune response in (meningococcal) sepsis evolves over time and is 
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characterised by an early and a late phase. Different models have been proposed 
seeking to increase the understanding of the disease process. Hotchkiss et al. delineate 
three patterns of immune response in patients with sepsis. Initially healthy persons 
with meningococcal sepsis undergo a vigorous inflammatory response followed by 
the secondary development of a hypoimmune state with a predominant activation 
of anti-inflammatory mediators. The authors also refer to another pattern of immune 
response mainly occurring in adults with severe underlying diseases. These patients 
have a diminished hyperimmune response or a predominant hypoimmune response 
on pathogens or their products.(7) Anti-inflammatory therapies may be detrimental in 
subjects with a hypoimmune response as has been suggested from work in animal 
models. Interestingly cytokine and endotoxin levels in patients with meningococcal 
sepsis decrease rapidly after the initiation of antibiotic and intensive care therapies. 
The hypoimmune state in these patients may be present within several hours instead 
of days as suggested by Hotchkiss and colleagues.
Netea et al. propose an alternative model. In the first contact with the host, microbes 
either induce a large amount of pro-inflammatory cytokines, leading to effective 
killing and recovery of the patient, or induce a poor initial cytokine response with 
an ineffective host defence. In the latter case, the microbial load expands greatly, 
Figure 1. Activation of the TLR4 receptor pathway through interaction with LPS. Interaction of TLR4 with 
LPS results in the stimulation of a cascade causing activation of NFκB. NFκB is a transcription factor that 
is involved in the activation of transcription of numerous cytokines and IκB. IκB inhibits the function of 
NFκB. 
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leading to massive production of cytokines and septic shock. Immune paralysis and 
death may follow.(9) However, there are many patients especially adults who initially 
have a low cytokine response and who do not show an increase of host defence 
mechanisms at any point of time. In these patients failure to induce an immune 
response possibly contributes to disease. 
Different mechanisms are involved in the transfer from a pro- to anti-inflammatory 
immune pattern. A shift from Th1 to Th2 response results in an increase of anti-
inflammatory cytokines. Second, anergy, defined by a decreased Th1 function without 
increased Th2 cytokine production, can occur. This may be induced by apoptotic cells, 
which have an immunosuppressive effect. Stress mediated endogenous release of 
glucocorticoids may induce apoptosis. Low levels of CD4 T cells, B cells and dendritic 
cells have been observed in the spleen of patients with sepsis. This observation is 
consistent with anergy. In addition, loss of MHC class II and costimulatory molecule 
expression on macrophages can prevent appropriate antigen presentation resulting 
in an impaired immune response.(7)
The central role of protein C
The severe deficiency of protein C is a critical component in the development of 
thrombosis in patients with purpura fulminans. Protein C is an anticoagulant that is 
normally present in an inactive form. For activation, thrombomodulin, thrombin and 
the endothelial protein C receptor are required. The serum levels of these factors 
are significantly decreased in children with sepsis. After activation, protein C needs 
its cofactor protein S to conduct its anticoagulatory function, through inhibition of 
factor Va and factor VIIIa. Plasminogen activator inhibitor 1 (PAI-1) inhibits fibrinolysis 
through inhibition of plasmin formation. Inhibition of PAI-1 by protein C therefore 
results in increased fibrinolysis. 
Activated protein C also decreases inflammation by inhibition of thrombin generation 
and the reduction of apoptosis (Figure 2).(7) Children with meningococcal sepsis have 
extremely low protein C concentrations on hospital admission, which are associated 
with an increased risk for morbidity and mortality.
Bernard et al. examined the efficacy and safety of recombinant human activated 
protein C (APC) in the treatment of severe sepsis in 1690 adults. Patients at high risk 
for bleeding were excluded. Patients received either a placebo or APC at 24 μg per 
kilogram of body weight per hour for a duration of 96 h. The investigators observed a 
significant decrease in mortality in the APC treated group versus the placebo group 
(30.8 to 24.7%). The risk of bleeding was slightly higher in the APC treated patient 
group (3.5% vs. 2.0%, p=0.06).(10)
Faust et al. investigated the activation process of protein C in children with 
meningococcal septic shock using plasma and skin biopsy samples. They found a lower 
expression of the endothelial protein C receptor and the endothelial thrombomodulin 
in patients with meningococcal sepsis than in controls, both in vessels with and in 
vessels without thrombosis. Plasma levels of thrombomodulin were increased while 
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plasma levels of protein C antigen, protein S antigen, and antithrombin antigen were 
lower in patients compared to controls. Administration of protein C to two patients did 
not lead to increased APC levels.(11)
Figure 2. Actions of Protein C. EPCR, Endothelial protein C receptor; T, Thrombin; TM, Thrombomodulin; 
PC, protein C; APC, activated protein C; PS, protein S. Activated protein C has several functions. First, 
it decreases coagulation through inhibition of fVa and fVIIIa. Protein C also decreases inflammation and 
apoptosis. A fourth effect of activated protein C is the increase of fibrinolysis through inhibition by PAI-1.
In contrast, in a phase II/III study including 38 children in three treatment groups and 
one placebo group, de Kleijn et al. did find activation of protein C after administration 
of protein C concentrate. 
The dosage levels used in the three treatment groups were 50, 100 and 150 IU/kg 
respectively. The treatment regimen was 3 days, 4 times daily or 4 days, 2 times daily 
in a bolus injection. Protein C levels were measured at different time points before 
and after infusion. Initially a dose-dependent increase in protein C was observed 
followed by a decline to 0.5-1 U protein C per ml in 6 hours. APC levels increased 
upon infusion of protein C concentrate. Additionally a dose dependent effect on 
coagulation parameters was observed.(12)
The data generated in adults and in children all point to a crucial role of APC in 
the pathogenesis of (meningococcal) sepsis and justify further phase 3 prospective 
randomised studies with PC or APC in children with meningococcal sepsis. 
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Anti-inflammatory and other therapies in patients with severe 
sepsis
In addition to the use of (activated) protein C many other therapies have been 
investigated mainly in adults with sepsis (Table 1). 
Table 1. Anti-inflammatory and other therapies in patients with severe sepsis.
1A + indicates a positive effect of therapy in the patient group. A – indictes no effect of therapy in the patient 
group. A +/- indicates conflicting results between different studies.
Physiologic dosages of corticosteroids have been administered to critically ill patients 
with a positive result, but careful patient selection has to take place to identify those 
who are most likely to benefit.(13) High doses of corticosteroids do not improve 
survival in sepsis patients and may even result in secondary infections. Intensive 
insulin therapy has recently been shown to improve survival and lower morbidity 
in critically ill adults.(14) The mechanism of the protective function of insulin may 
be the recovery of the phagocytic function of neutrophils which is impaired due to 
hyperglycaemia. Another potential mechanism is the anti-apoptotic effect of insulin. 
Anti-TNF-α antibodies have been successful in animal sepsis models in which TNF-α 
was used to induce sepsis. In adults and children with sepsis there was no beneficial 
effect. Levin et al. studied the effect of rBPI21, a recombinant N-terminal fragment 
of BPI which has LPS neutralizing capacities, in a phase III, randomized clinical 
trial in children with severe meningococcal sepsis. Patients receiving the drug had 
significantly less severe complications. A trend for decreased mortality was observed, 
but this was not significant.(15) However, it is likely that the ability to observe potential 
drug efficacy was decreased because of the rapid progression of meningococcal 
sepsis, and delays in study drug administration imposed by transport and study 
procedures. 
In adults, early goal-directed therapy, aiming at balancing oxygen delivery with 
oxygen demand, resulted in a decreased mortality (46.5 vs. 30.5%) compared to the 
standard treatment, in severe sepsis patients.(16)
Data from Dutch investigators show that 50% of the deaths in patients with 
meningococcal sepsis occur within the first 12 h after admission to a hospital or an 
intensive care unit, whilst 80% of all deaths occur within the first 18 h. This indicates 
that further improvements in the outcome of therapy can only be made in these first 
Table 1. A i i flammatory and other therapies in patients with severe sepsis.
Therapy Effect
1
Corticosteroids +/-
Anti-endotoxin antibodies (HA-1A, BPI) -
TNF-antagonists -
IL-1 receptor antagonists -
PAF antagonists -
Recombinant GCSF -
Ibuprofen -
Activated protein C +
TFPI, AT3 -
Insulin +
Early therapy to treat cellular oxygen deficit +
1
A + indicates a positive effect of therapy in the patient group. A – indictes no effect of therapy in the patient group. A +/-
indicates conflicting results between different studies.
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hours after hospital admission. This is confirmed by the fact that improvements in 
initial management of patients with meningococcal disease at referring hospitals, use 
of mobile intensive care service, and centralization of care resulted in a decreased 
mortality rate from 23% in 1992/93 to 2% in 1997 in a specialist unit in the United 
Kingdom. Severity of disease remained the same during the decade of the study.
(17)
Genetic polymorphisms and association with susceptibility, 
severity and outcome of meningococcal sepsis
Complement deficiencies and defects in sensing or opsonophagocytic pathways, like 
the rare TLR4 single nucleotide polymorphisms (SNPs) and combinations of inefficient 
variants of Fcγ-receptors, appear to play a major role in genetically determined 
susceptibility.(18-22) Individuals encountering a pathogenic meningococcal strain for 
the first time, not having specific antibodies are at risk for development of a severe 
meningococcal infection. FCGR2a and PAI1 polymorphisms clearly have a significant 
effect on the severity of meningococcal infections. (23-25) SNPs in properdin, PAI1 
and combinations of the -511C/T SNP in IL1B and the +2018C/T SNP in ILRN have 
also significant effects on outcome.(23, 24, 26, 27) Conflicting results were found for 
the effect of the -308G/A promoter polymorphism in TNFA.(26, 28, 29) This may reflect 
differences in group definitions between studies or the influence of additional SNPs in 
the TNFA promoter that, like IL6, can form haplotypes representing different cytokine 
production capacity.(30) For several SNPs, a supposed effect on susceptibility, 
severity or outcome of disease has not yet been independently confirmed.
PAI1 4G/5G promoter polymorphism: An example of a clinically 
relevant genetic marker for disease
PAI-1 is responsible for the inhibition of fibrinolysis both directly and indirectly through 
inhibition of t-PA. The gene encoding PAI-1 has several polymorphic loci, including a 
3’-HindIII site, a CA(n) repeat in intron 3 and a 4G/5G insertion deletion polymorphism 
at -675 in the promoter. PAI-1 activity has shown to be significantly higher in control 
subjects homozygous for the 4G allele than in subjects homozygous for the 5G allele.
(31) The production of PAI-1 mRNA after IL-1 stimulation appeared to be higher in 
HepG2 cells bearing the 4G allele.(32) In patients with meningococcal sepsis the 
levels of PAI-1 are related to severity of disease, outcome, cytokine levels, acute 
phase proteins and coagulation parameters.(33) In non-survivors PAI-1 levels are 1.9 
times higher for the same TNF-α levels than in survivors.(34) TNF-α induces PAI-1 
production. In children suffering from meningococcal disease a relationship has been 
observed between genotype, PAI-1 levels and outcome of disease. The subjects with 
the 4G homozygous genotype had higher PAI-1 levels and an increased risk of death. 
No association was observed with severity of disease.(23)
 Sepsis syndrome in children 79
A similar study performed by Westendorp et al. showed a higher incidence of the 
5G/5G genotype among relatives of patients with meningitis. Patients whose relatives 
were carriers of the 4G/4G genotype had a six-fold higher risk to develop septic 
shock than meningitis.(25) In a recent study including 510 UK paediatric patients, 
210 parents and 155 UK Caucasian controls, no association was found between 
the 4G/5G polymorphism and susceptibility. In patients with meningococcal sepsis 
the relative risk of death was 2.9 for the 4G homozygous patients compared to the 
combined 4G/5G and homozygous 5G genotypes. In survivors the risk of developing 
vascular complications was significantly higher in the patients homozygous for the 
4G allele.(24)
In adult patients suffering from sepsis after severe trauma an association was 
found between mortality and the PAI1 4G/5G polymorphism and polymorphisms in 
IL6, TNFB and IL1B. Patients with a combination of alleles that individually were 
associated with survival had the lowest mortality risk while, patients having multiple 
“bad outcome” alleles had increasing mortality risk, being the highest in patients 
having only mortality associated alleles.
These findings in combination with the data from Haralambous et al. suggest that 
host genetic make up contributes over one third to the susceptibility to meningococcal 
disease and imply that genetic studies in patients with sepsis may contribute toward 
improvements in research, diagnosis and care.(35)
Conclusions
The question asked in our title was “Sepsis syndrome in children: Can we do better?” 
And if so, how can we improve the case fatality rate (CFR) in children with sepsis?
Improved health care delivery certainly may result in a reduction of the CFR from 
paediatric meningococcal disease from 23% to 2% as has been shown by the 
infectious disease and intensive care groups in St Mary’s Hospital in London.(17) 
Early goal-directed therapy also reduces CFR from sepsis in adults.(16) Therefore, a 
better selection of patients and a more rapid intervention by experimental therapies 
may potentially further improve the CFR. Different interventions thus far have been 
associated with conflicting results. One must however consider that sepsis is a 
heterogeneous disease in which many interlinking pathways are involved. Parallel 
intervention in multiple components of the inflammatory and coagulation pathways 
may lead to better results. Also targeting of non-redundant components such as 
apoptosis factors or NFκB may in the future be beneficial. However, this approach 
may also invoke unwanted effects due to the wide spectrum in gene activation for 
which NFκB is responsible. Use of genetic diagnostic tests can help to identify 
patients who would benefit most from expensive experimental drugs such as protein 
C. Finally, there is an urgent need for clinical trials in children to evaluate the use of 
APC or PC.
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Abstract
Objective. The pathogenesis of meningococcal infections involves activation of the 
complement system, pro- and anti-inflammatory mediators, antimicrobial peptides 
and apoptosis. We hypothesize that variations in genes encoding these products are 
involved in the susceptibility to and severity of paediatric meningococcal infections.
Patients and methods. Polymorphisms in PARP, C1INH, IL4, IL10 and IL1B, DEFA4 
and DEFB1 were analyzed in two independent Caucasian case control cohorts from 
the UK and the Netherlands and in a family based TDT cohort from the UK
Results. In the UK case control cohort the DEFB1 -44 G/G homozygous genotype 
was overrepresented in patients with meningococcal disease compared to the 
G/C and C/C genotypes when combined (OR 1.57, 95% CI 1.12-2.20). The TDT 
analysis did not confirm this, but did find an association and linkage of the IL4 -524 
and the C1INH 480 polymorphisms with susceptibility to meningococcal infection. 
Haematological failure was present more often in UK patients with the DEFB1 -44 
G/G genotype compared to the C allele carriers (OR 2.17, 95% CI 1.22-3.85). 
Conclusions. Additional studies are necessary to elucidate the conflicting results 
obtained for the DEFB1, IL4 and C1INH polymorphisms and their role in susceptibility 
to and severity of meningococcal disease.
Introduction
Meningococcal infection is characterized by an imbalance between pro- and anti-
inflammatory processes. The hyper-inflammatory response may result in (multiple) 
organ dysfunction and even death. The European case fatality rate is approximately 
8%.(1) Different pathways including molecules involved in microbial recognition, 
pro- and anti-inflammatory cytokines, the complement system, apoptosis related 
molecules and coagulation and fibrinolysis are involved in the immune response 
against meningococci. Increasing interest has developed in the role of host genetic 
polymorphisms in infectious diseases including meningococcal infection.(2)
Human β defensins are thought to be broad acting antimicrobial peptides that are 
constitutively expressed in epithelial cells.(3) In addition to antimicrobial action, 
chemotactic activity has been reported.(4) Since β defensin 1 expression is reported 
to be increased upon stimulation with lipolysaccharides (LPS) a major component 
of the meningococcal cell wall, genetic variation in the gene encoding β defensin 
1 (DEFB1) may contribute to the susceptibility to meningococcal infections.(5) In 
addition α defensins are known for their antimicrobial action. They are expressed by 
neutrophils. One of these peptides, α defensin 4, was reported to also inhibit ACTH 
induced corticosteroid expression in rats.(6) Adrenal insufficiency is known to play a 
role in severe meningococcal sepsis.(7)
The complement system is important in the defence against meningococcal infections 
as may be illustrated by the increased susceptibility to infection in patients with 
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deficiencies of complement factors.(8) Over-activation of the complement cascade is 
prevented by the serine protease C1 inhibitor (C1-Inh), which is an important molecular 
regulator of the human complement system. This multifunctional protein also inhibits 
activity of contact system proteases, such as kallikrein and blood coagulation factor 
XII, and is involved in endothelial binding of leukocytes.(9-11) Recently we observed 
that a genetic polymorphism resulting in a valine to methionin substitution at amino 
acid position 480, was associated with S. aureus nasal carriage.(12) The role of 
this complement component polymorphism in meningococcal disease has not been 
studied.
Upon activation of the immune system a large variety of cytokines, both pro-
inflammatory (TNF-α, IL-6 and IL-1β) and anti-inflammatory (IL-10, IL-4) are produced, 
resulting in a net pro-inflammatory action. Previously, the IL4 -524 C allele was found 
to be associated with decreased transcriptional activity in reporter gene studies and 
carriage of the C allele is associated with a significantly lower serum concentration 
of IL-4.(13, 14) In addition, polymorphisms in the IL10 promoter region have been 
associated with altered expression levels.(15) Apoptosis is thought to play a role in 
the immune and inflammatory response in sepsis.(16) Poly (ADP-ribose) polymerase 
(PARP) plays a role in inflammation and apoptosis and is involved in maintaining 
genomic stability of cells upon oxidative stress.(17) The PARP 762Ala variant has 
recently been found to be associated with reduced activity after H2O2 exposure.(18)
We hypothesized that polymorphisms in promoter or coding regions of DEFB1, DEFA4, 
C1INH1, IL4, IL10, IL1B and PARP may be involved in meningococcal infection 
susceptibility and severity. We investigated this hypothesis in three independent 
populations from the United Kingdom (UK) and the Netherlands. 
Methods
Participants. Data from three separate cohorts of patients with meningococcal 
disease were collected and combined.
Imperial College (IC) cohort. Children with meningococcal disease who were admitted 
to the St.Mary’s Hospital between 1992 and 2002 were eligible for the study (n = 439; 
364 Caucasian, 75 non-Caucasian). Ethical approval was obtained. Children were 
enrolled after informed consent was given by their parents or guardians. Patients 
were diagnosed with meningococcal meningitis, sepsis or a combination of sepsis and 
meningitis. Disease severity was measured using disease severity scoring systems 
including the platelet and neutrophil counts (PN) product, the revised paediatric 
index of mortality (PIM2) score and its derived predicted death rate, and the Glasgow 
meningococcal septicaemia prognostic score (GMSPS).(19-21) In addition, failure of 
organ functions was assessed as previously described and outcome, alive or dead, 
was recorded.(22) Ethnicity, gender and age at onset of disease were recorded.
Meningitis Research Foundation (MRF) cohort. UK survivors of meningococcal 
disease (n = 104; 101 Caucasian, 3 non-Caucasian) were enrolled via the MRF 
between 1996 and 1999. There was no overlap between the IC and MRF cohort.
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Erasmus MC Sophia (EMC) cohort. This cohort consisted of 101 paediatric patients with 
meningococcal sepsis (85 Caucasian, 16 non-Caucasian) admitted to the paediatric 
intensive care unit (PICU) of the Erasmus MC Sophia (Rotterdam, the Netherlands) 
between 1988 and 2005. These patients had been enrolled in meningococcal 
sepsis studies.(7, 23-26) All studies have been approved by the ethical committee 
of the Erasmus Medical Centre and informed consent was obtained from parents 
or guardians. Inclusion criteria (tachycardia, tachypnea, rectal body temperature < 
36°C or > 38.5°C and petechiae) were in accordance with recommendations of the 
International Paediatric Sepsis Consensus Conference.(22) Clinical data, severity 
scores (PRISM and Rotterdam score based predicted death rate) and laboratory 
parameters were collected at study entry and at several time-points during the 
course of disease, as previously defined.(27, 28) The number of PICU free days was 
determined on day 28 after admission.
UK Caucasian controls. Healthy Caucasian, age matched unrelated contacts of 
patients at the time of meningococcal disease onset were collected throughout the 
UK (n = 242). Controls were enrolled via both the hospital and the MRF patients. For 
family based transmission disequilibrium test (TDT) analysis blood for DNA extraction 
was also collected from parents of patients.
Dutch Caucasian controls. Caucasian controls (n = 463) were derived from the Dutch 
Blood bank Sanquin and included healthy adult donors from the south west region of 
the Netherlands.
DNA isolation and genotyping. DNA was isolated from blood samples using 
standard techniques (QIAamp DNA blood Mini, Midi and Maxi kits, Qiagen, Crawley, 
UK). Single base extension analysis was used to genotype PARP Val762Ala 
(T/C; rs1136410), C1INH Val480Met (G/A; rs4926), IL4 C-524T (rs2243250), IL10 
G-1082A (rs1800896), IL10 C-819T (rs3021097) and IL1B C-31T (rs1143627) (http://
www.ncbi.nlm.nih.gov/SNP/). In brief, the genomic region of interest was amplified 
using PCR. After purification a single base extension was performed using a primer 
ending one nucleotide prior to the single nucleotide polymorphism (SNP) location. 
Up to three SNPs were analyzed in one multiplex assay. A poly-T-tail attached to the 
primer combined with the use of a Liz size marker served to distinguish SNPs in the 
multiplex analysis.
Two polymorphisms in 3’ UTR region of α-defensin (DEFA4) A/G (rs736227) and in the 
promoter region of human β defensin (DEFB1) G-44C (rs1800972) were genotyped 
using Taqman analysis. Primer and probe sequences are available on request. All 
genotypes were annotated independently by two investigators who were blinded for 
the clinical data. Only when identical genotypes were assigned by the investigators 
was the individual included in the analysis. This resulted in a different number of 
individuals for the various polymorphisms analysed.
Study design and statistical analysis. Both susceptibility and severity analyses 
were performed. Susceptibility to meningococcal infection was assessed comparing 
the Caucasian IC and MRF (combined together as “UK cohort”), with the UK control 
samples and Caucasian EMC patients with the Dutch controls. Non-Caucasian UK 
samples were only included in the family based TDT. In the TDT test an additional 
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100 patients (26 from IC and 74 from MRF) and relatives were included of whom 
ethnicity was unknown, this resulted in a total of 148 nuclear families available for 
TDT analysis. Severity analysis was performed on the IC and EMC Caucasian cohorts 
separately (n= 280 and 85, respectively).
Susceptibility analyses. Three independent analyses, two case control (UK and 
Dutch) and a family based TDT, were carried out. Case control studies consisted of 
Caucasian individuals only, whereas the TDT analysis included both Caucasian and 
non-Caucasian families. There was no overlap in patients and controls between case 
control and TDT analysis. Verification of Hardy-Weinberg equilibrium of genotypes 
was performed using the c2 test (1df). The case-control analyses were performed 
using SPSS 11.5. In the TDT analysis the transmission rate of the separate alleles 
from the parents to the affected offspring was calculated in 148 nuclear families using 
FBAT v 1.7.3.(29) A significant increase in the transmission of an allele above the 
expected indicates association and linkage to meningococcal disease, and is more 
powerful at locating true variants that have a role in disease susceptibility than case 
control studies where limited numbers of cases and controls are used.
Severity analysis. In the IC cohort clinical diagnosis (sepsis, meningitis, or mixed 
disease), actual mortality, predicted mortality (from PIM score) and the presence of 
organ failure were analyzed with respect to the different polymorphic genotypes.(22)
In the EMC cohort only patients admitted to the Paediatric Intensive Care Unit (PICU) 
requiring an arterial line were included. No analysis on differing clinical diagnosis was 
possible as no patients with meningitis only were included in the cohort. Predicted 
mortality (from the Rotterdam score), actual mortality, PRISM score, the number of 
PICU free days at day 28 after admission, need of ventilation, and presence of shock 
or disseminated intravascular coagulation were analyzed with respect to the different 
polymorphic genotypes. All analyses were performed using SPSS 11.5. Odds ratios 
were determined using logistic regression and nonparametric analyses were carried 
out using Kruskal-Wallis and Mann-Whitney U tests. P values smaller than 0.05 were 
considered significant.
Results
Comparison of UK Caucasian patients collected in the IC and MRF cohorts showed 
no statistical difference in the genotype distribution of the polymorphisms tested 
(data not shown). For this reason these two cohorts were combined for susceptibility 
analysis in the UK samples.
Susceptibility to meningococcal disease. Only the DEFB1 promoter genotype 
distribution was significantly different between patients and controls in the UK 
samples (Table 1). The DEFB1 -44 G/G genotype was overrepresented in patients 
compared to the G/C and C/C genotypes combined (OR 1.57, 95% CI 1.12-2.20). No 
significant differences between patients and controls were observed for any of the 
polymorphisms tested in the Dutch samples.
The TDT found no increased transmission of either allele (n = number of informative 
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nuclear families) of the PARP 762 (n = 28), IL1B -31 (n = 72), IL10 -1082 (n = 62), 
IL10 -819 (n = 40), DEFA (n = 72) and DEFB1 (n = 69) polymorphisms, indicating 
no linkage or association to meningococcal disease susceptibility. However, the 
IL4 -524 C allele was transmitted more often from parents to affected patients than 
expected (Z=2.60, p=0.009, 70 informative transmissions: C allele transmitted 57 
times). In addition the C1INH 480 Val allele was transmitted more often from parents 
to affected patients than expected (Z=2.53, p=0.01, 132 informative transmissions: 
Val allele transmitted 101 times). These results indicate evidence for both association 
and linkage of the IL4 -524 and the C1INH 480 polymorphisms with susceptibility to 
meningococcal infection.
Table 1. Analysis of SNPs in MRF and IC patient cohorts.
1c2.
Severity of meningococcal disease.
UK patients (IC and MRF cohorts). A total of 280 Caucasian patients of whom 140 
(50%) were male were included in the severity analysis. The median age (min-max) 
was 3.13 (0.08-19.83) years. Twelve (4.3%) patients died. In the UK samples the 
DEFB1 -44 G/G genotype was underrepresented in non-survivors. However, this 
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Table . nalysi  of SNPs in MRF and IC patient cohorts.
Caucasian UK samples Caucasian Dutch samples
SNP Controls
n (%)
Cases
n (%)
p
1
OR crude Controls
n (%)
Cases
n (%)
p
1
OR crude
PARP 762
Val/Val vs.
Val/Ala and
Ala/Ala
Val/Val vs.
Val/Ala and
Ala/Ala
Val/Val 137 (70) 278 (75) 0.41 1.29 (0.88-1.89) 299 (67) 61 (73) 0.52 1.33 (0.79-2.23)
Val/Ala 55 (28) 88 (24) 140 (31) 22 (26)
Ala/Ala 4 (2) 5 (1) 10 (2) 1 (1)
IL4 -524
C/C vs. C/T and
T/T
C/C vs. C/T and
T/T
C/C 164 (78) 283 (73) 0.31 0.75 (0.50-1.11) 339 (74) 63 (74) 0.28 0.98 (0.58-1.66)
C/T 44 (21) 99 (25) 112 (24) 18 (21)
T/T 2 (1) 7 (2) 9 (2) 4 (5)
C1INH 480
Val/Val 120 (56) 206 (53) 0.54 1.19 (0.61-2.35) 255 (55) 51 (60) 0.69 1.45 (0.49-4.30)
Val/Met 80 (37) 160 (41) 1.39 (0.70-2.78) 176 (38) 30 (35) 1.24 (0.41-3.77)
Met/Met 16 (7) 23 (6) 1 29 (6) 4 (5) 1
IL1B -31
C/C 22 (11) 41 (11) 0.75 1 57 (13) 10 (12) 0.84 0.88 (1.41-1.87)
C/T 94 (45) 162 (42) 0.93 (0.52-1.65) 214 (47) 37 (44) 0.86 (0.53-1.42)
T/T 92 (44) 182 (47) 1.06 (0.60-1.89) 185 (41) 37 (44) 1
Il10 -1082
G/G 56 (27) 89 (24) 0.61 0.79 (0.48-1.29) 123 (27) 21 (26) 0.55 1.18 (0.59-2.34)
G/A 108 (52) 200 (53) 0.92 (0.60-1.41) 219 (48) 44 (54) 1.38 (0.76-2.53)
A/A 44 (21) 89 (24) 1 117 (26) 17 (21) 1
IL10 -819
C/C 122 (61) 234 (62) 0.70 1.41 (0.63-3.16) 283 (62) 49 (62) 0.97 0.92 (0.37-2.33)
C/T 68 (34) 131 (35) 1.41 (0.62-3.24) 145 (32) 24 (30) 0.88 (0.33-2.34)
T/T 11 (6) 15 (4) 1 32 (7) 6 (8) 1
DEFA4 3’
UTR
A/A 109 (49) 170 (45) 0.56 0.95 (0.56-1.61) 114 (48) 32 (49) 0.37 0.69 (0.31-1.54)
A/G 85 (38) 161 (43) 1.15 (0.67-1.98) 98 (41) 22 (34) 0.55 (0.24-1.28)
G/G 28 (13) 46 (12) 1 27 (11) 11 (17) 1
DEFB1 -44
G/G vs G/C and
C/C
G/G vs G/C and
C/C
G/G 132 (58) 263 (68) 0.03 1.57 (1.12-2.20) 143 (61) 35 (54) 0.55 0.73 (0.42-1.28)
G/C 82 (36) 105 (27) 81 (35) 27 (42)
C/C 14 (6) 17 (4) 9 (4) 3 (5)
Chi square.
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did not reach significance (OR 0.33, 95% CI 0.10-1.09 when compared to C allele 
carriers) (Table 2). Haematological failure (defined as a platelet count < 80,000/mm3, 
or an international normalized ratio > 2: disseminated intravascular coagulation) was 
present more often in patients with the DEFB1 -44 G/G genotype compared to the C 
allele carriers (OR 2.17, 95% CI 1.22-3.85) (Table 3).(22) No significant differences in 
genotype distributions were observed between patients with and without circulatory 
failure or between patients with sepsis and patients with meningitis or a combination 
of the two (data not shown).
Table 2. Genotype distributions in survivors and non-survivors.
1 c2.
Dutch patients (EMC cohort). Eighty-five patients were included. The median (min-
max) age was 3.12 (0.26-15.48) years and 53 (62%) were male. The IL10 -819 
C/C genotype was underrepresented in non-survivors compared to the C/T and T/T 
genotypes combined (OR 0.21, 95% CI 0.05-0.91) (Table 2). In contrast to the UK 
patients, no significant difference was observed in the incidence of disseminated 
intravascular coagulation between the DEFB1 -44 genotypes (Table 3).
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Table 2. Genotype distributions in survivors and non-survivors.
Caucasian UK samples Caucasian Dutch samples
SNP Survivor
n (%)
Non-survivor
n (%)
p
1
OR crude Survivor
n (%)
Non-survivor
n (%)
p
1
OR crude
PARP 762
Val/Val vs.
Val/Ala and
Ala/Ala
Val/Val vs.
Val/Ala and
Ala/Ala
Val/Val 176 (72) 9 (75) 0.90 1.14 (0.30-4.35) 54 (73) 7 (70) 0.90 0.86 (0.20-3.67)
Val/Ala 63 (26) 3 (25) 19 (26) 3 (30)
Ala/Ala 4 (2) 0 (0) 1 (1) 0 (0)
IL4 -524
C/C vs. C/T and
T/T
C/C vs. C/T and
T/T
C/C 185 (74) 10 (83) 0.75 1.73 (0.37-8.11) 57 (76) 6 (60) 0.05 0.47 (0.12-1.87)
C/T 60 (24) 2 (17) 16 21) 2 (20)
T/T 4 (2) 0 (0) 2 (3) 2 (20)
C1INH 480
Val/Val vs.
Val/Met and
Met/Met
Val/Val 137 (55) 7 (58) 0.79 1.17 (0.36-3.77) 45 (60) 6 (60) 0.74 1.00 (0.26-3.85)
Val/Met 102 (41) 4 (33) 26 (35) 4 (40)
Met/Met 12 (5) 1 (8) 4 (5) 0 (0)
IL1B -31
C/C and C/T vs.
T/T
C/C and C/T vs.
T/T
C/C 30 (12) 1 (8) 0.93 0.91 (0.29-2.90) 10 (14) 0 (0) 0.36 1.21 (0.31-4.64)
C/T 102 (41) 5 (42) 31 (42) 6 (60)
T/T 120 (48) 6 (50) 33 (45) 4 (40)
Il10 -1082
G/G 68 (28) 3 (25) 0.79 1.28 (0.21-7.92) 20 (28) 1 (10) 0.44 0.23 (0.02-2.48)
G/A 120 (49) 7 (58) 1.69 (0.34-8.40) 38 (53) 6 (60) 0.74 (0.16-3.35)
A/A 58 (24) 2 (17) 1 14 (19) 3 (30) 1
IL10 -819
C/C vs. C/T and
T/T
C/C vs. C/T and
T/T
C/C 145 (59) 6 (50) 0.74 0.69 (0.22-2.20) 46 (67) 3 (30) 0.07 0.21 (0.05-0.91)
C/T 89 (36) 5 (42) 18 (26) 6 (60)
T/T 11 (5) 1 (8) 5 (7) 1 (10)
DEFA4 3’
UTR
A/A 114 (47) 3 (25) 0.32 0.32 (0.05-1.99) 27 (49) 5 (50) 0.94 0.83 (0.14-5.07)
A/G 106 (43) 7 (58) 0.79 (0.16-4.06) 19 (35) 3 (30) 0.71 (0.10-5.03)
G/G 24 (10) 2 (17) 1 9 (16) 2 (20) 1
DEFB1 -44
G/G vs G/C and
C/C
G/G vs G/C and
C/C
G/G 171 (68) 5 (42) 0.05 0.33 (0.10-1.09) 31 (56) 4 (40) 0.38 0.52 (0.13-2.04)
G/C 70 (28) 5 (42) 21 (38) 6 (60)
C/C 10 (4) 2 (17) 3 (7) 0 (0)
Chi square.
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No significant difference was observed in either cohort between the genotypes for 
respiratory failure and severity scores (data not shown).
Table 3. Genotype distribution in patients with meningococcal disease with and without 
disseminated intravascular coagulation.
1DIC disseminated intravascular coagulation.
2c2.
G/C and C/C versus G/G OR (95% CI) for UK patients and Dutch patients was 2.17 (1.22-3.85) and 1.29 
(0.71-5.21), respectively.
Discussion
In this study we assessed the possible role of genetic polymorphisms in genes involved 
in the pathophysiology in meningococcal infection susceptibility and severity.
In the UK cohort an association was observed for the DEFB1 -44 G/G genotype and 
susceptibility for meningococcal disease in a case control study. This genotype was 
also associated with DIC in the UK Caucasian patients. These associations could not 
be confirmed in the UK TDT and the Dutch studies. This may be due to insufficient 
informative meiosis and thus a lack of statistical power, specifically in the small Dutch 
population, for which the number of available genotypes is insufficient to observe 
an OR less than 2. In addition, the excessive transmission from parent to affected 
offspring of the IL4 -542 C allele and the C1INH 480 Val allele were not found in the 
case control studies of both UK and Dutch samples. These discrepancies may be 
the result from either false negative or false positive findings. With regard to DEFB1 
promoter polymorphism and susceptibility of disease, the genotype distribution in 
the smaller Dutch cohort in fact, shows overrepresentation of the -44 G/G genotype 
in controls, pointing into the opposite direction. This does, however, not exclude a 
possible association as was postulated by Lin et al., who introduced an explanatory 
hypothesis for the flip-flop phenomenon, in which the other allele of a marker is 
observed to be the risk allele in subsequent studies, explaining reverse associations 
through differences in linkage disequilibrium patterns and interaction with other risk 
factors.(30) For the IL4 and C1INH polymorphisms the cause of the discrepancy is 
less clear since the genotype distributions are rather similar. If an effect is present, 
we would expect it to be very limited. In addition, it must be noted that the P values 
presented do not include correction for multiple testing. When we corrected for this, 
none of the observed associations remained significant. In addition, Dutch patients 
all had sepsis or septic shock, while part of the UK patients presented with only 
meningitis, which usually is presented by somewhat milder symptoms. This may be 
an important confounder and have contributed to the inconsistent observations. IL4 
13
Table 3. Genotype distribution in patients with meningococcal disease with and without disseminated
ntravascular coagulation.
Caucasian UK patients Caucasian Dutch patients
SNP No DIC
1
n (%)
DIC
n (%)
2
No DIC
n (%)
DIC
n (%)
2
DEFB1 -44
G/G 37 (54) 128 (72) 0.02 12 (44) 23 (61) 0.36
G/C 29 (42) 42 (24) 14 (52) 13 (34)
C/C 3 (4) 9 (5) 1 (4) 2 (5)
DIC disseminated intravascular coagulation
2
Chi square.
G/C and C/C versus G/G OR (95% CI) for UK patients and Dutch patients was 2.17 (1.22-3.85) and 1.29 (0.71-5.21),
respectively.
p p
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polymorphisms have been associated with atopy, asthma and severe respiratory 
infections.(31-33) In addition, the IL4 -524 C/C genotype was previously associated 
with lower IL4 expression.(13) The role of IL-4 in systemic infection seems crucial 
since IL-4 deficient mice are more susceptible to shock induced with a combination of 
staphylococcal enterotoxin B and D-galactosamine than wild type mice.(34) In adult 
sepsis patients IL-4 mRNA levels were decreased when compared to patients with 
bacteraemia or controls.(35)
In this study we did not observe an association in any of the populations for the PARP 
762 Val/Ala, IL1B -31 T/C, DEFA4 3’UTR A/G, and IL10 -1082 G/A polymorphisms with 
regard to susceptibility to and severity of meningococcal infection. These results do, 
however, not imply that these genes are not at all involved in meningococcal disease. 
The IL1B -31 T/C polymorphism is known to be in linkage disequilibrium with the IL1B 
-511 C/T polymorphism that previously, in combination with polymorphisms in the IL1 
receptor antagonist (IL1RN), has been associated with outcome of meningococcal 
infection.(36, 37) Read et al discussed the hypothesis that altered inhibition of the IL1B 
transcription due to difference of LPS binding to the promoter region might be one 
explanation of the association reported for the IL1B polymorphism at position -511. 
The discrepancy between these and our findings might be explained by a possible 
linkage of the IL1B -511 polymorphism with a disease locus other than the IL1B -31 
C/T polymorphism. In addition, the number of non-survivors in both our UK and Dutch 
cohort were small, which may have prohibited finding an association in our study. 
Although in the Dutch cohort the IL10 -819 C/C genotype was underrepresented in 
non-survivors, this was not confirmed in the UK cohort. Additional studies with large 
numbers of patients are required to analyse the relevance of this finding, since a 
small change in numbers in the Dutch cohort as it is presented would very likely alter 
the results.
The IL10 -1082 G/A polymorphism has previously been reported by van der Pol 
et al. to be significantly associated with susceptibility to meningococcal disease in 
combination with a polymorphism in FcγRIIa.(38) This study compared observed 
genotype distributions to those expected in healthy controls and first-degree relatives 
of affected patients, but the IL10 -1082 polymorphism was not analyzed separately.
In conclusion, we found no association between polymorphisms in PARP, IL1B, 
and DEFA and meningococcal infection susceptibility or severity. We observed an 
association of a SNP in DEFB1 with susceptibility and severity in the UK cohort. 
This was not confirmed in the Dutch cohort. This discrepancy may be the result 
of either a false positive or false negative association. The association of the IL4 
-542 C and the C1INH 480 Val allele with susceptibility to meningococcal infection 
observed in the family based TDT analysis was also not confirmed in the additional 
cohorts. Additional functional and genetic association studies using large numbers 
of individuals, ensuring increased statistical power, are necessary to elucidate the 
conflicting results obtained for the DEFB1, IL4, IL10 and C1INH polymorphisms and 
their role in susceptibility to and severity of meningococcal disease.
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Abstract
Objective. In paediatric meningococcal sepsis, an imbalance between coagulation 
and fibrinolysis and proinflammatory action play major roles. We hypothesized that 
thrombin activatable fibrinolysis inhibitor (TAFI) and/or TAFI activation markers are 
involved in the pathogenesis of meningococcal sepsis.
Patients and methods. Children with severe meningococcal sepsis (n = 112) 
previously included in Rotterdam-based trials participated in this study. Clinical and 
laboratory parameters and severity scores were assessed. TAFI and TAFI activation 
markers were determined: TAFI activation peptide (TAFI-AP) and (in)activated TAFI 
(TAFIa(i)). The -438G/A, Ala147Thr, and Thr325Ile polymorphisms were genotyped. 
Results. TAFI levels were significantly decreased in patients with meningococcal 
disease at admission compared to the convalescence state. TAFI was decreased in 
patients with septic shock vs. those with no shock. TAFI-AP levels were increased in 
patients with disseminated intravascular coagulation (DIC) vs. patients without DIC. 
TAFI-AP and TAFIa(i) were significantly increased in non-survivors vs. survivors. TAFI-
AP levels and TAFI-AP/TAFI ratio were also strongly correlated to severity scores and 
laboratory parameters. The TAFI 325Ile/Ile genotype was overrepresented in patients 
with DIC.
Conclusions. Activation markers of TAFI were associated with the occurrence of 
DIC and mortality in meningococcal sepsis patients. A determination of TAFI, TAFI-
AP and TAFIa(i) is required to enable coherent interpretation of the role of TAFI in 
disease.
Introduction
The observed clinical phenotype in meningococcal infection is thought to be 
determined by the activation of inflammatory, coagulation and fibrinolysis pathways. 
While meningococcal infection results in a ‘mild’ sepsis with petechiae in some 
patients, others develop septic shock and/ or disseminated intravascular coagulation 
(DIC). This, in combination with ischemia, may result in multi-organ failure. Although 
improved treatment possibilities have resulted in a decreased mortality over the past 
15 years, up to 2% of meningococcal infections is still lethal in the developed countries.
(1) A significant number of patients suffer from long-term sequelae including minor or 
major amputations. Thrombin activatable fibrinolysis inhibitor (TAFI) was described to 
be a potent inhibitor of fibrinolysis in vitro.(2, 3) TAFI is a glycoprotein that is present 
in the plasma as a proenzyme and is activated by thrombin/thrombomodulin or 
plasmin by a single cleavage at Arg-92. This results in the activation peptide (TAFI-
AP) and in the exposure of the substrate binding site of activated TAFI (TAFIa). 
TAFIa is thermolabile (half-life of 8-15 minutes at 37°C) as a result of a spontaneous 
conformational conversion into an inactive form (TAFIai) which is prone to further 
proteolytic cleavage. TAFIa exerts its anti-fibrinolytic function by removing the 
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carboxy-terminal lysine residues of partially degraded fibrin. These lysine residues 
are required for binding of plasminogen and tissue-type plasminogen activator (t-PA) 
and efficient plasmin formation. Removal of the lysine residues results in decreased 
binding and activation of plasminogen and induces inhibition of fibrinolysis.(4, 5) Still, 
although plasma of TAFI-deficient mice fails to prolong clot lysis time in vitro, no 
differences are observed in in vivo markers of haemostasis and endotoxin-induced 
DIC between wild-type and TAFI-deficient mice.(6, 7)
Exuberant activation of TAFI could result in decreased degradation of thrombi and 
therefore in exacerbation of multi-organ failure. In addition, in vitro and animal 
studies have revealed that TAFIa also has an anti-inflammatory role by inactivating 
C5a, resulting in decreased vascular permeability and risk of septic shock.(8, 9) 
Furthermore, TAFI-deficient mice appear to be protected from sepsis-induced liver 
injury.(7) Which of these functions dominates is currently unknown. In studies on 
adults with sepsis, TAFI levels were decreased.(10, 11) The cause of this decrease, 
activation or consumption of TAFI was not revealed, because TAFI activation markers 
were not determined.(10) Knoefler et al. observed no differences in TAFI levels in 
children of different age groups with and without hematological malignancies.(12)
A variety of single nucleotide polymorphisms (SNPs) have been described for the 
TAFI gene. However, it remains rather unclear to what extent genetic variations in 
TAFI contribute to the disease severity.(13)
In this study we investigated the levels of TAFI, the activation markers TAFI-AP and 
TAFIa(i), and TAFI polymorphisms in a cohort of paediatric patients with severe 
meningococcal infection. We analyzed whether these parameters were associated 
with survival, the presence of shock as a marker for inflammatory activity, and the 
presence of DIC as marker for a possible involvement in fibrinolysis. We also analyzed 
the possible correlations of TAFI/TAFI activation markers with other coagulation and 
fibrinolysis related factors as well as inflammatory and endocrine factors.
Methods
Participants. Patients consecutively admitted to the paediatric intensive care 
unit (PICU) of the Erasmus University Medical Centre-Sophia (Rotterdam, the 
Netherlands) who previously participated in Rotterdam-based meningococcal sepsis 
studies between 1988 and 2005 were eligible for the current study (n = 279).(14-19) 
Children were enrolled in the study after obtaining approval of the medical ethical 
committee and informed consent from the parents or guardians. The 112 patients 
from whom DNA and/or citrate blood was available were included. Clinical inclusion 
criteria were presentation with tachycardia, tachypnea, body temperature < 36°C or 
> 38.5°C (rectal) and petechiae.(20) Prospective data on all patients were collected 
at various time-points. Both laboratory parameters and disease severity scoring 
systems, such as the PRISM-score, predicted death rate based on the Rotterdam 
score. and the presence of DIC, were selected as markers of severity of disease.(21-
23) DIC was scored on admission and during the first 24 h, as some patients do not 
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meet the criteria at first, but do develop DIC during the first hours in the PICU. 
All laboratory parameters were obtained at baseline from an arterial blood sample 
that was collected within 4 h after admission to the PICU (t = 0, n = 67). Additionally, 
blood was sampled at t = 1 day for TAFI measurements (n = 58). For some of the 
patients, blood was also drawn 0.5 days after admission (n = 28) and 90 days after 
admission (n = 13). Differences in the number of patients at the different time points 
are the result of inclusion of patients in several different studies, which did not all 
include a blood sample being drawn at t = 0.5 days. Additionally, no more blood 
samples were drawn when an arterial line was no longer available, when a patient 
was transported back to the referral hospital, or when a patient died. At t = 90 days, 
according to regulations of the medical ethical committee, blood could only be drawn 
from cooperative children.
N. meningitidis serotyping. The N. meningitidis serogroup was determined in 
cultured isolates at the Netherlands Reference Laboratory for Bacterial Meningitis 
Amsterdam using immunodiffusion with polyclonal antisera.(24)
TAFI concentration. Citrate blood was drawn and the plasma stored at -80°C until 
TAFI concentrations were determined without prior thawing. Three sandwich-type 
ELISAs (i.e. MA-T12D11/MA-T30E5-HRP, MA-T12D11/MA-T18A8-HRP and MA-
T30E5/MA-17D7-HRP) were used to quantify the plasma levels of TAFI, TAFI-AP 
and TAFIa(i), respectively.(25) To obtain pooled human plasma, blood samples (n = 
21 blood donors) were taken on 4% citrate according to the guidelines of the blood 
transfusion centre (Red Cross, Leuven, Belgium) and plasma was pooled. Either non-
activated pooled human plasma (MA-T12D11/MA-T30E5-HRP ELISA) or activated 
pooled human plasma (MA-T12D11/MA-T18A8-HRP and MA-T30E5/MA-17D7-HRP 
ELISAs) was used as a standard (1:40 dilution of plasma in PTAE buffer (PBS pH 
7.4 containing 0.002% Tween 80, 1 g/L BSA and 5 mM EDTA), followed by serial 
two-fold dilutions up to 1:2560). For preparation of the standard for the MA-T12D11/
MA-T18A8-HRP and MA-T30E5/MA-17D7-HRP ELISAs, pooled human plasma 
was incubated with thrombin (20 nM), thrombomodulin (5 nM) and CaCl2 (17 mM) in 
Hepes buffer at 37°C for 15 min. The reaction was stopped by addition of H-D-Phe-L-
Prolyl-L-arginine chloromethylketone (PPACK, 30 μM final concentration).
Plasma samples derived from patients were diluted 1:160 (MA-T12D11/MA-T30E5-
HRP ELISA), 1:80 (MA-T12D11/MA-T18A8-HRP ELISA) and 1:80 (MA-T30E5/MA-
17D7-HRP ELISA). All values of TAFI and TAFI activation markers are expressed 
relative to the levels in the pooled human plasma.
Determination of levels of cytokines, coagulation factors and endocrinological 
factors. Plasma or serum levels of different parameters were determined previously.
(14, 15, 18, 26)
DNA isolation and genotyping. DNA isolation from whole blood was performed 
with column methods using standard protocols (Qiagen). Bi-allelic discrimination with 
Taqman analysis was used to determine the TAFI -438 G/A (rs2146881), Ala147Thr 
(505G/A, rs3742264), and Thr325Ile (1040C/T, rs1926447) genotypes in Caucasian 
patients only (n = 82). Primer sequences are available upon request from the 
corresponding author.
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Statistical analysis. Statistical analysis was performed using SPSS 11.0. Binomial 
variables were analyzed using Pearson’s c2 test (2df) or Fisher’s exact test when 
appropriate. For continuous variables the Mann-Whitney U test was used. 
Spearman’s correlation was determined to assess the relation between TAFI 
levels and severity scores or laboratory parameters. TAFIa(i) and TAFI-AP levels 
were log transformed resulting in a near normal distribution. These log transformed 
levels were analyzed in relation to different outcome variables, severity scores, and 
genotypes using the Student’s t-test. Geometric mean and 95% CIs are depicted.(27) 
A comparison of genotype frequencies was made between outcome variables such 
as survival, need of ventilation and presence of DIC. Probability (P) values < 0.05 
were considered to be statistically significant. No correction was made for multiple 
testing.
Results
In total, 112 patients were included in this study. Sixty-nine (62%) were males and 
the median (range) age was 2.9 years (0.1-16.1). Septic shock was observed in 96 
(87%) patients. The median (range) PRISM score was 19 (1-43). Twelve patients did 
not survive (11%; Table 1). 
Table 1. Patient characteristics.
1Fisher’s Exact test or Mann-Whitney U test were performed when appropriate.
2DIC, disseminated intravascular coagulation; PRISM, paediatric risk of mortality.
3Related to the first six hours.
4Based on the Rotterdam score.
On admission 60 (54%) patients met the criteria for DIC, whereas an additional 16 
(14%) patients fulfilled the DIC criteria during the first 24 h of their stay in the PICU. 
In 95 (85%) patients blood cultures were positive for N. meningitidis. Serotype B was 
found in 72 of these, while 16 had serotype C. In the remaining seven, no serotype 
was determined. Additionally, N. menigitidis specific polymerase chain reaction (PCR) 
was positive in two patients. The remaining 15 patients had possible meningococcal 
infection based on clinical criteria.(28)
TAFI levels and survival. Plasma at t = 0 was available for 57 survivors and 10 
non-survivors. At t = 0.5 and 1 day, plasma was available from three and two non-
 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Pati t haracteristics. 
 Non survivor Survivor 
1
 
 n = 12  n = 100   
Male gender (%) 9 (75.0) 60 (60.0) 0.37 
Median age (min-max) 0.83 (0.46-9.43) 3.57 (0.12-16.11) 0.000 
Presence of shock (%) n = 111 12 (100) 84 (84.8) 0.36 
Mechanical ventilation (%) n = 110 12 (100) 55 (56.1) 0.003 
Presence of DIC
2
 (%) 12 (100) 48 (48) <0.001 
PRISM score
3
 (min-max) n = 100 31.5 (23-43) 18.0 (1-37) 0.000 
Predicted death rate
4
 (min-max) n = 104 95.9 (55.1-99.9) 5.7 (0.0-96.3) 0.000 
Meningococcal Serogroup 
 B (%) 
 C (%) 
 
9 (90.0) 
1 (10.0) 
 
63 (80.8) 
15 (19.2) 0.68 
Fisher’s Exact test or Mann-Whitney U-test were performed when appropriate. 
2
DIC, disseminated intravascular coagulation; PRISM, paediatric risk of mortality. 
3
Related to the first six hours. 
4
Based on the Rotterdam score. 
 
 
 
Table 2. TAFI, TAFI-AP en TAFIa(i) levels in plasma of paediatric patients with meningococcal sepsis. 
 
Time point (days) 0 0.5 1 90 
 n = 67 n = 28 n = 58 n = 13 
TAFI
1
 26.5 (10.6) 36.5 (13.5) 40.1 (11.0) 91.1 (16.9) 
TAFI-AP
2
 100 (80-126) 84 (61-115) 77 (66-90) 123 (100-150) 
TAFIa(i)
2
 61 (53-70) 73 (60-90) 59 (52-67) 137 (108-173) 
TAFI-AP/TAFI
3
 2.9 (0.8-47.5) 2.1 (0.9-19.4) 1.7 (0.8-8.6) 1.4 (0.9-3.1) 
TAFIa(i)/TAFI
3
 2.6 (0.7-11.0) 2.2 (0.7-4.7) 1.5 (0.5-3.6) 1.6 (0.8-2.6) 
Mean (sd) % relative to pooled normal plasma. 
2
Geometric mean (95% CI) % relative to pooled normal plasma. 
3
Ratio, median (range). 
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survivors, respectively. Other patients died in the period between blood sampling. At 
t = 0.5 and 1 day, plasma was available from 25 and 56 survivors, respectively. At 
admission, levels of TAFI and TAFIa(i) were strongly decreased in the total group of 
patients with meningococcal infection (Table 2). 
Table 2. TAFI, TAFI-AP en TAFIa(i) levels in plasma of paediatric patients with meningococcal 
sepsis.
1Mean (sd) % relative to pooled normal plasma.
2Geometric mean (95% CI) % relative to pooled normal plasma.
3Ratio, median (range).
TAFI-AP levels were normal at admission, but decreased to about 75% of normal 
reference levels during the first day. In survivors, TAFI levels returned to normal 90 
days after admission (Table 2). In subgroup analysis, non-survivors and survivors 
had similar levels of TAFI at all time points (Figure 1A). 
Figure 1. Plasma TAFI and activation marker levels in survivors and non-survivors. 
Geometric mean or mean plasma TAFI levels (% relative to normal controls) on admission and after 0.5 
and 1 and 90 days as listed. Error bars represent SD for TAFI and 95% CI for TAFI AP and TAFIa(i). 
Numbers of survivors at these time points are 57, 25, 56 and 13, respectively. The numbers of non-
survivors at these time points are 10, 3 and 2, respectively. As only very few non-survivors were left at t = 
0.5 and 1 day individual levels are depicted for these patients, and statistical analysis was performed only 
on admission. 1A. TAFI levels; 1B. TAFI-AP levels; 1C. TAFIa(i) levels. *, p<0.001; ^, p=0.047. 
The TAFI-AP levels were significantly higher in non-survivors than in survivors 
on admission (p<0.001, Figure 1B). In addition, TAFI-AP levels were three to six 
times increased at other time points in non-survivors compared to survivors and 
no overlap was present; however, because of the small number of patients in the 
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Table 1. Patient characteristics. 
 Non survivor Survivor 
1
 
 n = 12  n = 100   
Male gender (%) 9 (75.0) 60 (60.0) 0.37 
Median age (min-max) 0.83 (0.46-9.43) 3.57 (0.12-16.11) 0.000 
Presence of shock (%) n = 111 12 (100) 84 (84.8) 0.36 
Mechanical ventilation (%) n = 110 12 (100) 55 (56.1) 0.003 
Presence of DIC
2
 (%) 12 (100) 48 (48) <0.001 
PRISM score
3
 (min-max) n = 100 31.5 (23-43) 18.0 (1-37) 0.000 
Predicted death rate
4
 (min-max) n = 104 95.9 (55.1-99.9) 5.7 (0.0-96.3) 0.000 
Meningococcal Serogroup 
 B (%) 
 C (%) 
 
9 (90.0) 
1 (10.0) 
 
63 (80.8) 
15 (19.2) 0.68 
Fisher’s Exact test or Mann-Whitney U-test were performed when appropriate. 
2
DIC, disseminated intravascular coagulation; PRISM, paediatric risk of mortality. 
3
Related to the first six hours. 
4
Based on the Rotterdam score. 
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non-survivor group, no statistical analysis could be performed. In survivors, TAFI-AP 
levels were similar to the normal reference levels at all time points. On admission, the 
TAFIa(i) levels were significantly higher (p=0.047) in non-survivors than in survivors, 
corroborating an enhanced TAFI activation in the non-survivor group (Figure 1C).
TAFI levels and DIC and septic shock. Patients with septic shock showed lower 
TAFI levels compared to the small group of patients without septic shock, while no 
differences were observed for the TAFI activation markers (Figures 2A-C). 
Figure 2. Plasma TAFI and activation marker levels in patients with and without shock. 
Geometric mean or mean plasma TAFI levels (% relative to normal controls) on admission and after 0.5 
and 1 and 90 days as listed. Error bars represent SD for TAFI and 95% CI for TAFI AP and TAFIa(i). The 
numbers of patients with shock at these time points are 61, 28, 54 and 13, respectively. The numbers of 
patients without shock at the time points 0 and 1 day are 5 and 4, respectively. Data regarding shock were 
present for 66 out of 67 patients for whom TAFI and activation levels were determined at t = 0. 
2A. TAFI levels, #, p<0.01; 2B. TAFI-AP levels; 2C. TAFIa(i) levels. 
On admission, TAFI levels were slightly lower in patients with DIC than in patients 
without DIC (Figure 3A). TAFI-AP levels were significantly increased at t = 0, 0.5 
and 1 day in patients with DIC versus no DIC on admission, while no difference was 
observed on admission with regard to TAFIa(i) level (Figures 3B and 3C). When the 
presence of DIC was defined within the first 24 h after admission, similar results 
were obtained (data not shown).
Some of the patients received protein C concentrate after t = 0 (n = 26, 21, 19 and 
9 of the patients for whom TAFI levels are available at t = 0, 0.5, 1 and 90 days, 
respectively) because they participated in a randomized clinical trial. Because this 
may have influenced the results, analyses were also performed excluding these 
patients. The only difference observed was for the TAFIa(i) levels 1 day after 
admission. TAFIa(i) levels were significantly higher in the patients receiving protein 
C concentrate when compared to those receiving placebo (geometric mean (95% 
CI) 72.1% (56.2-92.6%) and 54.4% (32.4-91.2%), respectively; p=0.03), but this 
difference was already present on admission when no study medication had yet 
been administered (83.1% (66.9-103.3%) vs. 49.8% (42.6-58.1%), respectively 
(p<0.001)). When comparing placebo groups and groups who received different 
dosages of protein C concentrate (low, moderate or high), only at t = 0 a significant 
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Figure 3. Plasma TAFI and activation marker levels in patients with and without DIC on admission.
Geometric mean or mean plasma TAFI levels (% relative to normal controls) on admission and after 0.5 
and 1 and 90 days as listed. Error bars represent SD for TAFI and 95% CI for TAFI AP and TAFIa(i). The 
numbers of patients with DIC at these time points are 38, 19, 32 and 7, respectively. The numbers of 
patients without DIC at these time points are 29, 9, 26 and 6, respectively. 
3A. TAFI p=0.05 at t = 0; 3B. TAFI-AP levels; 3C. TAFIa(i) levels. *, p<0.001; #, p<0.01, ^, p=0.05.
difference was observed between the patients receiving high dosages of protein C 
and the placebo group (p=0.004, after Bonferroni correction). At this point, however, 
no protein C concentrate had been administered to any of the patients.
The TAFI 325Ile/Ile genotype was overrepresented in patients with DIC on admission 
when compared to the 325Thr/Thr genotype (crude OR (95% CI) 10.5 (1.3-88), 
adjusted for age OR (95% CI) 13.7 (1.5-123). No other significant differences or 
associations were observed in TAFI genotype distributions.
TAFI activation markers: correlation with other clinical parameters. No 
correlation was observed between TAFI-AP and TAFIa(i) at any of the time points. 
On admission, TAFI-AP was negatively correlated with age (n = 67, Spearman’s Rho 
-0.44, p<0.001). No correlation was observed between age and convalescent TAFI-
AP levels three months after admission. In contrast, TAFIa(i) convalescent levels 
positively correlated with age (n = 13, Spearman’s Rho 0.747, p=0.003), while no 
correlation was observed on admission. TAFI levels showed no correlation with age 
at any time point. TAFI-AP levels were positively correlated with PRISM score (n = 
67, Spearman’s Rho 0.529, p<0.001) and the predicted death rate calculated from 
the Rotterdam score (n = 66, Spearman’s Rho 0.584, p<0.001).
We hypothesized that the ratio between activation markers such as TAFI-AP and 
TAFI might give a more proper indication of TAFI activation. TAFI was considerably 
more decreased in the acute phase than its activation markers as reflected by 
the increased TAFI-AP/TAFI and TAFIa(i)/TAFI ratio’s (Table 2). However, a large 
variation between patients was found. The TAFI-AP/TAFI ratio was significantly 
increased in non-survivors compared to the survivors at all time points (median (min-
max) survivors 2.8 (0.8-47.5), 2.0 (0.9-8.8) and 1.7 (0.8-8.6) at t = 0, 0.5 and 1 day; 
non-survivors 15.8 (2.6-44), 7.3 (6.4-19.4) and 7.7 (7.5-7.9) at t = 0, 0.5 and 1day, 
p<0.001, p=0.008 and p=0.02, respectively). A trend for higher TAFI-AP/TAFI ratio 
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was observed for patients with septic shock compared to those without septic shock. 
Patients with DIC on admission had increased TAFI-AP/TAFI ratio’s at t = 0, 0.5 and 
1 day (median (min-max) with DIC 7.4 (1.5-47.5), 2.5 (1.1-19.4) and 2.4 (1.2-8.6) 
at t = 0, 0.5 and 1 day; without DIC 1.8 (0.8-6.9), 1.5 (0.9-2.5) and 1.3 (0.8-2.6) 
at t = 0, 0.5 and 1 day, p<0.001 for t = 0 and 1 day and p=0.005 for t = 0.5 day). 
No significant difference was observed in the ratios in the convalescence period. In 
addition, the TAFI-AP/TAFI ratio was negatively correlated with age (Spearman’s Rho 
-0.474, p<0.001), while it was positively correlated with PRISM score (Spearman’s 
Rho 0.622, p<0.001) and the predicted death rate calculated from the Rotterdam 
score (Spearman’s Rho 0.691, p<0.001).
TAFI levels in relation to other laboratory parameters. Strong correlations 
were observed between TAFI-AP and the TAFI-AP/TAFI ratio and other laboratory 
parameters, including cytokines and other coagulation factors. TAFI-AP levels were 
positively correlated with lactate and procalcitonin levels, while they were negatively 
Table 3. Spearman correlation coefficients of TAFI levels with other laboratory parameters on 
admission.
1Only patients for whom cytokine levels exceeded the detection limit of 5 pg/mL were included in the 
analysis.
2MIF, macrophage migration inhibitory factor; TAT, thrombin-antithrombin III complexes; PAI-1, plasminogen 
activator inhibitor-1; PAPc, plasmin-2antiplasmin complexes; sTM, soluble thrombomodulin.
A ‘-’ indicates non significant (Spearman’s correlation coefficients).
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Table 3. Spearman correlation coefficients of TAFI levels with other laboratory parameters on admission. 
 
Laboratory  Spearman’s Rho (p) 
parameter n TAFI TAFI-AP TAFIa(i) TAFI-AP/TAFI 
General factors      
Lactate 67 - 0.454 (<0.001) - 0.391  (0.001)  
C-reactive protein 66 - -0.363 (0.003) - -0.390 (0.001) 
Procalcitonin 35 - 0.542  (0.001)  - 0.596  (<0.001) 
Cholesterol 29 0.603 (0.001) - 0.569 (0.001) -0.401 (0.031) 
Cytokines      
IL-1! 291  - 0.755 (<0.001) 0.466 (0.01) 0.638 (<0.001) 
IL-1RA 36 - 0.801 (<0.001) - 0.803 (<0.001) 
TNF-" 231  - 0.698 (<0.001) 0.589 (0.003) 0.637 (0.001) 
sTNFR 36 - 0.660 (<0.001) - 0.675 (<0.001) 
IL-6 35 - 0.860 (<0.001) - 0.836 (<0.001) 
IL-8 35 - 0.783 (<0.001) - 0.774 (<0.001) 
IL-10 36 - 0.485 (0.003) - 0.539 (0.001) 
MIF
2
 66 - 0.580 (<0.001) - 0.667 (<0.001) 
Coagulation/Fibrinolyis      
Platelet count 67 0.246 (0.045) -0.490 (<0.001) - -0.626 (<0.001) 
Prothrombin 36 0.655 (<0.001) - 0.501 (0.002) -0.422 (0.01) 
TAT 35 - 0.658 (<0.001) 0.331 (0.052) 0.674 (<0.001) 
Protein C 36 0.638 (<0.001) - - -0.422 (0.010) 
Activated protein C 36 - 0.764 (<0.001) - 0.742 (<0.001) 
PAI-1 35 - 0.684 (<0.001) - 0.727 (<0.001) 
D-dimer 36 - 0.699 (<0.001) - 0.796 (<0.001) 
PAPc 35 - 0.687 (<0.001) - 0.758 (<0.001) 
sTM 36 - 0.530 (0.001) - 0.560 (<0.001) 
Factor V 14 - -0.662 (0.01) - -0.741 (0.002) 
Adrenal function      
ACTH 59 - 0.618 (<0.001) - 0.604 (<0.001) 
Cortisol 59 - -0.356 (0.006) - -0.484 (<0.001) 
Cortisol/ACTH ratio 57 - -0.611 (<0.001) - -0.637 (<0.001) 
Glucose 67 - -0.372 (0.002) - -0.404 (0.001) 
Only patients for whom cytokine levels exceeded the detection limit of 5 pg/mL were included in the analysis. 
2
MIF, macrophage migration inhibitory factor; TAT, thrombin-antithrombin III complexes; PAI-1, plasminogen activator  
inhibitor-1; PAPc, plasmin-2antiplasmin complexes; sTM, soluble thrombomodulin. 
A ‘-’ indicates non significant (Spearman’s correlation coefficients). 
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correlated with platelet counts and levels of coagulation factor V and C-reactive 
protein (CRP; Table 3). In addition, TAFI-AP levels were positively correlated with
cytokine levels and most coagulation/fibrinolysis markers. With regard to adrenal 
function as a measure for anti-inflammatory action, a positive correlation was 
observed with adrenocorticotropic hormone (ACTH), while a negative correlation was 
observed between TAFI-AP and cortisol, cortisol/ACTH ratio and glucose. TAFIa(i) 
level was positively correlated with prothrombin, thrombin-antithrombin III complexes 
(TAT), cholesterol and cytokines TNF-α and IL-1β. TAFI-AP/TAFI ratio was correlated 
to the different laboratory markers in a similar way as TAFI-AP (Table 3).
Discussion
In our study we observed strongly decreased TAFI levels in both survivors and non-
survivors of meningococcal sepsis in a paediatric cohort. Both markers of activation, 
and specifically TAFI-AP were strongly increased in non-survivors compared to 
survivors. It must be noted that most non-survivors, as expected, died within the 
first 12 h after admission, leaving only a few patients in the non-survivor group at 
0.5 and 1 day. For this reason, results after t = 0 should be interpreted with caution. 
TAFI levels were slightly more decreased in patients with DIC compared to those 
without DIC. TAFI-AP levels were increased in patients with DIC. In contrast, TAFIa(i) 
levels were similar for patients with and without DIC. This may be explained by the 
differences in the half-life of TAFI and its fragments in the circulation, which may 
prohibit the detection of differences between these fragments for the various clinical 
groups, specifically in meningococcal sepsis, which is known for its rapid onset and 
deleterious course. TAFI-AP may therefore be a more stable marker of activation. 
Also the TAFI-AP/TAFI ratio, reflecting the relative activation, was increased both in 
patients with DIC and in non-survivors. All levels were expressed as percentage of 
pooled human plasma from healthy adult blood donors. No paediatric healthy controls 
were available. In our study TAFI levels on admission were not correlated with age. 
This confirms the observation of Knoefler et al. who showed that TAFI levels were not 
significantly different between children of different age groups.(12) In addition, TAFI 
levels at t = 90 days, when patients were fully recovered, normalized to approximately 
100% of reference samples.
The association of TAFI-AP with DIC was illustrated by the negative correlation 
with platelet count and factor V, which are decreased in DIC because of extensive 
consumption, and by the positive correlation with plasminogen activator inhibitor-1 
(PAI-1), Thrombin-antithrombin (TAT) complexes, activated protein C and D-dimer. 
Both TAFI and PAI-1 are known to inhibit fibrinolysis as a result of interference with 
plasmin formation.(2-4, 29, 30) Exuberant activation of TAFI and increase of PAI-1 
might result in decreased degradation of thrombi and could therefore increase multi-
organ failure by promoting formation of multiple microthrombi. Our results indicate that 
increased activation of TAFI indeed is associated with a more severe clinical disease 
state reflected by the low survival rate in patients with the highest level of TAFI-AP. 
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However, the cause or effect of that increased severity remains to be established.
Another major feature of meningococcal septic shock is an increased vascular 
permeability, resulting in oedema and persistent hypovolemia and organ dysfunction.
(31) In animal models TAFIa was shown to inactivate C3a and C5a, factors responsible 
for the increased vascular leaking that is seen in septic shock patients.(8, 9) As the 
most severely ill patients have the highest C3a levels the decrease of TAFI levels in 
our study in patients with septic shock compared to those without may also result 
from an increased activation.(32) However, no difference in TAFI-AP or TAFIa(i) levels 
were observed. When only TAFI was considered, one might reason that activation of 
TAFI was even increased in patients with septic shock in contrast to what would be 
expected from the animal studies described above. It must be noted, however, that 
the patients in our study admitted to a PICU were only included if an arterial line was 
in situ because of the blood needed for the analyses. This implies that these patients 
were severely ill and the use of inotropic medication was at least considered and in 
most cases administered. Indeed, data on TAFI levels were only available in five and 
four patients without shock at t = 0 and 1 day, respectively. 
Supportive treatment of meningococcal sepsis has changed over the time period in 
which patients were included (more swift treatment because of public awareness, 
different inotropic agents and increased use of corticosteroids).(33) Because mortality 
from meningococcal sepsis has decreased with improved treatment possibilities, this 
may have influenced the results of our study with regard to survival. Results with 
regard to presence of shock or DIC, or correlations with the markers of severity are 
not likely influenced, as these were scored on admission.
TAFI-AP levels were positively correlated with markers for severity of disease such 
as the PRISM score, the predicted death rate calculated from the Rotterdam score, 
lactate, procalcitonin, cytokine levels and ACTH, while a negative correlation was 
found with CRP and cortisol. Low CRP levels on admission are associated with a 
rapid onset of disease and are associated with a poor prognosis.(21) 
In our study, different results have been obtained for TAFI, AP and TAFIa(i) with regard 
to outcome and correlation with other disease severity markers. It should be noted 
that all other studies published so far only described either intact TAFI levels or TAFIa 
levels upon full activation of intact TAFI and thus indirectly measuring intact TAFI 
levels.(10, 11, 34) The difference in levels of TAFI, TAFIa(i) and TAFI-AP and the ratio 
of individual markers may partially result from differences in the half-life or proteolytic 
degradation of the various fragments. Moreover, TAFIa converts spontaneously to 
TAFIai which is prone to further cleavage into two degradation products that are not 
detectable in the TAFIa(i) ELISA.(25) Our results stress the importance of studying 
both TAFI levels and TAFI activation markers at the same time.
Genetic polymorphisms in TAFI were previously associated with TAFI levels and its 
activation. Previous studies showed that the 325 Ile variant showed an extended half-
life of TAFIa in vitro to 15 min at 37°C, while the activation had not changed. Moreover, 
the antifibrinolytic activity of the 325 Ile variant was increased compared to the 325 
Thr variant, and it was therefore thought to be a more potent enzyme than the 325 Thr 
variant.(35, 36) The TAFI 325Ile/Ile genotype was overrepresented in patients with 
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DIC. This genotype was also reported to be overrepresented in parents of patients 
who died of meningococcal disease, while in survivors of meningococcal disease the 
genotype frequency was decreased compared to the general population.(37)
Given the association of TAFI-AP with mortality and DIC during the course of 
meningococcal sepsis, and the fact that the increase of TAFI-AP is not limited to 
the first couple of hours, as in cytokine expression, this molecule might serve as 
a prognostic marker. However, as increased TAFI-AP levels are indicative for an 
increased activation of TAFI, the current data also suggest that prevention of TAFI 
activation or pharmacological interaction with TAFIa might be a useful therapeutic 
intervention.(38)
In conclusion, activation markers of TAFI are associated with mortality and presence 
of DIC in meningococcal sepsis patients. In addition, an association with severity 
scores and laboratory parameters reflecting severity was observed. Determination 
of TAFI, TAFI-AP and TAFIa(i) is required to enable coherent interpretation of the 
role of TAFI in disease, while the role of genetic polymorphisms and possibilities for 
therapeutic intervention require further investigation.
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Abstract
Objective. Multiple organ failure is a common feature of paediatric meningococcal 
sepsis and is associated with an imbalance of coagulation and fibrinolysis. This is 
partly due to an increased secretion of prothrombotic Ultra Large Von Willebrand 
Factor (VWF) as the result of vascular endothelial damage. Another factor that 
may contribute is ADAMTS13, which converts VWF into smaller, less active, VWF 
multimers and thus influences VWF activity in plasma. We investigated the role of 
ADAMTS13 and VWF in the severity and outcome of sepsis.
Patients and methods. In 71 children with severe meningococcal sepsis we 
measured ADAMTS13 activity and antigen,Von Willebrand Factor collagen binding 
activity (VWF:CB) and antigen levels (VWF:Ag),VWF propeptide and Factor VIII at 
different time points during their stay in the paediatric intensive care unit.
Results. In the acute phase, both ADAMTS13 activity and antigen were decreased 
(median 23.4% and 33.7% of normal, resp.) and VWF:CB and VWF:Ag levels were 
strongly increased (325% and 348%, resp.) ADAMTS13 antigen (23.9% vs 34.6%; 
p=0.06) and VWF:CB (240% and 340%, p<0.001) were lower in non-survivors than 
in survivors. ADAMTS13 activity and VWF:CB were both correlated with the severity 
of the disease, as indicated by the Paediatric Risk of Mortality score (Rs= -0.38 and 
Rs= -0.50, respectively, p<0.001).
Conclusions. In the acute phase of severe sepsis decreased levels of ADAMTS13 
and increased levels of VWF are observed, and the changes are related to severity of 
disease and outcome. This may contribute to the formation of microthrombi and the 
severity of thrombotic sequelae of sepsis.
Introduction
Meningococcal sepsis is characterized by a systemic inflammatory response to an 
infection with Neiseria meningitidis and is associated with multiple organ failure and 
an imbalance between coagulation and fibrinolysis. Although improved treatment 
possibilities have resulted in a decreased mortality, to date approximately 2% of the 
meningococcal infections in developed countries are lethal.(1, 2)
In severe sepsis there is often excessive and sustained generalized activation of the 
endothelium. Prolonged endothelial activation results in pro-inflammatory stimulation 
and a procoagulant state. Anticoagulants, such as antithrombin, activated protein 
C and Tissue Factor Pathway Inhibitor are depleted during sepsis and at the same 
time, fibrinolysis is inhibited, which further potentiates the formation of microthrombi.
(3) A well-known marker of endothelial activation is Von Willebrand Factor (VWF). 
Upon endothelial cell stimulation or damage Ultra Large VWF (ULVWF) is actively 
secreted from the Weibel-Palade bodies in endothelial cells. VWF mediates platelet-
platelet and platelet-subendothelial interactions and has therefore an important role 
in primary haemostasis. Furthermore VWF is also a carrier protein of factor VIII. 
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When ULVWF enters the circulation it is rapidly cleaved by ADAMTS13 at the 1605-
1606 bond in the A2 domain of VWF into smaller less active forms.
VWF levels are elevated in patients with arterial thrombosis such as acute myocardial 
infarction, stroke and peripheral vascular diseases.(4-7) Also in sepsis elevated 
levels of VWF have been reported indicating a possible contribution to microthrombi 
formation.(8) Limited information is available on the role of ADAMTS13 in sepsis and 
only one small study (n = 21) reported on decreased ADAMTS13 levels in children 
with sepsis.(9-12) We hypothesized that reduced ADAMTS13 activity and increased 
VWF levels can contribute to the severity of the disease in children with severe 
meningococcal sepsis. We therefore studied the levels of VWF and ADAMTS13 in 
children with severe sepsis in the acute phase and the convalescent phase of the 
disease, in relation to inflammatory parameters, severity of disease and outcome.
Methods
Participants. Patients admitted to the paediatric intensive care unit (PICU) of the 
Erasmus MC Sophia who previously participated in Rotterdam based meningococcal 
sepsis studies, were eligible for the current study.(13, 14) These studies were 
approved by the medical ethical committee. Children were enrolled after obtaining 
informed consent of the parents or guardians. In total 71 patients from whom citrate 
blood was available, were included in this study.
Inclusion criteria were presentation with tachycardia, tachypnea, rectal temperature 
< 36ºC or > 38.5ºC, and petechiae. Data on all patients were collected at various 
time-points in the course of the disease (t = 0, t = 0.5 day, t = 1 day and t = 90 days). 
The paediatric risk of mortality (PRISM) score, predicted death rate based on the 
Rotterdam score, and the presence of disseminated intravascular coagulation (DIC) 
were collected as markers of severity of disease on admission.(15, 16) DIC was 
defined as having a score of 5 or more on the DIC score, which included platelets, 
FDP or D-dimers levels, PT and fibrinogen.(17)
Within 4 h after admission to the PICU a baseline plasma sample was collected (t 
= 0, n = 58). Additionally blood was drawn at t = 1 day, (n = 50). In an unselected 
patient group blood was also drawn 0.5 day after admission (n = 24) and 90 days 
after admission (n = 6). Differences in number of patients at different time-points are 
the result of the fact that patients, with similar baseline characteristics, were included 
in several studies that did not all include a blood sample at t = 0.5 day. Furthermore 
no samples were drawn when an arterial line was no longer available, when a patient 
was transported back to the referral hospital or when the patient died. Blood was 
drawn after 90 days to study the levels in the convalescent phase, but could only be 
obtained from 6 cooperative children. 
Plasma measurements. ADAMTS13 activity and antigen were measured using 
the Technozym ADAMTS13 ELISA and antigen kit (Technoclone, Vienna, Austria) 
performed as described by the manufacturer. Briefly, diluted plasma samples 
were incubated on micro-titer plates coated with a monoclonal antibody against 
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ADAMTS13. After two hours the plates were washed and an activity substrate was 
added. The fluorescence was measured for 15 minutes (1 measurement per minute) 
at 30ºC. The plate was then washed and incubated with a conjugate substrate. 
Antigen substrate was added and after an incubation of 15 min at 37ºC the reaction 
was stopped and the fluorescence was measured at 360/460 nm (Biotek reader 
FLX800, Vienna, Austria). Normal Human Pooled plasma provided with the kit was 
used as calibrator. The intra-assay variation was 14.9% for antigen and 9% for the 
activity. For the validation a pool of 40 healthy men were used. Values were expressed 
in percentage of normal pooled plasma.
Von Willebrand Factor antigen (VWF:Ag) was determined with an in-house ELISA 
assay using polyclonal rabbit antihuman VWF antibodies (DakoCytomation, Glostrop, 
Denmark) for catching and tagging. VWF collagen binding activity (VWF:CB) was 
measured by an in-house ELISA using type I collagen for catching (Sigma, St Louis, 
USA) and polyclonal rabbit antihuman VWF antibodies (DakoCytomation, Glostrop, 
Denmark) for tagging. Factor VIII:C was measured by means of an clotting-based 
assay (Automatic Coagulation Laboratory (ACL), Instrumental Laboratory, IJsselstein, 
The Netherlands) using FVIII deficient plasma (Ortho Diagnostic Systems, Beerse, 
Belgium). The intra-assay variation of VWF:Ag, VWF:CB and Factor VIII:C was 
14.1% ,12.4% and 5.1% respectively. For the ratio VWF:CB/ADAMTS13 activity 
we expressed VWF in percentages, where 1 U/mL equals 100% of normal pooled 
plasma. VWF propeptide levels were determined by an ELISA using a polyclonal 
antibody against recombinant VWF propeptide as capture and detection antibody, as 
described previously.(18)
The concentrations of C-reactive protein, Interleukin (IL-6), thrombin-antithrombin 
complex (TAT) and plasminogen activator inhibitor I (PAI-I) were determined as 
described previously.(19-21)
Statistical analysis. Continuous parameters were analyzed using the Mann-Whitney 
U test. Binomial variables were analyzed using Pearson’s c2 test or Fisher’s exact 
test when appropriate. Spearman correlation coefficient was determined to assess 
the correlation between ADAMTS13 levels and severity scores or other laboratory 
parameters. All ADAMTS13 levels were expressed as a percentage relative to normal 
pooled plasma. VWF levels were expressed in percentages of normal pooled plasma. 
The statistical analysis was performed using SPSS version 11.0. P values less than 
or equal to 0.05 were considered to be statistical significant.
 
Results
Patient characteristics. In total 71 patients with meningococcal sepsis were included 
in this study. The median age in this population was 5.5 years. The mortality rate was 
12.6%. The baseline patient characteristics are presented in Table 1. 
The median (min-max) ADAMTS13 activity (23.4% (8.3-49.4)) median (min-max) 
and antigen levels (33.7% (13.1-83.9)) at admission were significantly decreased 
in children with sepsis compared to normal pooled plasma and levels increased at 
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three months to 49.5% and 47.9%, respectively (Figure 1). The specific activity of 
ADAMTS13 (activity over antigen ratio) was 0.7 (0.3-1.2) on admission and 1.2 (1.1-1.8) 
after three months (n.s). VWF CB (325% (149-637)) and VWF:Ag (348% (200-660)) 
Table 1. Patient characteristics in survivors and non-survivors.
1Fisher’s Exact test or Mann-Whitney U test were performed when appropriate.
Data are presented as n (%) and median (min-max).
levels were strongly increased on admission and after t = 12 and t = 24 h and 
were (96% (54-120)) for VWF:CB and (76% (60-116)) for VWF:Ag at three months 
(Figure 1). 
Figure 1. ADAMTS13 and VWF levels in the total study population.
Median ADAMTS13 and VWF levels (% relative to normal pooled plasma for ADAMTS13 and for VWF) on 
admission, after 0.5, 1 and 90 days are listed. The bars depict the ranges. 
9
Table 1. Patient characteristics in survivors and non-survivors.
Characteristics Total group
(n = 71)
Non-survivor
(n = 9)
Survivor
(n = 62)
p-value
1
Male gender 44 (62%) 7 (78%) 37 (60%) 0.47
Age in years (min-max) 5.5 (0.1-16.1) 0.9 (0.5-9.4) 4.8 (0.1-16.1) 0.002
Presence of shock 65 (93%) 9 (100%) 56 (92%) 1.0
Mechanical ventilation 45 (64%) 9 (100%) 36 (59%) 0.02
Presence of DIC on admission 41 (58%) 9 (100%) 32 (52%) 0.008
DIC in first 24 h 51 (72%) 9 (100%) 42 (68%) 0.05
PRISM score (first 6 h) 21 (4-43) 33 (23-43) 19 (4-37) 0.001
Predicted death rate based on Rotterdam score 9 (0-99) 94 (55-100) 6 (0-96) <0.0001
Fisher’s Exact test or Mann Whitney U test were performed when appropriate.
Data are presented as n (%) and median (min-max).
Table 2. VWF:CB activity (%) / ADAMTS13 activity (%) ratio in survivors and non-survivors.
Time point Total group Survivors Non-survivors p-value
tT = 0 day 13 (6-40) 15 (7-40) 12 (6-28) 0.33
t = 0.5 day 10 (2-22) 10 (2-22) 4 (3-4) 0.04
t = 1 day 9 (3-24) 9 (3-24) 4 (4-6) 0.07
t = 90 days 1 (1-7) 1 (1-7)
Values depicted are median (min-max), VWF:CB 1 U/ml=100%.
P values are Mann-Whitney U test, 2 tailed (survivors versus non-survivors).
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The median (min-max) level of FVIII:C on admission was 67% (4-303). The ratio 
VWF:FVIII:C on admission was 4.6 (1.5-6.0) and 1.7 (1.4-8.0) after three months 
p=0.003. The ratio VWF:CB/ADAMTS13 activity was calculated at all time points and 
was 9 (4-27) at t=0 and normalized to 1 (1-5) at three months (Table 2). The median 
(min-max) VWF propeptide levels upon admission were increased to 27.8 nM (8.0-
47) and normalized after three months (4.5 nM (2.9-6.5), p=0.14). 
Table 2. VWF:CB activity (%) / ADAMTS13 activity (%) ratio in survivors and non-survivors.
Values depicted are median (min-max), VWF:CB 1 U/mL=100%.
P values are Mann-Whitney U test, 2 tailed (survivors versus non-survivors).
Plasma levels in survivors and non-survivors. On admission ADAMTS13 antigen 
was slightly higher (34.6% (14.5-83.9)) in survivors on admission, than in non-
survivors (23.9% (13.2-41.8)), (p=0.06) (Table 3). ADAMTS13 activity in survivors 
was 24.3% (11.5-49.4) vs. 19.4% (8.3-27.6) in non-survivors (p=0.19). In survivors 
the levels of VWF:Ag were higher than in non-survivors (370% (240-660)) vs. (240% 
(200-330), p<0.001). Also the VWF:CB was higher in survivors than in non-survivors, 
(340% (160-640)) vs. (240% (150-320), p<0.001) (Table 3). In survivors the levels of 
FVIII:C (0.20 U/ml (0-0.6)) were significantly lower than in non-survivors (0.8 U/ml 
(0-3.0)). 
Figure 2a. VWF propeptide levels in survivors and non-survivors.
Median levels of VWF propeptide levels in survivors and non-survivors are plotted. The closed circles 
represent the survivors and the open circles represent the non-survivors. The bar represents the range.
Figure 2b. VWF propetide levels in patients with DIC versus without DIC. 
Median levels of VWF propeptide levels in patients with DIC versus without DIC are plotted. The bar 
represents the range. The closed squares represent the patients without DIC and the open squares 
represent the patients without DIC. 
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Table 2. F:CB activity (%) / ADAMTS13 activity (%) ratio in survivors a d non-survivors.
Time point Total group Survivors Non-survivors p-value
t = 0 day 13 (6-40) 15 (7-40) 12 (6-28) 0.33
t = 0.5 day 10 (2-22) 10 (2-22) 4 (3-4) 0.04
t = 1 day 9 (3-24) 9 (3-24) 4 (4-6) 0.07
t = 90 days 1 (1-7) 1 (1-7)
Values depicted are median (min-max), VWF:CB 1 U/ml=100%.
P values are Mann-Whitney U test, 2 tailed (survivors versus non-survivors).
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The ratio VWF/FVIII:C on admission was 4.3 (1.5-46.2) in survivors and 9.7 (3.4-60) 
in non-survivors (p=0.003). The ratio VWF:CB/ ADAMTS13 activity was higher in 
survivors than in non-survivors after 0.5 day (Table 2). The propeptide levels were 
not significantly different in survivors compared to non-survivors: 28.7 nM (8.0-47.0) 
versus 22.2 nM (21.9-34.6), respectively (Figure 2A). At 90 days the VWF propeptide 
levels were normal in the survivors. 
Figure 3. ADAMTS13 and VWF antigen levels in patients with and without DIC. 
Median levels of ADAMTS13 and VWF in patients with and without DIC are plotted. The closed squares 
represent the patients without DIC, the open squares represent the patients with DIC. The bar represents 
the range.
Plasma levels in patients with DIC and without DIC. For ADAMTS13 antigen no 
statistical difference between patients with DIC and without DIC was observed (Figure 
3). However, ADAMTS13 activity (min-max) on admission was lower in patients with 
DIC (19.4% (8.3-35.2)) than in individuals without DIC (27.3% (11.5-49.4), p=0.01). 
On admission VWF:Ag was higher in the patients without DIC (390% (250-590)) than 
in patients with DIC (330% (200-660), p=0.03) (Figure 3). For VWF:CB there was 
no difference in levels at the various time points. FVIII:C levels on admission were 
significantly higher in patients without DIC (1.3 U/ml (0.5-3.0)) than in patients with 
DIC (0.4 U/ml (0.0-1.45), p<0.001). The ratio VWF/FVIII:C on admission was 2.7 
(1.5-5.6) in patient without DIC and 8.3 (3.4-60) in patients with DIC (p=0.001). There 
was no difference in the ratio VWF:CB/ADAMTS13 activity in patients with DIC or 
without DIC. 
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The VWF propeptide levels were similar in patients with DIC (28.5 nM (8.0-43.0)) 
compared to patients without DIC (26.5 nM (9.0-47.0), p=0.57) (Figure 2B). 
Correlations with severity of disease. Both ADAMTS13 and VWF were negatively 
correlated with the PRISM score and the predicted death rate based on the Rotterdam 
score (Table 4). There was no correlation between ADAMTS13 antigen or activity and 
DIC parameters, such as thrombin-antithrombin (TAT) complexes and plasminogen 
activator inhibitor I (PAI-1). A positive significant correlation was seen for VWF with 
the levels of CRP. Another inflammatory marker, IL-6, was negatively correlated with 
VWF activity (Table 4).
Table 4. Correlations of ADAMTS13 and VWF on admission.
Discussion
In the present study, we showed that the plasma levels of ADAMTS13 and VWF on 
admission were associated with the outcome of meningococcal sepsis in children. 
Furthermore, a strong decrease of ADAMTS13 and increase of VWF were seen in the 
first 24 hours of the disease and both correlated with disease severity. We observed a 
strong correlation between ADAMTS13 and markers for disease severity, such as the 
PRISM score, and the predicted death rate based on the Rotterdam score.
Since ADAMTS13 cleaves ultra large VWF multimers into smaller, less thrombogenic 
multimers, it is expected that low levels of ADAMTS13 will result in more ULVWF in 
plasma and is therefore expected to result in a more thrombogenic state. Recently 
Bockmeyer et al. indeed showed that inflammation-induced ADAMTS13 deficiency is 
associated with the appearance of ULVWF in plasma.(22) In sepsis patients in whom 
VWF levels are strongly increased this pro-thrombotic state may further worsen the 
outcome in these patients. 
In our study in a large population of children with meningococcal sepsis, we have 
shown a reduction in the levels of ADAMTS13 activity and antigen in the acute phase 
of the disease. These results are in concordance with previous studies in sepsis 
patients that reported that the levels of ADAMTS13 are decreased and levels of 
1
Table 4. Correlations of ADAMTS13 and VWF on admission.
Laboratory parameter n ADAMTS13
antigen (p)
ADAMTS13
activity (p)
n VWFag (p) VWFact (p)
Clinical parameters
Age in years 58 0.22 (0.10) 0.08 (0.58) 58 0.40 (0.00) 0.28 (0.03)
PRISM score (6 h) 58 -0.31 (0.02) -0.38 (0.01) 58 -0.46 (0.00) -0.50 (0.00)
Predicted death rate
(Rotterdam score)
58 -0.26 (0.05) -0.33 (0.02) 58 -0.56 (0.00) -0.58 (0.00)
IL-6 (ng/mL) 27 -0.21 (0.28) 0.02 (0.94) 27 -0.37 (0.05) -0.52 (0.01)
CRP (mg/L) 58 0.29 (0.03) 0.05 (0.72) 58 0.39 (0.00) 0.29 (0.03)
Haemostasis
Platelet count (*10
9
/ ) 58 0.17 (0.20) 0.34 (0.01) 58 0.51 (0.00) 0.39 (0.00)
TAT (ng/mL) 27 -0.25 (0.21) -0.03 (0.87) 27 -0.35 (0.07) -0.48 (0.01)
PAI-1(ng/mL) 27 -0.26 (0.19) -0.05 (0.81) 27 -0.41 (0.03) -0.38 (0.05)
Factor VIII:C (U/m ) 58 0.21 (0.11) 0.48 (0.00) 58 0.43 (0.00) 0.59 (0.00)
L
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VWF are increased.(9-12) Most of these studies were in adult patients with sepsis-
induced disseminated intravascular coagulation, and it was not yet known whether 
the contribution of ADAMTS13 to sepsis in children is similar to that in adults. Only 
one small study had been performed so far in children which is in agreement with our 
study.(12) In our study we showed for the first time that there is a relationship between 
ADAMTS13 and DIC and with outcome and severity of the disease in children. 
In addition, lower levels of ADAMTS13 were inversely related to outcome scores 
(Rotterdam score and PRISM score), which indicates that low ADAMTS13 levels are 
associated with poor prognosis. Levels of ADAMTS13 antigen on admission were 
indeed lower in the non-survivors than in survivors. ADAMTS13 was not correlated 
with age, but VWF was. Age may play a role, since an immature state of clotting 
system may cause a more severe coagulation state in young children.(23)
Interestingly, higher levels of VWF were observed in the survivors compared to the 
non-survivors. One explanation might be that this is caused by a decreased release 
of VWF in the non-survivors, but it is expected that a more severe disease results in 
increased endothelial damage and higher VWF levels. An alternative hypothesis is 
that differences in VWF levels result from an increased consumption of VWF in the 
non-survivors. To discriminate between these possible mechanisms, we measured 
the VWF propeptide, which is a marker for the secretion of VWF. VWF propeptide 
was significantly increased in the first 24 h and was normal after three months. No 
difference was seen for survivors versus non-survivors for the propeptide levels. This 
indicates that a decreased release of VWF is not the cause of the lower VWF levels 
in the non-survivors. The second mechanism, more consumption of VWF, is more 
likely since patients with DIC had significantly lower VWF levels than patients without 
DIC. This is further substantiated by the negative correlation between VWF with TAT, 
a marker of coagulation activation.
A limitation of the study was that we compared the levels of ADAMTS13 in septic 
children with the normal levels of ADAMTS13 in adults. Nguyen et al used as a 
control group children that were critically ill but did not have sepsis, and showed 
that in their control group of children ADAMTS13 levels were around 85% of adult 
reference values.(12)
Some patients with severe sepsis are treated with coagulation factor concentrates, 
such as activated protein C, to reduce coagulation activation, which may improve 
the prognosis.(24) The results of our study may indicate that ADAMTS13, of which a 
recombinant preparation has recently become available, might also be a therapeutic 
thrombotic agent in severe sepsis.(25) Theoretically, infusion of ADAMTS13 in these 
patients may result in increased cleavage of ULVWF and may therefore reduce the 
thrombogenicity in these patients.(26) However, additional studies on ADAMTS13 
levels in both children and adults with severe sepsis should be performed to confirm 
our findings before this approach is explored.
In conclusion, our study shows that levels of ADAMTS13 are strongly reduced and 
levels of VWF are strongly increased in children with meningococcal sepsis and 
that these levels are associated with severity and outcome of the disease, likely by 
promoting the formation of microthrombi in these affected children.
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Abstract
Objective. Identification of new therapeutic targets remains an imperative goal to 
improve the morbidity and mortality of severe sepsis and septic shock. Macrophage 
migration inhibitory factor (MIF), a pro-inflammatory cytokine and counterregulator of 
glucocorticoids, has recently emerged as a critical mediator of innate immunity and 
experimental sepsis, and is an attractive new target for treatment of sepsis. 
Patients and Methods. Circulating concentrations of MIF were measured in two 
clinical trial cohorts of 145 paediatric and adult patients with severe sepsis or septic 
shock caused predominantly by infection with Neisseria meningitidis or other Gram-
negative bacteria, to study the kinetics of MIF during sepsis, to analyze the interplay 
between MIF and other mediators of sepsis or stress hormones (adrenocorticotropic 
hormone and cortisol), and to determine whether MIF is associated with patient 
outcome.
Results. Circulating concentrations of MIF were markedly elevated in 96% of children 
and adults who had severe sepsis or septic shock, and they remained elevated for 
several days. MIF levels were correlated with sepsis severity scores, presence of 
shock, disseminated intravascular coagulation, urine output, blood pH and lactate 
and cytokines levels. High levels of MIF were associated with a rapidly fatal outcome. 
Moreover, in meningococcal sepsis, concentrations of MIF were positively correlated 
with adrenocorticotropic hormone levels and negatively correlated with cortisol levels 
and the cortisol:adrenocorticotropic hormone ratio, suggesting an inappropriate 
adrenal response to sepsis. 
Conclusions. MIF is markedly and persistently up-regulated in children and adults 
with Gram-negative sepsis and is associated with parameters of disease severity, 
with dysregulated pituitary-adrenal function in meningococcal sepsis and with early 
death.
Introduction
Numerous adjunctive therapies for patients with severe sepsis and septic shock 
have been tested in clinical trials. Until recently, most anti-sepsis therapies yielded 
disappointing results. However, the use of drotrecogin alpha activated, corticosteroid 
therapy, and early goal-directed therapy has recently given encouraging results 
in adult patients.(1-3) However, identification of new therapeutic targets to further 
improve the morbidity and mortality associated with severe sepsis and septic shock 
remains an imperative goal. 
Discovered 40 years ago as a T cell cytokine that inhibited macrophage motility, 
macrophage migration inhibitory factor (MIF) remained an enigmatic molecule until its 
rediscovery in the early 1990s as a neuroendocrine peptide and an effector molecule 
of innate immunity.(4-6) Constitutively expressed by endocrine and immune cells, MIF 
is released in an hormone-like fashion by the anterior pituitary gland and the adrenal 
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cortex after exposure to endotoxin (lipopolysaccharide (LPS)), corticotropin-releasing 
hormone or physiological stress.(6-9) MIF is also released by innate immune cells 
that are exposed to pro-inflammatory mediators and microbial products, and it acts to 
promote inflammatory and immune responses.(10, 11)
Interestingly, MIF and corticosteroids together function as a homeostatic counter-
regulatory dyad modulating inflammatory and immune responses.(7) Low doses of 
corticosteroids were found to induce MIF release, which, in turn, counterbalanced the 
immunosuppressive and anti-inflammatory effects of glucocorticoids. Cytoplasmic 
phospholipase A2 and mitogen-activated protein kinase phosphatase 1 have 
been identified as key molecular targets of MIF-glucocorticoid crosstalk.(12, 13) 
The expression of Toll-like receptor 4, the signal transducing molecule of the LPS 
receptor complex, is up-regulated by MIF thereby facilitating the detection of Gram-
negative bacteria.(14) Moreover, MIF has been shown to play an important role in 
experimental sepsis, acute respiratory distress syndrome and several inflammatory 
and auto-immune diseases.(6, 7, 11, 15-17) Thus, many lines of evidence indicate 
that MIF is an interesting candidate target for therapeutic intervention in patients who 
have severe sepsis.  
In the present study, we measured the circulating concentrations of MIF in two clinical 
trial cohorts of patients with severe sepsis or septic shock comprising children with 
meningococcal sepsis and adults with Gram-negative sepsis. We studied the kinetics 
of MIF release in the systemic circulation during sepsis; the interplay between MIF, 
mediators of sepsis and stress hormones (adrenocorticotropic hormone (ACTH) and 
cortisol) and whether MIF was associated with patient’s outcome, and if so, whether 
it might help to identify patients who may benefit from anti-MIF treatment strategies. 
Methods
Adult patients. The adult study population consisted of 68 patients with sepsis, 
severe sepsis or septic shock who were part of a prospective, double-blind study that 
investigated the efficacy of two IgG preparations for the treatment of Gram-negative 
severe sepsis and septic shock.(18) Severe sepsis and septic shock were defined 
as previously reported.(18, 19) Clinical and laboratory parameters were recorded 
at study entry (i.e. near the onset of severe sepsis or septic shock) and during the 
course of disease. The evaluation of the patient outcome was made prospectively at 
the time of the study.(18, 19) Patients were classified as having survived (“survivors”); 
as having died of fulminant, irreversible septic shock (“early death”); or as having 
died of an indirect consequence or of a relapse of shock after transient reversal of 
shock, defined as a normalization of blood pressure and discontinuation of supportive 
vasopressor therapy (“late death”). The severity of underlying diseases was reported 
according to the classification proposed by McCabe and Jackson.(20) Concentrations 
of MIF were also measured in 196 healthy subjects. The study was approved by the 
ethics committees of the participating centres and informed consent was obtained 
from patients or from their relatives.(19)
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Paediatric patients. The paediatric study population consisted of 77 patients 
admitted to the paediatric intensive care unit of the Erasmus MC Sophia (Rotterdam, 
the Netherlands) who had been enrolled in meningococcal sepsis studies.(21-25) 
All studies were approved by the ethical committee of the Erasmus Medical Center 
and informed consent was obtained from parents or guardians of patients. Inclusion 
criteria (tachycardia, tachypnea, rectal body temperature < 36°C or > 38.5°C, and 
petechiae) were in accordance with recommendations of the International Paediatric 
Sepsis Consensus Conference.(26) Clinical data, severity scores, and laboratory 
parameters were collected at study entry and during the course of disease, as has 
been previously defined.(27, 28) Neisseria meningitidis serogroups were determined 
at the Netherlands Reference Laboratory for Bacterial Meningitis (Academic Medical 
Center Amsterdam, Amsterdam, the Netherlands).
Blood sampling and cytokine, coagulation factors and stress hormones 
measurements. In adult patients serum was collected at study entry (i.e. before 
the infusion of immunoglobulins), 2 h thereafter (for 61 patients), at day 1 (for 57 
patients) and at day 10 (for 41 patients). In children, citrate plasma was obtained at 
baseline (i.e. within 4 h of PICU admission, for 71 patients and at later time-points for 6 
patients) and 12 h (for 23 patients) and 24 h (for 62 patients) thereafter. Convalescent 
blood samples, obtained 3 months after admission, were obtained from 13 patients. 
Serum and plasma samples were stored at -80oC and underwent, at most, two 
freeze and thaw cycles before being assayed blindly. Concentrations of MIF were 
measured using ELISA, as described elsewhere.(29) The analytic sensitivity of the 
human MIF ELISA was 39 pg/ml. Intra-run and inter-run coefficients of variation were 
6% and 12%, respectively. Concentrations of cholesterol, ACTH, cortisol, C-reactive 
protein, procalcitonin TNF, IL-1β, IL-1ra, IL-6, IL-8, IL-10, MIP-1β, activated protein 
C, thrombin-antithrombin III complexes and plasminogen activator inhibitor-1 were 
determined as previously described.(19, 22-25, 30, 31)
Statistical analysis. Comparison between groups was assessed using the Kruskall-
Wallis test for continuous variables and Pearson’s c2 or Fisher’s exact test for 
categorical variables as appropriate. Spearman’s correlation coefficient was used 
to evaluate the correlation between concentrations of MIF and other laboratory 
parameters. The interday differences for cytokine levels were evaluated using the 
Wilcoxon signed-rank test. The risk of death associated with blood MIF levels was 
assessed using logistic regression analyses. Two-sided P values of less than 0.05 
were considered to indicate statistical significance. Analyses were performed using 
SPSS software, version 14.0 (SPSS) and STATA software, version 9.0 (Statacorp).  
Results
Adult patients. Among the 68 adult patients, 15 (22%) presented with severe sepsis 
and 53 (78%) with septic shock. Thirty-two patients died (47%). Non-survivors had 
been prospectively subdivided into 2 groups: 20 patients (29%) who rapidly died of 
fulminant, irreversible septic shock (early death; median time to death, 2.5 days) and 
12 patients (18%) who experienced late death (median time to death, 14.5 days). 
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Table 1 lists the demographic, clinical, and laboratory characteristics of the survivor 
group, the early death group, and the late death group. 
Table 1. Characteristics of adult patients in the study population, by outcome.
Data are median (range), unless otherwise indicated. Adult patients were classified as having survived 
(survivors); as having died of fulminant, irreversible septic shock (early death group); or as having died of an 
indirect consequence or of a relapse of shock after transient reversal of shock, defined as a normalization 
of blood pressure and discontinuation of supportive vasopressor therapy (late death group). The three 
groups of patients differed in sex ratio (p=0.02), severity of the underlying disease (p=0.01), age (p=0.09), 
urine output (p=0.0001), arterial pH (p=0.02), and time to death (p=0.0002).
1Some patients had mixed infections.
Sepsis was caused by Gram-negative bacteria in 54 patients (80%), by Gram-
positive bacteria in 4 patients (6%) and by Candida albicans in 3 patients (4%). In 7 
patients (10%), all sample cultures remained had negative results. Blood cultures had 
positive results in 43 patients (63%) (Table 2). Polymicrobial bacteraemia occurred 
in 8 patients (12%). 
MIF was detected in the serum samples of all patients who were enrolled in the study. 
MIF levels were much higher among patients with sepsis (median level at study entry, 
103.7 ng/mL; range, 1.4-3200 ng/mL) than among healthy subjects (median level at 
study entry, 5.2 ng/mL; range, 2.8-15.5 ng/mL; p<10-6). Serum concentrations of MIF 
continued to increase within 2 h after study entry (median, 131.5 ng/mL; range, 2.5-
3200 ng/mL) and progressively decreased thereafter (median level at day 1, 73.7 ng/
mL; range, 5.2-1772 ng/mL; median at day 10, 50.3 ng/mL; range, 0-388 ng/mL). In 
12
Table 1. Characteristics of adult patients in the study population, by outcome.
Survivors
n = 36
Early death
n = 20
Late death
n = 12
Age (years) 52 (7-78) 58.5 (21-74) 67 (34-76)
Male sex, no. (%) 18 (50) 17 (85) 9 (75)
Severity of underlying
Diseases, no. of patients
Rapidly fatal 0 2 3
Ultimately fatal 7 5 5
Non-fatal 29 13 4
Corticosteroid use, no.(%) of patients
None 27 (75) 13 (65) 6 (50)
Chronic use 2 (6) 4 (20) 1 (8)
Acute use 7 (19) 3 (15) 5 (42)
Site of infection, no. of patients
Intra-abdominal 11 9 6
Respiratory tract 9 6 2
Genito-urinary tract 6 2 0
Skin and soft tissue 1 2 1
Central nervous system 3 1 0
Other site 0 0 1
No site identified 6 0 2
Pathogen, no. of patients
1
Gram-negative bacteria 19 13 5
Gram-positive bacteria 3 0 1
Fungi 3 0 0
Mixed infections 6 7 5
Not documented 5 0 1
Temperature, 
o
C 38.2 (35.0-40.4) 37.3 (35.6-40.4) 38.1 (35.9-39.4)
Mean arterial pressure, mmHg 63 (17-115) 60 (23-87) 62.5 (47-85)
Duration of hypotension, h 12 (2-36) 11.5 (0-96) 10 (3-144)
Urine output, mL/min 30 (0-200) 0 (0-170) 27.5 (0-60)
Arterial pH 7.39 (7.27-7.57) 7.30 (7.17-7.47) 7.38 (7.26-7.52)
Leukocyte count, G/L 10.25 (0.2-42.0) 6.2 (0.1-100) 6.95 (0.8-13.7)
Thrombocyte count, G/ 89.5 (17-516) 73 (22-352) 109 (12-400)
Data are median (range), unless otherwise indicated. Adult patients were classified as having survived (survivors); as having
died of fulminant, irreversible septic shock (early death group); or as having died of an indirect consequence or of a relapse
of shock after transient reversal of shock, defined as a normalization of blood pressure and discontinuation of supportive
vasopressor therapy (late death group). The three groups of patients differed in sex ratio (P=0.02), severity of the underlying
disease (P=0.01), age (P=0.09), urine output (P=0.0001), arterial pH (P=0.02), and time to death (P=0.0002).
1
S me patients had mixed infections.
L
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71% of the patients, peak levels of MIF were reached within 2 h of enrolment. Only 
3 patients (4%) had peak MIF levels (1.4, 5.9, and 6.5 ng/mL) that were within the 
range for healthy subjects, probably because of chemotherapy-induced neutropenia 
(defined as an absolute neutrophil count < 100 cells/mm3) in one patient and because 
of treatment with high doses of hydrocortisone or methylprednisolone in the other two 
patients. Twenty-two patients (32%) were receiving corticosteroid therapy at study 
entry, which had a significant impact on the circulating MIF levels measured at study 
entry (p=0.001). Interestingly, patients who had been receiving long-term prednisone 
therapy (n = 7) had higher MIF levels (median level, 350.3 ng/mL; range, 52.5-525 
ng/mL) than those who had not received corticosteroids (median level, 109.1 ng/mL; 
range, 4.2-1585.5 ng/mL; p=0.07), whereas patients who were treated shortly before 
enrollment with high doses of hydrocortisone, methyprednisolone or dexamethasone 
(n = 15) for the treatment of sepsis had much lower MIF levels (median level, 37.7 ng/
mL; range, 1.4-3200 ng/mL; p=0.003). 
Table 2. Micro-organisms isolated from blood samples obtained from adult study patients.
Peak MIF serum concentrations (defined as the highest MIF level within the first 2 h of 
study entry) were inversely correlated with urine output (R= -0.37; p=0.002) and, to a 
lesser extent, with arterial pH (R= -0.22; p=0.07). There was a trend toward a positive 
correlation between MIF levels and leucocyte counts (R=0.21; p=0.09), a finding that 
was in agreement with the observation of low MIF levels in a neutropenic patient. 
Serum concentrations of MIF were found to correlate with those of macrophage 
inflammatory protein-1β (p=0.001), IL-1β (p=0.05) and, to a lesser extent, with those 
of plasminogen activator inhibitor-1 (p=0.06), IL-8 (p=0.09) and IL-6 (p=0.10), but not 
with those of TNF (p=0.25)
Paediatric patients with meningococcal sepsis. The demographic, clinical, and 
microbiological characteristics of the 77 paediatric patients are shown in Table 3. 
Seventy-one patients (92%) presented with septic shock, and 6 (8%) presented 
13
Table 2. Micro-organisms isolated from blood samples obtained from adult study patients.
Microorganisms Number of isolates
Gram-negative bacteria
Escherichia coli 14
Pseudomonas species 7
Klebsiella species 4
Enterobacter species 3
Neisseria meningitidis 3
Serratia species 2
Citrobacter species 1
Proteus species 1
Bacteroides species 1
Other 2
Gram-positive bacteria
Staphylococcus aureus 1
Enterococcus faecalis 1
Coagulase-negative staphylococci 1
Fungi
Candida albicans 2
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with severe sepsis and 10 patients (13%) died. N. meningitidis was isolated from 
blood samples by culture in 65 patients and by PCR in 2. The other 10 patients had 
possible meningococcal infections on the basis of clinical criteria.(27) At study entry, 
concentrations of MIF were found to be negatively correlated with age (p<0.001) and 
positively correlated with paediatric risk of mortality score (p<0.001) and predicted 
mortality (p<0.001) on the basis of Rotterdam score. 
Table 3. Characteristics of paediatric patients with meningococcal sepsis, by outcome.
Data are no. (%) unless otherwise indicated. The two groups of patients differed in age (p=0.002), need for 
mechanical ventilation (p=0.03), presence of Disseminated intravascular coagulation (p=0.004), PRISM 
score (p=0.001), and predicted mortality (p<0.001). PRISM, paediatric risk of mortality.
MIF levels also were significantly higher in patients with disseminated intravascular 
coagulation (median level, 74 ng/mL; range, 22-560 ng/mL)than in those who did 
(median level, 36 ng/ML; range, 8-235 ng/mL; p<0.001) and higher in patients with 
shock (median level, 57 ng/mL; range, 18-560 ng/mL) than in those not experience 
shock (median level, 20 ng/mL; range, 2-35 ng/mL; p<0.001). Moreover, MIF levels 
were positively correlated with lactate and procalcitonin levels (p=0.006 and p=0.016, 
respectively), whereas they were negatively correlated with levels of C-reactive 
protein (p=0.02) and cholesterol (p=0.001). Serum concentrations of MIF were 
positively correlated with levels of IL-1β (p<0.001), IL-1ra (p=0.002), IL-6 (p=0.001), 
IL-8 (p=0.001), and soluble TNF receptor (p=0.01) and, to a lesser extent, with levels 
of TNF (p=0.08) and IL-10 (p=0.08). In addition, MIF was correlated with thrombin-
antithrombin III complexes (p=0.003), plasminogen activator inhibitor-1 (p=0.006) 
and activated protein C (p=0.02).
MIF and the hypothalamo-pituitary-adrenal (HPA) function. The relationship 
between circulating levels of MIF and stress hormones (ACTH and cortisol) 
was examined in children with meningococcal sepsis. Interestingly, circulating 
concentrations of MIF were found to be positively correlated with ACTH levels (p=10-6) 
(Figure 1A) and negatively correlated with cortisol levels (p=0.005) (Figure 1B) and 
with cortisol:ACTH ratio (p=10-6) (Figure 1C). Although ACTH stimulation tests were 
not performed, the stress hormones profile showing an inverse correlation between 
ACTH and cortisol levels (p=0.0003) was very suggestive of an inappropriate adrenal 
response to ACTH. This was particularly obvious in non-survivors in whom blood 
profiles exhibited a typical pattern of high MIF levels and low cortisol:ACTH ratio 
14
le 3. Char cteristics of paediatric patients with meningococcal sepsis, by outcom .
Survivors
n = 67
Non survivors
n = 10
Age, median years (range) 4.38 (0.12-16.11) 1.10 (0.46-9.43)
Male sex 41 (61) 8 (80)
Shock 61 (92) 10 (100)
Receipt of mechanical ventilation 41 (62) 10 (100)
Disseminated intravascular coagulation 34 (51%) 10 (100%)
PRISM score within first 6 h, median score (range) 20.0 (4-37) 31.5 (23-43)
Predicted mortality based on the Rotterdam score, % (range) 5.9 (0.0-96.3) 95.9 (55.1-99.6)
Documentation of Neisseria meningitidis infection
Blood culture 55 (82) 10 (100)
PCR 2 (3) 0
Neisseria meningitidis serogroup
B 39 (75) 7 (87.5)
C 13 (25) 1 (12.5)
Data are no. (%) unless otherwise indicated. The two groups of patients differed in age (P=0.002), need for mechanical
ventilation (P=0.03), presence of Disseminated intravascular coagulation (P=0.004), PRISM score (P=0.001), and predicted
mortality (P<0.001). PRISM, paediatric risk of mortality.
-
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pathognomonic of a dysregulated MIF-glucocorticoid balance with an exuberant pro-
inflammatory response (Figure 1C). 
Figure 1. Correlations between levels of macrophage migration inhibitory factor (MIF) and 
adrenocorticotrophic hormone (ACTH; A), MIF and cortisol levels (B), and MIF and cortisol:ACTH ratio 
(C), measured at admission to the hospital, in children with meningococcal severe sepsis and septic 
shock. Black circles, non-survivors; gray circles, survivors. Spearman’s correlation coefficients: R=0.597 
(A), R=-0.355 (B) and R=-0.627 (C).
MIF and survival. Peak serum levels of MIF differed markedly between the 3 groups 
of adult patients (p=0.0002) (Figure 2A). Levels were markedly higher in the 20
Figure 2. Box plots of macrophage migration inhibitory factor (MIF) levels in adults (A) and in children 
(B). The bottom, median and top lines of the box mark the 25th, 50th and 75th percentiles, respectively. 
The vertical line with whiskers shows the range of values. A, Survivors and non-survivors subdivided into 
those who experienced late death and those who experienced early death. Global P value, p=0.0002; 
those who experienced early death versus survivors, p=0.001, and those who experienced early death 
versus late death p=0.0001; survivors versus those who experienced late death, p=0.23. B, survivors and 
non-survivors, p=0.0001.
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patients in the early death group (median level, 425.9 ng/mL; range, 73.6- 3200 ng/
mL) than in the 36 survivors (median level, 108.2 ng/mL; range 5.9-1236.8 ng/mL; 
p=0.001) or in the 12 patients in the late death group (median level, 78.0 ng/mL; 
range, 2.5-350.3 ng/mL; p=0.0001) (p=0.23 for survivors vs. late death group). At 
study entry, each incremental elevation of 100 ng/mL of MIF increased the risk of 
early death by a factor of 1.67 (95% CI, 1.17-2.41; p=0.005). This finding remained 
significant (OR 1.49; 95 % CI 1.02-2.19; p=0.03) after adjustments for sex and urine 
output, two variables that were significantly associated with MIF levels and the risk of 
death. Table 4 shows the kinetics of MIF levels in survivors and non-survivors over a 
10-day period. 
Circulating concentrations of MIF were also associated with outcome in children with 
meningococcal sepsis. MIF levels were significantly higher in non-survivors than in 
survivors (at study entry, p=0.0001; at 12 h, p=0.005; and at 24 h, p=0.01) (Figure 2B 
and Table 4). Similar to the observation made in adults, each incremental elevation 
of 100 ng/mL of MIF increased the risk of death by a factor of 7.4 (95% CI, 2.1-
26; p=0.002). Levels of MIF measured in convalescent children three months after 
admission were significantly lower than those measured at admission (p=0.009).  
Table 4. Kinetics of blood macrophage migration factor (MIF) concentrations in adult and paediatric 
study patients, by outcome.
Values are median (range). Adult patients were classified as having survived (survivors); as having died 
of fulminant, irreversible septic shock (early death group); or as having died of an indirect consequence or 
of a relapse of shock after transient reversal of shock, defined as a normalization of blood pressure and 
discontinuation of supportive vasopressor therapy (late death group). Paediatric patients were classified 
as having survived (survivors) or as having died (non-survivors).
Discussion
Analyses of the kinetics of blood MIF in two cohorts of 145 patients with Gram-
negative severe sepsis and septic shock caused by N. meningitidis infection in 
children and predominantly by Enterobacteriaceae and Pseudomonas species 
infection in adults revealed that 96% of the paediatric and adult patients with severe 
sepsis or septic shock had elevated MIF levels that were 10 times above the normal 
range of MIF concentrations in healthy subjects. These results confirm and extend 
previous findings of four series of patients who had either systemic inflammatory 
response syndrome, severe sepsis, or septic shock.(32-35) MIF levels remained 
elevated for at least 10 days after the onset of severe sepsis and septic shock. This 
rather unique kinetic profile offers a wide window for therapeutic interventions likely 
1
MIF concentration Survivors Non-survivors Early death Late death
Adult Patients
At study entry 71 (4-717) 165 (124-369) 51 (14-350)
After 2 h 75 (3-1131) 447 (92-743) 106 (27-299)
On day 1 108 (5-862) 670 (110-1772) 87 (23-317)
On day 10 36 (0-273) 231 (118-388) 55 (4-191)
Paediatric patients
At study entry 53 (2-235) 161 (56-561)
After 12 h 43 (18-155) 207 (202-735)
After 24 h 32 (2-386) 347 (213-481)
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to be a major advantage for the design of future clinical trials with anti-MIF therapies 
that are currently under development.
MIF levels were correlated with sepsis severity scores (paediatric risk of mortality 
score and predicted mortality rates in children with meningococcal sepsis), morbidity 
(presence of shock, disseminated intravascular coagulation, low urine output and 
arterial pH, and high lactate levels), and, importantly, with mortality. Indeed, very high 
MIF levels at the onset of sepsis were associated with fulminant and rapidly fatal 
disease. In contrast, adults in the late death group of patients who initially recovered 
from shock but who died later from complications of shock or from a relapse of sepsis 
had MIF levels that were in the range of those of survivors. Therefore, measurement 
of blood MIF may help to identify patients with poor prognosis and in whom anti-MIF 
treatment strategies might improve survival. 
Consistent with its pro-inflammatory activities, MIF level was found to be correlated 
with markers of inflammation or sepsis (C-reactive protein and procalcitonin levels in 
children) and with pro-inflammatory cytokine levels. However, some discrepancies 
were observed between children and adults with respect to correlations between 
MIF and pro-inflammatory cytokine (TNF, IL-6 and IL-8) levels. Several factors 
may account for these discrepancies, such as the timing of blood sampling; the 
patient’s age, which might influence MIF responses (a hypothesis that deserves 
further investigation); the type of infections (community-acquired infections in 
children vs. a mixture of community-acquired and health-care related infections in 
adults); the underlying risk factors (e.g., meningococcal sepsis typically occurs in 
young, otherwise healthy subjects with low bactericidal antibody titers, whereas 
Gram-negative sepsis in adults occurs in the context of co-morbidities likely to affect 
the magnitude of cytokine responses); and, of course, the aetiology of sepsis (N. 
meningitidis infection in children vs. Enterobacteriaceae and Pseudomonas species 
infection in adults). Indeed, in contrast to other types of Gram-negative sepsis, 
meningococcal sepsis usually follows a fulminant course characterized by a rapid 
invasion of the bloodstream, very high concentrations of endotoxin in the systemic 
circulation, and the induction of a vigorous cytokine response and powerful activation 
of the complement and coagulation systems.(36) Consistent with these observations 
and previous findings of an association between increased plasminogen activator 
inhibitor-1 levels and increased mortality associated with meningococcal sepsis or 
Gram-negative septic shock, as well as with findings regarding the impact of activated 
protein C on LPS-induced MIF release, MIF levels were positively correlated with 
disseminated intravascular coagulation and with levels of plasminogen activator 
inhibitor-1, thrombin-antithrombin III complexes and activated protein C.(30, 37) 
Activation of the HPA is an essential feature of the systemic stress response to 
infection, resulting in the release of glucocorticoids, which play an essential role in the 
regulation of the host inflammatory and immune responses.(38) One of the intriguing 
features of MIF has been its abundant expression in the pituitary and adrenal 
glands and its circulation in the bloodstream with a circadian rhythm synchronous 
with that of glucocorticoids.(6, 8, 9, 39) Moreover, low doses of glucocorticoids 
have previously been shown to induce MIF release, while high doses were found to 
suppress MIF expression.(7, 40, 41) In turn, MIF overrides the immunosuppressive 
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and anti-inflammatory effects of glucocorticoids, leading to the concept that MIF and 
glucocorticoids function as a physiological counter-regulatory dyad that modulates 
inflammatory and immune responses.(7) In line with these observations, treatment 
with long-term corticosteroids was associated with a 3.5-fold up-regulation of MIF 
levels at study entry, whereas treatment with short-term high-dose corticosteroids 
caused a 3.0-fold down-regulation of MIF levels. The positive correlation noted 
between MIF and ACTH levels measured at admission in children with meningococcal 
septic shock are well in agreement with the fact that corticotropin-releasing hormone 
and LPS are powerful MIF secretagogues in the pituitary gland.(8) In contrast to what 
is observed in adults with sepsis, MIF levels were inversely correlated with cortisol in 
septic children and, thus, with cortisol:ACTH ratio, which is consistent with previous 
observations that high doses of corticosteroids inhibit MIF production.(7, 35, 40, 41) 
Cholesterol, the starting compound of cortisol synthesis, is a major lipid constituent 
of high-density lipoproteins, which are very potent inhibitors of LPS activity in vivo 
and a prognostic factor of susceptibility to and outcome of sepsis.(24, 42) When 
forming complexes with high-density lipoproteins and LPS, cholesterol may no 
longer be used for cortisol synthesis, providing a possible explanation for low cortisol 
levels in patients with meningococcal sepsis. The observation of high ACTH but low 
cortisol and low glucose levels was highly suggestive of relative adrenal insufficiency, 
commonly observed in severe meningococcal sepsis.(21, 25) Taken together with 
the observation of very high circulating concentrations of MIF in non-survivors, the 
stress hormone blood profile indicated that the immunoregulatory balancing act 
played by MIF and glucocorticoids was clearly leaning towards an overwhelming pro-
inflammatory response likely to contribute to multiple-organ dysfunction and death.  
In summary, the present data showed that MIF was markedly and persistently up-
regulated in children and adults who had Gram-negative sepsis. High MIF levels 
were associated with disease severity scores, pro-inflammatory markers of sepsis 
and dysregulated pituitary-adrenal function and early death, highlighting the presence 
of a marked imbalance between pro-inflammatory (MIF) and anti-inflammatory 
(glucocorticoids) regulatory systems in Gram-negative sepsis. Given the important 
position of MIF in innate immune responses to microbial pathogens, these results 
provide a strong rationale for the development of anti-MIF treatment strategies for the 
treatment of patients with severe sepsis and septic shock.
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Abstract
Objective. Meningococcal sepsis remains an important cause of childhood morbidity 
and mortality. Largely due to logistic complexities of research in young children with 
acute life-threatening disease, very little is known regarding differential expression 
kinetics and molecular regulation of immune response genes in leukocyte subsets. 
Materials and methods. In this prospective case-control study, six children with 
meningococcal sepsis were included. Blood was drawn at four time points (t = 0, t = 
8, t = 24 and t = 72 h after admission to the paediatric intensive care unit). Blood was 
also collected from matched controls. Detailed immunophenotyping of leukocytes 
was performed; RNA isolated from whole blood, lymphocytes, monocytes, and 
granulocytes was used to perform Affymetrix micro-array gene expression analysis.
Results and conclusion. There were no differences in total leukocyte count 
between patients and controls. In contrast to previous in vitro studies we observed 
an unexpected decrease in NK cell numbers, as well as downregulation of NK cell 
specific and cytotoxic T-cell related gene expression in patients with meningococcal 
septic shock. By contrast, expression of genes, involved in innate immunity and 
several other pathways, differed between the different leukocyte subpopulations in a 
dynamic fashion. Compared to previously reported gene expression profiles, it was 
possible to define a meningococcal sepsis specific expression profile.
Introduction
Meningococcal disease is caused by Neisseria meningitidis, an intracellular Gram-
negative diplococcus, and is known for its variable disease presentation.(1-3) 
The spectrum varies from mild disease to fulminant septic shock and even death. 
Especially in children, meningococcal sepsis and meningococcal septic shock are 
very rapidly progressive disease entities, which may lead to death within 24 h.(3) 
Mortality in children remains high despite intense clinical and research efforts, and 
varies from 4% (in meningitis) to 40% (in case of fulminant septic shock).(2, 4) 
Infection with Neisseria meningitidis results in a complex host response including 
activation of multiple pathways such as the complement system, secretion of pro- 
and anti-inflammatory mediators and coagulation and fibrinolysis. Several mediators 
such as complement factors, IL-10, IL-8, TNF-alpha, IL-6 and MIF have previously 
been identified to play a role, but many factors remain unknown.(5-8) A leading 
current concept on sepsis proposes that the initial immune and inflammatory hyper-
responsiveness is followed by a hyporesponsive period.(9) This concept is appealing 
but in urgent need of further experimental support from the true clinical situation. 
Although it is clear that NK-cells, T- and B-cells, granulocytes are all recruited in 
defence to meningococcal infection, the differential contribution of these leukocyte 
subsets to disease activity and sepsis are poorly known.(10-13) Furthermore, kinetics 
of differential immune response gene expression are essential to elucidate how the 
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reversal of immune hyper- to hyporesponsiveness comes about, and investigating 
these may lead to the identification of prognostic factors or disease progression 
markers to identify children with high chance of adverse outcome who may warrant 
prompt therapy intensification.
One way to further examine the role of inflammatory mediators is to obtain transcription 
profiles using RNA micro-arrays.(14-17) In this report we present a prospective case-
control pilot study which included six patients between the age of 1 month and 18 
years who were admitted to the PICU of Erasmus MC-Sophia Children’s Hospital 
with (suspected) meningococcal sepsis. Using RNA obtained from whole blood, as 
well as from monocytes and lymphocytes separately, RNA expression in the course 
of meningococcal sepsis was studied. In addition, the RNA expression profiles at 
admission were compared to those of healthy controls matched for age, gender and 
ethnic background.
Methods
Participants. A prospective case-control study was conducted between January 
2005 and March 2006 at Erasmus MC-Sophia Children’s Hospital. Six patients with 
(suspected) meningococcal sepsis and six healthy age and sex-matched controls 
were included.
Patients subsequently admitted to the Paediatric Intensive Care Unit (PICU) of 
Erasmus MC-Sophia Children’s Hospital with (suspected) meningococcal sepsis 
were included if they met the following criteria: a) age between 1 month and 18 years 
of age, b) tachycardia, c) tachypnea, d) rectal body temperature < 36oC or > 38.5oC, 
e) petechiae and/or purpura, and f) need of an arterial line. Exclusion criteria were; 
a) patients with known liver- or kidney malfunction, b) trauma, c) burns, d) organ 
transplantation, e) cardiogenic shock, f) uncontrollable bleeding, g) malignancies, 
h) absence of arterial line, i) recent systemic corticosteroid use, and j) pregnancy. 
The clinical and epidemiological parameters of these 6 patients were similar to those 
of 287 patients admitted to our hospital with petechia and purpura between August 
1988 and June 2006.(18)
Controls children admitted to the hospital for elective minor non-infectious surgery or 
MRI, and matched for age, gender and ethnic origin.(19) Additional inclusion criteria 
for controls were a good physical condition and a signed informed consent. Exclusion 
criteria were a) presence of fever, known immunodeficiencies, heart disease or 
coagulation disorders, b) current use of antibiotics, or anti-inflammatory medication, 
including inhalers, d) burns, e) liver- or kidney malfunction and f) organ transplant.
The study was approved by the medical ethics committee of Erasmus MC, and 
informed consent was obtained from the parents of the patients and controls.
Blood sampling. In meningococcal sepsis patients 12 ml of blood (sodium heparin 
vacutainers) was drawn from an arterial line and immediately processed at t = 0, 8, 
24 and 72 h. T = 0 was defined as the moment of the first blood sampling (max. 6 h 
after admission to the PICU). Sampling was terminated after 72 h, or prior to that time 
  Expression profiles in meningococcal infection 147
point when the arterial line was removed or patients were transferred to the referral 
hospital.
In controls 12 mL of blood (sodium heparin vacutainers) was drawn once before start 
of the surgical procedure or MRI. Blood samples were taken with informed parental 
consent and only after approval of the, independent, treating physician.
Immunophenotyping of leukocytes. Immunophenotyping was performed with 
standard flowcytometry on 0.5 ml whole blood using the following three 4-color 
marker combinations: 1) CD4, CD8, CD3, HLA-DR; 2) CD15, CD64, CD45, CD14; 3) 
CD3, CD16.56, CD45 and CD19.
RNA isolation from leukocyte subsets. One ml of whole blood was used for 
immediate RNA isolation (internal validation step) using QIAamp RNA Blood Kit 
(Qiagen, Hilden, Germany). The remaining 10 ml whole blood was used to perform 
a ficoll density separation using Lymphoprep (Nycomed Pharma, Oslo, Norway). 
Granulocytes and peripheral blood mononuclear cells (PBMCs) were isolated and 
immediately frozen at -80°C. From the PBMCs, CD14-positive cells (here referred 
to as monocytes) and CD14-negative cells, hence enriched for B- and T-cells (and 
therefore here referred to as lymphocytes) were separated using autoMACS (Miltenyi 
Biotec). RNA was isolated using RNeasy columns according to the standard protocol 
provided by the manufacturer (Qiagen, Hilden, Germany). The integrity of the 
RNA was assessed using the RNA 6000 Nano assay kit on a Bioanalyzer (Agilent 
Technologies).
Micro-array experiments. A micro-array analysis was performed using the one-
cycle target labelling and control reagents as described before (Affymetrix product 
number 900493).(20)
The fragmented cRNA was hybridized to HG U133 2.0+ microarrays (Affymetrix) and 
after washing and staining, the arrays were scanned in an HP/Affymetrix scanner at 
570 nm. In comparison experiments care was taken that the scaling factor, noise and 
presence calls were comparable.
Statistical analysis. Continuous variables in cases and controls were analyzed 
using the Mann-Whitney U test in SPSS 11.5.
Micro-array analysis. Background was removed using robust multichip analysis 
(RMA) and probe intensity levels were quantile normalized.(21, 22) Array groups 
were compared based on the perfect match (PM) probe intensity levels only, by 
performing a per-probeset two-way analysis of variance (ANOVA, with factors “probe” 
and “group”).(22) This results in average expression levels for each probeset in each 
group, as well as raw P values for the significance of the difference between the 
groups. The latter were adjusted for multiple testing using  Šidák step-up adjustment 
to control the family-wise error rate (FWER), i.e. the probability of incorrectly calling at 
least one probeset differentially expressed.(23) All differences with adjusted P values 
< 0.05 were considered significant. The Ingenuity program was used to analyse 
what pathophysiological pathways were differentially expressed between patients 
at t=0 and controls (Ingenuity Pathway Analysis; 5.5.1-1002).The data discussed in 
this publication have been deposited in NCBI’s Gene Expression Omnibus and are 
accessible through GEO Series accession number GSE11755 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE11755).(24)
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Results
Between January 2005 and March 2006 six patients with suspected or confirmed 
meningococcal sepsis were admitted to Erasmus MC-Sophia Children’s Hospital 
and included in the study (Table 1). They were boys who all survived the disease. 
Table 1. Patient characteristics.
1On admission; PRISM, Paediatric Risk of Mortality; DIC, disseminated intravascular coagulation; PIM, 
Paediatric index of mortality.
2Culture and PCR negative.
The median age was 1.94 years, ranging from 1.37-8.04 years. All had septic shock 
and needed mechanical ventilation, while 4 of them had disseminated intravascular 
coagulation (DIC). The mean Paediatric Risk of Mortality (PRISM) score in the study 
population was 24 (14-28). Laboratory parameters on admission are listed in Table 
2. The six controls were children admitted for minor non-inflammatory surgery (n = 
5) or MRI (n = 1).
Table 2. Laboratory parameters on admission.
1CRP, C-reactive protein; ACTH, adrenocorticotropic hormone. 
Leukocyte subsets in patients and controls. We aimed for as detailed as possible 
immunophenotyping of leukocytes in all patients at the different time points and in 
controls, with the purpose of obtaining a broad overall picture of the dynamics of 
various subsets of immune cells during the course of infection. Patients 3 and 4 had 
left the PICU and in patient 6 the arterial line was removed before t = 72 h. Therefore, 
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Tabl . Patient characteris ics.
Patient
1 2 3 4 5 6
Age (years) 5.06 1.37 1.79 2.09 1.51 8.04
Duration of PICU stay (days) 4 5 1 2 60 4
PRISM score
1
26 23 21 25 28 14
Predicted death rate from
Rotterdam score (%)
1
14.0 72.3 0.3 1.3 92.6 56.3
PIM score
1
30.0 16.0 8.7 12.5 100.0 48.4
N. meningitidis serotype B B
2
B B
DIC Y Y N Y Y N
Mechanical ventilation Y Y Y Y Y Y
On admission; PRISM, Paediatric Risk of Mortality; DIC, disseminated intravascular coagulation; PIM, Paediatric
index of mortality.
2
Culture and PCR negative.
Table 2. Laboratory parameters on admission.
Patient
1 2 3 4 5 6
Leukocyte count (*10
9
/L) 16.1 5.1 35.5 18.1 8.3 9.9
Platelet count (*10
9
/L) 111 26 184 91 116 124
CRP
1
 (mmol/L) 51 78 176 258 105 31
Glucose (mmol/L) 10.3 6.5 8.4 9.7 10.4 5.9
Lactate (mmol/L 9.0 5.7 1.7 1.8 9.5 2.2
Base excess (mmol/L) -9 -11 -7 -6 -12 -9
Creatinin (_mol/L) 85 92 25 55 73 53
Ureum (mmol/L) 7.0 7.4 4.4 11.4 7.6 6.0
Potassium (mmol/L) 3.0 3.7 3.2 3.4 3.2 3.4
Calcium (ionized) 1.04 0.94 1.21 0.77 0.85 1.11
Bilirubin (_mol/L) 6 9 3 3 12 8
Cortisol (nmol/L) 1047 244 415 1309 240 262
ACTH (ng/L) 13.6 179.0 4.3 3.9 303.0 4.9
CRP, C-reactive protein; ACTH, adrenocorticotropic hormone.
Table 3. Leukocyte subsets in patients on admission and in controls.
Blood cells Patients
median (min-max)
Controls
median (min-max)
1
Leukocytes (*10
9
/L) 13.0 (5.1-35.5) 8.1 (4.9-9.4) 0.17
% lymphocytes 7.5 (2.6-41.0) 51.3 (26.0-74.3) 0.01
% monocytes 3.8 (1.0-7.0) 5.7 (3.6-14.0) 0.18
% granulocytes 86.5 (58.0-92.4) 37.5 (20.2-65.0) 0.01
CD64 expression granulocytes 30.0 (18.3-47.0) 24.5 (10.0-60.0) 0.94
NK-cells (*10
9
/L) 0.06 (0.02-0.11) 0.22 (0.20-0.41) 0.01
B-cells (*10
9
/L) 0.54 (0.16-1.23) 0.70 (0.48-1.36) 0.48
T-cells (*10
9
/L) 0.79 (0.30-1.05) 2.57 (1.67-5.00) <0.01
T helper (%) 53.9 (37.3-63.0) 60.0 (46.3-65.6) 0.31
T cytotoxic (%) 39.6 (31.0-54.7) 33.1 (26.9-40.2) 0.18
CD4/CD8 ratio 1.4 (0.7-2.0) 1.8 (1.3-2.4) 0.18
Double negative (%) 6.9 (4.0-8.1) 5.3 (5.1-17.2) 0.82
Activated Th-cells (%) 1.2 (0.6-5.0) 2.9 (0.9-4.8) 0.24
Activated Tc-cells (%) 1.3 (0.5-6.2) 2.6 (1.0-8.4) 0.49
Activated T-cells (%) 2.4 (1.1-10.8) 5.1 (2.5-13.2) 0.31
One-tailed Mann-Whitney U test.
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no samples were available for these patients at this time point. In general a large 
variability was observed for the leukocyte (subset) cell counts. Total leukocyte counts 
did not differ significantly between patients and controls (Table 3). However, the
Table 3. Leukocyte subsets in patients on admission and in controls.
1One-tailed Mann-Whitney U test.
percentage of lymphocytes and absolute NK-cell numbers were 6.8 and 3.7 times 
decreased in patients compared to controls, respectively. The decrease in lymphocyte 
counts was mainly attributable to a decrease in T-cell counts, while the distribution 
of CD4+ and CD8+ T-cell was similar for patients and controls. The percentage 
of granulocytes in the leukocyte population was 2.3 times increased in patients 
compared to controls.
The absolute number of leukocytes at t = 0 was less than 20*109/L for all patients 
except patient 3 (Figure 1A). As expected from previous studies this patient had the 
lowest Paediatric Index of Mortality (PIM) score and predicted death rate based on 
the Rotterdam score. Only the PRISM score was similar to those of the other patients. 
In all patients a rise in the leukocyte counts was observed followed by a decline in 
four patients (1, 3, 5, and 6). The initial percentage of lymphocytes was highest in 
the two youngest patients (2 and 5), who also had the highest predicted death rate 
(Figure 1B), and this was followed by a decline. The percentage of granulocytes was 
markedly declined in these two patients (Figure 1D). The percentage of monocytes 
(CD14 +) increased over time in all but one patient (patient 4, Figure 1C). In all 
patients a rise in the number of B-lymphocytes was observed. Remarkably, after 
an initial substantial rise, a rapid decline in B-cell counts was observed in the most 
severely ill patient 5 (Figure 2A). 
This patient showed the most pronounced rise in T-cells. Whereas others exhibited 
a gradual increase of the T-cell population over time, in this patient the initial rise 
was followed by a rapid decline at t = 24 h. It must be noted that T-cell counts at t = 
24 h were similar for all patients (Figure 2B). NK-cell counts were low in all patients, 
when compared to the controls; patients 2 and 5 showed a subsequent temporarily 
increase in NK-cells (Figure 2C).
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Figure 1. Absolute numbers of leukocytes and subsets.
Total leukocyte counts (1A), percentage of lymphocytes (1B), monocytes (1C) and granulocytes (1D) for 
individual patients at the different time points, and the means for controls (dashed line).
Figure 2. Lymphocyte subsets.
Absolute number of B-lymphocytes (2A), T-lymphocytes (2B) and NK-cells (2C) for individual patients at 
the different time points, and the means for controls (dashed line). 
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mRNA expression profiling. Since the volume of blood that could be drawn from 
young and severely ill children was limited, only a minimum amount of material was 
available for all the analyses. The quantity and quality of RNA isolated was not always 
sufficient to allow micro-array analysis. Since no such problems occurred when 
optimizing the experiments using similar quantities of blood from healthy controls 
it appears likely that the extreme activation of inflammatory systems in patients 
with meningococcal sepsis results in loss of good quality RNA. We encountered 
this problem mainly in the isolation of granulocytes and the RNA from these cells, 
suggesting that myeloid protease activity is at least in part responsible for RNA 
degradation. For this reason RNA from granulocytes was not included for micro-array 
analyses. Table 4 summarizes the number of samples available for each leukocyte 
subset, and the results of the between-subject analyses at each time point. 
Table 4. Results of between-subject analyses.
SDE, significantly differentially expressed probeset (p<0.05).
1Numbers represent the patient identification numbers.
2Characters represent the individual controls.
3Number of SDE, when only molecules with mean expression > 100 in patients at t = 0 are included.
Only high quality samples, according to Affymetrix standards, were included in 
statistical analyses. In addition, samples that would require an additional amplification 
step (all samples from patient 5) were excluded from the current analysis. Using RMA 
based statistics and including molecules for which the mean expression level was 
higher than 100 for at least one time point (a measure roughly corresponding to the 
Affymetrix presence vs. absence call in our setting), a total of 21219, 20914 and 
17073 of the initial 54676 probesets were significantly expressed in whole blood, 
lymphocytes and monocytes respectively.
Known inflammatory mediators in sepsis. In Figure 3 the expression patterns in 
whole blood and leukocyte subtypes for inflammatory mediators IL-8, TNF, IL-1B, IL-
10, MIF, IL-6, and PFC (properdin), which are all molecules involved in meningococcal 
infection, are depicted.
Expression of IL8 in patients was increased in whole blood on admission, followed 
by a marked decrease at t = 24 h. This corresponds to the previously observed 
serum concentrations of IL-8 in patients with meningococcal sepsis.(25) Notably, IL-8 
expression was increased from t = 8 h onwards in lymphocytes. Absolute expression 
17
Table 4. esults of between-subject analyses.
Source Time point
(h)
Arrays patients at
t=0
1
Arrays controls/
patients at t=T 
1,2
#SDE,
ANOVA
#SDE,
ANOVA
3
Blood 0 2 3 a b c 2416 2336
Blood 8 2 3 2 240 235
Blood 24 2 3 1 2 3 1177 1157
Blood 72 2 3 1 2 896 878
Lymphocytes 0 2 3 a b c d 2294 2223
Lymphocytes 8 2 3 1 3 4 1461 1393
Lymphocytes 24 2 3 1 2 3 4 6 1585 1492
Lymphocytes 72 2 3 1 2 571 561
Monocytes 0 1 3 4 6 a b d 2482 2034
Monocytes 8 1 3 4 6 1 2 3 172 170
Monocytes 24 1 3 4 6 1 2 3 630 609
Monocytes 72 1 3 4 6 1 451 441
SDE, significantly differentially expressed probeset (p<0.05).
1
Numbers represent the patient identification numbers.
2
Characters represent the individual controls.
3
Number of SDE, when only molecules with mean expression >100 in patients at t=0 are included.
Table 5. Top 25 SDE molecules in whole bl o , monocytes and lymphocy es in patients when compared to
controls.
Function Whole blood Monocytes Lymphocytes
Immune response IL1R2, CEACAM1, HGF,
C190RF59,
MME,
HLA-DQA1
IL1R2, CXCR7, CD163,
C1QB, MRC1,
HLA-DQ1A, ERAP2,
ALDH1, HLA-DRB2,
HLA-DMB
HLA-DRB4, PPBP,
FCGR3B, TGFBI, CTSW,
KLRF1,
c-hluPGFS, BY55,
CX3CR1, TCRA,
FCER1A, HLA-DQ1A,
HLA-DR1B
Coagulation/fibrinolysis HGF TIMP4 PPBP
Signalling ANKRD22 ENPP2, MS4A4, CXCR7,
HM74, OLIG1
SPRY4,
MYBL1, LRRN3, TGFBI,
CX3CR1, EDG8
LPS/ bacterial n utralization LCN2, BPI MRC1 PPBP
Apoptosis LGALS2 GZMB, TGFBI, IGFBP7
Anti-apoptosis GW112, HGF CXCR7
Wound repair MMP8, HGF TMP4? TGFBI
Cell adhesion GW112, CEACAM1,
HGF
CXCR7?
Insulin resistance FIZZ3 FIZZ3 SPRY4?,
IGFBP7
Iron binding MMP8, LTF, HP, HPR
Metabolism PFKFB2, OLAH ENPP2, OLAH,
SLC21A12, METTL7B,
ALDH1
PPBP
Mast cell degranulation FCERA1 FCER1A
Metal transport SLC39A8
Unknown PRV1, NMES1, ASM3A,
ORF1-FL49, FLJ38815
NKG7,
IFI44L, FAM20A
PSPHL, CCDC146
Genes depicted in bold showed increased expression in patients when compared to controls. ‘?’ indicates possible
function for this molecule.
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levels were however markedly lower than in monocytes, in which IL-8 expression was 
initially decreased and increased only at t = 72 h, suggesting important differences 
between the adaptive and immune system in the regulated secretion of this cytokine. 
Ex vivo IL-8 expression in peripheral blood mononuclear cells (PBMC) retrieved 
from meningococcal sepsis patients was increased in response to stimulation with 
meningococcal outer membrane complexes (OMCs) compared to PBMCs derived 
from healthy controls.(26)
Figure 3. Expression patterns of well studied molecules in meningococcal disease.
Fold change expression of molecules in whole blood (3A), lymphocytes (3B) and monocytes (3C). At t = 0 the 
fold change expression of probesets in patients on admission is expressed relative to controls. At t = 8, 24 
and 72 h, the fold change expression of probesets in patients at these time points relative to the expression 
in patients at t = 0 is depicted. Horizontal lines at -1 and 1 are inserted to indicate no change (fold change = 
1). (IL, interleukin; TNF, tumor necrosis factor; PFC, properdin; MIF, macrophage migration inhibitory factor). 
Significant differences: A) in whole blood, IL8 at t = 0, 24 and 72; PFC at t = 0; MIF at t = 24 h. B) in 
lymphocytes IL8 at t = 8, 24 and 72 h; IL1B at t = 24 h; PFC at t = 0 and 24 h; MIF at t = 8 h. C) in monocytes 
IL8 at t = 8 and 72 h; IL1B at t = 0 and 72 h; IL6, IL10 and PFC at t = 0; MIF at t = 0, 24 and 72 h.
No significant alteration of expression levels was observed for TNF. Increased TNF 
expression is associated with increased mortality in meningococcal sepsis. In our 
study all patients survived. In addition, from animal studies it is known that TNF 
levels reach their maximum already at 1 h after infusion of endotoxin, followed by 
a decrease.(27) The median (min-max) duration of petechiae in the patients in our 
study was 9 (5.8-14) h, while the first symptoms occurred with a median (min-max) 
of 24 (19-27) h before admission to the PICU, which may explain the fact that no 
differential TNF expression is observed.
IL-1B expression in monocytes was decreased initially while no change in expression 
levels was observed in whole blood or lymphocytes. Similar to TNF it is suspected 
that an increased IL-1B expression occurs early in the preclinical phase of disease.
(28) IL-10 expression was increased in patient monocytes on admission. This was 
not reflected by an increased expression in whole blood, stressing the importance of 
analyzing purified subsets in profiling studies. Plasma IL-10 was previously shown to 
be increased in meningococcal septic shock, although a wide range was observed.
(29) Plasma MIF levels are persistently increased in children with meningococcal 
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sepsis.(8) RNA expression profiles of MIF showed an increased expression in 
monocytes on admission followed by a decline, while no differential expression was 
observed in whole blood. It must be noted that no expression profiles are available for 
macrophages, which, in addition to the pituitary gland, are one of the major sources 
of MIF production.(30, 31) IL-6 expression was markedly increased in monocytes 
of patients at t = 0 when compared to controls. IL-6 was previously found to be 
a mediator of cardial depression in meningococcal disease and is an important 
inflammatory mediator and involved in B-cell activation.(6)
Table 5. Top 25 SDE molecules in whole blood, monocytes and lymphocytes in patients when 
compared to controls.
Genes depicted in bold showed increased expression in patients when compared to controls. ‘?’ indicates 
possible function for this molecule.
Top 25 fold change differential expression in leukocyte subtypes. In whole blood, 
lymphocytes and monocytes differential expression was observed for 2336, 2223, 
and 2034 molecules, respectively, between controls and patients at t = 0 (Table 4). In 
whole blood predominantly an increased expression was observed (1367 increased 
versus 969 probesets decreased expression), while in lymphocytes and monocytes 
 
 
 
Function Whole blood Monocytes Lymphocytes 
Immune response IL1R2, CEACAM1, HGF, 
C190RF59, 
MME, 
HLA-DQA1 
IL1R2, CXCR7, CD163, 
C1QB, MRC1, 
HLA-DQ1A, ERAP2, 
ALDH1, HLA-DRB2, 
HLA-DMB 
HLA-DRB4, PPBP, 
FCGR3B, TGFBI, CTSW, 
KLRF1, 
c-hluPGFS, BY55, 
CX3CR1, TCRA, 
FCER1A, HLA-DQ1A, 
HLA-DR1B 
Coagulation/fibrinolysis HGF TIMP4 PPBP 
Signalling ANKRD22 ENPP2, MS4A4, CXCR7, 
HM74, OLIG1 
SPRY4, 
MYBL1, LRRN3, TGFBI, 
CX3CR1, EDG8 
LPS/ bacterial neutralization LCN2, BPI MRC1 PPBP 
Apoptosis  LGALS2 GZMB, TGFBI, IGFBP7 
Anti-apoptosis GW112, HGF CXCR7  
Wound repair MMP8, HGF TMP4? TGFBI 
Cell adhesion GW112, CEACAM1, 
HGF 
CXCR7?  
Insulin resistance FIZZ3 FIZZ3 SPRY4?, 
IGFBP7 
Iron binding MMP8, LTF, HP, HPR   
Metabolism  PFKFB2, OLAH ENPP2, OLAH, 
SLC21A12, METTL7B, 
ALDH1 
PPBP 
Mast cell degranulation  FCERA1 FCER1A 
Metal transport  SLC39A8  
Unknown PRV1, NMES1, ASM3A, 
ORF1-FL49, FLJ38815 
NKG7, 
IFI44L, FAM20A 
PSPHL, CCDC146 
enes depicted in bold showed increased expression in patients when compared to controls. ‘?’ indicates possible function for 
thi  mol c le. 
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little over half the probesets differentially expressed showed decreased expression 
at t = 0 when compared to controls (1206 versus 1017 probesets in lymphocytes 
and 1192 versus 842 probesets in monocytes, respectively). The significantly 
differentially (p<0.05) expressed probesets with the 25 highest fold changes in whole 
blood, lymphocytes and monocytes between patients at t = 0 and controls are listed 
in Tables 5, S1, S2, and S3, respectively.
Figure 4. Expression pattern of molecules in whole blood.
At t = 0 the fold change in expression of probesets in patients on admission is expressed relative to controls. 
At t = 8, 24 and 72 h, the fold change expression of probesets in patients at these time points relative to the 
expression in patients at t = 0 is depicted. Horizontal lines at -1 and 1 are inserted to indicate no change 
(fold change = 1). 4A. Probesets with increased expression at t = 0, when compared to controls, followed 
by a significant decrease at t = 24 h when compared to t = 0 in patients. 4B. Probesets with increased 
expression at t = 0, when compared to controls, followed by a decrease at t = 72 h when compared to t 
= 0 in patients. 4C. Probesets with increased expression at t = 0, when compared to controls, that show 
persistently increased expression. 4D. Probesets with decreased expression at t = 0, when compared to 
controls.
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Figure 4S. Expression pattern of molecules differentially expressed in whole blood in patients and 
controls.
Horizontally: arrays in blocks per time point, the numbers above indicate the patient id number. Vertically: 
probesets differentially expressed between controls and patients at t = 0, t = 8 and t = 0, t = 24 h and t 
= 0 and/or t = 72 h and t = 0, and an expression level of at least 100 on at least one array. Values are 
expressed as log2-ratios between the array and the average of the controls.
In whole blood the top 25 list includes several molecules expressed by granulocytes 
(MMP8, GW112, PRV1 and HGF), molecules involved in innate immune responses 
and LPS or bacterial neutralization (IL1R2, CEACAM1, HGF, C19ORF59, MME, 
LCN2, BPI and GPR84), iron binding (MMP8, LTF, HP and HPR), insulin resistance 
(FIZZ3), metabolism and signalling (PFKFB2, OLAH, and ANKRD22), and coagulation 
and fibrinolysis (HGF). Five molecules with unknown function were included in this 
list (PRV1, NMES1, ASM3A, ORF1-FL49 and FLJ 38815). The expression patterns 
of these molecules during the study period are depicted in Figure 4, and Figure 4S 
(including all differentially expressed molecules in whole blood). In contrast to previously, 
most probesets showed an increased expression even after 24 h (Figure 4C).
Markedly, twenty probesets differentially expressed in lymphocytes present in the top 
25 list showed a decreased expression in patients when compared to controls. Five 
out of these are specific for NK-cells. It is unclear whether this reflects the decreased 
number of NK cells or a true inhibition of NK cells, since multiple probesets involved 
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Figure 5. Expression pattern of molecules in lymphocytes.
At t = 0 the fold change expression of probesets in patients on admission is expressed relative to controls. 
At t = 8, 24 and 72 h, the fold change expression of probesets in patients at these time points relative 
to the expression in patients at t = 0 is depicted. Horizontal lines at -1 and 1 are inserted to indicate no 
change (fold change = 1). In bold the NK-cell specific probesets are depicted. 5A. Probesets with increased 
expression in patients throughout the study period. 5B. Probesets with decreased expression at t = 0, when 
compared to controls, that show significantly increased expression at t = 8 h. 5C. Probesets with decreased 
expression at t = 0, when compared to controls, that show significantly increased expression at t = 24 h. 5D. 
Probesets with decreased expression at t = 0, when compared to controls, that show significantly increased 
expression at t = 72 h. 5E. Probesets with decreased expression in patients throughout the study period.
in immune response and signalling pathways showed decreased expression in the 
lymphocyte population. Expression of half of the depressed probesets remained 
decreased throughout the study period (Figures 5 and 5S). Two of the probesets in 
the top 25 have an unknown function (PSPHL and CCDC146).
Most differentially expressed probesets in monocytes represented molecules involved 
in innate immune responses (IL1R2, CXCR7, CD163, C1QB, MRC1, ERAP2, ALDH1, 
and HLA-DRB2), metabolism (ENPP2, OLAH, SLC21A12, METTL7B, and ALDH1) or 
signalling pathways (ENPP2, MS4A4, CXCR7, HM74, and OLIG1). Three probesets 
of unknown function were in the top 25 (NKG7, IFI44L, and FAM20A). Most of the 
probesets that exhibited an increased expression at t = 0 showed a significant decline 
after the first 24 h (Figures 6 and 6S).
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Figure 6. Expression pattern of molecules in monocytes.
The expression level at t = 0 is set to 1. All expression levels at t = 8, 24 
and 72 are fold changes relative to t = 0. 6A. Probesets with increased 
expression at t = 0, when compared to controls. 6B. Probesets with 
increased expression at t = 0, when compared to controls, that 
show significantly decreased expression at t = 8 h. 6C. Probesets 
with increased expression at t = 0, when compared to controls, that 
show significantly decreased expression at t = 24 h. 6D. Probesets 
with increased expression at t = 0, when compared to controls, that 
show significantly decreased expression at t = 72 h. 6E. Probesets 
with decreased expression at t = 0, when compared to controls, that 
show significantly increased expression at t = 24 h. 6F. Probesets 
with decreased expression at t = 0, when compared to controls, that 
show significantly increased expression at t = 72 h. 6G. Probesets 
with decreased expression in patients throughout the study period.
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Figure 5S. Expression pattern of molecules differentially expressed in lymphocytes in patients and controls.
Horizontally: arrays in blocks per time point, the numbers above indicate the patient id number. Vertically: 
probe sets differentially expressed between controls and patients at t = 0, t = 8 and t = 0, t = 24 h, and 
t = 0 and/or t = 72 h, and t = 0, and an expression level of at least 100 on at least one array. Values are 
expressed as log2-ratios between the array and the average of the controls.
Markedly some B-cell specific markers showed differential expression in the 
monocytes. This most likely reflects B-cell contamination in the monocyte population, 
resulting from the autoMACS method used to isolate the monocytes. Most results, 
however, can be considered true reflections of expression in monocytes, as they 
relate to moncyte-specific genes.
Most importantly, the differentially expressed probesets identified in whole blood, 
lymphocytes and monocytes in this study can serve as a disease-specific signature 
for meningococcal sepsis.
Pathway analysis. Using Ingenuity Pathway Analysis (5.5.1-1002) we analyzed 
the pathways corresponding to genes differentially expressed between patients and 
controls (Top 10 in Tables 6, 7, and 8, and complete overview in supplemental Tables 
S4, S5, and S6). 
At admission, an overall increase in both pro-inflammatory and anti-inflammatory 
pathways was observed in whole blood and monocytes (Tables 6 and 8). In 
contrast, expression profiles were mainly down regulated in lymphocytes (Table 7). 
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Figure 6S. Expression pattern of molecules differentially expressed in monocytes in patients and controls.
Horizontally: arrays in blocks per time point, the numbers above indicate the patient id number. Vertically: 
probesets differentially expressed between controls and patients at t = 0, t = 8 and t = 0, t = 24 h and 
t = 0 and/or t = 72 h and t = 0, and an expression level of at least 100 on at least one array. Values are 
expressed as log2-ratios between the array and the average of the controls.
Table 6. Pathways differentially expressed at t = 0 in whole blood.
The molecules not represented in the dataset account for the missing numbers and will make up to 
100%.
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a le 6. Pathways differentially expressed at t = 0 in whole blood. 
 
  In patients compared to controls 
Pathway  -Log(p-value) Ratio Upregulated  Downregulated  
Protein ubiquitination pathway 2.09E+01 8.03E-01 95/203 (47%) 78/203 (38%) 
B cell receptor signalling 1.92E+01 8.58E-01 80/148 (54%) 47/148 (32%) 
Glucocorticoid receptor signalling 1.42E+01 7.06E-01 117/265 (44%) 72/265 (27%) 
SAPK/JNK signalling 1.31E+01 8.23E-01 75/147 (51%) 46/147 (31%) 
Oxidative phosphorylation 1.30E+01 6.90E-01 54/158 (34%) 57/158 (36%) 
Huntington's disease signalling 1.26E+01 7.20E-01 112/232 (48%) 57/232 (25%) 
Apoptosis signalling 1.22E+01 8.31E-01 69/136 (51%) 44/136 (32%) 
PI3K/AKT signalling 1.22E+01 7.50E-01 83/176 (47%) 49/176 (28%) 
Mitochondrial dysfunction 1.14E+01 6.06E-01 51/165 (31%) 49/165 (30%) 
T cell receptor signalling 1.09E+01 8.04E-01 43/102 (42%) 39/102 (38%) 
The molecules not represented in the dataset account for the missing numbers and will make up to 100%. 
 
 
 
 
 
 
 
Table 7. Pathways differentially expressed at t = 0 in lymphocytes. 
 
  In patients compared to controls 
Pathway  - og(p-value) Ratio Upregulated  Downregulated  
Protein ubiquitination pathway 2.81E+01 8.28E-01 85/203 (42%) 93/203 (46%) 
B cell receptor signalling 2.02E+01 8.51E-01 46/148 (31%) 80/148 (54%) 
Glucocorticoid receptor signalling 1.49E+01 6.94E-01 70/265 (26%) 116/265 (44%) 
Huntington's disease signalling 1.47E+01 7.20E-01 62/232 (27%) 107/232 (46%) 
PI3K/AKT signalling 1.40E+01 7.50E-01 52/176 (30%) 81/176 (46%) 
Apoptosis signalling 1.38E+01 8.31E-01 44/136 (32%) 69/136 (51%) 
SAPK/JNK signalling 1.34E+01 8.10E-01 47/147 (32%) 72/147 (49%) 
Natural killer cell signalling 1.34E+01 8.27E-01 15/110 (14%) 76/110 (69%) 
Mitochondrial dysfunction 1.28E+01 6.06E-01 28/165 (17%) 72/165 (44%) 
Oxidative phosphorylation 1.24E+01 6.71E-01 25/158 (16%) 83/158 (53%) 
The molecules not represented in the dataset account for the missing numbers and will make up to 100%. 
 
 
 
 
Table 8. Top 10 pathways differentially expressed at t = 0 in monocytes. 
 
  In patients compared to controles 
Pathway  -Log(p-value) Ratio Upregulated  Downregulated  
Protein ubiquitination pathway 2.40E+01 7.64E-01 72/203 (35%) 86/203 (42%) 
B cell receptor signalling 2.05E+01 8.11E-01 36/148 (24%) 84/148 (57%) 
Huntington's disease signalling 1.76E+01 6.94E-01 64/232 (28%) 98/232 (42%) 
Oxidative phosphorylation 1.71E+01 6.71E-01 67/158 (42%) 40/158 (25%) 
Mitochondrial dysfunction 1.65E+01 6.00E-01 55/165 (33%) 44/165 (27%) 
Glucocorticoid receptor signalling 1.63E+01 6.57E-01 56/265 (21%) 119/265 (45%) 
Apoptosis signalling 1.57E+01 8.01E-01 38/136 (28%) 71/136 (52%) 
PI3K/AKT signalling 1.54E+01 7.16E-01 42/176 (24%) 84/176 (48%) 
NRF2-mediated oxidative stress 
response 1.47E+01 7.33E-01 60/180 (33%) 72/180 (40%) 
SAPK/JNK signalling 1.36E+01 7.62E-01 35/147 (24%) 77/147 (52%) 
The molecules not represented in the dataset account for the missing numbers and will make up to 100%. 
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Table 7. Pathways differentially expressed at t = 0 in lymphocytes.
The molecules not represented in the dataset account for the missing numbers and will make up to 
100%.
Table 8. Top 10 pathways differentially expressed at t = 0 in monocytes.
The molecules not represented in the dataset account for the missing numbers and will make up to 
100%.
Depending on the leukocyte subset analyzed, the interpretation may differ as
reflected for instance by an overall increase in the number of genes involved in B-cell 
receptor signalling and glucocorticoid receptor signalling in whole blood, while in 
lymphocytes and monocytes a decrease in many of these genes is noted. However, 
as both positive and negative regulators of each pathway are scored, these results 
show that both B-cell signalling and glucocorticoid receptor signalling are activated. 
Consistent with analysis of the individual probesets, most NK-cell related genes are 
downregulated in expression (70%). In addition, for the oxidative phosphorylation 
pathway, approximately equal numbers of up- and down-regulated probesets were 
observed in whole blood, while in lymphocytes a general down-regulation and in 
monocytes a general up-regulation was observed.
Table 6. Pathways differentially expressed at t = 0 in whole blood. 
 
  In patients compared to controls 
Pathway  -Log(p-value) Ratio Upregulated  Downregulated  
Protein ubiquitination pathway 2.09E+01 8.03E-01 95/203 (47%) 78/203 (38%) 
B cell receptor signalling 1.92E+01 8.58E-01 80/148 (54%) 47/148 (32%) 
Glucocorticoid receptor signalling 1.42E+01 7.06E-01 117/265 (44%) 72/265 (27%) 
SAPK/JNK signalling 1.31E+01 8.23E-01 75/147 (51%) 46/147 (31%) 
Oxidative phosphorylation 1.30E+01 6.90E-01 54/158 (34%) 57/158 (36%) 
Huntington's disease signalling 1.26E+01 7.20E-01 112/232 (48%) 57/232 (25%) 
Apoptosis signalling 1.22E+01 8.31E-01 69/136 (51%) 44/136 (32%) 
PI3K/AKT signalling 1.22E+01 7.50E-01 83/176 (47%) 49/176 (28%) 
Mitochondrial dysfunction 1.14E+01 6.06E-01 51/165 (31%) 49/165 (30%) 
T cell receptor signalling 1.09E+01 8.04E-01 43/102 (42%) 39/102 (38%) 
The molecules not represented in the dataset account for the missing numbers and will make up to 100%. 
 
 
 
 
 
 
 
le 7. Pathways differentially expressed at t = 0 in lymphocytes. 
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Discussion
Our study is the first to report global gene expression profiling on leukocyte subsets 
isolated from children with severe meningococcal sepsis over the first 72 h after 
admission to the PICU. Previous reports were limited to ex vivo or in vitro studies 
using cell cultures. Although in vitro cell culture studies allow for the exact timing 
of sampling, they do not allow interaction between multiple different cell types and 
can only minimally mirror the complexities occurring between bacterium and host in 
clinical settings.
The design and implementation were elaborate, in terms of ethical acceptability, 
study logistics, as well as sample acquisition, volume and sample processing. 
Furthermore, meningococcal sepsis has an exceedingly complex and very poorly 
understood mechanistic basis, requiring repeated sampling over a short time span. 
To avoid inter researcher variation, we involved as few people as possible in the 
actual clinical sampling. Subsequent experimentation and interpretation of the results 
was performed by an interdisciplinary team including paediatricians, immunologists, 
intensive care specialists and bioinformaticians. We were able to identify numerous 
differentially expressed probesets. In the discussion below, we outline our findings 
and provide several recommendations for further research.
We have hereby defined a disease-specific candidate molecular signature for 
meningococcal sepsis. Seminal work by Ramilo et al. has identified mRNA expression 
signatures discriminating E. coli versus S. aureus infections, or patients with either 
influenza A, E. coli, or S. pneumoniae infection.(32) We have overlap of a few genes, 
as can be expected as common immune response genes likely are involved in any 
type of bacterial infection. The only 16 overlapping probesets between that and our 
study are ZNF6, PFDN5, ACTG1, GAPD, RGS2, AF1Q, LRRN3, RASA1, SMAD2, 
IGHG3, ALOX5AP, P2RX1, SCA1, MAP1LC3B, FLJ10262, and RAC2, which were 
differentially expressed in lymphocytes between patients and controls. As a caveat 
in this comparison, several factors should be mentioned. First, we only included 
patients early in infection in the PICU, while Ramilo et al. included patients with 
microbiologically confirmed infection. In addition, Ramilo et al. analyzed expression 
profiles in complete PBMC while we purified monocytes and lymphocytes, allowing 
assessment of expression profiles in lymphocytes separately. Finally, we studied the 
kinetics of the expression profiles during the stay in the PICU.
Patient parameters and leukocyte counts. All patients included were in need of 
mechanical ventilation and four out of six had DIC. Despite the high disease severity, 
none of the patients in our study died. Five out of six patients had relatively very severe 
disease, which may result from the fact that these patients were 5 years or younger.
(18, 33-36) Although total leukocyte counts did not differ significantly between patients 
and controls, one could argue that a relative leukopenia was observed in patients 2, 
5 and 6, considering the disease severity. This has been observed previously, and 
ranges in meningococcal infection vary from absolute leukopenia to leukocytosis.
Results of immunophenotyping of leukocyte subsets showed high granulocyte and 
low lymphocyte percentages, as expected in bacterial infection. The decreased 
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percentage of lymphocytes was attributable to decreased numbers of T-cells and 
NK-cells. The relative contribution of T-cell subsets (CD4+ and CD8+) was similar in 
patients and controls. The increase in granulocyte number was not accompanied by 
a significantly increased expression of CD64, an Fc receptor which is upregulated 
during inflammation, indicating that the increased activity mainly results from the 
increased number of cells rather than the activation of individual cells.
Four patients already showed high granulocyte percentages at t = 0, whereas in the 
two youngest patients a gradual increase over 72 h was observed. These were also 
the patients that showed the highest lymphocyte percentage and the lowest total 
leukocyte count on admission. This may reflect admission to the PICU at distinct time 
points of disease course. Another explanation could be the lower age of the latter two 
patients.(37) Together with patient 3, these two patients showed an increase in T-cell 
counts at t = 8, which was not observed in the older patients. In addition B- en NK-
cells counts were increased. This may indicate a general activation of the immune 
system in this rapid onset severe infectious disease, rather than a more directed 
activation.
The two youngest patients (1.37 and 1.51 years) showed an initial increase in 
leukocyte counts after admission, followed by a gradual decrease. Most likely 
this reflects consumption of leukocytes/granulocytes in the immune response 
against meningococci. However, after the initial proinflammatory response, an anti-
inflammatory response is elicited. This is essential in controlling potential secondary 
damage of pro-inflammatory mediators.(38) The pro-inflammatory state results from 
the initial release of pro-inflammatory mediators elicited by LPS. The short pro-
inflammatory peak is then followed by an increase in the counterregulatory cytokines 
(e.g. IL-10), thus resulting in the counterinflammatory response as observed in the 
decrease of total leukocytes, lymphocytes, monocytes and T-cells. A more detailed 
analysis of cell counts is not feasible due to the small number of patients included.
Kinetics of global gene expression in early sepsis. Previous studies in adults 
using expression profiling showed that infection with Gram-positive or Gram-negative 
microbes results in distinct responses.(39) While infection with Gram-negative 
organisms resulted in increased expression of molecules involved in inflammation 
and innate immunity, Gram-positive pathogens elicit expression of genes related to 
protein synthesis, ribosomal proteins and cell-cycling.(39) Infection with the Gram-
negative N. meningitidis has a special position, since it is characterized by a very 
rapid onset of disease in previously healthy individuals.
As expected, analyses of the RNA expression profiles showed an increase of both 
inflammatory pathways, such as IL-6 and NFκB, and anti-inflammatory pathways, 
such as IL-10. In addition, Toll like receptor and B-cell receptor signalling pathways 
showed increased expression. Remarkably, in lymphocytes a downregulation of 
most pathways was observed, and in addition decreased lymphocyte percentages 
were observed. Unfortunately, in granulocytes, the contribution of which to the total 
leukocyte counts was increased in patients when compared to controls, RNA isolation 
was not successful in patients. Possibly an immense increase of pro-inflammatory 
mediators resulted in increased degradation of RNA in vivo in meningococcal disease, 
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since no problems were encountered using the same techniques for granulocytes 
from patients with viral infections or healthy controls. In addition, the samples of the 
most severely ill patients had to be excluded from the RNA expression analysis due 
to technical problems that prohibited a reliable comparison of results.
Since it is likely that expression profiles in granulocytes provide important information, 
future efforts will have to be focused on solving the technical difficulties in RNA 
isolation from activated granulocytes. Fortunately however, since the granulocytes 
contributed most to the total leukocyte count, several granulocyte specific probesets 
were identified in whole blood to show increased expression (MMP8, GW112, 
PRV1 and HGF). Apparently whole blood analysis allows a significant number of 
granulocytes to remain extractable for RNA isolation.
When assessing the lymphocyte population, a decreased expression of five probesets 
specific for NK-cells was observed in the top 25-fold change list. This was also 
observed when assessing differentially expressed pathways in lymphocytes in which 
70% of molecules in the NK-cell signalling pathway were down regulated. This may 
in part reflect the relatively decreased number of NK cells in patients. In contrast, in 
meningococcal carriage, NK cells are responsible for the increased IFN-γ levels.(40) 
In vitro NK cells, but not B or T cells are responsible for antibody dependent cellular 
cytotoxicity (ADCC).(11, 41) For acute meningococcal infection, only few reports 
regarding the (innate) cellular immune response exist, and none include NK cell 
involvement. Possibly the contribution of leukocyte subsets differs for meningococcal 
colonization and acute infection.
Our data on monocytes ex vivo can be compared to those of Suzuki et al. who 
assessed RNA expression using SAGE, in ex vivo monocytes from healthy adult 
donors that were stimulated with LPS for three hours. In line with Suzuki’s study, 
we found increased expression of IL-6 and Cystatin B and decreased expression of 
CASP, Aldehyde dehydrogenase 2, ATP synthase subunit C, transketolase, lysozyme, 
CD37 and Jun D.(42) For other molecules, their observations were not confirmed by 
our results or even in contrast with our results (Gelsolin, NFKB, IL1B, IL7R, IFN 
stimulated protein 15 kD, RANTES, COX2, IFN inducible protein 78 kD, MARCKS, 
and interferon-inducible gene I-8D). In mice, differences have been observed in 
expression profiles in macrophages derived from young and old mice upon ex vivo 
stimulation with LPS.(43) Immune response and signal transduction genes were 
specifically decreased in aged mouse macrophages. Moreover, in vivo interaction 
with other cell types is likely to alter gene expression profiles when compared to the 
ex-vivo or in vitro systems. In addition, both in the study by Suzuki et al. and our 
study, groups were small (8 donors and 4 patients and 3 controls, respectively).
Differences in expression profiles upon stimulation of PBMCs derived from different 
donors have previously been described.(44) These differences are even more 
pronounced when different cell lines are used to study LPS response.(44)
Limitations and recommendations. Our study is limited in the number of patients 
due to complexities in studying severely ill children. In order to validate our findings, a 
larger, prospective, case-control study should be performed. Despite the differences in 
expression profiles observed in studies with regard to the use of different cell types and 
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diverse pathogens, there seems to be a common host-transcriptional-response.(45)
Our study is the first to investigate RNA expression profiles in paediatric meningococcal 
sepsis patients. Most studies focused on cell culture or animal models using LPS as a 
stimulus.(44, 46, 47) In the study by Prucha et al. in adult sepsis patients, a list of 50 
differentially expressed genes was compiled indicating a homogeneous expression 
profile using inflammation specific arrays.(48) Despite the heterogeneous group 
of patients, sepsis patients could be distinguished from patients undergoing spine 
surgery for which no inflammatory symptoms were observed. Prucha et al. used only 
whole blood and no leukocyte subset analyses were performed.(48) 
In our study, expression analysis was performed on both whole blood and leukocyte 
subsets. For logistic reasons and diagnostic efficiency the possibility to study whole 
blood expression patterns is favourable. However, we observed that expression 
patterns differ between leukocyte subsets, and moreover, the relative contribution 
of the leukocyte subsets to the whole leukocyte counts differs between patients. 
Using only whole blood therefore leads to biased and limited results. Previous 
studies showed that the concordance of expression patterns was higher within one 
healthy individuals’ samples than between different healthy individuals, and that the 
concordance was higher in healthy individuals when compared to trauma patients. 
Moreover, concordance in leukocyte subsets was higher than in total leukocyte 
expression patterns, while the expression patterns between the different subsets 
differed markedly.(49) For these reasons we would argue to analyze leukocyte subsets 
instead of whole blood. As in our study we realize that this is not always possible due 
to the limited amounts of blood that can be drawn, which is especially true in severely 
ill (paediatric) patients. The development of novel methods that require low amounts of 
RNA to perform gene expression profiling will increase the possibility of further subset 
testing. To improve the quality and avoid finding differential expression resulting from 
contamination with other leukocyte subtypes, purity of isolated leukocyte subset 
should be optimized using stringent selection criteria.
Biological, immunological and clinical interpretation of the results requires the 
involvement of specialists in the field of immunology, paediatric intensive care, 
paediatric infectious diseases, and bioinformatics.
In conclusion, while leukocyte counts showed no overall difference between patients 
and controls, the percentage of granulocytes was increased in patients, while the 
contribution of lymphocytes, and markedly, NK-cells, was decreased.
Overall, as expected, RNA expression profiles were upregulated for diverse pathways, 
both pro- and anti-inflammatory, indicative for a complex pathogenesis. In lymphocytes, 
RNA expression was more often down regulated. Markedly a number of NK-cell and 
cytotoxic T-cell function specific probesets showed decreased expression, reflecting 
a possibly less important role for this leukocyte subset in meningococcal infection. 
Compared to haematological malignancies, gene expression profiling of infectious 
diseases, especially in paediatric settings is still in its infancy. However, similar to 
leukemias, strict guidelines on handling of samples, purification of leukocyte subsets 
and data interpretation are required.(50) Efforts formulating such guidelines and 
inclusion of larger cohorts of patients are currently being undertaken.
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Supplemental tables
Table S1. Top 25 SDE molecules in whole blood in patients when compared to controls.
1Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that 
expression in patients is increased compared to controls. EST; expressed sequence tag.
 
 
Supple ental tables 
 
Table S  25 SDE molecules in whole blood in patie ts whe  compared to controls. 
 
Gene Description Fold  
Change1 
accession no 
MMP8 matrix metalloproteinase 8 preproprotein 108.95 gb:NM_002424.1 
 ESTs 104.83 gb:AW337833 
GW112 differentially expressed in hematopoietic lineages 69.24 gb:AL390736 
LCN2 lipocalin 2 (oncogene 24p3) 47.97 gb:NM_005564.1 
FIZZ3 resistin 42.43 gb:NM_020415.2 
LTF lactotransferrin 39.87 gb:NM_002343.1 
PRV1 polycythemia rubra vera 1; cell surface receptor 35.66 gb:NM_020406.1 
HPR haptoglobin-related protein 22.42 gb:NM_020995.1 
BPI bactericidal/permeability-increasing protein precursor 21.17 gb:NM_001725.1 
GPR84 orphan G protein-coupled receptor 84 20.96 gb:AF237762.1 
NMES1 normal mucosa of oesophagus specific 1 18.72 gb:AF228422.1 
ANKRD22 ankyrin repeat domain 22, transcription factor 18.16 gb:AI925518 
IL1R2 soluble type II interleukin-1 receptor 17.97 gb:U64094.1 
NCA non-specific cross reacting antigen 17.66 gb:M33326.1 
CEACAM1 TM1-CEA preprotein, transmembrane carcinoembryonic antigen 
BGPa (biliary glycoprotein) 
16.54 gb:X16354.1 
C19ORF59 ESTs, possibly involved in immune response 15.18 gb:BF433657 
OLAH oleoyl-ACP hydrolase 14.95 gb:NM_018324.1 
HP haptoglobin 14.48 gb:NM_005143.1 
FLJ38815 Homo sapiens cDNA FLJ38815 fis, clone LIVER2007548 14.23 gb:AK096134.1 
PFKFB2 6-phosphofructo-2-kinase heart isoform 12.56 gb:AB044805.1 
HGF competitive HGF antagonist 12.18 gb:M77227.1 
ASM3A acid sphingomyelinase-like phosphodiesterase 11.86 gb:AA873600 
ORF1-FL49 Homo sapiens mRNA for putative nuclear protein (ORF1-FL49) 11.75 gb:AL522667 
MME membrane metallo-endopeptidase (neutral endopeptidase, 
enkephalinase, CALLA, CD10) 
-12.15 gb:AI433463 
HLA-DQA1 DC class II histocompatibility antigen alpha-chain -14.33 gb:X00452.1 
Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that expression in patients is 
increased compared to controls. EST; expressed sequence tag. 
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Table S2. Top 25 SDE molecules in lymphocytes in patients when compared to controls.
1Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that 
expression in patients is increased compared to controls. EST; expressed sequence tag.
 
 
 
 
Table S2. Top 25 SDE molecules in lymphocytes in patients when compared to controls. 
Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that expression in patients is 
increased compared to controls. EST; expressed sequence tag. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Description Fold 
change1 
accession no 
HLA-DRB4 Major histocompatibility complex, class II, DR beta 4 17.44 gb:BC005312.1 
 ESTs 17.05 gb:AW262311 
PPBP pro-platelet basic protein 5.50 gb:R64130 
SPRY4 sprouty (Drosophila) homolog 4 5.08 gb:AI355441 
 ESTs 4.47 gb:AA740831 
TCRA T-cell receptor alpha -4.01 gb:X72501.1 
FCGR3B Fc fragment of IgG, low affinity IIIb, receptor for 
(CD16) 
-4.18 gb:NM_000570.1 
 ESTs -4.35 gb:AI814092 
GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-
associated serine esterase 1) 
-4.43 gb:M36118.1 
KSP37 Ksp37, Killer specific secretory protein, 37-KD -4.85 gb:AB021123.1 
MYBL1 v-myb avian myeloblastosis viral oncogene homolog-
like 1 
-5.09 gb:AW592266 
FLJ11129 LRRN3 similar to murine leucine-rich repeat protein -5.12 gb:AI221950 
CCDC146 Coiled coil domain containing 146 -5.24 gb:AW135176 
TGFBI transforming growth factor, beta-induced, 68kD -5.26 gb:NM_000358.1 
CTSW cathepsin W (lymphopain) -5.29 gb:NM_001335.1 
KLRF1 killer cell lectin-like receptor F1 -5.56 gb:NM_016523.1 
IGFBP7 insulin-like growth factor binding protein 7 -5.68 gb:NM_001553.1 
c-hluPGFS Prostaglandin F synthase -6.15 gb:AB018580.1 
BY55 natural killer cell receptor, immunoglobulin superfamily 
member 
-6.22 gb:NM_007053.1 
CX3CR1 V28 -6.81 gb:U20350.1 
PSPHL L-3-phosphoserine phosphatase homolog -8.21 gb:NM_003832.1 
 ESTs, possible tissue factor precursor -9.21 gb:AI377755 
FLJ23356 Homo sapiens cDNA: FLJ23356 fis, clone HEP14919 -10.77 gb:AV711904 
FCER1A Fc fragment of IgE, high affinity I, receptor for; alpha 
polypeptide 
-11.13 gb:BC005912.1 
HLA-DQA1 DC class II histocompatibility antigen alpha-chain -19.66 gb:X00452.1 
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Table S3. Top 25 SDE in monocytes blood in patients when compared to controls.
1Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that 
expression in patients is increased compared to controls.
 
 
 
 
 
 
Table 3. Top 25 SDE in monocytes blood in patients when compared to controls. 
 
Gene Description Fold 
change  
accession no 
IL1R2 interleukin 1 receptor, type II 55.62 gb:NM_004633.1 
ENPP2 autotaxin, phosphodiesterase I alpha 42.65 gb:L35594.1 
METTL7B methyltransferase like 7B 34.18 gb:AI827972 
BIGMo-103 BCG induced integral membrane protein BIGMo-103 23.26 gb:AB040120.1 
OLAH oleoyl ACP hydrolase 20.98 gb:NM_018324.1 
MS4A4 membrane-spanning 4-domains, subfamily A, member 4 16.09 gb:NM_024021.1 
FIZZ3 resistin 16.08 gb:NM_020415.2 
SLC21A12 organic anion transporter OATP-E 14.86 gb:NM_016354.1 
TIMP4 tissue inhibitor of metalloproteinase 4 precursor 14.20 gb:NM_003256.1 
CD163 M130 antigen cytoplasmic variant 2 13.41 gb:Z22970.1 
NKG7 natural killer cell group 7 sequence 12.62 gb:NM_005601.1 
FAM20A family with sequence similarity 20, member A 10.59 gb:AI860568 
CXCR7 RDC1, G protein-coupled receptor 10.28 gb:AI817041 
C1QB complement component 1, q subcomponent, 
beta polypeptide precursor 
10.11 gb:NM_000491.2 
MRC1 mannose receptor, C type 1 9.88 gb:NM_002438.1 
HLA-DRB2 major histocompatibility complex, class II, DQ beta 1 -9.04 gb:M16276.1 
HLA-DMB major histocompatibility complex, class II, DM beta -9.25 gb:NM_002118.1 
FCERA1 receptor for Fc fragment of IgE, high affinity I; alpha 
polypeptide 
-10.22 gb:BC005912.1 
IFI44L interferon-induced protein 44-like -10.36 gb:NM_006820.1 
HM74 putative chemokine receptor; GTP-binding protein -12.04 gb:NM_006018.1 
HLA-DQA1 DC classII histocompatibility antigen alpha-chain -12.70 gb:X00452.1 
ERAP2 endoplasmic reticulum endopeptidase 2 -13.45 gb:NM_022350.1 
ALDH1 aldehyde dehydrogenase 1, soluble -14.44 gb:NM_000689.1 
OLIG1 oligodendrocyte transcription factor 1 -20.91 gb:AL355743.1 
LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) -24.83 gb:NM_006498.1 
Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that expression in patients is 
increased compared to controls. 
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Table S4. Pathways differentially expressed at t = 0 in whole blood.
In patients compared to controls
Pathway  -Log(p-value) Ratio Upregulated Downregulated 
Protein ubiquitination pathway 2.09E+01 8.03E-01 95/203 (47%) 78/203 (38%)
B cell receptor signalling 1.92E+01 8.58E-01 80/148 (54%) 47/148 (32%)
Glucocorticoid receptor signalling 1.42E+01 7.06E-01 117/265 (44%) 72/265 (27%)
SAPK/JNK signalling 1.31E+01 8.23E-01 75/147 (51%) 46/147 (31%)
Oxidative phosphorylation 1.30E+01 6.90E-01 54/158 (34%) 57/158 (36%)
Huntington's disease signalling 1.26E+01 7.20E-01 112/232 (48%) 57/232 (25%)
Apoptosis signalling 1.22E+01 8.31E-01 69/136 (51%) 44/136 (32%)
PI3K/AKT signalling 1.22E+01 7.50E-01 83/176 (47%) 49/176 (28%)
Mitochondrial dysfunction 1.14E+01 6.06E-01 51/165 (31%) 49/165 (30%)
T cell receptor signalling 1.09E+01 8.04E-01 43/102 (42%) 39/102 (38%)
NRF2-mediated oxidative stress 
response 1.06E+01 7.61E-01 81/180 (45%) 56/180 (31%)
Hypoxia signalling in the cardiovascular 
system 8.92E+00 8.31E-01 41/71 (58%) 18/71 (25%)
Integrin signalling 8.85E+00 7.60E-01 100/192 (52%) 46/192 (24%)
Inositol phosphate metabolism 8.62E+00 6.07E-01 65/173 (38%) 41/173 (24%)
Natural killer cell signalling 8.43E+00 7.82E-01 45/110 (41%) 41/110 (37%)
ERK/MAPK signalling 8.24E+00 7.39E-01 110/226 (49%) 57/226 (25%)
GM-CSF signalling 7.91E+00 8.71E-01 36/62 (58%) 18/62 (29%)
Toll-like receptor signalling 7.91E+00 8.43E-01 32/51 (63%) 11/51 (22%)
Insulin receptor signalling 7.75E+00 7.29E-01 61/133 (46%) 36/133 (27%)
JAK/Stat signalling 7.71E+00 8.98E-01 36/59 (61%) 17/59 (29%)
Death receptor signalling 7.31E+00 8.36E-01 28/61 (46%) 23/61 (38%)
Estrogen receptor signalling 7.27E+00 7.54E-01 61/118 (52%) 29/118 (25%)
IL-2 signalling 6.98E+00 8.68E-01 33/53 (62%) 13/53 (25%)
Ubiquinone biosynthesis 6.98E+00 4.38E-01 18/105 (17%) 29/105 (28%)
NF-KB signalling 6.73E+00 7.27E-01 67/143 (47%) 37/143 (26%)
VEGF signalling 6.72E+00 7.39E-01 39/92 (42%) 29/92 (32%)
PDGF signalling 6.57E+00 7.97E-01 41/74 (55%) 18/74 (24%)
EGF signalling 6.46E+00 8.51E-01 25/47 (53%) 15/47 (32%)
IGF-1 signalling 6.21E+00 7.61E-01 48/92 (52%) 22/92 (24%)
IL-10 signalling 6.14E+00 7.50E-01 36/68 (53%) 15/68 (22%)
PPARA/RXRA activation 6.06E+00 6.36E-01 72/176 (41%) 40/176 (23%)
IL-4 signalling 5.99E+00 7.79E-01 29/68 (43%) 24/68 (35%)
Pyrimidine metabolism 5.93E+00 4.91E-01 53/226 (23%) 62/226 (27%)
IL-6 signalling 5.82E+00 7.69E-01 55/91 (60%) 15/91 (16%)
p53 signalling 5.61E+00 8.16E-01 39/87 (45%) 32/87 (37%)
Antigen presentation pathway 5.52E+00 7.18E-01 7/39 (18%) 21/39 (54%)
Purine metabolism 5.40E+00 4.69E-01 93/416 (22%) 106/416 (25%)
Actin cytoskeleton signalling 5.24E+00 6.55E-01 120/267 (45%) 55/267 (21%)
Ephrin receptor signalling 5.09E+00 6.59E-01 105/232 (45%) 48/232 (21%)
PPAR signalling 4.91E+00 6.74E-01 45/95 (47%) 19/95 (20%)
PTEN signalling 4.82E+00 7.39E-01 44/92 (48%) 24/92 (26%)
Citrate cycle 4.49E+00 4.58E-01 13/59 (22%) 15/59 (25%)
Fc epsilon RI signalling 4.17E+00 7.20E-01 43/100 (43%) 29/100 (29%)
Leukocyte extravasation signalling 3.90E+00 6.70E-01 85/188 (45%) 42/188 (22%)
Aminoacyl-tRNA biosynthesis 3.78E+00 4.12E-01 16/85 (19%) 21/85 (25%)
Cell cycle: G1/S checkpoint regulation 3.65E+00 7.33E-01 23/60 (38%) 21/60 (35%)
Amyloid processing 3.55E+00 7.88E-01 29/52 (56%) 12/52 (23%)
Neuregulin signalling 3.43E+00 6.81E-01 34/91 (37%) 28/91 (31%)
N-Glycan biosynthesis 3.39E+00 4.60E-01 27/87 (31%) 13/87 (15%)
Aryl hydrocarbon receptor signalling 3.39E+00 6.12E-01 54/152 (36%) 39/152 (26%)
Nucleotide excision repair pathway 3.37E+00 8.57E-01 14/35 (40%) 17/35 (49%)
Fructose and mannose metabolism 3.36E+00 2.50E-01 22/140 (16%) 13/140 (9%)
chemokine signalling 3.33E+00 7.33E-01 35/75 (47%) 20/75 (27%)
 
 
 
 
 
 
Table 3. Top 25 SDE in monocy es blood in pati nts when compared to controls. 
 
Gene Description Fold 
change  
accession no 
IL1R2 interleukin 1 receptor, type II 55.62 gb:NM_004633.1 
ENPP2 autotaxin, phosphodiesterase I alpha 42.65 gb:L35594.1 
METTL7B methyltransferase like 7B 34.18 gb:AI827972 
BIGMo-103 BCG induced integral membrane protein BIGMo-103 23.26 gb:AB040120.1 
OLAH oleoyl ACP hydrolase 20.98 gb:NM_018324.1 
MS4A4 membrane-spanning 4-domains, subfamily A, member 4 16.09 gb:NM_024021.1 
FIZZ3 resistin 16.08 gb:NM_020415.2 
SLC21A12 organic anion transporter OATP-E 14.86 gb:NM_016354.1 
TIMP4 tissue inhibitor of metalloproteinase 4 precursor 14.20 gb:NM_003256.1 
CD163 M130 antigen cytoplasmic variant 2 13.41 gb:Z22970.1 
NKG7 natural killer cell group 7 sequence 12.62 gb:NM_005601.1 
FAM20A family with sequence similarity 20, member A 10.59 gb:AI860568 
CXCR7 RDC1, G protein-coupled receptor 10.28 gb:AI8 7041 
C1QB complement component 1, q subcomponent, 
beta polypeptide precursor 
10.11 gb:NM_000491.2 
MRC1 mannose receptor, C type 1 9.88 gb:NM_002438.1 
HLA-DRB2 major histocompatibility complex, class II, DQ beta 1 -9.04 gb:M16276.1 
HLA-DMB major histocompatibility complex, class II, DM beta -9.25 gb:NM_002118.1 
FCERA1 receptor for Fc fragment of IgE, high affinity I; alpha 
polypeptide 
-10.22 gb:BC005912.1 
IFI44L interferon-induced protein 44-like -10.36 gb:NM_006820.1 
HM74 putative chemokine receptor; GTP-binding protein -12.04 gb:NM_006018.1 
HLA-DQA1 DC classII histocompatibility antigen alpha-chain -12.70 gb:X00452.1 
ERAP2 endoplasmic reticulum endopeptidase 2 -13.45 gb:NM_022350.1 
ALDH1 aldehyde dehydrogenase 1, soluble -14.44 gb:NM_000689.1 
OLIG1 oligodendrocyte transcription factor 1 -20.91 gb:AL355743.1 
LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) -24.83 gb:NM_006498.1 
Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that expression in patients is 
increased compared to controls. 
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The molecules not represented in the dataset account for the missing numbers and will make up to a 
100%.
In patients compared to controls
Pathway  -Log(p-value) Ratio Upregulated Downregulated 
Protein ubiquitination pathway 2.09E+01 8.03E-01 95/203 (47%) 78/203 (38%)
B cell receptor signalling 1.92E+01 8.58E-01 80/148 (54%) 47/148 (32%)
Glucocorticoid receptor signalling 1.42E+01 7.06E-01 117/265 (44%) 72/265 (27%)
SAPK/JNK signalling 1.31E+01 8.23E-01 75/147 (51%) 46/147 (31%)
Oxidative phosphorylation 1.30E+01 6.90E-01 54/158 (34%) 57/158 (36%)
Huntington's disease signalling 1.26E+01 7.20E-01 112/232 (48%) 57/232 (25%)
Apoptosis signalling 1.22E+01 8.31E-01 69/136 (51%) 44/136 (32%)
PI3K/AKT signalling 1.22E+01 7.50E-01 83/176 (47%) 49/176 (28%)
Mitochondrial dysfunction 1.14E+01 6.06E-01 51/165 (31%) 49/165 (30%)
T cell receptor signalling 1.09E+01 8.04E-01 43/102 (42%) 39/102 (38%)
NRF2-mediated oxidative stress 
response 1.06E+01 7.61E-01 81/180 (45%) 56/180 (31%)
Hypoxia signalling in the cardiovascular 
system 8.92E+00 8.31E-01 41/71 (58%) 18/71 (25%)
Integrin signalling 8.85E+00 7.60E-01 100/192 (52%) 46/192 (24%)
Inositol phosphate metabolism 8.62E+00 6.07E-01 65/173 (38%) 41/173 (24%)
Natural killer cell signalling 8.43E+00 7.82E-01 45/110 (41%) 41/110 (37%)
ERK/MAPK signalling 8.24E+00 7.39E-01 110/226 (49%) 57/226 (25%)
GM-CSF signalling 7.91E+00 8.71E-01 36/62 (58%) 18/62 (29%)
Toll-like receptor signalling 7.91E+00 8.43E-01 32/51 (63%) 11/51 (22%)
Insulin receptor signalling 7.75E+00 7.29E-01 61/133 (46%) 36/133 (27%)
JAK/Stat signalling 7.71E+00 8.98E-01 36/59 (61%) 17/59 (29%)
Death receptor signalling 7.31E+00 8.36E-01 28/61 (46%) 23/61 (38%)
Estrogen receptor signalling 7.27E+00 7.54E-01 61/118 (52%) 29/118 (25%)
IL-2 signalling 6.98E+00 8.68E-01 33/53 (62%) 13/53 (25%)
Ubiquinone biosynthesis 6.98E+00 4.38E-01 18/105 (17%) 29/105 (28%)
NF-KB signalling 6.73E+00 7.27E-01 67/143 (47%) 37/143 (26%)
VEGF signalling 6.72E+00 7.39E-01 39/92 (42%) 29/92 (32%)
PDGF signalling 6.57E+00 7.97E-01 41/74 (55%) 18/74 (24%)
EGF signalling 6.46E+00 8.51E-01 25/47 (53%) 15/47 (32%)
IGF-1 signalling 6.21E+00 7.61E-01 48/92 (52%) 22/92 (24%)
IL-10 signalling 6.14E+00 7.50E-01 36/68 (53%) 15/68 (22%)
PPARA/RXRA activation 6.06E+00 6.36E-01 72/176 (41%) 40/176 (23%)
IL-4 signalling 5.99E+00 7.79E-01 29/68 (43%) 24/68 (35%)
Pyrimidine metabolism 5.93E+00 4.91E-01 53/226 (23%) 62/226 (27%)
IL-6 signalling 5.82E+00 7.69E-01 55/91 (60%) 15/91 (16%)
p53 signalling 5.61E+00 8.16E-01 39/87 (45%) 32/87 (37%)
Antigen presentation pathway 5.52E+00 7.18E-01 7/39 (18%) 21/39 (54%)
Purine metabolism 5.40E+00 4.69E-01 93/416 (22%) 106/416 (25%)
Actin cytoskeleton signalling 5.24E+00 6.55E-01 120/267 (45%) 55/267 (21%)
Ephrin receptor signalling 5.09E+00 6.59E-01 105/232 (45%) 48/232 (21%)
PPAR signalling 4.91E+00 6.74E-01 45/95 (47%) 19/95 (20%)
PTEN signalling 4.82E+00 7.39E-01 44/92 (48%) 24/92 (26%)
Citrate cycle 4.49E+00 4.58E-01 13/59 (22%) 15/59 (25%)
Fc epsilon RI signalling 4.17E+00 7.20E-01 43/100 (43%) 29/100 (29%)
Leukocyte extravasation signalling 3.90E+00 6.70E-01 85/188 (45%) 42/188 (22%)
Aminoacyl-tRNA biosynthesis 3.78E+00 4.12E-01 16/85 (19%) 21/85 (25%)
Cell cycle: G1/S checkpoint regulation 3.65E+00 7.33E-01 23/60 (38%) 21/60 (35%)
Amyloid processing 3.55E+00 7.88E-01 29/52 (56%) 12/52 (23%)
Neuregulin signalling 3.43E+00 6.81E-01 34/91 (37%) 28/91 (31%)
N-Glycan biosynthesis 3.39E+00 4.60E-01 27/87 (31%) 13/87 (15%)
Aryl hydrocarbon receptor signalling 3.39E+00 6.12E-01 54/152 (36%) 39/152 (26%)
Nucleotide excision repair pathway 3.37E+00 8.57E-01 14/35 (40%) 17/35 (49%)
Fructose and mannose metabolism 3.36E+00 2.50E-01 22/140 (16%) 13/140 (9%)
chemokine signalling 3.33E+00 7.33E-01 35/75 (47%) 20/75 (27%)
 
 
 
 
 
 
Table S3. Top 25 SDE in monocytes blood in patients when compared to controls. 
 
Gene Description Fold 
change  
accession no 
IL1R2 interleukin 1 receptor, type II 55.62 gb:NM_004633.1 
ENPP2 autotaxin, phosphodiesterase I alpha 42.65 gb:L35594.1 
METTL7B methyltransferase like 7B 34.18 gb:AI827972 
BIGMo-103 BCG induced integral membrane protein BIGMo-103 23.26 gb:AB040120.1 
OLAH oleoyl ACP hydrolase 20.98 gb:NM_018324.1 
MS4A4 membrane-spanning 4-domains, subfamily A, member 4 16.09 gb:NM_024021.1 
FIZZ3 resistin 16.08 gb:NM_020415.2 
SLC21A12 organic anion transporter OATP-E 14.86 gb:NM_016354.1 
TIMP4 tissue inhibitor of metalloproteinase 4 precursor 14.20 gb:NM_003256.1 
CD163 M130 antigen cytoplasmic variant 2 13.41 gb:Z22970.1 
NKG7 natural killer cell group 7 sequence 12.62 gb:NM_005601.1 
FAM20A family with sequence similarity 20, member A 10.59 gb:AI860568 
CXCR7 RDC1, G protein-coupled receptor 10.28 gb:AI817041 
C1QB complement component 1, q subcomponent, 
beta polypeptide precursor 
10.11 gb:NM_000491.2 
MRC1 mannose receptor, C type 1 9.88 gb:NM_002438.1 
HLA-DRB2 major histocompatibility complex, class II, DQ beta 1 -9.04 gb:M16276.1 
HLA-DMB major histocompatibility complex, class II, DM beta -9.25 gb:NM_002118.1 
FCERA1 receptor for Fc fragment of IgE, high affinity I; alpha 
polypeptide 
-10.22 gb:BC005912.1 
IFI44L interferon-induced protein 44-like -10.36 gb:NM_006820.1 
HM74 putative chemokine receptor; GTP-binding protein -12.04 gb:NM_006018.1 
HLA-DQA1 DC classII histocompatibility antigen alpha-chain -12.70 gb:X00452.1 
ERAP2 endoplasmic reticulum endopeptidase 2 -13.45 gb:NM_022350.1 
ALDH1 aldehyde dehydrogenase 1, soluble -14.44 gb:NM_000689.1 
OLIG1 oligodendrocyte transcription factor 1 -20.91 gb:AL355743.1 
LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) -24.83 gb:NM_006498.1 
Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that expression in patients is 
increased compared to controls. 
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Table S5. Pathways differentially expressed at t = 0 in lymphocytes.
In patients compared to controls
Pathway  -Log(p-value) Ratio Upregulated Downregulated 
Protein ubiquitination pathway 2.81E+01 8.28E-01 85/203 (42%) 93/203 (46%)
B cell receptor signalling 2.02E+01 8.51E-01 46/148 (31%) 80/148 (54%)
Glucocorticoid receptor signalling 1.49E+01 6.94E-01 70/265 (26%) 116/265 (44%)
Huntington's disease signalling 1.47E+01 7.20E-01 62/232 (27%) 107/232 (46%)
PI3K/AKT signalling 1.40E+01 7.50E-01 52/176 (30%) 81/176 (46%)
Apoptosis signalling 1.38E+01 8.31E-01 44/136 (32%) 69/136 (51%)
SAPK/JNK signalling 1.34E+01 8.10E-01 47/147 (32%) 72/147 (49%)
Natural killer cell signalling 1.34E+01 8.27E-01 15/110 (14%) 76/110 (69%)
Mitochondrial dysfunction 1.28E+01 6.06E-01 28/165 (17%) 72/165 (44%)
Oxidative phosphorylation 1.24E+01 6.71E-01 25/158 (16%) 83/158 (53%)
T cell receptor signalling 1.21E+01 8.04E-01 23/102 (23%) 59/102 (58%)
NRF2-mediated oxidative stress 
response 1.02E+01 7.39E-01 52/180 (29%) 81/180 (45%)
Pyrimidine metabolism 1.01E+01 5.18E-01 65/226 (29%) 57/226 (25%)
JAK/Stat signalling 9.48E+00 9.15E-01 19/59 (32%) 35/59 (59%)
IL-4 signalling 9.19E+00 8.24E-01 21/68 (31%) 35/68 (51%)
Death receptor signalling 9.03E+00 8.52E-01 17/61 (28%) 35/61 (57%)
p53 signalling 8.98E+00 8.62E-01 33/87 (38%) 42/87 (48%)
Hypoxia signalling in the cardiovascular 
system 8.94E+00 8.17E-01 26/71 (37%) 33/71 (46%)
Ubiquinone biosynthesis 8.69E+00 4.48E-01 12/105 (11%) 35/105 (33%)
Purine metabolism 8.67E+00 4.81E-01 97/416 (23%) 108/416 (26%)
Insulin receptor signalling 8.44E+00 7.22E-01 35/133 (26%) 61/133 (46%)
Estrogen receptor signalling 8.41E+00 7.54E-01 37/118 (31%) 53/118 (45%)
Inositol Phosphate Metabolism 8.34E+00 5.90E-01 46/173 (27%) 58/173 (34%)
GM-CSF signalling 7.88E+00 8.55E-01 15/62 (24%) 38/62 (61%)
IL-2 signalling 7.70E+00 8.68E-01 16/53 (30%) 30/53 (57%)
ERK/MAPK signalling 7.69E+00 7.12E-01 49/226 (22%) 113/226 (50%)
Aminoacyl-tRNA biosynthesis 7.68E+00 4.59E-01 29/85 (34%) 12/85 (14%)
Integrin signalling 7.52E+00 7.24E-01 40/192 (21%) 99/192 (52%)
EGF signalling 7.10E+00 8.51E-01 18/47 (38%) 22/47 (47%)
VEGF signalling 7.02E+00 7.28E-01 25/92 (27%) 42/92 (46%)
Cell cycle: G1/S checkpoint regulation 6.85E+00 8.00E-01 19/60 (32%) 29/60 (48%)
IGF-1 signalling 6.55E+00 7.50E-01 25/92 (27%) 44/92 (48%)
Nucleotide excision repair pathway 6.29E+00 9.43E-01 12/35 (34%) 22/35 (63%)
Ephrin receptor signalling 6.16E+00 6.55E-01 57/232 (25%) 95/232 (41%)
Antigen presentation pathway 5.99E+00 7.18E-01 7/39 (18%) 23/39 (59%)
PPARA/RXRA activation 5.68E+00 6.14E-01 44/176 (25%) 64/176 (36%)
PDGF signalling 5.49E+00 7.57E-01 24/74 (32%) 32/74 (43%)
Amyloid processing 5.32E+00 8.27E-01 16/52 (31%) 27/52 (52%)
PTEN signalling 5.15E+00 7.28E-01 22/92 (24%) 45/92 (49%)
Citrate cycle 4.92E+00 4.58E-01 8/59 (14%) 20/59 (34%)
NF-KB signalling 4.62E+00 6.71E-01 33/143 (23%) 63/143 (44%)
IL-10 signalling 4.34E+00 6.91E-01 16/68 (24%) 31/68 (46%)
Valine, Leucine and Isoleucine 
degradation 4.34E+00 4.39E-01 25/107 (23%) 23/107 (21%)
IL-6 signalling 4.25E+00 7.14E-01 26/91 (29%) 39/91 (43%)
Neuregulin signalling 4.10E+00 6.81E-01 22/91 (24%) 40/91 (44%)
Actin cytoskeleton signalling 4.05E+00 6.18E-01 51/267 (19%) 114/267 (43%)
Aryl hydrocarbon receptor signalling 3.92E+00 6.05E-01 37/152 (24%) 55/152 (36%)
Neurotrophin/TRK signalling 3.81E+00 6.58E-01 17/73 (23%) 31/73 (42%)
Toll-like Receptor signalling 3.77E+00 7.25E-01 14/51 (27%) 23/51 (45%)
Fc Epsilon RI signalling 3.76E+00 6.90E-01 24/100 (24%) 45/100 (45%)
Cell Cycle: G2/M DNA damage 
checkpoint regulation 3.71E+00 7.44E-01 13/43 (30%) 19/43 (44%)
Interferon signalling 3.63E+00 8.28E-01 14/29 (48%) 10/29 (34%)
Pentose phosphate pathway 3.41E+00 3.15E-01 11/89 (12%) 18/89 (20%)
N-Glycan biosynthesis 3.38E+00 4.48E-01 21/87 (24%) 19/87 (22%)
 
 
 
 
 
 
Table 3. Top 25 SDE in monocy es blood in pati nts when compared to con rols. 
 
Gene Description Fold 
change  
accession no 
IL1R2 interleukin 1 receptor, type II 55.62 gb:NM_004633.1 
ENPP2 autotaxin, phosphodiesterase I alpha 42.65 gb:L 5594.1 
METTL7B methyltransferase like 7B 34.18 gb:AI827972 
BIGMo-103 BCG induced integral membrane protein BIGMo-103 23.26 gb:AB040120.1 
OLAH oleoyl ACP hydrolase 20.98 gb:NM_018324.1 
MS4A4 membrane-spanning 4-domains, subfamily A, member 4 16.09 gb:NM_024021.1 
FIZZ3 resistin 16.08 gb:NM_020415.2 
SLC21A12 organic anion transporter OATP-E 14.86 gb:NM_016354.1 
TIMP4 tissue inhibitor of metalloproteinase 4 precursor 14.20 gb:NM_003256.1 
CD163 M130 antigen cytoplasmic variant 2 13.41 gb:Z22970.1 
NKG7 natural killer cell group 7 sequence 12.62 gb:NM_005601.1 
FAM20A family with sequence similarity 20, member A 10.59 gb:AI860568 
CXCR7 RDC1, G protein-coupled receptor 10.28 gb:AI817041 
C1QB complement component 1, q subcomponent, 
beta polypeptide precursor 
10.11 gb:NM_000491.2 
MRC1 mannose receptor, C type 1 9.88 gb:NM_002438.1 
HLA-DRB2 major histocompatibility complex, class II, DQ beta 1 -9.04 gb:M16276.1 
HLA-DMB major histocompatibility complex, class II, DM beta -9.25 gb:NM_002118.1 
FCERA1 receptor for Fc fragment of IgE, high affinity I; alpha 
polypeptide 
-10.22 gb:BC005912.1 
IFI44L interferon-induced protein 44-like -10.36 gb:NM_006820.1 
HM74 putative chemokine receptor; GTP-binding protein -12.04 gb:NM_006018.1 
HLA-DQA1 DC classII histocompatibility antigen alpha-chain -12.70 gb:X00452.1 
ERAP2 endoplasmic reticulum endopeptidase 2 -13.45 gb:NM_022350.1 
ALDH1 aldehyde dehydrogenase 1, soluble -14.44 gb:NM_000689.1 
OLIG1 oligodendrocyte transcription factor 1 -20.91 gb:AL355743.1 
LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) -24.83 gb:NM_006498.1 
Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that expression in patients is 
increased compared to controls. 
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The molecules not represented in the dataset account for the missing numbers and will make up to a 
100%.
In patients compared to controls
Pathway  -Log(p-value) Ratio Upregulated Downregulated 
Protein ubiquitination pathway 2.81E+01 8.28E-01 85/203 (42%) 93/203 (46%)
B cell receptor signalling 2.02E+01 8.51E-01 46/148 (31%) 80/148 (54%)
Glucocorticoid receptor signalling 1.49E+01 6.94E-01 70/265 (26%) 116/265 (44%)
Huntington's disease signalling 1.47E+01 7.20E-01 62/232 (27%) 107/232 (46%)
PI3K/AKT signalling 1.40E+01 7.50E-01 52/176 (30%) 81/176 (46%)
Apoptosis signalling 1.38E+01 8.31E-01 44/136 (32%) 69/136 (51%)
SAPK/JNK signalling 1.34E+01 8.10E-01 47/147 (32%) 72/147 (49%)
Natural killer cell signalling 1.34E+01 8.27E-01 15/110 (14%) 76/110 (69%)
Mitochondrial dysfunction 1.28E+01 6.06E-01 28/165 (17%) 72/165 (44%)
Oxidative phosphorylation 1.24E+01 6.71E-01 25/158 (16%) 83/158 (53%)
T cell receptor signalling 1.21E+01 8.04E-01 23/102 (23%) 59/102 (58%)
NRF2-mediated oxidative stress 
response 1.02E+01 7.39E-01 52/180 (29%) 81/180 (45%)
Pyrimidine metabolism 1.01E+01 5.18E-01 65/226 (29%) 57/226 (25%)
JAK/Stat signalling 9.48E+00 9.15E-01 19/59 (32%) 35/59 (59%)
IL-4 signalling 9.19E+00 8.24E-01 21/68 (31%) 35/68 (51%)
Death receptor signalling 9.03E+00 8.52E-01 17/61 (28%) 35/61 (57%)
p53 signalling 8.98E+00 8.62E-01 33/87 (38%) 42/87 (48%)
Hypoxia signalling in the cardiovascular 
system 8.94E+00 8.17E-01 26/71 (37%) 33/71 (46%)
Ubiquinone biosynthesis 8.69E+00 4.48E-01 12/105 (11%) 35/105 (33%)
Purine metabolism 8.67E+00 4.81E-01 97/416 (23%) 108/416 (26%)
Insulin receptor signalling 8.44E+00 7.22E-01 35/133 (26%) 61/133 (46%)
Estrogen receptor signalling 8.41E+00 7.54E-01 37/118 (31%) 53/118 (45%)
Inositol Phosphate Metabolism 8.34E+00 5.90E-01 46/173 (27%) 58/173 (34%)
GM-CSF signalling 7.88E+00 8.55E-01 15/62 (24%) 38/62 (61%)
IL-2 signalling 7.70E+00 8.68E-01 16/53 (30%) 30/53 (57%)
ERK/MAPK signalling 7.69E+00 7.12E-01 49/226 (22%) 113/226 (50%)
Aminoacyl-tRNA biosynthesis 7.68E+00 4.59E-01 29/85 (34%) 12/85 (14%)
Integrin signalling 7.52E+00 7.24E-01 40/192 (21%) 99/192 (52%)
EGF signalling 7.10E+00 8.51E-01 18/47 (38%) 22/47 (47%)
VEGF signalling 7.02E+00 7.28E-01 25/92 (27%) 42/92 (46%)
Cell cycle: G1/S checkpoint regulation 6.85E+00 8.00E-01 19/60 (32%) 29/60 (48%)
IGF-1 signalling 6.55E+00 7.50E-01 25/92 (27%) 44/92 (48%)
Nucleotide excision repair pathway 6.29E+00 9.43E-01 12/35 (34%) 22/35 (63%)
Ephrin receptor signalling 6.16E+00 6.55E-01 57/232 (25%) 95/232 (41%)
Antigen presentation pathway 5.99E+00 7.18E-01 7/39 (18%) 23/39 (59%)
PPARA/RXRA activation 5.68E+00 6.14E-01 44/176 (25%) 64/176 (36%)
PDGF signalling 5.49E+00 7.57E-01 24/74 (32%) 32/74 (43%)
Amyloid processing 5.32E+00 8.27E-01 16/52 (31%) 27/52 (52%)
PTEN signalling 5.15E+00 7.28E-01 22/92 (24%) 45/92 (49%)
Citrate cycle 4.92E+00 4.58E-01 8/59 (14%) 20/59 (34%)
NF-KB signalling 4.62E+00 6.71E-01 33/143 (23%) 63/143 (44%)
IL-10 signalling 4.34E+00 6.91E-01 16/68 (24%) 31/68 (46%)
Valine, Leucine and Isoleucine 
degradation 4.34E+00 4.39E-01 25/107 (23%) 23/107 (21%)
IL-6 signalling 4.25E+00 7.14E-01 26/91 (29%) 39/91 (43%)
Neuregulin signalling 4.10E+00 6.81E-01 22/91 (24%) 40/91 (44%)
Actin cytoskeleton signalling 4.05E+00 6.18E-01 51/267 (19%) 114/267 (43%)
Aryl hydrocarbon receptor signalling 3.92E+00 6.05E-01 37/152 (24%) 55/152 (36%)
Neurotrophin/TRK signalling 3.81E+00 6.58E-01 17/73 (23%) 31/73 (42%)
Toll-like Receptor signalling 3.77E+00 7.25E-01 14/51 (27%) 23/51 (45%)
Fc Epsilon RI signalling 3.76E+00 6.90E-01 24/100 (24%) 45/100 (45%)
Cell Cycle: G2/M DNA damage 
checkpoint regulation 3.71E+00 7.44E-01 13/43 (30%) 19/43 (44%)
Interferon signalling 3.63E+00 8.28E-01 14/29 (48%) 10/29 (34%)
Pentose phosphate pathway 3.41E+00 3.15E-01 11/89 (12%) 18/89 (20%)
N-Glycan biosynthesis 3.38E+00 4.48E-01 21/87 (24%) 19/87 (22%)
 
 
 
 
 
 
Table S3. Top 25 SDE in monocytes blood in patients when compared to controls. 
 
Gene Description Fold 
change  
accession no 
IL1R2 interleukin 1 receptor, type II 55.62 gb:NM_004633.1 
ENPP2 autotaxin, phosphodiesterase I alpha 42.65 gb:L35594.1 
METTL7B methyltransferase like 7B 34.18 gb:AI827972 
BIGMo-103 BCG induced integral membrane protein BIGMo-103 23.26 gb:AB040120.1 
OLAH oleoyl ACP hydrolase 20.98 gb:NM_018324.1 
MS4A4 membrane-spanning 4-domains, subfamily A, member 4 16.09 gb:NM_024021.1 
FIZZ3 resistin 16.08 gb:NM_020415.2 
SLC21A12 organic anion transporter OATP-E 14.86 gb:NM_016354.1 
TIMP4 tissue inhibitor of metalloproteinase 4 precursor 14.20 gb:NM_003256.1 
CD163 M130 antigen cytoplasmic variant 2 13.41 gb:Z22970.1 
NKG7 natural killer cell group 7 sequence 12.62 gb:NM_005601.1 
FAM20A family with sequence similarity 20, member A 10.59 gb:AI860568 
CXCR7 RDC1, G protein-coupled receptor 10.28 gb:AI817041 
C1QB complement component 1, q subcomponent, 
beta polypeptide precursor 
10.11 gb:NM_000491.2 
MRC1 mannose receptor, C type 1 9.88 gb:NM_002438.1 
HLA-DRB2 major histocompatibility complex, class II, DQ beta 1 -9.04 gb:M16276.1 
HLA-DMB major histocompatibility complex, class II, DM beta -9.25 gb:NM_002118.1 
FCERA1 receptor for Fc fragment of IgE, high affinity I; alpha 
polypeptide 
-10.22 gb:BC005912.1 
IFI44L interferon-induced protein 44-like -10.36 gb:NM_006820.1 
HM74 putative chemokine receptor; GTP-binding protein -12.04 gb:NM_006018.1 
HLA-DQA1 DC classII histocompatibility antigen alpha-chain -12.70 gb:X00452.1 
ERAP2 endoplasmic reticulum endopeptidase 2 -13.45 gb:NM_022350.1 
ALDH1 aldehyde dehydrogenase 1, soluble -14.44 gb:NM_000689.1 
OLIG1 oligodendrocyte transcription factor 1 -20.91 gb:AL355743.1 
LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) -24.83 gb:NM_006498.1 
Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that expression in patients is 
increased compared to controls. 
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Table S6. Pathways differentially expressed at t = 0 in monocytes.
In patients compared to controls
Pathway  -Log(P-value) Ratio Upregulated Downregulated 
Protein ubiquitination pathway 2.40E+01 7.64E-01 72/203 (35%) 86/203 (42%)
B cell receptor signalling 2.05E+01 8.11E-01 36/148 (24%) 84/148 (57%)
Huntington's disease signalling 1.76E+01 6.94E-01 64/232 (28%) 98/232 (42%)
Oxidative phosphorylation 1.71E+01 6.71E-01 67/158 (42%) 40/158 (25%)
Mitochondrial dysfunction 1.65E+01 6.00E-01 55/165 (33%) 44/165 (27%)
Glucocorticoid receptor signalling 1.63E+01 6.57E-01 56/265 (21%) 119/265 (45%)
Apoptosis signalling 1.57E+01 8.01E-01 38/136 (28%) 71/136 (52%)
PI3K/AKT signalling 1.54E+01 7.16E-01 42/176 (24%) 84/176 (48%)
NRF2-mediated oxidative stress 
response 1.47E+01 7.33E-01 60/180 (33%) 72/180 (40%)
SAPK/JNK signalling 1.36E+01 7.62E-01 35/147 (24%) 77/147 (52%)
ERK/MAPK signalling 1.30E+01 7.12E-01 56/226 (25%) 105/226 (46%)
Hypoxia signalling in the cardiovascular 
system 1.27E+01 8.31E-01 24/71 (34%) 36/71 (51%)
Estrogen receptor signalling 1.01E+01 7.29E-01 34/118 (29%) 52/118 (44%)
Inositol phosphate metabolism 9.97E+00 5.66E-01 28/173 (16%) 70/173 (40%)
Insulin receptor signalling 9.83E+00 6.92E-01 28/133 (21%) 64/133 (48%)
T Cell receptor signalling 9.58E+00 7.25E-01 21/102 (21%) 53/102 (52%)
GM-CSF Signalling 9.44E+00 8.39E-01 17/62 (27%) 35/62 (56%)
PDGF signalling 9.22E+00 7.84E-01 14/74 (19%) 44/74 (59%)
VEGF signalling 9.13E+00 7.17E-01 22/92 (24%) 44/92 (48%)
EGF signalling 9.04E+00 8.51E-01 9/47 (19%) 31/47 (66%)
Ubiquinone biosynthesis 8.92E+00 4.29E-01 27/105 (26%) 19/105 (18%)
PPARA/RXRA activation 8.81E+00 6.08E-01 37/176 (21%) 70/176 (40%)
Purine metabolism 8.80E+00 4.42E-01 99/416 (24%) 89/416 (21%)
IGF-1 signalling 8.69E+00 7.39E-01 23/92 (25%) 45/92 (49%)
Death receptor signalling 8.68E+00 8.03E-01 19/61 (31%) 30/61 (49%)
Integrin signalling 8.65E+00 6.82E-01 45/192 (23%) 86/192 (45%)
Pyrimidine metabolism 8.18E+00 4.65E-01 56/226 (25%) 53/226 (23%)
p53 signalling 8.10E+00 7.93E-01 19/87 (22%) 50/87 (57%)
IL-2 signalling 8.02E+00 8.30E-01 11/53 (21%) 33/53 (62%)
Antigen presentation pathway 7.41E+00 7.18E-01 5/39 (13%) 23/39 (59%)
JAK/Stat signalling 6.87E+00 8.14E-01 13/59 (22%) 35/59 (59%)
IL-4 signalling 6.87E+00 7.35E-01 11/68 (16%) 39/68 (57%)
NF-KB signalling 6.84E+00 6.57E-01 33/143 (23%) 61/143 (43%)
Ephrin receptor signalling 6.71E+00 6.08E-01 51/232 (22%) 90/232 (39%)
PTEN Signalling 6.57E+00 7.07E-01 20/92 (22%) 45/92 (49%)
IL-10 signalling 6.21E+00 6.91E-01 20/68 (29%) 27/68 (40%)
Toll-like receptor signalling 5.99E+00 7.45E-01 15/51 (29%) 23/51 (45%)
Nucleotide excision repair pathway 5.92E+00 8.86E-01 14/35 (40%) 17/35 (49%)
Aminoacyl-tRNA biosynthesis 5.78E+00 4.12E-01 22/85 (26%) 18/85 (21%)
Citrate cycle 5.25E+00 4.41E-01 13/59 (22%) 16/59 (27%)
IL-6 signalling 5.10E+00 6.81E-01 24/91 (26%) 38/91 (42%)
PPAR signalling 4.95E+00 6.11E-01 22/95 (23%) 36/95 (38%)
Actin cytoskeleton signalling 4.53E+00 5.69E-01 56/267 (21%) 97/267 (36%)
Natural killer cell signalling 4.43E+00 6.36E-01 21/110 (19%) 49/110 (45%)
Neuregulin signalling 4.41E+00 6.37E-01 22/91 (24%) 36/91 (40%)
Fc epsilon RI signalling 4.33E+00 6.50E-01 19/100 (19%) 46/100 (46%)
N-Glycan biosynthesis 4.31E+00 4.37E-01 19/87 (22%) 20/87 (23%)
Neurotrophin/TRK signalling 4.05E+00 6.16E-01 13/73 (18%) 32/73 (44%)
Chemokine signalling 4.01E+00 6.80E-01 21/75 (28%) 30/75 (40%)
Propanoate metabolism 3.98E+00 3.41E-01 24/126 (19%) 20/126 (16%)
Amyloid processing 3.97E+00 7.31E-01 13/52 (25%) 25/52 (48%)
Aryl hydrocarbon receptor signalling 3.84E+00 5.53E-01 35/152 (23%) 49/152 (32%)
p38 MAPK Signalling 3.74E+00 6.74E-01 25/95 (26%) 39/95 (41%)
Nicotinate and nicotinamide metabolism 3.57E+00 4.65E-01 19/129 (15%) 41/129 (32%)
Fructose and mannose metabolism 3.46E+00 2.29E-01 15/140 (11%) 18/140 (13%)
Lysine degradation 3.43E+00 3.19E-01 22/144 (15%) 25/144 (17%)
Xenobiotic metabolism signalling 3.24E+00 5.32E-01 54/250 (22%) 80/250 (32%)
Interferon signalling 3.22E+00 7.59E-01 6/29 (21%) 16/29 (55%)
Valine, Leucine and Isoleucine 
degradation 3.10E+00 3.83E-01 23/107 (21%) 18/107 (17%)
Fatty acid biosynthesis 3.07E+00 2.04E-01 6/49 (12%) 4/49 (8%)
Leukocyte extravasation signalling 3.06E+00 5.74E-01 29/188 (15%) 79/188 (42%)
Endoplasmic reticulum stress pathway 3.00E+00 8.33E-01 7/18 (39%) 8/18 (44%)
 
 
 
 
 
 
Table 3. Top 25 SDE in monocytes blood in patients when compared to controls. 
 
Gene Description Fold 
change  
accession no 
IL1R2 interleukin 1 receptor, type II 55.62 gb:NM_004633.1 
ENPP2 autotaxin, phosphodiesterase I alpha 42.65 gb:L35594.1 
METTL7B methyltransferase like 7B 34.18 gb:AI827972 
BIGMo-103 BCG induced integral membrane protein BIGMo-103 23.26 gb:AB040120.1 
OLAH oleoyl ACP hydrolase 20.98 gb:NM_018324.1 
MS4A4 membrane-spanning 4-domains, subfamily A, member 4 16.09 gb:NM_024021.1 
FIZZ3 resistin 16.08 gb:NM_020415.2 
SLC21A12 organic anion transporter OATP-E 14.86 gb:NM_016354.1 
TIMP4 tissue inhibitor of metalloproteinase 4 precursor 14.20 gb:NM_003256.1 
CD163 M130 antigen cytoplasmic variant 2 13.41 gb:Z22970.1 
NKG7 natural killer cell group 7 sequence 12.62 gb:NM_005601.1 
FAM20A family with sequence similarity 20, member A 10.59 gb:AI860568 
CXCR7 RDC1, G protein-coupled receptor 10.28 gb:AI817041 
C1QB complement component 1, q subcomponent, 
beta polypeptide precursor 
10.11 gb:NM_000491.2 
MRC1 mannose receptor, C type 1 9.88 gb:NM_002438.1 
HLA-DRB2 major histocompatibility complex, class II, DQ beta 1 -9.04 gb:M16276.1 
HLA-DMB major histocompatibility complex, class II, DM beta -9.25 gb:NM_002118.1 
FCERA1 receptor for Fc fragment of IgE, high affinity I; alpha 
polypeptide 
-10.22 gb:BC005912.1 
IFI44L interferon-induced protein 44-like -10.36 gb:NM_006820.1 
HM74 putative chemokine receptor; GTP-binding protein -12.04 gb:NM_006018.1 
HLA-DQA1 DC classII histocompatibility antigen alpha-chain -12.70 gb:X00452.1 
ERAP2 endoplasmic reticulum endopeptidase 2 -13.45 gb:NM_022350.1 
ALDH1 aldehyde dehydrogenase 1, soluble -14.44 gb:NM_000689.1 
OLIG1 oligodendrocyte transcription factor 1 -20.91 gb:AL355743.1 
LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) -24.83 gb:NM_006498.1 
Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that expression in patients is 
increa ed compared to controls. 
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The molecules not represented in the dataset account for the missing numbers and will make up to a 
100%.
In patients compared to controls
Pathway  -Log(P-value) Ratio Upregulated Downregulated 
Protein ubiquitination pathway 2.40E+01 7.64E-01 72/203 (35%) 86/203 (42%)
B cell receptor signalling 2.05E+01 8.11E-01 36/148 (24%) 84/148 (57%)
Huntington's disease signalling 1.76E+01 6.94E-01 64/232 (28%) 98/232 (42%)
Oxidative phosphorylation 1.71E+01 6.71E-01 67/158 (42%) 40/158 (25%)
Mitochondrial dysfunction 1.65E+01 6.00E-01 55/165 (33%) 44/165 (27%)
Glucocorticoid receptor signalling 1.63E+01 6.57E-01 56/265 (21%) 119/265 (45%)
Apoptosis signalling 1.57E+01 8.01E-01 38/136 (28%) 71/136 (52%)
PI3K/AKT signalling 1.54E+01 7.16E-01 42/176 (24%) 84/176 (48%)
NRF2-mediated oxidative stress 
response 1.47E+01 7.33E-01 60/180 (33%) 72/180 (40%)
SAPK/JNK signalling 1.36E+01 7.62E-01 35/147 (24%) 77/147 (52%)
ERK/MAPK signalling 1.30E+01 7.12E-01 56/226 (25%) 105/226 (46%)
Hypoxia signalling in the cardiovascular 
system 1.27E+01 8.31E-01 24/71 (34%) 36/71 (51%)
Estrogen receptor signalling 1.01E+01 7.29E-01 34/118 (29%) 52/118 (44%)
Inositol phosphate metabolism 9.97E+00 5.66E-01 28/173 (16%) 70/173 (40%)
Insulin receptor signalling 9.83E+00 6.92E-01 28/133 (21%) 64/133 (48%)
T Cell receptor signalling 9.58E+00 7.25E-01 21/102 (21%) 53/102 (52%)
GM-CSF Signalling 9.44E+00 8.39E-01 17/62 (27%) 35/62 (56%)
PDGF signalling 9.22E+00 7.84E-01 14/74 (19%) 44/74 (59%)
VEGF signalling 9.13E+00 7.17E-01 22/92 (24%) 44/92 (48%)
EGF signalling 9.04E+00 8.51E-01 9/47 (19%) 31/47 (66%)
Ubiquinone biosynthesis 8.92E+00 4.29E-01 27/105 (26%) 19/105 (18%)
PPARA/RXRA activation 8.81E+00 6.08E-01 37/176 (21%) 70/176 (40%)
Purine metabolism 8.80E+00 4.42E-01 99/416 (24%) 89/416 (21%)
IGF-1 signalling 8.69E+00 7.39E-01 23/92 (25%) 45/92 (49%)
Death receptor signalling 8.68E+00 8.03E-01 19/61 (31%) 30/61 (49%)
Integrin signalling 8.65E+00 6.82E-01 45/192 (23%) 86/192 (45%)
Pyrimidine metabolism 8.18E+00 4.65E-01 56/226 (25%) 53/226 (23%)
p53 signalling 8.10E+00 7.93E-01 19/87 (22%) 50/87 (57%)
IL-2 signalling 8.02E+00 8.30E-01 11/53 (21%) 33/53 (62%)
Antigen presentation pathway 7.41E+00 7.18E-01 5/39 (13%) 23/39 (59%)
JAK/Stat signalling 6.87E+00 8.14E-01 13/59 (22%) 35/59 (59%)
IL-4 signalling 6.87E+00 7.35E-01 11/68 (16%) 39/68 (57%)
NF-KB signalling 6.84E+00 6.57E-01 33/143 (23%) 61/143 (43%)
Ephrin receptor signalling 6.71E+00 6.08E-01 51/232 (22%) 90/232 (39%)
PTEN Signalling 6.57E+00 7.07E-01 20/92 (22%) 45/92 (49%)
IL-10 signalling 6.21E+00 6.91E-01 20/68 (29%) 27/68 (40%)
Toll-like receptor signalling 5.99E+00 7.45E-01 15/51 (29%) 23/51 (45%)
Nucleotide excision repair pathway 5.92E+00 8.86E-01 14/35 (40%) 17/35 (49%)
Aminoacyl-tRNA biosynthesis 5.78E+00 4.12E-01 22/85 (26%) 18/85 (21%)
Citrate cycle 5.25E+00 4.41E-01 13/59 (22%) 16/59 (27%)
IL-6 signalling 5.10E+00 6.81E-01 24/91 (26%) 38/91 (42%)
PPAR signalling 4.95E+00 6.11E-01 22/95 (23%) 36/95 (38%)
Actin cytoskeleton signalling 4.53E+00 5.69E-01 56/267 (21%) 97/267 (36%)
Natural killer cell signalling 4.43E+00 6.36E-01 21/110 (19%) 49/110 (45%)
Neuregulin signalling 4.41E+00 6.37E-01 22/91 (24%) 36/91 (40%)
Fc epsilon RI signalling 4.33E+00 6.50E-01 19/100 (19%) 46/100 (46%)
N-Glycan biosynthesis 4.31E+00 4.37E-01 19/87 (22%) 20/87 (23%)
Neurotrophin/TRK signalling 4.05E+00 6.16E-01 13/73 (18%) 32/73 (44%)
Chemokine signalling 4.01E+00 6.80E-01 21/75 (28%) 30/75 (40%)
Propanoate metabolism 3.98E+00 3.41E-01 24/126 (19%) 20/126 (16%)
Amyloid processing 3.97E+00 7.31E-01 13/52 (25%) 25/52 (48%)
Aryl hydrocarbon receptor signalling 3.84E+00 5.53E-01 35/152 (23%) 49/152 (32%)
p38 MAPK Signalling 3.74E+00 6.74E-01 25/95 (26%) 39/95 (41%)
Nicotinate and nicotinamide metabolism 3.57E+00 4.65E-01 19/129 (15%) 41/129 (32%)
Fructose and mannose metabolism 3.46E+00 2.29E-01 15/140 (11%) 18/140 (13%)
Lysine degradation 3.43E+00 3.19E-01 22/144 (15%) 25/144 (17%)
Xenobiotic metabolism signalling 3.24E+00 5.32E-01 54/250 (22%) 80/250 (32%)
Interferon signalling 3.22E+00 7.59E-01 6/29 (21%) 16/29 (55%)
Valine, Leucine and Isoleucine 
degradation 3.10E+00 3.83E-01 23/107 (21%) 18/107 (17%)
Fatty acid biosynthesis 3.07E+00 2.04E-01 6/49 (12%) 4/49 (8%)
Leukocyte extravasation signalling 3.06E+00 5.74E-01 29/188 (15%) 79/188 (42%)
Endoplasmic reticulum stress pathway 3.00E+00 8.33E-01 7/18 (39%) 8/18 (44%)
 
 
 
 
 
 
Table S3. Top 25 SDE in monocytes blood in patients when compared to controls. 
 
Gene Description Fold 
change  
accession no 
IL1R2 interleukin 1 receptor, type II 55.62 gb:NM_004633.1 
ENPP2 autotaxin, phosphodiesterase I alpha 42.65 gb:L35594.1 
METTL7B methyltransferase like 7B 34.18 gb:AI827972 
BIGMo-103 BCG induced integral membrane protein BIGMo-103 23.26 gb:AB040120.1 
OLAH oleoyl ACP hydrolase 20.98 gb:NM_018324.1 
MS4A4 membrane-spanning 4-domains, subfamily A, member 4 16.09 gb:NM_024021.1 
FIZZ3 resistin 16.08 gb:NM_020415.2 
SLC21A12 organic anion transporter OATP-E 14.86 gb:NM_016354.1 
TIMP4 tissue inhibitor of metalloproteinase 4 precursor 14.20 gb:NM_003256.1 
CD163 M130 antigen cytoplasmic variant 2 13.41 gb:Z22970.1 
NKG7 natural killer cell group 7 sequence 12.62 gb:NM_005601.1 
FAM20A family with sequence similarity 20, member A 10.59 gb:AI860568 
CXCR7 RDC1, G protein-coupled receptor 10.28 gb:AI817041 
C1QB complement component 1, q subcomponent, 
beta polypeptide precursor 
10.11 gb:NM_000491.2 
MRC1 mannose receptor, C type 1 9.88 gb:NM_002438.1 
HLA-DRB2 major histocompatibility complex, class II, DQ beta 1 -9.04 gb:M16276.1 
HLA-DMB major histocompatibility complex, class II, DM beta -9.25 gb:NM_002118.1 
FCERA1 receptor for Fc fragment of IgE, high affinity I; alpha 
polypeptide 
-10.22 gb:BC005912.1 
IFI44L interferon-induced protein 44-like -10.36 gb:NM_006820.1 
HM74 putative chemokine receptor; GTP-binding protein -12.04 gb:NM_006018.1 
HLA-DQA1 DC classII histocompatibility antigen alpha-chain -12.70 gb:X00452.1 
ERAP2 endoplasmic reticulum endopeptidase 2 -13.45 gb:NM_022350.1 
ALDH1 aldehyde dehydrogenase 1, soluble -14.44 gb:NM_000689.1 
OLIG1 oligodendrocyte transcription factor 1 -20.91 gb:AL355743.1 
LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) -24.83 gb:NM_006498.1 
Fold change between expression in patients at t = 0 and controls; a positive fold change indicates that expression in patients is 
increased compared to controls. 
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Abstract
Objective. While the association of PAI1 4G/5G polymorphism with sepsis and 
outcome was repeatedly shown in meningococcal disease, no confirmatory results 
have been presented regarding its association with the clinical course after severe 
trauma. Our objective was to study the PAI1 4G/5G polymorphism in an independent 
cohort of multiple trauma patients.
Patients and methods. The PAI1 4G/5G polymorphism was genotyped in 136 
patients with multiple trauma admitted to the ICU. Injury Severity Score (ISS) and 
Apache II scores were assessed on admittance and at onset of sepsis with or without 
multiple-organ dysfunction. Additionally, the PAI1 polymorphism was genotyped in 
463 healthy controls.
Results. Sepsis was observed in 28 (93%) of fatal cases, compared to 38 (36%) 
of survivors. Patients with the PAI1 4G/4G genotype had an increased risk for 
sepsis compared with those homozygous for the 5G variant. However, no significant 
difference in PAI1 genotype distributions was observed between survivors and non-
survivors. 
Conclusions. The PAI1 4G/4G genotype, previously shown to be associated with 
increased PAI-1 serum levels, was confirmed to be associated with increased risk of 
sepsis in an independent cohort of severe trauma patients. Both less severe disease 
and improved treatment regimes of the current study population are considered to 
have contributed to improved survival, and consequently, to the lack of previously 
observed association with mortality.
Introduction
The 4G/5G plasminogen-activator-inhibitor-1 (PAI1) promoter polymorphism was 
previously associated with altered expression levels. Both inhibitory and stimulatory 
transcription factors can bind the 5G variant promoter region, while in the 4G 
variant only a transcription activator can bind, resulting in increased transcription 
upon stimulation.(1, 2) The PAI1 4G/4G genotype has repeatedly been associated 
with severity and mortality in meningococcal disease.(3-6) In patients with dengue 
infection, however, no association was observed between PAI1 polymorphism and 
outcome or PAI-1 plasma concentrations, even though PAI-1 levels were highest in 
non-survivors.(7)
Upon severe trauma, an adequate stress response including activation of the immune 
system and coagulation and fibrinolytic pathways are required. Previously, an 
increase of PAI-1 concentrations has been observed in trauma patients. Additionally, 
the PAI1 4G/4G promoter genotype, which results in increased PAI-1 transcription 
upon activation was associated with increased mortality.(8)
In the current study we further investigated the role of PAI1 4G/5G polymorphism in 
the development of sepsis and outcome in an independent multiple trauma patient 
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cohort. We confirmed the association of the PAI1 4G/4G genotype with increased 
disease severity, but not with survival.
Methods
Participants. Between January 1999 and December 2002 136 multiple trauma 
patients consecutively admitted to the intensive care unit (ICU) participated in our 
study. Patients were enrolled in the study after obtaining approval of the Ethic Study 
Board of the University of Giessen. Informed consent was obtained from the legal 
custodian at baseline and from all patients upon recovery of their mental status. 
The clinical criteria for inclusion were: severe injuries of at least two body regions 
or three major fractures, and admission to the ICU within 12 h after the accident. 
The exclusion criteria were: less severe injuries, pregnancy, pre-existing coagulation 
abnormalities, and malignant disease. Apache II and ISS scores were determined.
(9-11) The patients were categorized as having or not having sepsis and/or multiple 
organ dysfunction syndrome (MODS) by the intensivist on duty who was blinded to 
the genotype and the aim of the study.(12) Patients received standard treatment 
according to hospital protocols. Additionally, healthy Caucasian controls (n = 463), 
were derived from the Dutch Blood bank Sanquin South West region.
Experimental procedures. DNA was extracted from peripheral blood leukocytes 
using standard protocols (DNA minikit; Qiagen, Hilden, Germany). The PAI1 4G/5G 
genotype (rs1799889) was determined using Bi-allelic discrimination with Taqman 
analysis (ABIPrism 7700, Applied Biosystems, Darmstadt, Germany). Forward and 
reverse primers were PAI-675-675F 5’GCCAGACAAGGTTGTTGACACA3’ and PAI-
675-675R 5’GCCGCCTCCGATGATACA3’, respectively. The probe to detect the 4G 
allele was FAM-CTGACTCCCCACGTGT, and the VIC-CTGGACCCCCCACGTG 
probe was used to detect the 5G variant.
Statistical analyses. Statistical analyses were performed using SPSS 11.0. For 
univariate analyses Fisher’s Exact test or Mann-Whitney U test were performed 
when appropriate. Verification of Hardy-Weinberg equilibrium (HWE) of genotypes 
was performed using the c2 test (1df). A comparison of genotype frequencies was 
made between survivors and non-survivors and between patients with and without 
sepsis, using binary logistic regression adjusting for age (log transformed to obtain a 
normal distribution). Probability (P) values ≤ 0.05 were considered to be statistically 
significant. Apache II and ISS scores were compared between the different genotypes 
using non-parametric analyses.
Results
In total 136 multiple trauma patients were included in our study. Thirty (22%) of 
them died. Males represented 85 (62.5%) of patients. Gender was not significantly 
different between survivors and non-survivors (Table 1). Non-survivors were older 
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than survivors and had increased severity scores compared to survivors. Twenty-
eight (93.3%) of the non-survivors developed sepsis, while this was only 35.8% 
in survivors. The two non-survivors, who had no signs of sepsis, died of cerebral 
stroke and fulminant thromboembolism of the lung, respectively. Sepsis patients, who 
died had more severe disease compared to patients who survived sepsis. Despite 
increased incubation time for blood cultures and denaturing HLPC testing of the 
samples, no microbial pathogens were detected in any of the patients with sepsis 
(13). It must be noted that all patients received antibiotic treatment from the start of 
therapy on admission to the hospital.
Table 1. Patient characteristics.
The PAI1 4G/5G genotype distribution (%) for the 5G/5G, 5G/4G and 4G/4G 
genotypes in controls was 99 (21.4%), 241 (52.1%), and 123 (26.6%), respectively. 
The corresponding frequencies in patients were 31 (22.8%), 60 (44.1%) and 45 
(33.1%), respectively. Genotype distribution in both groups reached HWE (p=0.35 
and 0.21, respectively). The 4G/4G genotype was over-represented in patients with 
Table 2. Plasminogen activator inhibitor-1 genotype distribution in trauma patients with and without 
sepsis.
1Adjusted analysis included log(age).
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Table 1. Patient aracteristics.
Survivors
n = 106
Non-survivors
n = 30 p-value
Male gender (%) 67 (63.2) 18 (60) 0.83
Age (years) 33 (18-74) 44.5 (21-79) 0.001
Weight (kg) 79 (50-130) 75.5 (60-100) 0.28
Scores at admission to ICU:
Injury severity score (ISS)
APACHE II
18 (5-63)
7.5 (1-26)
34 (10-58)
13 (2-26)
<0.001
<0.001
Sepsis (% of total) 38 (35.8) 28 (93.3)
Male gender (% of sepsis patients) 25 (65.8) 16 (57.1) 0.61
Age (years) 32 (18-74) 44.5 (21-79) <0.01
Weight (kg) 80 (50-120) 75.5 (50-100) 0.05
Sepsis patients:
Injury severity score (ISS)
APACHE II at admission
APACHE II at onset sepsis
14.5 (7-63)
8 (1-26)
11.5 (5-24)
34.5 (10-58)
13 (2-26)
21 (7-28)
0.04
0.001
<0.001
Table 2. Plasminogen activator inhibitor-1 genotype distribution in trauma patients with and without sepsis.
Genotype distribution Logistic regression analyis
No sepsis Sepsis OR (p) OR (p)
crude
1
PAI1 n = 70 n = 66
4G/4G 19 (27.1) 26 (39.4) 2.87 (0.03) 2.72 (0.046)
4G/5G 30 (42.9) 30 (45.5) 2.10 (0.11) 2.04 (0.13)
5G/5G 21 (30.0) 10 (15.2) 1 1
Adjusted analysis included log(age).
Table 3. Plasminogen activator inhibitor-1 genotype distribution in trauma patients.
Survivors vs. non-survivors
Survivors Non- OR (p) OR (p)
No sepsis Sepsis
survivors
crude djusted
1
PAI1 n = 68 n = 38 n = 30
4G/4G 17 (25.0) 17 (44.7) 11 (36.7) 1.11 (0.85) 0.71 (0.55)
4G/5G 30 (44.1) 18 (47.4) 12 (40.0) 0.86 (0.77) 0.59 (0.37)
5G/5G 21 (30.9) 3 (7.9) 7 (23.3) 1 1
Adjusted analysis included log(age).
adjusted
a
8
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sepsis compared to patients who did not develop sepsis (crude OR 2.87, p=0.03; 
adjusted OR 2.72, p=0.046) (Table 2). 
Since only 11 patients met the MODS criteria, genotype distributions were not 
compared between patients with and without MODS. Assessing the effect of PAI1 
genotypes on severity using Apache II and ISS scores, no significant difference was 
observed for the latter (p=0.54). Individuals having the 4G/4G genotype displayed 
slightly increased median Apache II scores (min-max) on admission compared 
to those with the 4G/5G and 5G/5G genotype (10 (3-26), 7 (2-26) and 8 (1-24), 
respectively; p=0.035).
In contrast to previous observations, no association was observed between the PAI1 
genotype and survival (Table 3). Similar results were obtained when the two patients, 
who died of causes other than sepsis, were excluded from the analysis.
Table 3. Plasminogen activator inhibitor-1 genotype distribution in trauma patients.
1Adjusted analysis included log(age).
Discussion
In the current study we demonstrated that the 4G homozygous genotype was 
associated with increased occurrence of sepsis in multiple trauma patients. However, 
in contrast with our previous study no association of the PAI1 4G allele with fatal 
outcome of multiple trauma was observed.(8) The discrepancy between the two 
studies could have several causes. While mortality was 34% (21/61) in the previous 
study, only 22% of the patients died in the current study. This may be related to the 
less severe disease observed, according to the decreased ISS scores, in the current 
patient cohort. Additionally, in recent years substantial progress has been made in the 
supportive treatment of multiple trauma and sepsis patients resulting in decreased 
mortality. Tight glycaemic control, intensivated insulin therapy, hydrocortisone 
administration in septic shock and improved detoxification have been implemented 
in the ICU in the last trimester of 2001, and a substantial part of the patients (n=40) 
was eligible for this therapy.(14-16) PAI-1 gene expression in vascular endothelial 
cells is suggested to be induced by hyperglycaemia, and control of blood glucose 
levels may have had a major impact on PAI-1 plasma levels and on mortality.(17) 
Since outcome of severe multiple trauma is dependent on multiple factors, improved 
treatment options in the current study may have resulted in decreased mortality even 
despite increased PAI-1 levels.
In addition, PAI-1 transcription is induced by IL-1β and TNF-α.(1, 18) Differences 
8
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in expression of these cytokines are therefore expected to result in altered PAI-
1 expression. A correlation between TNF-α and PAI-1 levels has indeed been 
observed in meningococcal sepsis.(19) Additionally, meningococcal sepsis non-
survivors display increased PAI-1 levels compared to survivors with similar TNFα 
concentrations. These differences in PAI-1 concentrations are associated with the 
PAI1 4G/5G polymorphism. This indicates that the stress response induced by 
infection or inflammation is complex and involves interaction of immune response, 
fibrinolysis and coagulation, and endocrinological pathways. The same holds true 
for multiple trauma patients. Notably, no causative micro-organisms were detected 
despite laborious efforts. While this may result from the fact that all patients received 
antibiotics from the start of treatment before blood cultures were drawn, this may also 
imply that the sepsis syndrome observed in multiple trauma patients has a different 
pathogenesis than microbial infection. The combination of variations in the individual 
pathways involved is expected to co-determine the observed phenotype. In the current 
study population, factors other than PAI-1, such as improved treatment options may 
have had a higher impact on survival. Consequently, this may have resulted in the 
finding that no longer an association was observed with mortality although PAI1 4G 
homozygosity was associated with the occurrence of sepsis. Another explanation 
for the differences observed between the prior and the current study might be that 
either the first study showed a false positive association or the current study a false 
negative with regard to mortality. First publications regarding polymorphisms and 
their association with disease are usually positive and therefore more likely to be 
false positive results.(20) In addition, association studies in small populations have 
an increased risk of false positive results since a small shift in patient numbers for 
different outcomes results in large percentage changes.(21) The first study comprised 
the data of only 61 multiple trauma patients, while in the current study 136 patients 
were included. The observation that the PAI1 4G homozygous genotype is confirmed 
to be associated with increased risk of sepsis strengthens the assumption that PAI-1 
is an important risk factor for more severe disease course after multiple trauma.
In conclusion, the PAI1 4G/5G polymorphism was confirmed to be associated with 
severity but not with mortality. Less severe disease and improved treatment options 
are likely involved in co-determining occurrence of sepsis and outcome.
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Abstract
Objective. Macrophages infiltrate peripheral nerves and may contribute to neural 
damage in the Guillain-Barré syndrome (GBS). 
Patients and methods. We determined whether single nucleotide polymorphisms 
(SNP) in genes encoding macrophage-mediators are related to the susceptibility and 
severity of GBS.
Results and conclusion. The frequencies of SNPs in the TNFA, MMP9, IL10, and 
NOS2a genes did not differ between 263 GBS patients and 210 healthy subjects. The 
MMP9 C(-1562)T and TNFA C(-863)A SNP were associated with severe weakness 
and poor outcome, indicating that these SNPs may be one of the factors predisposing 
to a severe form of GBS.
Introduction 
Macrophages seem to play a crucial role in the pathogenesis of the various variants 
of the Guillain-Barré syndrome (GBS). These cells phagocytose myelin in patients 
with acute inflammatory demyelinating neuropathy (AIDP) and axons in patients 
with acute motor axonal neuropathy (AMAN).(1) Macrophages usually exert their 
functions by the release of cytokines and other inflammatory mediators. Tumour 
necrosis factor-alpha (TNF-α), matrix metalloproteinase 9 (MMP-9) and inducible 
nitric oxide synthase (iNOS) are involved in leukocyte attraction, extracellular matrix 
degradation, demyelination and axonal degeneration. IL-10, another mediator 
released by macrophages, may exert pro-inflammatory as well as anti-inflammatory 
effects, since it promotes both antibody production as well as the termination of 
inflammatory response and tissue destruction.(2) These mediators of inflammation 
probably play a decisive role in the actions of macrophages at the peripheral nerves 
of patients with GBS. 
Single nucleotide polymorphisms (SNP) in genes encoding these mediators affect the 
levels or functions of these mediators and may control the extent of the macrophage-
related nerve damage in GBS. Previous studies showed that elevated levels of TNF-α 
and MMP-9 are associated with disease severity and electrophysiological changes 
in GBS patients.(3-6) Another report showed that a SNP in the promoter region of 
IL10 associated with high IL-10 production was a susceptibility factor for the onset of 
GBS.(7)
In this study we determined whether SNP in the promoter region of TNFA, MMP9, 
IL10, and in the coding region of NOS2a are susceptibility factors or disease modifying 
factors in a cohort of clinically well-characterized GBS patients (n = 263). 
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Methods
Study population. In this study were included 263 Caucasian patients (median age 
at disease onset 45.0 years, range 7-82 years, male/female ratio = 1.10), who fulfilled 
the diagnostic criteria for GBS. Caucasian healthy blood bank donors (n = 210, median 
age 35 years, range 19-60 years, male/female-ratio = 0.64) served as controls. Of the 
patients, 149 had participated in one of the Dutch randomized clinical trials and were 
clinically and serologically documented in detail.(8) Twenty-five patients participated in 
a Dutch prospective study, 19 in a trial investigating the effect of amantidin in patients 
with fatigue as one of the major residual deficits, and six patients in a pilot study 
studying the effect of intravenous immunoglobulin, methylprednisolon combined with 
mycophenolate mofetil.(9-11) The other patients visited the outpatient’s clinic. Severe 
(versus mild) GBS was defined as a nadir with (1) an MRC-sumscore of less than 40 
out of 60 (ranging from 60 (normal strength) to 0 (tetraparalysis)) or (2) the inability to 
walk independently (GBS disability score of 3, 4 or 5). Poor outcome was defined as 
the inability to walk independently after six months of follow-up. 
DNA isolation.  Isolation of genomic DNA from EDTA anti-coagulated peripheral 
blood samples was performed with the use of the Invisorb® MaxiBlood kit (Invitek, 
Berlin, Germany) according to the manufacturer’s instruction.
SNP detection. The C(-1562)T polymorphism in MMP9 was genotyped with the 
restriction fragment length polymorphism (RFLP)-technique using the restriction 
enzyme Sph1. Genotyping of the SNPs in the promoter region of TNFA (C(-863)T, 
G(-308)A, G(-238)A), two SNPs in the promoter region of IL10 (G(-1082)A and 
C(-819)T), and one SNP in the coding region of NOS2a (S608L) were performed 
by using multiplex single base extension reactions. Primers and conditions for the 
conventional PCR-reactions and multiplex SBE reactions are listed in Tables 1 and 2.
Table 1. PCR primer sequences.
Table 2. Primer sequences for SBE reactions.
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Table 1. PCR primer sequences.
Gene Upper 5’! 3’ Lower 5’ ! 3’ SNPnumber hange
NOS2a GCAGGGCTAGGAGTAGGA AGCCCCATATGTAAACCAA rs2297518 608 S/L
IL10 TCCCCTTACCTTCTACACAC GACCCCTACCGTCTCTATTT rs1800896 G-1082A
rs3021097 C-819T
TNFa.2 GGAGAATGTCCAGGGCTATG AAAATCAGGGACCCCAGAGT
rs1800630 A-863C
TNFa.1 CCCCTCCCAGTTCTAGTT GGGACACACAAGCATCA rs361525 G-238A
rs1800629 G-308A
MMP-9 AAATGGCAGAGCCGGGAT ACCAGCAGCCTCCCTCACT rs3918242 C-1562T
Table 2. Primer sequences for SBE reactions.
Primer sequence Primer length
5’ ! 3’
PrNOS2aU TTTTGCTCTTTCAGCATGAAGAGC 24
PrTNFa_2863U AGTCGAGTATGTGGACCCCC 20
PrIL10_1082L TTTTTTTTTTTTACCTATCCCTACTTCCCC 30
PrTNFa1238U TTTTTTTTTTTTTTTTTTTTTTAGAAGACCCCCCTCGGAATC 42
PrTNFa_1308L TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTAGAGGCTGAACCCCGTCC 54
PrIL10_819U TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCCTTGTACAGGTGATGTAA 82
C
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Statistical analysis. Verification of Hardy-Weinberg equilibrium and comparison of 
genotype and allele frequencies were performed using Pearson’s c2 test or Fisher’s 
exact test when appropriate. An expectation-maximization algorithm was used to test 
for linkage disequilibrium and to compare the estimated haplotype distributions.(12) 
P values < 0.05 were considered to be statistically significant.
Results
In this study all SNPs were in Hardy-Weinberg equilibrium and the genotype 
distributions and allele frequencies did not differ between GBS patients and healthy 
controls (Table 3). No associations were found between the SNP in TNFA, MMP9, 
NOS2a and IL10 and the parameters age, sex, antecedent infection and the presence 
of anti-ganglioside antibodies. The three SNP in the promoter region of TNFA and the 
two SNP in the promoter region of IL10 were in linkage disequilibrium (p<0.001). 
Table 3. Genotype distribution in Guillain-Barré patients versus healthy controls
MMP9, gene encoding matrix metalloproteinase 9; TNF, gene encoding tumour necrosis factor alpha; IL10, gene encoding 
interleukin 10; NOS2a, gene encoding inducible nitric oxide synthase. No significant differences were found.
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Table 3. Genotype distribution in Guillain-Barré patients versus
healthy controls.
MMP9, gene encoding matrix metalloproteinase 9; TNF, gene encoding tumour necrosis factor alpha; IL10, gene
encoding interleukin 10; NOS2a, gene encoding inducible nitric oxide synthase. No significant differences were
found.
SNP Guillain-Barré patients ealthy controls
= 210
 % %
MMP9 C (-1562)T
CC 78.3 78.1
CT 21.3 21.9
TT 0.4 0
TNFA C(-863)A
CC 70.7 70.9
CA 25.9 26.7
AA 3.4 2.4
TNFA  G(-308)A
GG 73.4 65.2
AG 22.1 32.9
AA 4.5 1.9
TNFA  G(-238)A
GG 87.4 86.7
AG 11.8 13.3
AA 0.8 0
IL-10 G(-1082)A
GG 27.0 27.1
AG 46.4 45.2
AA 26.6 27.6
IL-10 C(-819)T
CC 61.6 63.3
CT 32.7 30.0
TT 5.7 6.7
NOS2a S608L
GG 63.9 61.0
AG 32.3 33.3
AA 3.8 5.7
n = 263   n
H
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Therefore, the haplotype distributions between GBS patients and controls could 
be compared, and these were also not significantly different between patients and 
controls. 
Considering the role of the macrophage in nerve damage and the clinical heterogeneity 
of GBS we determined whether the SNPs were associated with disease severity and 
outcome. The SNP at position -1562 of the MMP9 gene and at position -863 of the 
TNFA gene were significantly associated with disease severity in patients with GBS 
(Table 4). In addition, the variant allele of the SNP at position -1562 of the MMP9 
gene was more frequent in patients with severe GBS (MRC-sumscore < 40) than in 
patients with mild GBS (13.6% vs. 5.7%, OR 2.6, 95% CI 1.1 to 6.0, p=0.02). 
Table 4. Genotype distributions in severely versus mildly affected GBS patients.
Severity of disease was based on the Medical Research Council-sumscore at nadir ranging from 
tetraparalysis (score 0) to normal muscle strength (score 60). Patients with a MRC-sumscore at nadir of < 40 
were defined as severely affected. GBS, Guillain-Barré syndrome; OR, odds ratio; CI, confidence interval; 
TNFA, gene encoding tumour necrosis factor-alpha; MMP9, gene encoding matrix metalloproteinase 9.
A similar difference between severe and mild cases was found for the variant allele 
of the SNP at position -863 of TNFA (23.6% vs. 12.7%, OR 2.1, 95% CI 1.1 to 3.9, 
p=0.01). The haplotype distribution of the three SNPs in the promoter region of TNFA 
did not significantly differ between mildly and severely affected patients. 
The genotype distribution of the SNP at position -863 of TNFA also differs between the 
subgroup of patients with poor prognosis and the patients with good prognosis (Table 
5). The variant allele of this SNP was also more frequently found in the subgroup with 
unfavourable outcome (36.7% vs. 15.7%, OR 3.1, 95% CI 1.4 to 7.0, p=0.004).
Table 5. Genotype distribution of TNFA C(-863)A polymorphism in GBS patients with poor or good 
outcome.
The GBS functional disability score at six months was used to define the clinical outcome. Patients who 
were not able to walk independently after six months of follow-up were defined as having a poor outcome. 
GBS, Guillain-Barré syndrome; OR, odds ratio; CI, confidence interval; TNFA, gene encoding tumour 
necrosis factor-alpha.
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Table 4. Genotype distributi  rsus ildly affected GBS patients.
 ildly affected (n = 79) OR (95% CI) p-value
 % %   
MMP9
C/C 72.9 88.6 0.01
C/T 17.1 11.4 2.9 (1.2-7.0)
TNFA -863
C/C 58.6 77.2 0.049
C/A 35.7 20.3 2.3 (1.1-4.9)
A/A 5.7 2.5 2.9 (0.5-17.4)  
Severity of disease  on the Medical Res arch Council-sumscore at nadir ranging from tetraparalysis
(score 0) to normal muscle strength (score 60). Pati nts with a MRC-sumscore at nadir of < 40 were defined as
severely affected. GBS, Guillain-Barré syndrome; OR, odds ratio; CI, confidence interval; TNFA, gene encoding
tumour necrosis factor-alpha; MMP9, gene encoding matrix metalloproteinase 9.
Table 5. Genotype distribution of TNFA C(-863)A polymorphism GBS patients with po r or good outcome.
ood outcome (n = 134) OR (95% CI) p-value
% %   
TNFA -863
C/C 40.0 71.4 0.02
C/A 46.7 25.6 3.3 (0.3-10.7)
A/A 13.3 3.0 7.9 (1.2-53.9)
The GBS functional disability score at six months was used to define the clinical outcome. Patients who were not
a l  to walk independently after six months of follow-up were defined as having a poor outcome. GBS, Guillain-Barré
syndrome; OR, odds ratio; CI, confidence interval; TNFA, gene encoding tumour necrosis factor-alpha.
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Poor outcome (n = 15) G
Severely affected (n = 70) M
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Discussion
The variant alleles of two SNPs in the promoter region of the MMP9 gene and TNFA 
gene were associated with more severe weakness in patients with GBS. Moreover, 
the variant allele of TNFA was also associated with poor outcome at six months of 
follow-up. These SNP may therefore predispose to the development of severe forms 
of GBS. A previous study showed that the A-allele at position -863 of TNFA was 
associated with higher TNF-α concentration due to an inadequate down regulation 
of its production.(13) In the case of the SNP at position -1562 of MMP9, the T-allele 
is associated with an increased promoter activity that might result in higher MMP-9 
levels.(14) Previous reports also showed that high serum levels of MMP-9 as well as 
TNF-α were associated with severity of disease.(3-6, 15) MMPs play an important 
role in the recruitment of macrophages and penetration of the blood-nerve barrier 
and macrophage-derived TNF-α propagates inflammation within the peripheral 
nervous system.(2) Therefore, these genetic polymorphisms may partly determine 
the patient’s outcome by influencing the levels of pro-inflammatory cytokines.
In this study we did not confirm the previously reported associations between the SNP 
at position -819 in the promoter region of IL10 and disease susceptibility (n = 87), 
and between a TNFA microsatellite marker and Campylobacter jejuni-positive GBS 
patients (n = 81).(7, 16) This discrepancy could be caused by chance, but also by the 
higher sample size of our study (n = 263), or the inclusion of a different population 
of GBS patients. The expected effects of SNPs in disease development and severity 
are usually small, underlining the importance of using large cohorts of well-defined 
patients in genetic association studies. Also our results need further confirmation in 
new studies with larger cohorts and evaluation in meta-analysis. Larger cohorts are 
also required to study the effect of the haplotype in the promoter region of TNFA.
In principle, SNPs may both influence the susceptibility and course of disease. Thus 
far, genetic studies in our cohort of GBS patients have identified polymorphisms that 
predominantly influence the severity of disease, including SNPs in the mannose-
binding lectin and Fcgamma-receptorIIIB genes.(17, 18) Accordingly, the current 
study identified SNPs in the MMP9 and TNFA genes as other disease-modifying 
factors. In the future, these factors may be used as biological markers to delineate 
the clinical subgroups in GBS and help to identify patients with poor outcome who 
need additional forms of treatment.   
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Abstract
Objective. Various cytokines and inflammatory mediators are known to be involved in 
the pathogenesis of rheumatoid arthritis (RA). We hypothesized that polymorphisms 
in selected inflammatory response and tissue repair genes contribute to the 
susceptibility to and severity of RA.
Patients and Methods. Polymorphisms in TNFA, IL1B, IL4, IL6, IL8, IL10, PAI1, 
NOS2a, C1INH, PARP, TLR2 and TLR4 were genotyped in 376 Caucasian RA 
patients and 463 healthy Caucasian controls using single base extension. Genotype 
distributions in patients were compared with those in controls. In addition, the 
association of polymorphisms with the need for anti-TNF-α treatment as a marker of 
RA severity was assessed.
Results. The IL6 -174 G/G, IL8 781 C/C and PAI1 5G/5G genotypes were 
independently associated with RA susceptibility when adjusted for age and gender. 
In addition, we showed that in patients diagnosed with RA, the TNFA -308 G/G and 
-238 A/A genotypes were associated with RA severity.
Conclusions. We here for the first time report an association between IL8 and PAI1 
polymorphisms and RA susceptibility. In addition, carriage of the IL6 -174 C allele was 
associated with susceptibility to RA, while two TNFA polymorphisms were associated 
with RA severity. Our findings support the role for variations in these genes involved 
in the immune response and in tissue repair in RA pathogenesis.
Introduction
Rheumatoid arthritis (RA) is a severely disabling chronic inflammatory disease that 
affects millions of people worldwide. Like in other autoimmune diseases females 
are affected more often than males. The disease course differs widely between 
patients. While some have low grade disease which is easily controlled by therapy 
with one disease-modifying anti-rheumatic drug (DMARD), others suffer from rapidly 
progressive disease with erosions that is therapy resistant, resulting in the use 
of many different DMARDs or even the need for therapy with the new biologicals 
directed against TNF-α. Cytokines and other proteins involved in the inflammatory 
response play a role in RA. Pro-inflammatory cytokines such as TNF-α and IL-1β are 
regarded as key players in the pathogenesis of RA.(1, 2) This is further underlined by 
the development of several anti-cytokine drugs in the treatment of RA, with anti-TNF 
monoclonal antibodies and soluble TNF-α receptor being the most effective. TNF-α 
is an important pro-inflammatory cytokine. IL-1β in its turn, stimulates expression 
of IL-6 and IL-8.(2) Antibodies directed against the IL-6 receptor are effective in 
the treatment of RA.(3) IL-4 and IL-10 on the other hand, have been suggested to 
ameliorate arthritis.(4, 5) Deficiency of IL-4 is associated with increased severity of 
arthritis in a mouse model.(6) In addition, the V50 variant in the IL-4 receptor causing 
unresponsiveness to IL-4, is associated with rapidly erosive RA.(7) 
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In addition to inflammatory tissue destruction, factors involved in tissue repair and 
necrosis or apoptosis are likely to be involved in erosive disease and may also 
codetermine disease susceptibility. Plasminogen activator inhibitor 1 (PAI-1) inhibits 
fibrinolysis and tissue repair.(8, 9) Plasminogen deficiency is associated with 
decreased susceptibility to and severity of arthritis in mice models for RA.(10)
Previously the influence of genetic polymorphisms in inflammatory diseases such 
as RA has become evident. The association with the HLA DRB1 locus is the best 
characterized and replicated.(11, 12) Linkage studies in RA families and genome 
wide screening in case control studies have identified multiple additional genetic 
loci associated with RA.(11, 13) However, many studies only focus on a single 
polymorphism and/or only include few patients thereby lacking sufficient power. 
Polymorphisms of interest include those in genes known or expected to be involved in 
RA, specifically those with known or proposed effect on transcription or function such 
as in IL4, IL6, PAI1, PARP, IL10 and IL1B.(14-20) In addition, polymorphisms, such 
as in TNFA and IL8, previously associated with RA or other inflammatory diseases 
were considered relevant as well.(21-24)
Therefore, in this study including 376 RA patients and 463 controls, we investigated 
the possible association of polymorphisms in immune response genes (TNFA, IL1B, 
IL4, IL6, IL8, IL10, C1INH, TLR2, TLR4) and genes involved in tissue repair and 
apoptosis (PAI1, NOS2a, PARP) in relation to RA susceptibility, and with the use of 
anti-TNF-α therapy as selected marker of disease severity. 
Methods
Participants. Non-related Caucasian patients who met the 1987 ACR criteria for RA 
and visited the rheumatology outpatient clinic of the Erasmus MC university hospital 
(n = 76), the Medical Centre Rijnmond Zuid (n = 195) or the St. Franciscus Gasthuis 
Hospital (n = 105), were included in the study. Additionally, the patients had to have 
at least either a positive rheumatoid factor test, or a positive anti-CCP test, or joint 
erosions. The study was approved by the medical ethical boards of the participating 
hospitals. Patients were included after informed consent. Gender, age at inclusion 
in the study, age at diagnosis, clinical parameters and current and prior medication 
were derived from the clinical charts. The need for therapy with biologicals directed 
towards TNF was used as a marker of disease severity, since in the Netherlands the 
prescription of anti-TNF is strictly regulated and the costs for anti-TNF treatment are 
only reimbursed by the health insurance companies for RA-patients with therapy-
resistant disease. This latter has been defined as failure on at least two DMARDs, 
including methotrexate and still active disease (defined as DAS28 > 3.2) despite 
therapy with methotrexate 25 mg weekly or with methotrexate at the maximum 
tolerated dosis. Blood was drawn for DNA isolation and routine laboratory analysis. 
Since the anti-CCP test has only recently been introduced into routine patient care, 
only for a minority of patients (n = 125) anti CCP status was known. Caucasian controls 
representing the general adult population (n = 463) were derived from the Sanquin
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Blood Bank South West Region. 
DNA isolation. For RA patients DNA isolation from heparinized whole blood 
was performed as described previously.(25) DNA from controls was derived from 
whole blood with column methods using standard protocols (Qiagen, Leusden, the 
Netherlands). 
Genotyping. Single base extension (SBE) analysis was used to determine genotypes 
of inducible nitric oxide synthase (NOS2A) S608L (rs2297518), poly (ADP-ribose) 
polymerase (PARP) V762A (rs1136410), complement component inhibitor-1 (C1INH) 
V480M (rs4926), PAI1 -675 4G/5G (rs1799889), IL4 C-524T (rs2243250), IL10 
G-1082A (rs1800896), IL10 C-819T (rs3021097), IL1B C-31T (rs1143627), TNFA 
A-863C (rs1800630), TNFA T-857C (rs1799724), TNFA G-376A (rs3093659), TNFA 
G-308A (rs1800629), TNFA G-238A (rs361525), IL6 G-174C (rs1800795), IL8 C781T 
intron (rs2227306), TLR4 D299G (rs4986790) and TLR4 T399I (rs4986791) (http://
www.ncbi.nlm.nih.gov/SNP/, Applied Biosystems, SNaPShot, Nieuwerkerk aan den 
IJssel, the Netherlands). The genomic region of interest was amplified by PCR. 
After purification, a single base extension was performed using a primer ending one 
nucleotide prior to the single nucleotide polymorphism (SNP) location. Both forward 
and reverse strands were tested. In a multiplex assay one of the primers was used 
to genotype the SNP of interest. Up to seven SNPs were analysed in one assay. A 
poly-T-tail attached to the primer combined with the use of a Liz size marker served to 
distinguish SNPs in the multiplex analysis. A subset of PCR samples was sequenced 
to confirm genotypes. Primer and probe sequences are available on request. All 
genotypes were annotated independently by two investigators who were blinded for 
the clinical data.
Statistical analysis. Statistical analysis was performed using SPSS 11.5. Haplotype 
analysis was carried out with Thesias version 2.(26, 27) Genotype frequencies were 
compared between patients with RA and controls using the Cochrane-Armitage trend 
test for additive effects. In addition, genotypes were compared after adjusting for age 
and gender, using binary logistic regression.(28) The median number of different 
drugs used per year since the moment of diagnosis was assessed. Additionally, 
genotype distributions between patients who received anti-TNF-α medication were 
compared with those who did not. These analyses were adjusted for age using 
binary logistic regression. Subsequently, all SNPs that were considered relevant in 
univariate analyses were assessed together in one multivariate logistic regression 
model with regard to outcome, to assess their individual contributions in relation to 
the other SNPs. Binomial variables were analysed using Pearson’s c2 test (2df) or 
Fisher’s exact test when appropriate. For continuous variables Student’s t test or 
Mann-Whitney U test were used when appropriate. Verification of Hardy Weinberg 
equilibrium (HWE) of genotypes was performed using c2 test (1df). Probability (P) 
values < 0.05 were considered to be statistically significant. Since no international 
consensus exists on what method to use best in genetic studies no correction was 
made for multiple testing. Power calculations using Quanto revealed a power of 0.8 
to detect an OR of 1.5 comparing patients and controls given an allele frequency of 
0.1 and α of 0.05.(29)
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Results
Patient characteristics. 376 patients, mean age (sd) 59.3 years (13.7) and 463 
controls mean age (sd) 39.1 years (8.5), were included in the study (p<0.001). In 
the patient and control cohort 277 (73.7%) and 230 (49.7%) individuals were female, 
respectively (p<0.001). All patients were included when comparing RA patients with 
healthy controls. For 6 patients records regarding medication use were incomplete 
due to (multiple) transfers of patients from other hospitals. For this reason the 370 
patients for whom medication data was complete were included in the analysis 
regarding disease severity (Table 1).
Table 1. Patient characteristics.
1Anti-CCP was not routinely analyzed.
Genotypes and disease susceptibility. SNPs not mentioned in the results section 
showed no significant associations and only significant associations will be discussed 
further. In controls, genotype distribution of all SNPs except the IL10 G-819A 
polymorphism reached Hardy Weinberg Equilibrium (HWE). To rule out a technical 
problem, an initial set of individuals was typed using both the reverse and forward 
primer in the single base extension reaction. Results for both strands were identical. 
Sequencing of a subset of 13 random controls showed identical genotypes excluding 
technical errors (data not shown). Allele frequencies of polymorphisms in controls 
and RA patients are listed in Table 2.
An association was observed for the IL6 -174 G/C polymorphism. The IL6 -174 
G/G genotype was significantly overrepresented in RA patients when compared to 
controls even when corrected for age and gender (crude OR (95% CI) 1.66 (1.24-
2.22), p=0.001, adjusted OR (95% CI) 1.90 (1.22-2.96), p=0.004) (Table 3). 12
Table 1. Pati aracteristics.
Mean age (sd) RA patients
n = 370
Mean age (sd) 59.1 (13.7)
Female gender (%) 272 (73.5)
Median nr years with RA (min-max) 8.5 (0-54)
Anti-CCP positive (%)
1
104/125 (83.2)
Rheumatoid factor positive (%) 337/369 (91.3)
Erosion (%) 291/357 (81.5)
Median number of DMARDs (min-max) 3 (1-13)
Median number of DMARDs per disease year (min-max) 0.35 (0.03-18)
Number of patients with past or present used DMARDs (%)
Methotrexate 331 (89.5)
Salazopyrine 262 (70.8)
Antimalaria 176 (47.6)
Leflunomide 33 (8.9)
Intramuscular gold 55 (14.9)
Infliximab 35 (9.5)
Etanercept 61 (16.5)
Adalilumab 60 (16.2)
Anakinra 14 (3.8)
Oral corticosteroids 164 (44.3)
Azathioprine 33 (8.9)
Others n = 1 32 (8.6)
n = 2 5 (1.4)
Anti-CCP was not routinely analyzed.
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Table 2. Allele frequencies in RA patients and controls.
1P value represents analysis not corrected for multiple testing. When Bonferroni correction is applied only 
the TNFA -238 polymorphism remain significant (p=0.02).
2The IL10 -819 C/T genotype distribution did not reach Hardy Weinberg equilibrium in controls. For this 
reason no p value is given. The genotype distribution did not differ significantly between patients and 
controls.
For other polymorphisms, associations were only observed in either logistic regression 
models without correction for age and gender (TNFA -863, TNFA -376, TNFA -238) or 
with correction (PAI1 -675 4G/5G, IL8 781 C/T) for age and gender. Analysis of TNFA 
haplotypes yielded similar results as for the individual SNPs (Table 4).
When all significant polymorphisms were included in a logistic regression model 
comparing all RA patients with healthy controls without correction for age and gender, 
only IL6 genotypes were differentially distributed (OR (95% CI) IL6 -174 G/G vs. 
G/C and C/C 1.62 (1.20-2.18), p=0.002). A trend was observed for the TNFA -238 
A allele carriers (OR (95% CI) 0.54 (0.27-1.07), p=0.08). When adjusting for age 
and gender the IL6 -174 G/G, the IL8 781 C/C and the PAI1 5G/5G genotypes were 
independently associated with increased risk for RA (Table 3).
Since RA patients were significantly older than healthy controls and controls are by 
definition still ‘at risk’ to develop RA at a later age, the difference observed may also 
13
Table 2. All  frequencies in RA patien s and controls.
SNP Allele Controls
n (%)
RA Patients
n (%)
1
TNFA -863 C 775 (84) 601 (81) 0.16
A 147 (16) 137 (19)
TNFA -857 C 838 (92) 676 (93) 0.29
T 76 (8) 50 (7)
TNFA -376 G 907 (98) 746 (99) 0.04
A 15 (2) 4 (1)
TNFA -308 G 747 (81) 615 (82) 0.60
A 175 (19) 135 (18)
TNFA -238 G 876 (95) 734 (98) 0.002
A 46 (5) 16 (2)
IL1B -31 C 328 (36) 261 (35) 0.62
T 584 (64) 489 (65)
IL4 -524 C 790 (86) 625 (84) 0.30
T 130 (14) 119 (16)
IL6 -174 C 395 (43) 245 (37) 0.01
G 523 (57) 425 (63)
IL8 781 C 538 (58) 453 (60) 0.40
T 386 (42) 299 (40)
IL10 -1082 G 465 (51) 348 (49) 0.49
A 453 (49) 364 (51)
IL10 -819 C 711 (77) 566 (77)
T 209 (23) 166 (23)
PAI1 -675 5G 438 (47) 374 (51) 0.12
4G 486 (53) 356 (49)
NOS2a 608 S 742 (80) 612 (83) 0.22
L 182 (20) 128 (17)
PARP 762 V 738 (82) 618 (84) 0.40
A 160 (18) 120 (16)
C1INH 480 V 686 (75) 551 (76) 0.47
M 234 (25) 173 (24)
TLR4 299 D 804 (93) 684 (92) 0.62
G 60 (7) 56 (8)
TLR4 399 T 810 (93) 683 (92) 0.42
I 58 (7) 57 (8)
P value represents analysis not corrected for multiple testing. When Bonferroni correction is applied only the TNFA -
238 polymorphism remain significant (p=0.02).
2
The IL10 -819 C/T genotype distribution did not reach Hardy Weinberg equilibrium in controls. For this reason no p
value is given. The genotype distribution did not differ significantly between patients and controls.
p
2
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Table 3. Genotype frequencies in RA patients and controls.1
1Polymorphisms for which no significant association was observed are not shown; genotype data are 
available on request.
2Adjusted OR for age and gender.
3Adjusted OR for age and gender including the following SNPs in the model: IL6 -174, IL8 781, PAI1 
4G/5G, TNFA -863, TNFA -376 and TNFA -238.
4Cochrane-Armitage trend test for additive effects.
result from a difference in susceptibility to develop RA at a younger age. For this 
reason the relation of all SNPs with the age at diagnosis was analysed. Indeed, the 
TNFA -376 A allele carriers were diagnosed at a significantly younger age than those 
with the G/G genotype (mean age (SD) at diagnosis 30.3 (14) and 48.4 (14) years, 
respectively, p=0.01). The IL8 781 C/C genotype was associated with younger age 
14
l  3. Genotype fr qu nci s in RA patients nd controls.
1
SNP Genotype frequency Patients vs. Log regression
Controls RA patients controls OR crude OR adjusted
2
OR adjusted
3
n (%) n (%) p
4
(95% CI) (95% CI)
IL6 -174 G/G vs. C/G and C/C
C/C 82 (17.9) 56 (16.7) 0.01 1.66 (1.24-2.22) 1.90 (1.22-2.96) 1.75 (1.11-2.78)
C/G 231 (50.3) 133 (39.7)
G/G 146 (31.8) 146 (43.6)
IL8 781
C/C 152 (32.9) 141 (37.5) 0.40 1.10 (0.74-1.65) 2.14 (1.15-3.99) 2.04 (1.05-3.94)
C/T 234 (50.6) 171 (45.5) 0.87 (0.59-1.28) 1.00 (0.55-1.82) 0.84 (0.45-1.58)
T/T 76 (16.5) 64 (17.0) 1 1 1
PAI1 4/5G
5G/5G 99 (21.4) 101 (27.7) 0.12 1.36 (0.93-2.01) 2.12 (1.17-3.87) 1.96 (1.03-3.74)
5G/4G 240 (51.9) 172 (47.1) 0.96 (0.69-1.34) 1.29 (0.78-2.12) 1.24 (0.72-2.14)
4G/4G 123 (26.6) 92 (25.2) 1 1 1
TNFA -863 C/C vs. C/A and A/A
C/C 329 (71.4) 239 (64.8) 0.16 0.74 (0.55-0.99) 0.68 (0.44-1.05) 0.66 (0.41-1.06)
C/A 117 (25.4) 123 (33.3)
A/A 15 (3.3) 7 (1.9)
TNFA -857 C/C vs. C/T and T/T
C/C 386 (84.5) 314 (86.5) 0.29 1.18 (0.80-1.75) 1.02 (0.56-1.89)
C/T 66 (14.4) 48 (13.2)
T/T 5 (1.1) 1 (0.3)
TNFA -376
G/G 446 (96.7) 371 (98.9) 0.04
G/A 15 (3.3) 4 (1.1) 0.32 (0.11-0.98) 0.71 (0.18-2.81) 0.96 (0.14-6.80)
A/A
TNFA -308 G/G vs. G/A and A/A
G/G 300 (65.1) 248 (66.1) 0.60 1.05 (0.79-1.40) 1.24 (0.81-1.90)
G/A 147 (31.9) 119 (31.7)
A/A 14 (3.0) 8 (2.1)
TNFA -238
G/G 415 (90.0) 359 (95.7) 0.002
G/A 46 (10.0) 16 (4.3) 0.40 (0.22-0.72) 0.55 (0.24-1.25) 0.50 (0.17-1.43)
A/A
Polymorphisms for which no significant association was observed are not shown; genotype data are available
on request.
2
Adjusted OR for age and gender.
3
Adjusted OR for age and gender including the following SNPs in the model: IL6 -174, IL8 781, PAI1 4G/5G,
TNFA -863, TNFA -376 and TNFA -238.
4
Cochrane-Armitage trend test for a ditive effects.
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at RA diagnosis compared to both the IL8 781 C/T and T/T genotype (mean age 
(SD): IL8 781 T/T 52.2 (14) years, T/C 50.0 (14) years and C/C 44.2 (13) years, 
respectively, p<0.001). No associations with age at diagnosis were observed for the 
PAI1 -675, IL6 -174 and the TNFA -863 and TNFA -238 polymorphisms.
Table 4. TNFA haplotypes in RA patients and controls.
1Haplotype: TNFA -863 C/A, -857 C/T, -308 G/A, -238 G/A.
2Adjusted analyses include sex and age. Haplotype analyses were performed using Thesias.
Genetic polymorphisms and severity of disease. The use of TNF-α modifying 
therapy was considered to be an indicator of severe disease. Anti-TNF-α drugs were 
administered to 120 of 370 patients. The mean age (sd) of patients who used anti-
TNF-α was 55.7 (12.8) years compared with 60.8 (13.9) years in the group that did 
not receive anti-TNF-α (p=0.001). The TNFA -308 G/G genotype was consistently 
associated with severe disease even after adjusting for age (p=0.05; Table 5). 
Carriage of the TNFA -238 A allele was also associated with severe disease (p=0.05), 
however, this was no longer significant after correction for age (=0.09). A trend was 
observed for IL6 -174 C allele carriage and severe disease when only the IL6 -174 
genotype was included in the statistical model (p=0.10). A trend for severe disease 
was also observed for the PARP 762 C allele carriers (p=0.08).
Including the PARP 762 T/C, IL6 C/G and the TNFA -308 G/A and -238 G/A 
polymorphisms in one multivariate logistic regression model, the TNFA -308 G/G 
genotype was significantly (p=0.04) associated with severe disease after adjusting 
for age (Table 5).
Discussion
In this study we observed that polymorphisms in IL6, PAI1, IL8 and TNFA were 
associated with RA susceptibility. Two promoter polymorphisms in TNFA, at positions 
-308 and -238, were associated with severity of RA, while a trend toward RA severity 
was observed for polymorphisms in PARP and IL6.
The most evident association was observed for the IL6 -174 G/G genotype that was 
overrepresented in RA patients when compared to healthy controls. The association 
observed in our study remained significant even after adjusting for age, gender and 
the effect of other polymorphisms that showed a significant association in univariate 
analysis. Recently, the importance of IL-6 in the pathogenesis of RA was shown 
by Maini et al. who reported a substantial improvement of RA upon treatment with 
15
Table 4. TNFA haplotypes in RA patients and controls.
TNFA
haplotype
1
Controls
n = 463 (%)
RA patients
n = 376 (%)
OR crude
(95% CI)
OR adjusted (95% CI)
2
CCGG 51.9 54.3 1 1
CCGA 5.0 2.1 0.40 (0.22-0.72) 0.53 (0.23-1.20)
CCAG 19.0 18.0 0.90 (0.69-1.18) 0.79 (0.51-1.22)
CTGG 8.1 6.9 0.82 (0.54-1.24) 0.85 (0.46-1.58)
ACGG 15.8 18.6 1.12 (0.85-1.49) 1.13 (0.74-1.72)
ATGG 0.2 0.1 - -
Haplotype: TNFA -863 C/A, -857 C/T, -308 G/A, -238 G/A.
2
Adjusted analyses include sex and age. Haplotype analyses were performed using Thesias.
Table 5. Comparison of genotype frequencies between RA patients with or without anti-TNF therapy, as
marker of disease severity.
1
SNP Genotype frequency Log regression
No anti-TNF Anti-TNF P
2
OR crude
3
OR adjusted
4
OR adjusted
5
OR adjusted
6
250 n (%) 120 n (%) (95% CI) (95% CI) (95% CI) (95% CI)
PARP 762 T/T vs. T/C and C/C
T/T 180 (73.2) 75 (64.1) 0.37 0.66 (0.41-1.05) 0.64 (0.39-1.03) 0.63 (0.37-1.03) 0.62 (0.37-1.03)
T/C 55 (22.4) 41 (35.0)
C/C 11 (4.5) 1 (0.9)
TNFA -308 G/G vs. G/A and A/A
G/G 156 (62.4) 89 (74.2) 0.13 1.73 (1.07-2.80) 1.65 (1.01-2.68) 1.81 (1.07-3.06) 1.71 (1.00-2.91)
G/A 91 (36.4) 26 (21.7)
A/A 3 (1.2) 5 (4.2)
TNFA -238
G/G 243 (97.2) 111 (92.5) 0.04 0.36 (0.13-0.98) 0.41 (0.15-1.15) 0.28 (0.09-0.87) 0.31 (0.10-0.97)
G/A 7 (2.8) 9 (7.5) 1 1 1 1
A/A
IL6 -174
C/C 33 (15.1) 22 (19.8) 0.06 1.72 (0.90-3.29) 1.76 (0.91-3.42) 1.82 (0.92-3.61) 1.85 (0.93-3.68)
C/G 83 (37.9) 49 (44.1) 1.52 (0.92-2.52) 1.62 (0.97-2.73) 1.62 (0.96-2.75) 1.71 (1.00-2.92)
G/G 103 (47.0) 40 (36.0) 1 1 1 1
Only patients for whom data regarding medication were complete (n=370) were included.
1
Polymorphisms for which no significant association was observed are not shown; genotype data are available on
request.
2
Cochrane-Armitage trend test for additive effects.
3
Univariate analysis.
4
As in 3, adjusted for age.
5
This multivariate model includes the PARP  762 T/C, the TNFA  -308 G/A and -238 G/A and the IL6 C/G
polymorphism simultaneously.
6
As in 5, adjusted for age.
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Table 5. Comparison of genotype frequencies between RA patients with or without anti-TNF therapy, 
as marker of disease severity.1
Only patients for whom data regarding medication were complete (n = 370) were included. 
1Polymorphisms for which no significant association was observed are not shown; genotype data are 
available on request.
2Cochrane-Armitage trend test for additive effects.
3Univariate analysis.
4As in 3, adjusted for age.
5This multivariate model includes the PARP 762 T/C, the TNFA -308 G/A and -238 G/A and the IL6 C/G 
polymorphism simultaneously.
6As in 5, adjusted for age.
anti-IL-6 receptor antibody.(3) The IL6 G/G genotype is associated with increased 
IL-6 levels compared to the C/C genotype, contributing to the complex regulation 
of IL-6 production.(15, 30-32) IL-6 expression in synovial tissue is higher in end-
stage RA than in chronic active RA.(33) Furthermore, IL-6 expression is influenced by 
TNF-α, and interaction of polymorphisms in these and other genes may co-determine 
the disease phenotype. Indeed, although the TNFA -308 polymorphism was not 
differentially distributed between our RA patients and controls, the TNFA -238A allele 
was underrepresented in RA-patients. However, this was no longer significant after 
correction for age and gender. The findings for the TNFA -238 polymorphism match 
those reported for both a Mexican and a Colombian cohort.(23, 24) Additionally, in 
the Mexican cohort, the -308 A allele was associated with more severe disease, while 
it is also reported to be associated with erosion in RA patients.(23, 34) Moreover, 
carriage of the TNFA -308A allele, related to higher TNF-α production, was previously 
reported to be associated with non-response to anti-TNF-α in patients with different 
autoimmune diseases among which RA.(35-37) In the past numerous studies have 
been performed to investigate the association of TNFA promoter polymorphisms and 
TNF-α levels in different inflammatory and infectious diseases, reporting contradictory 
15
Table 4. TNFA haplotypes in RA patients and controls.
TNFA
haplotype
1
Controls
n = 463 (%)
RA patients
n = 376 (%)
OR crude
(95% CI)
OR adjusted (95% CI)
2
CCGG 51.9 54.3 1 1
CCGA 5.0 2.1 0.40 (0.22-0.72) 0.53 (0.23-1.20)
CCAG 19.0 18.0 0.90 (0.69-1.18) 0.79 (0.51-1.22)
CTGG 8.1 6.9 0.82 (0.54-1.24) 0.85 (0.46-1.58)
ACGG 15.8 18.6 1.12 (0.85-1.49) 1.13 (0.74-1.72)
ATGG 0.2 0.1 - -
Haplotype: TNFA -863 C/A, -857 C/T, -308 G/A, -238 G/A.
2
Adjusted analyses include sex and age. Haplotype analyses were performed using Thesias.
Table 5. Comparison of genotype frequencies between RA patients with or without anti-TNF therapy, as
marker of disease severity.
1
SNP Genotype frequency Log regression
No anti-TNF Anti-TNF P
2
OR crude
3
OR adjusted
4
OR adjusted
5
OR adjusted
6
250 n (%) 120 n (%) (95% CI) (95% CI) (95% CI) (95% CI)
PARP 762 T/T vs. T/C and C/C
T/T 180 (73.2) 75 (64.1) 0.37 0.66 (0.41-1.05) 0.64 (0.39-1.03) 0.63 (0.37-1.03) 0.62 (0.37-1.03)
T/C 55 (22.4) 41 (35.0)
C/C 11 (4.5) 1 (0.9)
TNFA -308 G/G vs. G/A and A/A
G/G 156 (62.4) 89 (74.2) 0.13 1.73 (1.07-2.80) 1.65 (1.01-2.68) 1.81 (1.07-3.06) 1.71 (1.00-2.91)
G/A 91 (36.4) 26 (21.7)
A/A 3 (1.2) 5 (4.2)
TNFA -238
G/G 243 (97.2) 111 (92.5) 0.04 0.36 (0.13-0.98) 0.41 (0.15-1.15) 0.28 (0.09-0.87) 0.31 (0.10-0.97)
G/A 7 (2.8) 9 (7.5) 1 1 1 1
A/A
IL6 -174
C/C 33 (15.1) 22 (19.8) 0.06 1.72 (0.90-3.29) 1.76 (0.91-3.42) 1.82 (0.92-3.61) 1.85 (0.93-3.68)
C/G 83 (37.9) 49 (44.1) 1.52 (0.92-2.52) 1.62 (0.97-2.73) 1.62 (0.96-2.75) 1.71 (1.00-2.92)
G/G 103 (47.0) 40 (36.0) 1 1 1 1
Only patients for whom data regarding medication were complete (n=370) were included.
1
Polymor isms for which no significant association was observed are not shown; genotype data are available on
request.
2
Cochrane-Armitage trend test for additive effects.
3
Univariate analysis.
4
As in 3, adjusted for age.
5
This multivariate model includes the PARP  762 T/C, the TNFA  -308 G/A and -238 G/A and the IL6 C/G
polymorphism simultaneously.
6
As in 5, adjusted for age.
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results.(38) TNF-α expression is probably not determined by one but by a combination 
of polymorphisms in TNFA and -associated genes. In our study, and in contrast to 
those described above, the TNFA -308 G/G genotype and the TNFA -238A allele 
were associated with the severe disease (Table 5). It must however be noted that 
the allele frequency is very low and a slight difference in genotype distribution would 
markedly alter the results. 
Two other polymorphisms, the PAI1 4G/5G and the IL8 781 C/T polymorphisms, 
were associated with susceptibility to RA. The PAI1 4G homozygous variant was 
previously shown to be associated with increased expression of PAI-1 compared to 
the PAI1 5G/5G genotype.(16, 21, 39, 40) The PAI1 5G homozygous variant, related 
to low PAI-1 levels and therefore decreased inhibition of plasminogen activator was 
associated with RA when compared with controls. No link was observed with severity 
of disease. Plasminogen deficiency has been associated with decreased susceptibility 
to and or severity of arthritis in mice models.(10) PAI-1 deficiency, however, has also 
been associated with decreased severity in murine antigen-induced arthritis.(41)
The IL8 781 C/C genotype was overrepresented in RA patients when compared with 
normal controls. Increased IL-8 expression was associated with RA when compared 
with osteoarthritis.(42) No data are available on the effect of the intronic IL8 781C/T 
polymorphism on IL-8 expression. It must be noted that the effect of this polymorphism 
appears to be age dependent. IL8 781 C/C genotype was associated with a younger 
age at RA diagnosis.
With regard to RA severity, a trend was observed for carriers of the PARP 762 C allele, 
who were overrepresented in RA patients receiving anti-TNF-α therapy compared to 
those who did not. PARP plays a role in inflammation and apoptosis and is involved in 
maintaining genomic stability of cells upon oxidative stress.(43) The C allele represents 
the valine to alanine amino acid substitution at position 762 in the regulatory domain, 
which is associated with reduced activity after H2O2 exposure.(17) This might result 
in increased tissue damage, increased disease severity, and thus the need for more 
extensive anti-inflammatory medication. Previously the PARP promoter haplotype 
B (410C-[A]11-[CA]13-20-1362T) was reported to be overrepresented in an RA patient 
group compared to healthy controls in a Spanish population.(44) Like in other studies 
we observed no association between RA and polymorphisms in the gene encoding 
inducible nitric oxide synthase, which is also involved in apoptosis.(45)
No association was observed for the IL10 polymorphisms with RA susceptibility 
or severity. Previously, contrasting results were reported for the role of IL10 
polymorphisms in RA.(46, 47) 
Although a polymorphism in TLR4 has previously been associated with rapid response 
to treatment in RA no association with RA was observed for the TLR4 polymorphisms 
in our study.(48)
Many would argue that functional studies are preferred over genetic association studies 
to elucidate the pathogenesis of RA. However, interpretation of RNA expression 
analyses is difficult due to the intra and inter-patient variation.(49) Careful sampling 
may overcome this problem and reduce the finding of false positive differentially 
expressed genes. With the exception of those studies assessing cytokine expression 
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only in patients without DMARDs at diagnosis, results are likely to be influenced by 
the use of these DMARDs and disease progression. For this reason comparison of 
the results of different studies is limited. 
One can question whether therapy with anti-TNF is an appropriate marker for disease 
severity. In the modern era of aggressive treatment of RA medication is intensified 
till the goal of low disease activity or even remission is achieved. That disease 
activity was low is underscored by the low geometric mean ESR level in our cohort 
of RA-patients (16.2; 95% CI 14.7-17.7 mm/h), which was not different (p=0.17) 
between patients on conventional DMARDs (15.4; 95% CI 13.8-17.3 mm/h) or those 
on biologicals (17.6; 95% CI 15.1-20.5 mm/h). It was therefore decided not to use 
disease activity as marker of disease severity, but whether low disease activity could 
be achieved by conventional DMARDs or by use of biologicals directed against TNF. 
That therapy with a biological against TNF could be used as a marker of disease 
severity in this study is also due to the fact that its use is strictly regulated in the 
Netherlands; therapy with biologicals against TNF is available for all RA-patients that 
failed on two DMARDs and still have active disease (DAS28 > 3.2) despite therapy 
with methotrexate 25 mg weekly or at the maximal tolerated dose.
In summary we here for the first time report an association between IL8 and PAI1 
polymorphisms and RA susceptibility. In addition, we confirm genetic associations 
or support previous functional findings on polymorphisms in TNFA and PARP. For 
other polymorphisms we could not confirm previous findings or found contrasting 
results such as for TLR4. For the IL6 -174G allele and the IL8 781 C/C and PAI1 
5G/5G genotypes we observed an independent association with RA susceptibility 
even after adjusting for other polymorphisms and cofactors. This illustrates the need 
for additional large studies to elucidate the contributing factor of polymorphisms in the 
susceptibility to and severity of RA. Carefully designed functional studies regarding 
expression of mRNA and protein levels in combination with genetic analyses are 
warranted to elucidate the contribution of polymorphisms to disease severity and will 
contribute to improving our knowledge on RA pathogenesis.
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Abstract
Objective. Patients with Barrett oesophagus are at increased risk for malignancy. 
Progression to invasive adenocarcinoma follows the metaplasia-dysplasia-carcinoma 
sequence. The eradication of H. pylori influences gastric acid production and reflux 
disease. Therefore, polymorphisms in genes regulating gastric acid secretion (IL1), 
immune regulation (IL1 family) and bacterial recognition genes (CD14 and TLR4) 
may be involved in the susceptibility to develop Barrett oesophagus.
Patients and methods. 210 Dutch Caucasian Barrett patients and 334 ethnically 
matched controls were typed for IL1B-511, IL1RN +2018, CD14 -260 and TLR4 +896 
single nucleotide polymorphisms. 
Results. The IL1RN*C allele at position +2018 was significantly increased in Barrett’s 
patients compared to controls (p=0.033; OR 1.5, 95% CI 1.1-2.1). CD14 -260 T/T 
homozygotes were significantly decreased in Barrett’s patients compared to controls 
(p=0.040; OR 0.6, 95% CI 1.0-2.7) and carriers of CD14 -260 T/T with TLR4 +896 A/A 
were also significantly decreased in patients (p=0.007; OR 0.5, 95% CI 0.33-0.83). 
Combined carriage of specific combinations of these four genes confers protection 
from Barrett oesophagus. Multivariate logistic regression analysis showed a strong 
correlation between IL1RN +2018 and development of Barrett oesophagus (p=0.006; 
OR 2.2, 95% CI 1.3-3.0).
Conclusions. IL1B, IL1RN, CD14 and TLR4 gene polymorphisms influence 
susceptibility to Barrett oesophagus. IL1RN correlates very strongly in multivariate 
analysis with Barrett oesophagus. 
Introduction
Patients with Barrett oesophagus are at increased risk for malignancy and progression 
to invasive adenocarcinoma is reflected histologically by the metaplasia-dysplasia-
carcinoma sequence. The incidence of development of high grade dysplasia or 
adenocarcinoma from Barrett oesophagus is small (estimated annual risk 0.2-
2.0%), however the risk is 30-125 times that of an age matched population.(1, 2) 
The presence of low grade dysplasia and long duration of reflux symptoms are 
independent risk factors for development of high grade dysplasia and oesophageal 
carcinoma.(3) The diagnosis of Barrett oesophagus is made endoscopically and 
confirmed by histological examination of biopsies.
Decreasing rates of H. pylori infection are reported to coincide with increased rates 
of Barrett oesophagus in the Western countries. Other risk factors appear to be age 
over 40, male gender, Caucasian race and increased body mass. Protective factors 
may be high fibre diets and successful antireflux surgery.(3-6)
Recent studies have implicated the involvement of the host immune system in the 
pathogenesis of gastrointestinal tract diseases.(7) Although comparatively little is 
known about the immunogenetics of upper gastrointestinal tract diseases, recent 
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studies have shown clear associations between polymorphisms in genes encoding 
cytokines and the development of gastric cancer.(8, 9) For instance, carriage of 
polymorphisms in IL1B, IL10, TNFA and IL1RN increases the risk for non-cardia 
gastric cancer as compared to single gene analysis OR 2.8 (single gene) vs. OR 
27.3 (multiple genes).(8) Furthermore, twin studies have reported the role of genetic 
factors in the aetiology of reflux disease.(10, 11)
The interleukin 1 (IL1) gene family is involved in a wide variety of physiologic processes, 
including the regulation of inflammatory, metabolic, haematopoietic and immunologic 
mechanisms. IL-1β induces lymphokine expression and activates natural killer cells, 
T cells, and B cells.(12) Furthermore, it is a powerful inhibitor of gastric acid secretion 
and an up regulator of COX2 expression.(13) The IL-1 receptor antagonist (IL-1ra) 
is the natural inhibitor of IL-1β. Polymorphisms have been described in both genes. 
The polymorphism at position -31 in the IL1B gene is located in a TATA-box and 
influences DNA-protein interactions. This polymorphism is associated with decreased 
IL-1β production.(14) The polymorphism at position +2018 in the IL1RN gene is in 
linkage disequilibrium with the IL1RN 86bp tandem repeat, which is associated with 
increased IL-1ra production.(15)
The Toll Like Receptor (TLR) family is a group of pattern recognition receptors, 
which recognize several microbial products, including bacterial cell wall components 
and DNA.(16) CD14 acts as a co-receptor for TLR4 and confers responsiveness to 
LPS, a component of the cell wall of most Gram-negative bacteria. CD14 forms a 
complex with LPS and the LPS-binding protein (LBP).(17) Combined with TLR4 this 
complex induces NF-κB associated immune responses including the release of a 
broad spectrum of cytokines that include tumour necrosis factor alpha (TNF-α), IL-1, 
IL-6, and IL-8, to initiate immune responses.(18) The TLR4 gene contains an A>G 
substitution at position +896, which is associated with LPS hyporesponsiveness.(19) 
The promoter region of the CD14 gene contains a single nucleotide polymorphism 
(SNP) at position -260. The -260 C>T genetic variation affects the binding of 
transcription factors and has been associated with increased expression of levels of 
soluble CD14 and membrane-bound CD14.(20) Since H. pylori infection has been 
described in relation to the pathogenesis of reflux disease and Barrett oesophagus 
development, recognition of H. pylori and the subsequent immune response to its 
presence might be important. 
The aim of this study was to identify whether or not polymorphisms in the IL1B and 
IL1RN genes (immune regulation), and in the TLR4 and CD14 genes (bacterial 
recognition) influence the susceptibility to and severity of Barrett oesophagus both in 
single gene and carrier trait analysis.
Methods
Participants. The study comprised of 210 Dutch Caucasian patients, attending the 
outpatient departments of Gastroenterology of the VU University Medical Centre (n 
= 88) and the Academic Medical Centre (n = 122), Amsterdam, the Netherlands. A 
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total of 334 ethnically matched healthy controls were included. The mean age was 
59y (21y-81y) and 43y (19y-92y) in the Barrett and control cohorts respectively, 
while 80.5% was male in the Barrett cohort as compared to 52.7% in the control 
cohort. All patients underwent an upper gastrointestinal (GI) endoscopy and biopsies 
(duodenum, antrum, corpus, and Barrett) were taken at regular intervals. Presence 
of Barrett epithelium and intestinal metaplasia was confirmed by histology. Patients 
who underwent multiple GI endoscopies were classified as suffering from Barrett 
oesophagus if this condition was diagnosed in at least 1 endoscopy and confirmed by 
histology in the biopsy samples. Data was available on alcohol use and smoking for 
one-third of the patients for logistic regression (gender distribution was equal to the 
total population). Patients were defined as non-user, previous user or current user of 
alcohol and/or tobacco. The patient characteristics are presented in table 1.
Table 1. Patient characteristics.
N/A, not available.
DNA isolation. Peripheral venous blood was collected in 10ml EDTA-tubes and stored 
at room temperature until the genomic DNA was extracted from peripheral blood 
mononuclear cells (PBMC) according to an in-house DNAzol extraction procedure 
(Invitrogen, the Netherlands).
Genotyping. All samples were genotyped for the IL1RN T+2018C (rs419598), 
CD14 C-260T (rs2569190), IL1B C-511T (rs16944) and TLR4 A+896G (rs4986790) 
polymorphisms using PCR-RFLP or TaqMan analyses.
The detection of the CD14 C-260T and TLR4 A+896G polymorphisms was performed 
as described previously by our group.(21, 22) The IL1B C-511T was assessed by 
PCR-RFLP as described previously by Di Giovine et al.(23) The IL1RN T+2018C, of 
which the mutant (C) allele is in linkage disequilibrium with the second allele of the 
IL1RN VNTR (rs2234663), was assessed according standard TaqMan protocol in 96 
well plates (Greiner Bio-One), using the primers: forward: 5’- CAA CCA CTC ACC 
TTC TAA ATT GAC AT -3’, and reverse: 5’- CTG AGT CCT TTT CCT TTT CAG AAT 
CT -3’. The probes used were: AGT ATC CAG CAA CTA GT-FAM for the T allele and 
CAA GTA TCC GGC AAC TA-VIC for the C allele.
Statistical analyses. All groups were tested for Hardy-Weinberg equilibrium to 
check for Mendelian inheritance. Statistical analyses were performed using Instat 
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Table 1. Patient characteristics.
Cases
n = 210
Controls
n = 334
Remarks
Age (years) 59 (21-81) 43 (19-92)
Males (%) 80.5 52.7
Smokers (%) N/A Data in 71 patients only
Never 12.7
Previous   7.0
Current 80.3
Alcohol use (%) N/A Data in 73 patients only
Never 37.0
Previous 21.9
Current 41.1
N/A, not available.
Table 2. TLR4 genotype and allel  frequencies in cases and controls.
Cases Controls
n = 191 n = 334
TLR4 n (%) n (%)
Genotype
A/A 161 (84.3) 289 (86.5)
A/G 30 (15.7) 44 (13.2)
G/G 0 (0) 1 (0.3)
Allele
A 352 (92.1) 622 (93.1)
G 30 (7.9) 46 (6.9)
Table 3. CD14 genotype and allele frequencies in cases and controls.
Cases Co trols
n = 191 n = 334
CD14 n (%) n (%)
Genotype
C/C 65 (34.0) 86 (25.7)
C/T 85 (44.5) 154 (46.1)
T/T 41 (21.5) 94 (28.1)
Allele
C 215 (56.3) 326 (48.8)
T 167 (43.7) 342 (51.2)
Table 4. IL1RN genotype and allele frequencies in cases and controls.
Cases Controls
n = 191 n = 334
IL1RN n (%) n (%)
Genotype
1
T/T 99 (51.8) 205 (61.4)
T/C 70 (36.6) 107 (32.0)
C/C 22 (11.5) 22 (6.6)
Allele
T 268 (70.2) 517 (77.4)
C 112 (29.8) 151 (22.6)
C/C and C/T: cases vs. controls: 48.1% vs. 38.6%; p=0.033; OR: 1.5, 95% CI 1.1 – 2.1. P values calculated using 2 by 2 !2
test.
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Graphpad and SPSS version 11. Fisher exact and c2 tests were used to test for 
differences in allele / genotype / carrier frequencies between the (sub)groups and P 
values < 0.05 were considered statistically significant. Logistic regression analysis 
was used to assess the association of different genotypes with Barrett oesophagus, 
adjusted for age and gender.
Results
All genotype distributions were in Hardy-Weinberg equilibrium, confirming genotype 
distributions according to Mendelian inheritance principles. 
Single gene analyses. An increased prevalence of the IL1RN*C allele was found 
in patients with Barrett oesophagus compared to controls (C/C and C/T: 48.1% vs. 
38.6%; p=0.033; OR 1.5, 95% CI 1.1 - 2.1). 
The IL1B -511 alleles were equally distributed among cases and controls. The 
distribution of genotypes and allele frequencies in cases and controls is shown in 
tables 2 - 5.
Table 2. TLR4 genotype and allele frequencies in cases and controls.
Table 3. CD14 genotype and allele frequencies in cases and controls.
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Table 4. IL1RN genotype and allele frequencies in cases and controls.
1C/C and C/T: cases vs. controls: 48.1% vs. 38.6%; p=0.033; OR 1.5, 95% CI 1.1 - 2.1. P values calculated 
using 2 by 2 c2 test.
Table 5. IL1B genotype and allele frequencies in cases and controls.
Carrier trait analysis. Carriage of the CD14 -260 T/T genotype together with the 
TLR4 A/A genotype is significantly associated with a decreased risk for Barrett 
oesophagus compared to controls (14.8% vs. 24.6% (controls); p=0.007; OR 0.5, 
95% CI 1.2 - 3.0) (Table 6). 
Table 6. Multiple gene analysis of CD14, TLR4, IL1B and IL1RN gene polymorphisms in Dutch 
Caucasian Barrett’s oesophagus patients and controls.
Combination of the two carrier traits. Combining the regulatory and bacteria-sensing 
carrier traits into a larger carrier trait resulted in significant differences between cases 
and controls. Homozygous wild type carriage of the IL1B and IL1RN genes combined 
with heterozygous carriage of the CD14 and TLR4 genes is significantly decreased in 
cases compared to controls (0.6% vs. 4.0%; p=0.013; OR 0.1, 95% CI 0.014 - 0.83) 
(Table 6). 
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Table 5. IL1B genotype and allele frequencies in cases and controls.
Cases Controls
n = 191 n = 334
IL1B n (%) n (%)
Genotype
C/C 81 (42.4) 141 (42.2)
C/T 89 (46.6) 151 (45.2)
T/T 21 (11.0) 42 (12.6)
Allele
C 251 (65.7) 333 (64.8)
T 131 (34.3) 235 (35.2)
Table 6. Multiple gene analysis of CD14, TLR4, IL1B and IL1RN gene polymorphisms in Dutch Caucasian Barrett’s
oesophagus patients and controls.
CD14
-260 C>T
TLR4
+896 A>G
IL-1B
-511 C>T
IL-1RN
+2018 T>C
Cases
(%)
Controls
(%)
Effect p Odd’s
ratio
T/T A/A 14.8 24.6 Protection 0.007 0.5
T/T A/A C/T T/T 1.8 6.1 Protection 0.030 0.3
T/C A/G C/C T/T 0.6 4.0 Protection 0.013 0.1
Table 7. Logistic regression analysis of the IL-1B, IL-1RN, CD14, TLR4 genotyp s in patients suffering from Barrett
Oesophagus.
p OR 95% CI
Lower Upper
Gender < 0.001 5.830 3.031 11.214
IL1RN
1
0.006 2.241 1.266   3.969
TLR4
1
0.119 1.782  0.862   3.687
Age < 0.001  0.852  0.827    0.877
CD14
1
0.251  0.718  0.407   1.265
IL1B
1
0.081  0.601  0.339   1.065
Mutation carriers vs. homozygous wild type.
Table 8. Overview of current known factors associated with Barrett oesophagus.
Variable OR (95% CI) Reference
Gender (Male) 2.7 (2.2 – 3.4) Ford, 2005 (4)
BMI (Obesity) 3.0 (1.6 – 6.7) Bu, 2006 (45)
4.0 (1.4 – 11.1) El-Serag, 2005 (46)
Ethnicity (Caucasian) 6.0 (3.6 – 10) Ford, 2005 (4)
Diet (vitamin C) 0.44 (0.2 – 0.98) Veugelers, 2006 (47)
Hiatal hernia 5.4 (3.1 – 9.4) García Rodríguez, 2006 (48)
Socio-economical status 1.6 (1.2 – 2.2) Ford, 2005 (4)
Oesophagitis 1.8 (1.6 – 2.0) Ford, 2005 (4)
Drinking p=0.001
1
Conio, 2002 (49)
Medication (NSAIDs) 0.40 (0.19 – 0.81) Anderson, 2006 (50)
No OR given.
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Carriage of the carrier trait IL1B -511*C/T, IL1RN +2018*T/T, CD14 -260*C/T and 
TLR4 +896*A/A is significantly decreased in patients with Barrett oesophagus 
compared to controls (1.8% vs. 6.1%; p=0.030; OR 0.3, 95% CI 0.1 - 0.91). The 
results are summarized in table 6.
Logistic regression analysis. Logistic regression analysis was used to assess 
the association of different genotypes with Barrett oesophagus, adjusted for age 
and gender. Age, gender and carriage of the IL1RN +2018 SNP were significantly 
associated with Barrett oesophagus, with gender and IL1RN being risk factors (Table 
7). We analyzed the immune regulatory, bacteria sensing, and combined carrier traits 
in the logistic regression model; however this did not reach statistical significance.
Table 7. Logistic regression analysis of the IL-1B, IL-1RN, CD14, TLR4 genotypes in patients 
suffering from Barrett Oesophagus.
1Mutation carriers vs. homozygous wild type.
Discussion
In this study we found on a single gene level that the IL-1RN+2018*C allele was 
significantly increased in Barrett patients compared to controls. The carrier trait CD14-
260 T/T - TLR4+896 A/A was significantly decreased in patients. Combined carriage 
of specific combinations of these four genes confers protection against Barrett 
oesophagus (table 6). Finally, multivariate logistic regression analysis showed a 
strong correlation between IL-1RN+2018 and development of Barrett oesophagus.
The studied SNP in IL1RN was shown to be associated with altered inflammatory 
responses. Carriage of the IL1RN*C allele is associated with risk for Barrett 
oesophagus. These results concur with those reported in the literature, namely, 
IL-1β increases COX2 production which is known to up-regulate Th2 cytokines 
when associated with oesophageal carcinogenesis.(24, 25) Moons et al. have 
demonstrated that a predominantly humoral immune response is characteristic for 
Barrett oesophagus.(26) Furthermore, an increased inflammatory response and/or 
chronic inflammation may result in increased tissue damage and carcinogenesis.
(27) 
In Japanese it was shown that IL1B genotypes protect against gastro-oesophageal 
reflux disease through induction of corpus atrophy.(28) Even though this population 
is Japanese, while our population consists of Dutch Caucasian patients, these results 
indicate that the genetic risk factors for the development of Barrett oesophagus could 
differ between different ethnicities. The increased expression of CD14 in CD14-260*T 
carriers might explain the association with protection against Barrett oesophagus. A 
p OR                         95% CI
Lower Upper
Gender < 0.001 5.830  3.031 11.214
IL1RN
1
   0.006 2.241  1.266   3.969
TLR4
1
   0.119 1.782  0.862   3.687
Age < 0.001  0.852  0.827   0.877
CD14
1
   0.251  0.718  0.407   1.265
IL1B
1
   0.081  0.601  0.339   1.065
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better recognition of an antrum predominant H. pylori infection which is associated 
with increased acid production may result in a stronger inflammatory response.(29) 
CD14 stimulates both IL-1 and TNF-α production.(18) Both cytokines reduce gastric 
acid production and thus reduce the effect of gastric acid in the oesophagus and 
so reduce the risk for development of Barrett oesophagus.(13, 30, 31) The mutant 
allele of TLR4 has been associated with a reduced LPS recognition. The mutant 
TLR4*G allele affects the extracellular domain of the TLR4 receptor thus blunting the 
response to LPS.(19) We observed a trend towards risk for Barrett oesophagus in 
carriers of this mutant allele. 
When the regulatory and bacteria-sensing carrier traits were combined in a larger 
carrier trait, significant differences between cases and controls could be observed. 
Specific carrier traits of the IL1B, IL1RN, CD14, and TLR4 genes were significantly 
decreased in patients with Barrett oesophagus when compared to controls. 
Recent literature has provided conflicting evidence for the role of IL1 polymorphisms 
and H. pylori infections in Barrett oesophagus. For instance, Gough et al. have 
shown that the IL1RN +2018 2.2 genotype was associated with Barrett oesophagus 
when compared to oesophagitis, while Moons and colleagues failed to confirm this 
association in a similar population.(32, 33) In another paper, Moons et al. demonstrated 
a predominantly humoral immune response in patients with Barrett oesophagus, 
which may explain a lack of association with the Th1 type cytokine IL-1. 
Combined carriage of the CD14 T/T genotype and the TLR4 A/A genotype confers 
optimal recognition of H. pylori and thus protection in an antrum predominant infection. 
In a corpus predominant infection which is associated with reduced acid production, 
this effect may be reversed and this effect of the location of H. pylori infection should 
be researched in a population with clearly defined corpus or antrum gastritis.(34) It 
should be noted that conflicting reports have been published on the role of TLR4 in H. 
pylori infection. Both positive and negative associations have been reported.(35-38) 
Different H. pylori LPS types and TLR4 expression and subcellular distribution, have 
been reported as possible explanations for these conflicting results.(39-41)
Equally conflicting reports have been published on the effect of H. pylori on 
development of reflux disease and Barrett oesophagus. However, recent findings 
may offer an explanation. An antrum predominant gastritis results in increased 
acid production, while a corpus predominant (atrophic) gastritis results in reduced 
gastric acid secretion.(29, 34) These differences in infection pattern may explain the 
differences in reported influences of H. pylori on reflux disease, since increased acid 
production has been associated with reflux disease after eradication of the bacteria.
(42, 43) Unfortunately, we currently do not have data on H. pylori infection in this 
cohort, so we can not comment on the influence of H. pylori on Barrett oesophagus.
Pei and colleagues have recently described a variety of bacterial species in 
oesophageal biopsy specimens in patients with oesophageal reflux related disorders.
(44) These bacteria might influence development of oesophagitis and Barrett 
oesophagus. The interaction between these bacterial species and CD14 – TLR4, and 
the regulation of the immune response against these bacteria by IL-1 may influence 
pathogenesis of Barrett oesophagus. However, it should be noted that the study of 
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Pei et al., is only a preliminary report and further studies are required to confirm the 
results, to elucidate the role of the bacterial species in oesophageal reflux related 
disorders, and to elucidate the role of the IL1B, IL1RN, TLR4, and CD14 genes in 
upper gastrointestinal tract pathogenesis.
Complex mechanisms underlay development of Barrett oesophagus and pathogenic 
mechanisms in one disease may be protective against another. An overview of 
variables currently associated with Barrett oesophagus is presented in table 8. 
Further research is required to elucidate these pathological mechanisms and to gain 
a better understanding of Barrett oesophagus. The results of this study and those 
of published studies suggest that a combined analysis of environmental, bacterial 
and host factors will help to identify patients at high risk for development of Barrett 
oesophagus and oesophageal cancer.
Table 8. Overview of current known factors associated with Barrett oesophagus.
1No OR given.
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Abstract
Objective. Treatment of hepatitis C virus (HCV) infection by peginterferon alfa-2a and 
ribavirin is beneficial only in part of the patients. Since the innate immune response 
appears to codetermine outcome, we investigated the role of polymorphisms in innate 
response genes in initial and sustained treatment response.
Patients and methods. Caucasian controls (n = 463) and patients with chronic HCV 
infection (n = 262) were included. Polymorphisms in INFAR1, IFNAR2, STAT2, TNFA, 
IL1B, IL4, IL6, IL10, IL8, NOS2A, PARP, C1INH, PAI1 and TLR4 were genotyped. 
Possible associations of genotypes with initial virological response, end of treatment 
response (ETR) and sustained virological response (SVR) were analysed.
Results. The IL6 -174G allele was overrepresented in patients when compared 
to healthy controls. The IL6 -174 G/C genotype distributions differed significantly 
between patients and controls, also after correction for multiple testing. Carriage of 
the IL10 -819T allele and the IL10 -1082A;-819T haplotype may be involved in rapid 
virological response, ETR and SVR. The PAI1 5G/5G genotype was overrepresented 
in patients with SVR.
Conclusions.  Polymorphisms in innate immune response genes appear to influence 
HCV infection susceptibility and treatment response. Viral load, HCV genotype and 
fibrosis stage, however, are considered to play a more important role in treatment 
response than the currently assessed genetic polymorphisms.
Introduction
Infection with hepatitis C virus (HCV) is one of the most important causes of liver 
disease. While some infected individuals are capable of clearing the infection 
spontaneously, 50-75% suffer from persistent infection.(1) Only 55-65% of patients 
receiving combination therapy with peginterferon alfa and ribavirin for 48 weeks 
achieve a sustained virological response (SVR).(2, 3) The reason for this is 
multifactorial. Age, body weight, but mainly the hepatitis genotype, viral load and 
presence of fibrosis codetermine outcome.(4) In addition, an early virological 
response seems to predict SVR.(2) The importance of the immune system in 
disease progress, measured as inflammation and fibrosis, and treatment response is 
recognized but its precise role remains unclear. Figure 1 summarizes these factors 
that provided the rationale for the selection of single nucleotide polymorphisms in 
genes that are likely to be involved. First, an imbalance between pro-inflammatory 
and anti-inflammatory cytokines is, together with apoptosis inducing proteins, involved 
in the development of liver tissue damage and fibrosis. Loss of tissue integrity may 
facilitate ongoing infection and can possibly result in lack of treatment response. 
Second, chemokines like IL-8 seem to increase viral replication and may therefore 
hinder an appropriate treatment response.(5, 6) Third, factors involved in the IFN-α 
pathway are likely to be involved in treatment response and even susceptibility to 
ongoing infection.(7) Variations in immune response genes like IL10 and IL4 have 
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been associated with altered cytokine expression levels, and altered function because 
of amino acid substitutions has been reported for polymorphisms in TLR4.(8-10) 
This implies that polymorphisms in immune response genes might codetermine 
susceptibility to infection and treatment outcome. Indeed polymorphisms in genes 
such as TNFA, IL10, IL1B and TGFB have been studied before in relation to HCV 
infection, however, results were contradictory and mostly only small patient groups 
were evaluated.(11-19)
In this study, we investigated if variations in INFAR1, IFNAR2, STAT2, TNFA, IL1B, IL4, 
IL6, IL10, IL8, NOS2A, PARP, C1INH, PAI1 and TLR4 are involved in the susceptibility 
to HCV infection or in the early, end of treatment and sustained virological response 
in chronic HCV infection in a large multi-centre treatment trial.
Figure 1. Overview of factors involved in HCV infection and treatment response. This figure depicts major 
events and pathways likely to be involved in HCV susceptibility, disease course and treatment response 
(boxed). Candidate genes in which polymorphisms were assessed in this study are indicated below the 
boxes. HCV, hepatitis C virus; TNFA, tumour necrosis factor alpha; IL, interleukin; IFN, interferon; NOS2A, 
inducible nitric oxide synthase; PARP, poly (ADP-ribose) polymerase; C1INH, complement component 
inhibitor-1, PAI1, plasminogen activator inhibitor 1; TLR4 Toll-like receptor 4; IFNAR1/2, interferon alpha 
receptor 1/2; STAT2, Signal transducer and activator of transcription 2; Th1/2, T helper cell 1/2.
Methods
Participants. Patients included in this study participated in an international, metacentre, 
randomized, controlled study comparing dynamically individualized versus standard 
treatment of chronic hepatitis C (n = 270; inclusion period February 2001-November 
2003).(20) Only patients who completed at least the randomization phase of the study 
and of whom DNA derived from blood was available, were included (n = 262 (97%), of 
whom 250 Caucasian) after obtaining approval of the medical ethical committee of the 
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Erasmus Medical Centre. All patients provided written informed consent. All patients 
were previously untreated, had a positive test for anti-HCV antibody and had a pre-
treatment liver biopsy consistent with chronic hepatitis C. Patient characteristics were 
previously described by the DITTO-HCV Study Group.(20) In short, 22 patients (8%) 
showed no response (NUR) after 6 weeks of treatment while 10 (4%) were defined 
as flat partial responders (FPR), 62 (24%) as slow partial responders (SPR) and 168 
(64%) as rapid virological responders (RVR). In the intention to treat analysis, 201 
(77%) patients had a successful response by the end of treatment (ETR). SVR 24 
weeks after the end of treatment was observed in 165 (63%) patients. HCV genotype 
1 was found in 171 (65%) of patients, while 23 (9%) had genotype 2, 54 (21%) had 
genotype 3, and 14 (5%) had genotype 4 infection.
Caucasian controls representing the general healthy adult population (n = 463) were 
derived from the Sanquin Blood Bank (the Netherlands, inclusion period 2002- 2004). 
All controls were anti-HCV negative. No data are available on anti-HBc status since 
this was not routinely determined.
Genotyping. Genotyping analysis was performed at the Erasmus MC University 
Hospital (the Netherlands). Single base extension analysis was used to determine 
genotypes of inducible nitric oxide synthase (NOS2A) S608L (rs2297518), poly (ADP-
ribose) polymerase (PARP) V762A (rs1136410), complement component inhibitor-1 
(C1INH) V480M (rs4926), PAI1 -675 4G/5G (rs1799889), IL4 C-524T (rs2243250), 
IL10 G-1082A (rs1800896), IL10 C-819T (rs3021097), IL1B C-31T (rs1143627), 
TNFA A-863C (rs1800630), TNFA T-857C (rs1799724), TNFA G-376A (rs3093659), 
TNFA G-308A (rs1800629), TNFA G-238A (rs361525), IL6 G-174C (rs1800795), IL8 
C781T intron (rs2227306), TLR4 D299G (rs4986790) and TLR4 T399I (rs4986791) 
(http://www.ncbi.nlm.nih.gov/SNP/). The genomic region of interest was amplified 
by PCR. After purification a single base extension was performed using a primer 
ending one nucleotide prior to the single nucleotide polymorphism (SNP) location. 
Up to seven SNPs were analysed in one assay. A poly-T-tail attached to the primer 
combined with the use of a Liz size marker served to distinguish SNPs in the 
multiplex analysis. A subset of PCR samples was sequenced to confirm genotypes. 
Genotypes of IFNAR1 L168V (rs2257167), IFNAR2 V10F (rs7279064) and STAT2 
I294M (rs2066807) were determined using Taqman analysis. Primer and probe 
sequences, and PCR specifications are available on request. All genotypes were 
annotated independently by two investigators who were blinded for the clinical data. 
Only when identical genotypes were assigned by the investigators was the individual 
included in the analysis. This resulted in a different number of individuals for the 
various polymorphisms analysed. No selection was made with regard to outcome 
when batches were analyzed.
Statistical analysis. Statistical analysis was performed using SPSS 11.0. Haplotype 
analysis was carried out with Thesias version 2 or Haplostat.(21, 22) Verification of 
Hardy-Weinberg equilibrium (HWE) of genotypes was performed using c2 test (1df). 
Statistical analyses within the patient cohort represent intention to treat analyses. 
Binomial variables were analysed using Pearson’s c2 test (2df) or Fisher’s exact test 
when appropriate. For continuous variables the Student’s t test or Mann-Whitney 
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U test were used. A comparison of genotype frequencies was made between the 
different initial virological response groups at 6 weeks of treatment, and between 
patients with and without ETR and SVR, 24 weeks after the end of treatment, 
using logistic regression. A correction was made for possible confounding factors. 
The effect of genotypes on the initial treatment response was assessed using two 
different approaches. First a logistic regression analysis comparing the RVR vs. other 
responses was performed. Second an ordinal regression was performed where initial 
response was defined as NUR and FPR, SPR or RVR. NUR and FPR were considered 
to be one group since numbers were small and the clinical consequence similar, i.e. 
no (adequate) response. Additionally genotype frequencies were compared between 
patients with chronic hepatitis C and healthy controls using a multiplicative model.
(23) Since age and gender distribution differed significantly between patients and 
controls, this was accounted for in the logistic regression analysis. Non-Caucasian 
patients, who were evenly distributed among the different response subgroups, were 
excluded from the analyses comparing patients with healthy Caucasian controls. 
Probability (P) values ≤ 0.05 were considered to be statistically significant. Genetic 
analyses were performed with and without correction for multiple testing (Bonferroni, 
times 14 for the number of genes tested). 
Results
In controls, genotype distribution of all SNPs except the IL10 C-819T polymorphism 
reached HWE. To rule out a technical problem an initial set of individuals was typed 
using both the reverse and forward primer in the single base extension reaction. 
Results for both strands were identical. Sequencing of a subset of the controls showed 
identical genotypes, (data not shown), excluding technical errors. Allele frequencies 
of all SNPs are depicted in Table 1. Only significant associations will be discussed. 
SNPs not mentioned in the results section showed no significant associations.
TNFA and IL6 genotype distributions differ between patients and healthy 
controls. In Caucasian chronic HCV patients and controls 169 of 250 (67.6%) and 
233 of 463 (50.3) were males, respectively (p<0.001). The mean age was 41.6 
years (SD 10.1) and 39.1 years (SD 8.5), respectively (p<0.001). The TNFA -857 
T and the IL6 -174 G allele were overrepresented in chronic HCV patients even 
after correction for multiple testing (Table 1). The TNFA -308 A/A and IFNAR1 168 
V/V variants were underrepresented in patients compared to controls assuming a 
multiplicative model (crude OR 0.70 (p=0.02) and OR 0.72 (p=0.04), respectively). In 
addition, the TNFA -857 T/T and the IL6 -174 G/G genotype were overrepresented 
in the patients with chronic HCV OR 1.71 (p=0.002, corrected p=0.03) and OR 1.63 
(p<0.0001, corrected p<0.001), respectively (Table 2). Only the association with the 
IL6 -174 polymorphism remained significant after adjusting for gender and age and 
correction for multiple testing. When significantly associated polymorphisms were 
included in the regression model simultaneously, similar results were obtained. The 
TNFA promoter haplotype frequencies are significantly different between patients and 
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controls (global test p=0.003, corrected p=0.04, 4df) (Table 3). The TNFA haplotype 
-863C, -857T, -376G, -308G and -238G (CTGGG) was overrepresented in patients, 
while the CCGAG genotype was underrepresented in patients.
Table 1. Allele frequencies in Caucasian patients and controls.
1P value represents analysis not corrected for multiple testing. When Bonferroni correction is applied only 
the TNFA -857 and the IL6 -174 polymorphism remain significant (p=0.03 and p<0.01, respectively).
2The IL10 -819 C/T genotype distribution did not reach Hardy Weinberg equilibrium in controls. For this 
reason no p value is given. The genotype distribution did not differ significantly between patients and 
controls.
IL10 polymorphism in rapid initial virological response to treatment. Viral load, 
HCV genotype (1 or 4 versus other) and fibrosis stage were independently associated 
with treatment response. Age and gender were not statistically different between 
the groups. Carriage of the IL10 -819T allele was significantly associated with RVR 
Table 1. A lel encies in Caucasian patients and controls.
SNP Allele Controls
n (%)
Patients
n (%)
p
1
TNFA -863 C 775 (84) 410 (83) 0.61
A 147 (16)  84 (17)
TNFA -857 C 838 (92) 428 (86) 0.002
T 76 (8)  68 (14)
TNFA -376 G 907 (98) 490 (99) 0.55
A 15 (2)  6 (1)
TNFA -308 G 747 (81) 427 (86) 0.02
A 175 (19)  71 (14)
TNFA -238 G 876 (95) 480 (96) 0.23
A 46 (5) 18 (4)
IL1B -31 C 328 (36) 188 (38) 0.42
T 584 (64) 306 (62)
IL4 -524 C 790 (86) 414 (84) 0.39
T 130 (14)  78 (16)
IL6 -174 C 395 (43) 152 (31) <0.001
G 523 (57) 332 (69)
IL8 781 C 538 (58) 292 (59) 0.68
T 386 (42) 200 (41)
IL10 -1082 G 465 (51) 230 (47) 0.15
A 453 (49) 264 (53)
IL10 -819 C 711 (77) 355 (75)
2
T 209 (23) 117 (25)
PAI1 -675 5G 438 (47) 225 (47) 0.85
4G 486 (53) 255 (53)
NOS2a 608 S 742 (80) 393 (79) 0.64
L 182 (20) 103 (21)
PARP 762 V 738 (82) 404 (81) 0.52
A 160 (18)  96 (19)
C1INH 480 V 686 (75) 364 (74) 0.72
M 234 (25) 130 (26)
TLR4 299 D 804 (93) 467 (95) 0.17
G 60 (7) 25 (5)
TLR4 399 T 810 (93) 465 (94) 0.55
I 58 (7) 29 (6)
IFNAR1 L168V L 107 (12)  74 (16) 0.04
V 775 (88) 382 (84)
IFNAR2 V10F V 567 (65) 307 (67) 0.49
F 307 (35) 153 (33)
STAT2 I594M M 817 (94) 386 (97) 0.08
I 51 (6) 14 (3)
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using either ordinal regression or binary logistic regression (Table 4). However, when 
confounding factors where included in the statistical model or when correction for 
multiple testing was applied, this association was no longer significant. A similar trend 
was observed when patients with HCV genotype 1 and 4 were analysed separately 
(p=0.07).
Table 2. Comparison of genotype frequencies between HCV patients and controls.
1Only Caucasian patients were included, when initial treatment was completed.
2OR adjusted 1; adjusted for gender and age, one SNP per model. OR female gender 0.5 (p<0.001); OR 
age 1.03 (p<0.01).
3OR adjusted 2: model including gender, age and polymorphisms TNFA -857 and -308, IL6 and IFNAR1. 
Only SNPs significant in the adjusted (1) analyses were included.
4Only the IL6 -174 polymorphism was significantly associated after correction for multiple testing (correction 
factor 14 (Bonferroni)).
12
Table 2. C rison of genotype frequencies b twe n HCV patients and controls.
 SNP Controls
HCV
patients
1
OR crude OR adjusted 
2
OR adjusted 
3
 
n = 463
n (%)
n = 250
n (%) (95% CI) (95% CI) (95% CI)
TNFA -863
C/C 329 (71.4) 170 (68.8) 1.08 (0.81-1.44) 1.10 (0.82-1.48)
C/A 117 (25.4) 70 (28.3)
A/A 15 (3.3) 7 (2.8)
TNFA -857
C/C 386 (84.5) 186 (75.0) 1.71 (1.21-2.40) 1.63 (1.15-2.31) 1.56 (1.06-2.30)
C/T 66 (14.4) 56 (22.6)
T/T 5 (1.1) 6 (2.4)
TNFA -376
G/G 446 (96.7) 243 (98.0) 0.76 (0.30-1.90) 0.74 (0.29-1.87)
G/A 15 (3.3) 4 (1.6)
A/A 1 (0.4)
TNFA -308
G/G 300 (65.1) 181 (72.7) 0.70 (0.51-0.95) 0.64 (0.47-0.88) 0.67 (0.48-0.94)
G/A 147 (31.9) 65 (26.1)
A/A 14 (3.0) 3 (1.2)
TNFA -238
G/G 415 (90.0) 232 (93.2) 0.71 (0.41-1.25) 0.70 (0.40-1.23)
G/A 46 (10.0) 16 (6.4)
A/A 1 (0.4)
IL6 -174
C/C 82 (17.8) 31 (12.8) 1.63 (1.62-2.66)
4
1.64 (1.29-2.08)
4
1.68 (1.31-2.16)
4
C/G 231 (50.3) 90 (37.2)
G/G 146 (31.8) 121 (50.0)
IFNAR1 L168V
L/L 7 (1.6) 7 (3.1) 0.72 (0.52-0.99) 0.72 (0.52-0.99) 0.68 (0.49-0.95)
L/V 93 (21.1) 60 (26.3)
V/V 341 (77.3) 161 (70.6)
Only Caucasian patients were included, when initial treatment was completed.
2
OR adjusted 1; adjusted for gender and age, one SNP per model. OR female gender 0.5 (p <0.001); OR age 1.03
(p<0.01).
3
OR adjusted 2: model including gender, age and polymorphisms TNFA -857 and -308, IL6 and IFNAR1. Only SNPs
significant in the adjusted (1) analyses were included.
4
Only the IL6 -174 polymorphism was significantly associated after correction for multiple testing (correction factor 14
(Bonferroni)).
Table 3. TNFA haplotypes in patients and controls.
Haplotype
1
Controls
n = 463 (%)
Patients
2
n = 250 (%)
Crude OR
3
(p)
Adjusted OR
4
(p)
CCGGG 51.9 51.6 0.95 (0.86) 1
CCGAG 19.0 14.0  0.68 (0.02) 0.41 (0.02)
ACGGG 15.7 17.1 1.09 (0.54) 1.23 (0.58)
CTGGG 8.1 13.7 1.77 (0.001) 2.83 (0.02)
Global test p=0.003, corrected for multiple testing p=0.04
Haplotype: -863 C/A, -857 C/T, -376 G/A, -308 G/A, -238 G/A.
2
Non Caucasians were excluded from the analysis.
3
Haplotypic odds ratio, not adjusted for multiple testing. Only the distribution of the CTGGG haplotype remains
significantly different after correction for multiple testing (crude).
4
Adjusted for age, sex and other haplotypes with frequency above 0.05.
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Table 3. TNFA haplotypes in patients and controls.
1Haplotype: -863 C/A, -857 C/T, -376 G/A, -308 G/A, -238 G/A.
2Non Caucasians were excluded from the analysis.
3Haplotypic odds ratio, not adjusted for multiple testing. Only the distribution of the CTGGG haplotype 
remains significantly different after correction for multiple testing (crude).
4Adjusted for age, sex and other haplotypes with frequency above 0.05.
A possible role for IL10 and PARP polymorphisms in virological ETR. Successful 
ETR was observed in 201 (77%) patients. The PARP 762 V/V and IL10 -1082 A/A 
genotypes and the IL10 -819T allele were overrepresented in patients who had 
undetectable HCV-RNA levels at the end of treatment (p= 0.045, p=0.03 and p=0.02, 
respectively) (Table 4).
Table 4. Comparison of genotype frequencies between different initial treatment response 
groups.
1Adjusted analysis includes infection with HCV genotype 1 or 4 vs non 1 or 4, log (viral load) at the start of 
treatment and the stage of fibrosis (0-6).
2Not corrected for multiple testing.
When viral load at the start of treatment, HCV genotype (1 or 4 vs. others) and 
fibrosis stage were included in the model or correction for multiple testing was 
applied, these associations were no longer significant. Since the IL10 SNPs are 
in linkage disequilibrium, the effect of the haplotype was assessed (Table 5). Only 
the 246 patients for who complete genotype data was available were included in 
the analysis. The IL10 promoter -1082A;-819T haplotype was associated with end 
of treatment response in the univariate analysis (crude OR 1.81, p=0.03, adjusted 
OR 1.63, p=0.11). When correction for multiple testing is applied, the IL10 promotor 
haplotype this is no longer significant. When patients infected with HCV genotype 1 
or 4 were analysed separately, similar results were obtained for the crude OR (data 
not shown). 
A possible role for IL10 and PAI1 polymorphisms in SVR. SVR 24 weeks after 
treatment was observed in 165 (63%) patients. The PAI1 high producer 4G/4G 
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Table 2. Comparison of genotype frequencies between HCV patients and controls.
 SNP Controls
HCV
patients
1
OR crude OR adjusted 
2
OR adjusted 
3
 
n = 463
n (%)
n = 250
n (%) (95% CI) (95% CI) (95% CI)
TNFA -863
C/C 329 (71.4) 170 (68.8) 1.08 (0.81-1.44) 1.10 (0.82-1.48)
C/A 117 (25.4) 70 (28.3)
A/A 15 (3.3) 7 (2.8)
TNFA -857
C/C 386 (84.5) 186 (75.0) 1.71 (1.21-2.40) 1.63 (1.15-2.31) 1.56 (1.06-2.30)
C/T 66 (14.4) 56 (22.6)
T/T 5 (1.1) 6 (2.4)
TNFA -376
G/G 446 (96.7) 243 (98.0) 0.76 (0.30-1.90) 0.74 (0.29-1.87)
G/A 15 (3.3) 4 (1.6)
A/A 1 (0.4)
TNFA -308
G/G 300 (65.1) 181 (72.7) 0.70 (0.51-0.95) 0.64 (0.47-0.88) 0.67 (0.48-0.94)
G/A 147 (31.9) 65 (26.1)
A/A 14 (3.0) 3 (1.2)
TNFA -238
G/G 415 (90.0) 232 (93.2) 0.71 (0.41-1.25) 0.70 (0.40-1.23)
G/A 46 (10.0) 16 (6.4)
A/A 1 (0.4)
IL6 -174
C/C 82 (17.8) 31 (12.8) 1.63 (1.62-2.66)
4
1.64 (1.29-2.08)
4
1.68 (1.31-2.16)
4
C/G 231 (50.3) 90 (37.2)
G/G 146 (31.8) 121 (50.0)
IFNAR1 L168V
L/L 7 (1.6) 7 (3.1) 0.72 (0.52-0.99) 0.72 (0.52-0.99) 0.68 (0.49-0.95)
L/V 93 (21.1) 60 (26.3)
V/V 341 (77.3) 161 (70.6)
Only Caucasian patients were included, when initial treatment was completed.
2
OR adjusted 1; adjusted for gender and age, one SNP per model. OR female gender 0.5 (p <0.001); OR age 1.03
(p<0.01).
3
OR adjusted 2: model including gender, age and polymorphisms TNFA -857 and -308, IL6 and IFNAR1. Only SNPs
significant in the adjusted (1) analyses were included.
4
Only the IL6 -174 polymorphism was significantly associated after correction for multiple testing (correction factor 14
(Bonferroni)).
Table 3. T plotypes in patients and contr ls.
Haplotype
1
Controls
n = 463 (%)
Patients
2
n = 250 (%)
Crude OR
3
(p)
Adjusted OR
4
(p)
CCGGG 51.9 51.6 0.95 (0.86) 1
CCGAG 19.0 14.0  0.68 (0.02) 0.41 (0.02)
ACGGG 15.7 17.1 1.09 (0.54) 1.23 (0.58)
CTGGG 8.1 13.7 1.77 (0.001) 2.83 (0.02)
Global test p=0.003, corrected for multiple testing p=0.04
Haplotype: -863 C/A, -857 C/T, -376 G/A, -308 G/A, -238 G/A.
2
Non Caucasians were excluded from the analysis.
3
Haplotypic odds ratio, not adjusted for multiple testing. Only the distribution of the CTGGG haplotype remains
significantly different after correction for multiple testing (crude).
4
Adjusted for age, sex and other haplotypes with frequency above 0.05.
13
Table 4. Comparison of genotype frequencies between different initial treatment response groups.
SNP Initial virological treatment response Logistic regression
RVR vs NUR, FPR and SPR
NUR and FPR SPR RVR Crude Adjusted
1
Total n (%) n (%) n (%) OR (95% CI)
2
OR (95% CI)
2
IL10 -819 31 56 161 C/C vs C/T And T/T
C/C 21 (68) 36 (64) 81 (50) 0.53 (0.31-0.91) 0.62 (0.33-1.17)
C/T 7 (23) 16 (29) 70 (44)
T/T 3 (10) 4 (7) 10 (6)
Adjusted analysis includes infection with HCV genotype 1 or 4 vs non 1 or 4, log (viral load) at the start of treatment
and the stage of fibrosis (0-6).
2
Not corrected for multiple testing.
Table 5. Genotype frequencies and IL10 haplotypes in chronic HCV patients with and without ETR.
SNP End of treatment response Logistic regression
 No Yes Crude OR Adjusted OR
1
 Total
n (%)
61
n (%)
201 (95 % CI
2
) (95 % CI
2
)
PARP 762 V/V vs V/A and A/A
V/V 34 (56) 140 (70) 1.82 (1.01-3.28) 1.85 (0.97-3.53)
V/A 23 (38) 54 (27)
A/A 4 (7) 7 (4)
IL10 -1082
G/G 17 (28) 34 (17) 0.39 (0.17-0.92) 0.41 (0.16-1.04)
G/A 31 (52) 104 (52) 0.66 (0.32-1.38) 0.71 (0.32-1.56)
A/A 12 (20) 61 (31) 1 1
IL10 -819 C/C vs C/T and T/T
C/C 40 (69) 98 (52) 0.48 (0.26-0.90) 0.55 (0.27-1.09)
C/T 14 (24) 79 (42)
T/T 4 (7) 13 (7)
IL10 haplotype
3
n = 57 (%) n = 189 (%)
AT 19.3 27.5 1.81 (1.05-3.12) 1.63 (0.89-2.95)
AC 26.3 29.6 1.43 (0.87-2.35) 1.49 (0.86-2.57)
GC 54.4 42.9 1 1
Adjusted analysis includes infection with HCV genotype 1 or 4 vs non 1 or 4, log (viral load) at the start of treatment
and the stage of fibrosis (0-6).
2
Not corrected for multiple testing.
3
Haplotype: -1082 A/G, -819 C/T
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genotype was overrepresented in patients who did not have SVR compared to the 
5G/5G genotype (crude OR 2.19, p=0.04, adjusted OR 2.62, p=0.02, respectively) 
(Table 6). Carriage of the IL10 -819T allele was associated with SVR. Similar results 
were obtained for the PAI1 genotype, while a trend was observed for carriage of the 
IL10 -819 T allele, when only patients infected with the HCV genotype 1 or 4 were 
analysed (data not shown). The IL10 promoter AT haplotype was associated with SVR 
(crude OR 1.81 p=0.01, adjusted OR 1.69, p=0.05) (Table 6). These associations 
were no longer significant after correction for multiple testing.
Table 5. Genotype frequencies and IL10 haplotypes in chronic HCV patients with and without 
ETR.
1Adjusted analysis includes infection with HCV genotype 1 or 4 vs non 1 or 4, log (viral load) at the start of 
treatment and the stage of fibrosis (0-6).
2Not corrected for multiple testing.
3Haplotype: -1082 A/G, -819 C/T
Discussion
In this study we found that IL6 -174 and the TNFA -857 genotypes were differentially 
distributed between patients with chronic HCV infection and healthy controls. The 
high producer variant -174G in the IL6 promoter was observed more often in chronic 
HCV infected patients than controls. Barrett et al. found the high producer variant 
to be more prevalent in persistent HCV infection compared with spontaneous viral 
clearance.(18) Increased IL-6 expression was observed in patients with chronic 
hepatitis C compared to healthy controls. Whether this is secondary to infection or 
reflects increased susceptibility to or reduced clearance of infection with HCV in
13
Table 4. Comparison of genotype frequencies between different initial treatment response groups.
SNP Initial virological treatment response Logistic regression
RVR vs NUR, FPR and SPR
NUR and FPR SPR RVR Crude Adjusted
1
Total n (%) n (%) n (%) OR (95% CI)
2
OR (95% CI)
2
IL10 -819 31 56 161 C/C vs C/T And T/T
C/C 21 (68) 36 (64) 81 (50) 0.53 (0.31-0.91) 0.62 (0.33-1.17)
C/T 7 (23) 16 (29) 70 (44)
T/T 3 (10) 4 (7) 10 (6)
Adjusted analysis includes infection with HCV genotype 1 or 4 vs non 1 or 4, log (viral load) at the start of treatment
and the stage of fibrosis (0-6).
2
Not corrected for multi le testing.
able 5. Genotype frequencies and IL10 haplotypes in chronic HCV patients with and without ETR.
SNP End of treatment response Logistic regression
 No Yes Crude OR Adjusted OR
1
 Total
n (%)
61
n (%)
201 (95 % CI
2
) (95 % CI
2
)
PARP 762 V/V vs V/A and A/A
V/V 34 (56) 140 (70) 1.82 (1.01-3.28) 1.85 (0.97-3.53)
V/A 23 (38) 54 (27)
A/A 4 (7) 7 (4)
IL10 -1082
G/G 17 (28) 34 (17) 0.39 (0.17-0.92) 0.41 (0.16-1.04)
G/A 31 (52) 104 (52) 0.66 (0.32-1.38) 0.71 (0.32-1.56)
A/A 12 (20) 61 (31) 1 1
IL10 -819 C/C vs C/T and T/T
C/C 40 (69) 98 (52) 0.48 (0.26-0.90) 0.55 (0.27-1.09)
C/T 14 (24) 79 (42)
T/T 4 (7) 13 (7)
IL10 haplotype
3
n = 57 (%) n = 189 (%)
AT 19.3 27.5 1.81 (1.05-3.12) 1.63 (0.89-2.95)
AC 26.3 29.6 1.43 (0.87-2.35) 1.49 (0.86-2.57)
GC 54.4 42.9 1 1
Adjusted analysis includes infection with HCV genotype 1 or 4 vs non 1 or 4, log (viral load) at the start of treatment
and the stage of fibrosis (0-6).
2
Not corrected for multiple testing.
3
Haplotype: -1082 A/G, -819 C/T
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Table 6. Genotype frequencies and IL10 haplotypes in chronic HCV patients with and without 
SVR.
1Adjusted analysis includes infection with HCV genotype 1 or 4 vs non 1 or 4, log (viral load) at the start of 
treatment and the stage of fibrosis (0-6).
2Not corrected for multiple testing.
3Haplotype: -1082 A/G, -819 C/T
high IL-6 producers is not clear.(24) Additionally, the TNFA -857T variant was 
overrepresented in patients versus healthy controls. Other studies investigating this 
or other TNFA promoter polymorphisms did not find a difference between patients 
and healthy controls or between patients with chronic infection and individuals with 
spontaneous viral clearance.(12-14, 25, 26) Hohler et al. found the -238A allele to be 
overrepresented in patients, but no significant difference was observed for the TNFA 
-308 genotype.(27) Control groups were small however, and studies were therefore 
probably underpowered. TNFA polymorphisms have been related to differences in 
expression levels. Results are, however, contradictory and the contribution of each 
individual polymorphism remains unclear.(28, 29)
Although we realize that a control cohort for whom exposure followed by spontaneous 
viral clearance is preferred over healthy controls and interpretation of these findings 
is limited, our current findings do warrant further research.
In this study we found an association between polymorphisms in immune response 
genes IL10, PARP, PAI1 and TNFA and HCV treatment response. It must be noted, 
however, that these associations lost significance after correction for multiple testing. 
Carriage of the IL10 -819T allele was associated with RVR response at 6 weeks of 
treatment with peginterferon alfa-2a and ribavirin. The IL10 promoter low producer 
-1082A;-819T haplotype was associated with ETR and SVR after 24 weeks. When 
known treatment response predictors like viral load, HCV genotype and fibrosis were 
14
Table 6. Genotype frequencies and IL10 haplotypes in chronic HCV patients with and without SVR.
SNP Sustained response Logistic regression
 No Yes Crude Adjusted
1
 Total
n (%)
97
n (%)
165  OR (95 % CI
2
) OR (95 % CI
2
)
PAI1 -675 4/5G
5G/5G 17 (18) 44 (28) 2.19 (1.06-4.53) 2.62 (1.13-6.05)
5G/4G 45 (47) 74 (47) 1.39 (0.77-2.52) 1.16 (0.58-2.30)
4G/4G 33 (35) 39 (25) 1 1
IL10 -1082
G/G 24 (25) 27 (17) 0.55 (0.26-1.15) 0.57 (0.24-1.32)
G/A 48 (50) 87 (53) 0.89 (0.49-1.62) 0.96 (0.49-1.88)
A/A 24 (25) 49 (30) 1 1
IL10 -819 C/C vs C/T And T/T
C/C 61 (67) 77 (49) 0.47 (0.28-0.81) 0.54 (0.30-0.99)
C/T and T/T 30 (34) 80 (51) 1 1
IL10 haplotype
3
n = 90 (%) n = 156 (%)
AT 19.4 29.2 1.81 (1.13-2.91) 1.69 (0.99-2.88)
AC 29.4 28.5 1.17 (0.76-1.80) 1.25 (0.76-2.04)
GC 51.1 42.3 1 1
Adjusted analysis includes infection with HCV genotype 1 or 4 (OR 0.10; p<0.001), log (viral load) (OR 0.45;
p=0.001) and for the stage of fibrosis (OR 0.73; p=0.001).
2
Not corrected for multiple testing.
3
Haplotype: -1082 A/G, -819 C/T
Figure legends
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included in the statistical model simultaneously, only the association of the IL10 AT 
haplotype with SVR remained significant. This was attributable to the combination of 
the confounders. This indicates that, although an effect of IL10 promoter haplotype 
is present, its contribution to outcome is limited. This is also reflected by the loss of 
significance after correction for multiple testing. Treatment response is considered to 
be determined by multiple factors. The effect of individual genetic polymorphisms is 
expected to be limited, and multiple SNPs are expected to be involved besides other 
host and environmental factors. Genetic polymorphisms have been implied to play a 
role in the progression rate of fibrosis. Results have however been contradictory.(30) 
Carriage of the PARP 762A allele was associated with a lack of ETR. PARP plays a 
role in inflammation and apoptosis and is involved in maintaining genomic stability 
of cells upon oxidative stress.(31) The PARP 762A variant has recently been found 
to be associated with reduced activity after H2O2 exposure.(32) Although a protective 
effect of PARP inhibition is reported in inflammatory diseases in the early phase, it 
may be worsening fibrosis formation in a later stage by increasing collagen synthesis.
(33) Another factor involved in fibrosis is the pleiotropic PAI-1.(34) The -675 4G/4G 
promoter genotype is associated with high PAI-1 expression.(35, 36) Since increased 
PAI-1 levels inhibit wound healing and induce fibrosis, it is reasonable to assume 
that this mechanism contributes to non sustained response in PAI1 4G homozygous 
patients. Additionally, PAI-1 deficiency protects against fibrosis formation in diverse 
animal disease models.(37) Furthermore, plasminogen deficiency interferes with 
clearance of debris after acute injury, and results in activation of hepatic stellate cells 
known to be involved in fibrosis progression.(38, 39)
In contrast to previous studies no associations were observed in treatment response 
for genetic polymorphisms in the IFN pathway.(40, 41) Matsuyama et al. investigated 
promoter polymorphisms in IFNAR1 and IFNAR2 while we analysed SNPs resulting in 
an amino acid substitution in the coding regions. For IFNAR1 the dinucleotide repeat 
in the promoter in the Japanese patients was associated with treatment response. 
The IFNAR1 V168L polymorphism was not associated with treatment response in the 
European patients in our study. However, a difference was observed between patients 
and healthy controls that was significant also after adjusting for confounding factors 
and independent of other polymorphisms, but lost significance after correction for 
multiple testing. This implies a possible role for IFNAR1 in the endogenous response 
to viral infection. Previously the IFNAR 168L/L genotype was shown to be associated 
with susceptibility to multiple sclerosis but not to IFN-β treatment response.(42) 
Although previous studies suggested a role for TLR, the complement system, 
apoptosis and interleukins 1, 4 and 8 in the pathogenesis of HCV infection, we 
found no associations with treatment response or a difference between patients and 
controls for selected polymorphisms in genes encoding TLR4, C1INH, IL-1β, IL-4, 
iNOS, STAT2 and IL-8.(5, 6, 14, 43-49)
Studies regarding variations in immune response genes in HCV infection and 
treatment response have yielded contradictory results, likely due to several reasons. 
First, the relatively small sample sizes, since it is known that they predispose to finding 
both false positive and false negative associations.(50) Second, HCV infection and 
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treatment response are determined by multiple host and environment factors, and 
some may have different effects depending on disease stage. Th1 and Th2 responses 
for instance, might be either beneficial of deleterious. The Th1 response appears to be 
essential in viral clearance, however, over-stimulation of the inflammatory response 
may result in increased tissue damage, which might be limited by anti-inflammatory 
action of IL-10.(47) The balance in these responses therefore appears to determine 
outcome. In addition to SNPs in host genes, genetic variations in HCV play a role 
in the early viral clearance by combination therapy with IFN and ribavirin.(51) This 
needs to be accounted for when effects of SNPs are assessed and may explain the 
differences observed in our study when treatment response is defined at different 
time points.
In conclusion, the polymorphisms in innate immune response genes TNFA and IL6 
appear to affect susceptibility to HCV infection. In addition, polymorphisms in IL10, 
PAI1, IFNAR1 and PARP may play a role in the susceptibility to HCV infection or 
treatment response. The combination of HCV genotype, viral load and fibrosis stage, 
however, is considered to play a more important role. Given the multifactorial nature 
of HCV disease course and the likelihood that various genotypes interact both with 
each other and numerous environmental and host factors, additional functional 
and genetic studies are warranted to elucidate their individual contributions to HCV 
infection.
Acknowledgements
The Sanquin Blood Bank South West Region provided samples of healthy blood 
donors. We thank Jon Laman PhD, Department of Immunology, Erasmus MC, 
Rotterdam, and Ronald de Groot PhD MD, Department of Paediatrics, Radboud 
University Nijmegen Medical Centre, Nijmegen, for critically reading the manuscript. 
The DITTO study was financially supported by the European Community (QLK2-
2000-00836) and Hoffmann La-Roche. Funding of the work was independent of the 
study design, collection, analysis and interpretation of the data, and the writing of the 
report.
References
1. Alter, H. 2006. Viral hepatitis. Hepatology 43:S230.
2. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., et al. 
2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 
347:975.
3. Hadziyannis, S. J., H. Sette, Jr., T. R. Morgan, V. Balan, M. Diago, P. Marcellin, et al. 2004. 
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized 
study of treatment duration and ribavirin dose. Ann Intern Med 140:346.
4. Zeuzem, S. 2004. Heterogeneous virologic response rates to interferon-based therapy in 
patients with chronic hepatitis C: who responds less well? Ann Intern Med 140:370.
5. Polyak, S. J., K. S. Khabar, D. M. Paschal, H. J. Ezelle, G. Duverlie, G. N. Barber, et al. 2001. 
238
C
h
a
p
te
r 
3
.4
Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the 
interferon-induced antiviral response. J Virol 75:6095.
6. Polyak, S. J., K. S. Khabar, M. Rezeiq, and D. R. Gretch. 2001. Elevated levels of interleukin-8 
in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J 
Virol 75:6209.
7. Katze, M. G., Y. He, and M. Gale, Jr. 2002. Viruses and interferon: a fight for supremacy. Nat Rev 
Immunol 2:675.
8. Arbour, N. C., E. Lorenz, B. C. Schutte, J. Zabner, J. N. Kline, M. Jones, et al. 2000. TLR4 
mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25:187.
9. Turner, D. M., D. M. Williams, D. Sankaran, M. Lazarus, P. J. Sinnott, and I. V. Hutchinson. 
1997. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 
24:1.
10. Rosenwasser, L. J., and L. Borish. 1997. Genetics of atopy and asthma: the rationale 
behind promoter-based candidate gene studies (IL-4 and IL-10). Am J Respir Crit Care Med 
156:S152.
11. Dai, C. Y., W. L. Chuang, W. Y. Chang, S. C. Chen, L. P. Lee, M. Y. Hsieh, et al. 2006. Tumor 
necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination 
therapy in hepatitis C virus infection. J Infect Dis 193:98.
12. Rosen, H. R., J. G. McHutchison, A. J. Conrad, J. J. Lentz, G. Marousek, S. L. Rose, et al. 2002. 
Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with 
chronic hepatitis C. Am J Gastroenterol 97:714.
13. Vidigal, P. G., J. J. Germer, and N. N. Zein. 2002. Polymorphisms in the interleukin-10, tumor 
necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients 
treated with interferon and ribavirin. J Hepatol 36:271.
14. Wang, Y., N. Kato, Y. Hoshida, H. Yoshida, H. Taniguchi, T. Goto, et al. 2003. Interleukin-1beta 
gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. 
Hepatology 37:65.
15. Abbas, Z., T. Moatter, A. Hussainy, and W. Jafri. 2005. Effect of cytokine gene polymorphism on 
histological activity index, viral load and response to treatment in patients with chronic hepatitis 
C genotype 3. World J Gastroenterol 11:6656.
16. Abbott, W. G., E. Rigopoulou, P. Haigh, H. Cooksley, I. Mullerova, M. Novelli, et al. 2004. Single 
nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence 
chronic hepatitis C severity or T-cell reactivity to hepatitis C virus. Liver Int 24:90.
17. Bahr, M. J., M. el Menuawy, K. H. Boeker, P. B. Musholt, M. P. Manns, and R. Lichtinghagen. 
2003. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with 
chronic hepatitis C. Liver Int 23:420.
18. Barrett, S., M. Collins, C. Kenny, E. Ryan, C. O. Keane, and J. Crowe. 2003. Polymorphisms 
in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, 
interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 71:212.
19. Constantini, P. K., M. Wawrzynowicz-Syczewska, M. Clare, A. Boron-Kaczmarska, I. G. 
McFarlane, M. E. Cramp, et al. 2002. Interleukin-1, interleukin-10 and tumour necrosis factor-
alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with 
spontaneous viral clearance and response to alpha-interferon therapy. Liver 22:404.
20. Zeuzem, S., J. M. Pawlotsky, E. Lukasiewicz, M. von Wagner, I. Goulis, Y. Lurie, et al. 2005. 
International, multicenter, randomized, controlled study comparing dynamically individualized 
versus standard treatment in patients with chronic hepatitis C. J Hepatol 43:250.
21. Tregouet, D. A., S. Escolano, L. Tiret, A. Mallet, and J. L. Golmard. 2004. A new algorithm for 
haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet 68:165.
22. Schaid, D. J., C. M. Rowland, D. E. Tines, R. M. Jacobson, and G. A. Poland. 2002. Score tests 
for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum 
Genet 70:425.
23. Sasieni, P. D. 1997. From genotypes to genes: doubling the sample size. Biometrics 53:1253.
24. Oyanagi, Y., T. Takahashi, S. Matsui, S. Takahashi, S. Boku, K. Takahashi, et al. 1999. Enhanced 
 Polymorphisms in hepatitis C virus infection 239
expression of interleukin-6 in chronic hepatitis C. Liver 19:464.
25. Goyal, A., S. N. Kazim, P. Sakhuja, V. Malhotra, N. Arora, and S. K. Sarin. 2004. Association of 
TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. J 
Med Virol 72:60.
26. Thursz, M., R. Yallop, R. Goldin, C. Trepo, and H. C. Thomas. 1999. Influence of MHC class 
II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C 
European Network for Cooperative Research. Lancet 354:2119.
27. Hohler, T., A. Kruger, G. Gerken, P. M. Schneider, K. H. Meyer zum Buschenfelde, and C. Rittner. 
1998. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with 
chronic active hepatitis C infection. J Med Virol 54:173.
28. Bayley, J. P., T. H. Ottenhoff, and C. L. Verweij. 2004. Is there a future for TNF promoter 
polymorphisms? Genes Immun 5:315.
29. Hajeer, A. H., and I. V. Hutchinson. 2001. Influence of TNFalpha gene polymorphisms on 
TNFalpha production and disease. Hum Immunol 62:1191.
30. Bataller, R., K. E. North, and D. A. Brenner. 2003. Genetic polymorphisms and the progression 
of liver fibrosis: a critical appraisal. Hepatology 37:493.
31. Masutani, M., H. Nakagama, and T. Sugimura. 2005. Poly(ADP-ribosyl)ation in relation to cancer 
and autoimmune disease. Cell Mol Life Sci 62:769.
32. Lockett, K. L., M. C. Hall, J. Xu, S. L. Zheng, M. Berwick, S. C. Chuang, et al. 2004. The 
ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme 
function. Cancer Res 64:6344.
33. Virag, L. 2005. Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol Res 
52:83.
34. Matsuo, S., J. M. Lopez-Guisa, X. Cai, D. M. Okamura, C. E. Alpers, R. E. Bumgarner, et al. 
2005. Multifunctionality of PAI-1 in fibrogenesis: Evidence from obstructive nephropathy in PAI-
1-overexpressing mice. Kidney Int 67:2221.
35. Dawson, S. J., B. Wiman, A. Hamsten, F. Green, S. Humphries, and A. M. Henney. 1993. 
The two allele sequences of a common polymorphism in the promoter of the plasminogen 
activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 
268:10739.
36. Eriksson, P., B. Kallin, F. M. van ‘t Hooft, P. Bavenholm, and A. Hamsten. 1995. Allele-specific 
increase in basal transcription of the plasminogen- activator inhibitor 1 gene is associated with 
myocardial infarction. Proc Natl Acad Sci U S A 92:1851.
37. Lijnen, H. R. 2005. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 
3:35.
38. Ng, V. L., G. E. Sabla, H. Melin-Aldana, N. Kelley-Loughnane, J. L. Degen, and J. A. Bezerra. 
2001. Plasminogen deficiency results in poor clearance of non-fibrin matrix and persistent 
activation of hepatic stellate cells after an acute injury. J Hepatol 35:781.
39. Safadi, R., and S. L. Friedman. 2002. Hepatic fibrosis--role of hepatic stellate cell activation. 
MedGenMed 4:27.
40. Knapp, S., L. J. Yee, A. J. Frodsham, B. J. Hennig, S. Hellier, L. Zhang, et al. 2003. Polymorphisms 
in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 
and PKR. Genes Immun 4:411.
41. Matsuyama, N., S. Mishiro, M. Sugimoto, Y. Furuichi, M. Hashimoto, M. Hijikata, et al. 2003. 
The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with 
responsiveness of hepatitis C patients to interferon. Hepatol Res 25:221.
42. Leyva, L., O. Fernandez, M. Fedetz, E. Blanco, V. E. Fernandez, B. Oliver, et al. 2005. IFNAR1 
and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta 
treatment response. J Neuroimmunol 163:165.
43. Khabar, K. S., and S. J. Polyak. 2002. Hepatitis C virus-host interactions: the NS5A protein and 
the interferon/chemokine systems. J Interferon Cytokine Res 22:1005.
44. Dolganiuc, A., C. Garcia, K. Kodys, and G. Szabo. 2006. Distinct Toll-like receptor expression in 
monocytes and T cells in chronic HCV infection. World J Gastroenterol 12:1198.
240
C
h
a
p
te
r 
3
.4
45. Matsushita, M., M. Hijikata, Y. Ohta, and S. Mishiro. 1998. Association of mannose-binding lectin 
gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese 
patients. J Hepatol 29:695.
46. Machida, K., K. T. Cheng, V. M. Sung, A. M. Levine, S. Foung, and M. M. Lai. 2006. Hepatitis C 
virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon 
and interleukin-6. J Virol 80:866.
47. Napoli, J., G. A. Bishop, P. H. McGuinness, D. M. Painter, and G. W. McCaughan. 1996. 
Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic 
expression of Th1-associated cytokines. Hepatology 24:759.
48. Fukuda, R., N. Ishimura, S. Ishihara, A. Chowdhury, N. Morlyama, C. Nogami, et al. 1996. 
Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic 
hepatitis C. Liver 16:390.
49. Yee, L. J., S. Knapp, D. Burgner, B. J. Hennig, A. J. Frodsham, M. Wright, et al. 2004. Inducible 
nitric oxide synthase gene (NOS2A) haplotypes and the outcome of hepatitis C virus infection. 
Genes Immun 5:183.
50. Colhoun, H. M., P. M. McKeigue, and G. Davey Smith. 2003. Problems of reporting genetic 
associations with complex outcomes. Lancet 361:865.
51. Hofmann, W. P., S. Zeuzem, and C. Sarrazin. 2005. Hepatitis C virus-related resistance 
mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 32:86.
4Chapter 4SNPs in immune response genes and their effects in otitis media

Chapter 4.1
The 4G/4G plasminogen activator inhibitor-1 
genotype is associated with frequent recurrence 
of acute otitis media
M. Emonts, S.P. Wiertsema, R.H. Veenhoven, J.J. Houwing-
Duistermaat, V. Walraven, R. de Groot, P.W.M. Hermans, 
and E.A.M. Sanders
Pediatrics 120(2):e317-323, 2007

 PAI1 4G/5G polymorphism in acute otitis media 245
Abstract
Objective. Plasminogen activator inhibitor-1 (PAI-1) counterregulates cell migration, 
adhesion and tissue repair. The PAI1 4G/5G promoter polymorphism has an effect on 
expression levels of PAI1. After a first acute otitis media (AOM) episode, children are 
at increased risk for a next episode. Because the PAI1 4G allele is associated with 
higher PAI-1 production and, hence, decreased tissue repair, we hypothesize that 
this allele may contribute to increased recurrence of AOM.
Patients and Methods. The PAI1 4G/5G polymorphism was genotyped in 348 Dutch 
children aged 1 to 7 years who were suffering from recurrent AOM and participating 
in a randomized, controlled trial, and 463 healthy control subjects, representative of 
the general population. 
Results. No significant difference in PAI1 genotype distribution between the whole 
AOM group and control subjects (p=0.32) was observed. However, children with 
the PAI1 4G/4G genotype had an increased risk of more frequent AOM episodes 
compared with those who were homozygous for the 5G variant, also after correction 
for cofactors (p=0.03, OR 2.31). This finding was attributable to children < 4 years of 
age (p=0.02, OR 2.97).
Conclusions. Our findings suggest that the PAI1 4G/4G genotype is associated 
with an increased risk for the otitis-prone condition, potentially because of impaired 
healing after a previous otitis media episode.
Introduction
Acute otitis media (AOM) is the most common infection in children, but the number of 
AOM episodes varies markedly between patients. Around 10% to15% of all children 
suffer from ≥ 4 episodes per year and are considered otitis prone.(1-3) One of the most 
prominent risk factors appears to be a first episode of AOM early in life predisposing 
to a next event.(4, 5) Other issues affecting the risk of developing recurrent middle 
ear infections include host factors like gender, age, atopy, and ethnic background. 
(6) Environmental factors associated with recurrent AOM episodes are microbial 
exposure, like in day care or from older siblings, or triggers, like lack of breastfeeding 
or exposure to tobacco smoke. Often there is a family history of otitis media.(4, 6, 7) 
Twin studies have shown a heritability of 57% for acute ear infections and 72% for 
chronic ear infections.(8-12) Furthermore, the correlation for recurrent otitis media is 
twofold higher in monozygotic twins (65-71%) compared to dizygotic twins (25-34%). 
(13) Genetic factors involved in inflammation and tissue repair may play a role in 
the development of recurrent AOM episodes and the otitis-prone condition. Delayed 
downregulation of the inflammatory response to infections in the middle ear cavity 
may play a role in priming the individual for additional AOM episodes. Plasminogen 
activator inhibitor (PAI-1) is known to have an important role in fibrinolysis.(14, 15) 
In addition, PAI-1 is involved in the inflammatory reaction, inhibits cell adhesion and 
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migration, and delays tissue repair.(16, 17) The 4G/5G insertion deletion polymorphism 
at position -675 of the PAI1 gene is known to influence the expression of PAI-1.(18, 
19) Individuals homozygous for the 4G allele have higher PAI-1 concentrations in 
peripheral blood than those with the 4G/5G or 5G/5G genotypes.(20, 21) The PAI1 
4G allele has been reported previously to be associated with asthma, as well as with 
increased morbidity and mortality in meningococcal disease.(20, 22-25)
We hypothesized that the PAI1 4G/4G genotype, known to result in high PAI-1 
concentrations, which is associated with decreased tissue integrity, is associated 
with recurrence of otitis media. In this study we investigated the association between 
this PAI1 polymorphism and recurrent AOM. Our results show that 4G homozygous 
individuals have an increased risk for an otitis prone condition, especially under the 
age of 4 years.
Methods
Participants. Patients who initially participated in a randomized, controlled study 
on prevention of recurrent AOM by pneumococcal vaccinations were included in 
this study.(26) Parents were informed about the study by primary care physicians, 
paediatricians, and otolaryngologists from across the Netherlands. Children were 
enrolled in the study after obtaining approval of the medical ethical committee of the 
Utrecht University Medical Centre and informed consent from the parents or guardians. 
DNA was available from 348 Dutch Caucasian children, 1 to 7 years of age, who 
were suffering from recurrent AOM defined as ≥ 2 AOM episodes in the preceding 
year. The number of AOM episodes before vaccination was based both on parental 
report (AOM defined as having one or more of the symptoms: acute earache, new-
onset otorrhea, irritability, and fever) and on clinical information of the diagnosis by a 
physician. In the present study cohort, 122 children suffered from 2 to 3 otitis media 
episodes in the year preceding inclusion, whereas 226 suffered from ≥ 4 episodes 
(otitis-prone condition).(3) No children with < 2 AOM episodes were included in the 
vaccination trial. In addition, children with primary or secondary immunodeficiency, 
cystic fibrosis, immotile cilia syndrome, chromosomal abnormalities such as Down’s 
syndrome, and craniofacial abnormalities such as cleft palate were excluded from 
the study. The history of atopy, defined as eczema, hay fever, recurrent wheezing or 
asthma and the number of AOM episodes in the year before inclusion was assessed 
by the questionnaire filled out by all of the patients and their parents at inclusion in 
the study. Otorrhea duration was assessed in 214 children for whom PAI1 genotype 
were available. Patient characteristics are described in Table 1. Healthy adult Dutch 
Caucasian controls (n = 463) were derived from the Dutch Blood bank Sanquin. No 
records of previous history regarding AOM were available for these control subjects; 
however, in the general population, a total number of ≤ 3.2 AOM episodes is expected 
in childhood.(3) This implies that control subjects will have had, on average, much 
fewer AOM episodes per year than the patients. Blood was sampled for DNA isolation. 
DNA isolation from donor buffycoats was performed according to standard protocols 
using a QIAamp DNA mini kit (Qiagen, Valencia, CA).
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Table 1. Characteristics of patients with recurrent acute otitis media.
1Fisher’s Exact test, Mann-Whitney U test, and t test were performed when appropriate.
2Atopy was defined as having eczema, hay fever, or recurrent wheezing or asthma.
Experimental procedures. PAI1 -675 genotype (rs1799889) was determined 
using single base extension analysis, a technique commonly used in our laboratory 
(ABI Prism®, SNaPshot™ Multiplex Kit, Applied Biosystems, Foster City, CA). The 
genomic region of interest was amplified using polymerase chain reaction (37 cycles; 
annealing temperature of 60 oC; total volume of 10 μl) with the following primers: 
forward, 5’-CAGCCAGACAAGGTTGTT-3’ and reverse 5’-CCACCCGGTGCTCT-3’. 
Amplification resulted in a 265-nucleotides polymerase chain reaction product. 
After purification with Shrimp Alkaline Phosphatase and Exonuclease I (both from 
Amersham Biosciences, Upsala, Sweden), a single base extension with fluorescently 
labeled dideoxynucleotide triphosphates was performed using the reverse primer 
5’-TTTTTGATACACGGCTGACTCCCC-3’. The poly-T tail allows us to distinguish 
primers in a multiplex analysis for which this assay was originally designed. The 
products generated were analyzed on an ABI Prism® 3100 genetic analyzer using 
GeneScan Analysis Software (Applied Biosystems). When no clear genotype was 
obtained or no consensus was reached between two independent investigators, 
genotypes were excluded from the analyses.
Statistical analyses. Statistical analyses were performed using SPSS 11.0 (SPSS 
Inc., Chicago, IL). A comparison of genotype frequencies was made between 
patients and blood donor control subjects assuming a multiplicative model.(27) 
Binomial variables were analyzed using Pearson’s c2 test or Fisher’s exact test when 
appropriate. Continuous variables were compared for the different genotypes using the 
Mann-Whitney U test (nonparametric) or t test (normal distribution). Within the patient 
sample, only genotype distributions of children suffering from 2 to 3 episodes per year 
before vaccination were compared with those individuals who had ≥ 4 episodes after 
correction for age at study entry, gender, number of siblings and the log-transformed 
Table 1. Characteristics of patients with 2 or more AOM episodes.
 Characteristics 2-3 AOM episodes   4 AOM episodes p-value
1
n=122 n=226
Male gender, n (%) 84 (69) 128 (57) 0.03
Median age (min-max), y 2.42 (1.0-6.3) 2.10 (1.0-7.0) 0.40
Age group (12-48 months), n (%) 84 (69) 180 (80) 0.03
Geometric mean age at first AOM (SD), months 10.1 (2.0) 7.7 (2.1) 0.001
Breastfeeding ! 3 months, n (%) 57 (47) 96 (43) 0.50
Tobacco smoke exposure indoors, n (%) 41 (34) 70 (31) 0.63
Day care
At age 12-24 months, n/N (%) 22/44 (50) 42/99 (42) 0.47
At age 25-48 months, n/N (%) 70/78 (90) 113/127 (89) 1.00
Median number of siblings (min-max), (mean) 1.0 (0-3)
(0.93)
1.0 (0-7)
(1.17)
0.02
Family history positive for AOM
Parents (121/225), n (%) 79 (65) 131 (58) 0.21
Siblings, n/N (%) 48/86 (56) 98/182 (54) 0.79
Atopy, n (%)
2
54 (44) 117 (52) 0.22
Fisher’s Exact test, Mann-Whitney U test, and t test were performed when appropriate.
2
Atopy was defined as having eczema, hay fever, or recurrent wheezing or asthma.
r
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age at the time of the first episode of AOM, using binary logistic regression. The log-
transformed age at the time of the first AOM episode was included in the analysis, 
because age at the first AOM episode itself did not show a normal distribution and an 
early first infection predisposes to a second AOM episode. A child who has had a first 
AOM episode at a younger age has had a longer period of time to develop multiple 
AOM episodes than a child of the same age who suffered from the first infection at 
a later age. Because the interaction between the age at the first AOM episode and 
the age of inclusion was significant, this was accounted for in the analyses. Because 
the pathogenesis of AOM in young children may differ from older children due to an 
immature immune system and different anatomic features such as the Eustachian 
tube, we also analyzed separately the frequencies of the number of AOM episodes 
in the year before inclusion in patients 1 to 4 years of age and patients > 4 years. 
Presence of atopy did not differ between the otitis-prone children and those with fewer 
episodes. Because asthma cannot, by definition, be diagnosed in children < 6 years 
of age, which applies to the main fraction of our patient cohort, recurrent wheezing 
and asthma as reported by the parents were considered the same in the statistical 
analyses. In addition to the multiplicative model, the effect of PAI1 genotype on the 
number of AOM episodes was also assessed comparing 4G/4G homozygotes with 
those homozygous for the 5G allele.
Results
The PAI1 4G/4G genotype is not associated with initial susceptibility to AOM. 
The PAI1 -675 polymorphism was successfully genotyped in 463 control subjects and 
317 children with recurrent AOM. PAI1 genotype frequencies in the control population 
were in Hardy-Weinberg equilibrium, and the allele frequencies were similar to results 
published previously.(24) The distribution of genotypes in control subjects was as 
follows: 5G/5G 99 (21.4%), 4G/5G 241 (52.1%) and 4G/4G 123 (26.6%). A significant 
difference in genotype distribution was only found between control subjects and those 
patients suffering from ≥ 4 episodes of AOM (p=0.02). No difference was observed 
between patients having 2 to 3 AOM episodes a year and control subjects (p=0.34; 
Table 2).
Related epidemiological findings. In our patient population log-transformed age at 
first AOM, gender, and the number of siblings were related to AOM recurrence rates 
(Table 1). Children who suffered from ≥ 4 episodes in the year before inclusion had 
their first AOM episode at a significantly younger age compared with the children 
suffering from 2 to 3 episodes. Although the majority in the total group of children 
with AOM were boys, girls were overrepresented in the group of children suffering 
from ≥ 4 AOM episodes when compared with the group of children with 2 to 3 AOM 
episodes. The number of siblings was higher in the otitis-prone group compared with 
the children with 2 to 3 episodes. Age at inclusion was not significantly different when 
comparing the group of children suffering from 2 to 3 AOM episodes with the group 
with ≥ 4 episodes. However, when children were divided into groups under and over
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Table 2. Comparison of PAI1 4G/5G genotype distribution in patients with recurrent otitis media 
and control subjects.
1Data for patients with 2-3 episodes of AOM (acute otitis media) versus control subjects: p=0.45 (c2 ).
2Data for patients with ≥ 4 episodes of AOM versus control subjects: p=0.05 (c2).
3Adjusted Odds ratio’s depicted were corrected for age at study entry, gender, number of siblings and the 
log-transformed age at the time of the first episode of AOM.
4Odds ratio’s represent the effect of the PAI1 4G/5G polymorphism (binary logistic regression analysis, 
multiplicative model).
5The reference OR = 1.
6Data are for the 4G homozygous vs. 5G homozygous patients, crude or adjusted, binary logistic 
regression analysis. In this analysis the PAI1 -675 polymorphism was included in the model as a 
categorical variable.
the age of four years, the distribution of AOM frequency differed significantly (Figure 
1). The occurrence of atopy and the presence of a family history positive for AOM did 
not differ between children with 2 to 3 vs ≥ 4 episodes of AOM.
The PAI1 4G/4G genotype is associated with the otitis-prone condition in 
children < 4 years of age. Comparing patients having 2 to 3 AOM episodes to 
patients with ≥ 4 episodes, the log-odds ratio (OR) of the 4G/4G versus the 5G/5G 
genotype was about two times the logOR of the 4G/5G versus 5G/5G genotype (OR 
4G/4G vs 5G/5G = 2.52, logOR 0.4 and OR 4G/5G versus 5G/5G = 1.52, logOR 0.19, 
respectively; Table 2). Hence, the 4G allele probably has a multiplicative effect on 
AOM recurrence rate (27). After correction for confounding factors as described in the 
”Statistical analysis,” we still found that the PAI1 4G/4G genotype was associated with 
recurrence of disease in patients (p=0.01, crude OR 1.59; p=0.03, adjusted OR 1.52). 
The PAI1 4G/4G individuals had an increased risk for ≥ 4 AOM episodes compared 
to patients homozygous for the 5G variant (p=0.01, crude OR 2.52; p=0.03, adjusted 
OR 2.31). Because the distribution of the number of AOM episodes differed between 
the groups of children 1 to 4 years of age and > 4 years of age, these groups were 
also analyzed separately (Figure 1). The association of the PAI1 4G/4G genotype with 
the otitis-prone condition was only found in the group of children 1 to 4 years of age 
(p=0.01, crude OR 1.75; p=0.02 adjusted OR 1.72; Table 2). Comparing the children 
with PAI1 4G/4G genotype with the 5G homozygotes yielded a crude OR of 3.14 
Table 2. parison of PAI1 4G/5  genotype distribution in patients with recurrent otitis media and control
subjects.
PAI1
4G/5G
controls 2-3 episodes
of AOM
! 4 episodes
of AOM
Co vs. 2-3
OR
1
 (p)
Co vs. ! 4
OR
2
 (p)
2-3 vs. ! 4
OR (p)
2-3 vs. ! 4
OR (p)
All patients 4G/4G vs. 5G/5G rude Adjusted
3
n = 463
Number (%)
n = 115
Number (%)
n = 202
Number (%)
1.59
4
 (0.01) 1.52
4
(0.03)
5G/5G 99 (21.4) 26 (22.6) 28 (13.9) 1
5
1
5
1
5
1
5
4G/5G 241 (52.1) 65 (55.6) 109 (54.0) 1.03 (0.92) 1.60 (0.05) 1.56 (0.16) 1.57 (0.18)
4G/4G 123 (26.6) 24 (20.9) 65 (32.2) 0.74 (0.34) 1.87 (0.02) 2.52
6
(0.01) 2.31
6
(0.03)
Patients < 4 years 1.75
4
 (0.01) 1.72
4
 (0.02)
5G/5G 18 (23.4) 25 (15.8) 1
5
1
5
4G/5G 48 (62.3) 85 (53.8) 1.28 (0.50) 1.32 (0.47)
4G/4G 11 (14.3) 48 (30.4) 3.14
6 (0.01) 2.97
6 (0.02)
Patients ! 4 years 1.534 (0.21) 1.174 (0.69)
5G/5G 8 (21.1) 3 (6.8) 1
5
1
5
4G/5G 17 (44.7) 24 (54.5) 3.77 (0.08) 5.25 (0.06)
4G/4G 13 (34.2) 17 (38.6) 3.49
6
(0.11) 2.50
6
(0.30)
C
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(p=0.01; adjusted OR 2.97, p=0.02). The PAI1 4G/4G genotype was not significantly 
associated with the otitis-prone condition in children > 4 years of age. The number of 
days with otorrhoea showed a trend toward longer duration in the 4G homozygous 
children (geometric mean days (SD) for genotypes: 5G/5G 5.3 (3.9); 4G/5G 6.5 (4.0); 
and 4G/4G 7.2 (4.2)). This was, however, not significant (p=0.66, ANOVA).
Figure 1. Distribution of the number of AOM episodes for different age categories at the time of inclusion.
The number of patients (age category in years) for the group of children with 2 to 3 AOM episodes in the 
year before inclusion is 44 (1-2), 27 (2-3), 13 (3-4), 16 (4-5), 17 (5-6) and 5 (6-7). The number of patients 
(age category) for the group of children with ≥ 4 AOM episodes in the year before inclusion is 99 (1-2), 44 
(2-3), 37 (3-4), 12 (4-5), 20 (5-6) and 14 (6-7). The distribution of 2 to 3 versus ≥ 4 AOM episodes differs 
between patients < 4 and > 4 years of age (p=0.03).
Discussion
In this study we show that, in the patient group with a history of ≥ 2 AOM episodes, 
children 1 to 4 years of age, with the PAI1 4G/4G genotype, which is related to high 
PAI-1 levels, have increased risk for more frequent recurrent AOM.(18, 19) The 
association is significant even after correction for possible confounding factors, with 
only a minimal change in odds ratios. PAI-1 inhibits cellular migration and invasion, 
processes essential in tissue repair in inflammatory disease.(16, 17) Hence, higher 
PAI-1 levels might result in longer persistence of tissue inflammation, or abnormally 
repaired tissue, prone to bacterial colonization and new infections.
Two possible mechanisms for PAI-1 interaction and inhibition of tissue repair have 
been proposed. First, PAI-1 may inhibit a proteolytic cascade at the cell surface 
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that results in matrix destruction, allowing cellular migration and invasion for tissue 
repair. The proteolytic cascade mechanism involves the activation of surface-bound 
plasminogen by surface bound urokinase plasminogen activator (uPA). PAI-1 can 
bind to uPA on the cell surface and inhibit its proteolytic activity and, hence, tissue 
repair.(15, 28, 29) A second proposed pathway involves competitive binding of PAI-1 
and integrin to vitronectin. Both share the same binding site region on vitronectin. 
Vitronectin/integrin interaction is needed for cell migration and adhesion. The 
inhibiting effect of PAI-1 is negated when excess nonsurface-bound uPA forms a 
complex with PAI-1 resulting in a release of PAI-1 from vitronectin, which is then 
available for interaction with integrin, favouring cell adhesion.(30) 
A possible role for high PAI-1 concentrations in the stronger inhibition of healing 
of inflamed otolaryngeal tissue that may, thus, favour an otitis-prone condition is 
supported by the results of Hansson et al. that imply a further role for PAI-1 and 
plasminogen in tissue repair. They have shown that perforated tympanic membranes 
(TMs) of plasminogen-deficient mice exhibit reduced healing 15 days after 
myringectomy compared with TM from wild-type mice.(31) Intravenous administration 
of plasminogen, in plasminogen-deficient mice, resulted in restored TM healing 
even if plasminogen was administered 30 days after perforation. The distribution of 
inflammatory cells in the perforated TM differed significantly between plasminogen-
deficient and wild-type mice in vivo. Plasminogen-deficient mice with initially normal 
TMs showed spontaneous development of middle ear effusion. Interestingly, in an 
otherwise healthy 10 year old boy with a history of chronic otitis media, low levels 
of serum plasminogen were detected.(32) Interaction of PAI-1 with uPA prohibits 
catalytic activation of plasminogen to plasmin. High PAI-1 levels might, therefore, 
result in similar clinical findings as seen in plasminogen deficiency.
Furthermore, in skin wound healing, PAI-1, uPA, and uPA receptor are expressed 
at the site of regenerative epithelial outgrowths at the edge of the wound.(33, 34) 
Plasminogen-deficient mice showed impaired wound healing.(35) In addition, Chen 
et al. reported that uPA expression is increased upon infection with Streptococcus 
pneumoniae in an otitis media model in the rat.(36) S. pneumoniae is one of the 
major causative microbes of otitis media in humans.(37-39) We recognize that these 
findings do not prove a role for PAI-1 in AOM, but we do feel that they deserve 
further attention. Additional functional assays in an otitis model are needed to further 
investigate the precise role of PAI-1 in AOM. These studies would preferably also be 
directed toward analyzing the therapeutic role of PAI-1 inhibitors and plasminogen 
in overcoming the effect of high PAI-1 expression and their effects on recurrence of 
otitis media.
We found that PAI1 4G/4G had no effect on the initial susceptibility to AOM as 
reflected by the lack of significant differences between AOM patients and control 
subjects. This fits in our concept of tissue repair where only once an episode of AOM 
has occurred may impaired tissue healing in 4G homozygous individuals facilitate 
microbial reinfection and the recurrence of otitis media. We realize that the control 
group was not an age-matched group without any AOM episodes, which may have 
biased our results. However, occurrence of AOM in the control subjects was < 2 
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episodes per year based on the prevalence of AOM in childhood. The association 
between PAI1 4G/4G genotype and the otitis-prone condition remained significant 
even after correction of the effect of the polymorphism on AOM recurrence rates for 
gender, number of siblings, and both age and age at first AOM for the children < 4 years 
of age. After 4 years of age we found a difference in the distribution of the number of 
AOM episodes compared with the younger children. AOM (and recurrence) has its 
peak in the first years of life. Ongoing recurrence in older children most likely selects 
a specific group that differs from the larger group of 10% to 15% of all children with 
recurrent AOM at early age. We possibly selected for the older patients as a result 
of the nature of the vaccination trial in which the patients participated selecting more 
otitis-prone children and particularly at older age those who had ongoing recurrent 
disease.
We only studied one genetic polymorphism in a complex multifactorial disease. As for 
many risk factors, only a small increase in risk can be found, which may be related 
to other risk factors as well. These may be both genetic and environmental. The 
balance of the different risk factors will determine the phenotype observed. Studying 
multiple factors simultaneously does, however, require large numbers of individuals. 
It must be mentioned that the association found in this study may reflect the result of 
linkage disequilibrium, meaning that not the PAI1 polymorphism itself but a genetic 
variation linked to this polymorphism is the actual disease associated genetic variant. 
Additional studies are, therefore, required to confirm our findings. However, our data 
show that studies of genes involved in the inflammatory responses and tissue repair 
will be of significance in understanding recurrent AOM. 
In conclusion, 4G homozygous individuals show an increased risk for an otitis-prone 
condition, especially under the age of 4 years. Impaired tissue integrity, because of 
high PAI-1 levels in PAI1 4G homozygous individuals once an episode of AOM has 
occurred, may possibly facilitate bacterial colonization, and, thereby, the recurrence 
of otitis media.
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Abstract
Objective. Cytokines and other inflammatory mediators are involved in the 
pathogenesis of otitis media. We hypothesized that polymorphisms in inflammatory 
response genes contribute to the increased susceptibility to acute otitis media (AOM) 
in otitis-prone children. 
Patients and Methods. DNA samples from 348 children with ≥ 2 AOM episodes 
participating in a randomized controlled vaccination trial, and from 463 healthy adult 
controls were included. Polymorphisms in TNFA, IL1B, IL4, IL6, IL10, IL8, NOS2A, 
C1INH, PARP, TLR2 and TLR4 were genotyped. Genotype distributions in children 
with AOM were compared with those in controls. Within the patient group, the number 
of AOM episodes before vaccination and the clinical and immunological response to 
pneumococcal conjugate vaccinations were analyzed.
Results. The IL6 -174 G/G genotype was overrepresented in children with AOM 
when compared to controls. In the patient group, TNFA promoter genotypes -238 
G/G and -376 G/G and the TLR4 299 A/A genotype were associated with an otitis-
prone condition. Furthermore, lower specific anticapsular antibody production after 
complete vaccination was observed in patients with the TNFA -238 G/G genotype 
or TNFA -863 A allele carriage. Finally, the IL10 -1082 A/A genotype contributed to 
protection from recurrence of AOM after pneumococcal vaccination. 
Conclusion. Variation in innate immune response genes like TNFA -863A, -376G 
and -238G, IL10 -1082 A and IL6 -174G alleles in the promoter sequences may result 
in altered cytokine production that leads to altered inflammatory responses, and, 
hence, contributes to an otitis-prone condition.
Introduction
Acute otitis media (AOM) is the most common bacterial infection in children. Overall, 
10% to 15% of all children suffer from ≥ 4 AOM episodes per year, which causes 
a great disease burden.(1) Genetic polymorphisms in immune response genes are 
known to influence susceptibility to and severity of infectious diseases. For example, 
allelic variations in TNFA, IL1B and IL6 have been associated with meningococcal 
infection.(2) Although cytokines and other inflammatory mediators are also involved 
in the pathogenesis of otitis media, the role of polymorphisms in immune response 
genes in recurrent AOM is relatively unexplored thus far. Increased expression of 
TNF-α, IL-1β, IL-6 and IL-10 was observed during experimental otitis media in animals.
(3, 4) Therefore, in a common disease such as otitis media, genetic variations may 
lead to altered inflammatory responses and an otitis-prone condition. For instance, 
bacterial endotoxin is recognized by several Toll-like receptors (TLRs), which in turn 
stimulate TNF-α production, thus affecting numerous other pathways such as cytokine 
production, immunoglobulin responses, and mucin production.(5-8) Remarkably, IL-
1β, IL-6 and TNF-α levels in nasopharyngeal secretions were found to be lower in 
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children with recurrent otitis media than in healthy children.(9) 
The influence of genetically determined variations on otitis media can be illustrated 
by twin studies, which have shown a heritability of 57% for acute ear infections 
and 72% for chronic ear infections.(10-14) Correlation for recurrent otitis media is 
higher in monozygotic twins (65%-71%) compared to dizygotic twins (25%-34%). 
(15) Streptococcus pneumoniae is an important pathogen in otitis media, involved 
in at least 20% to 40% of all cases.(16-18) Hence, genetic polymorphisms that 
influence recurrence of otitis media may also be related to response to pneumococcal 
antigens.
The effect of polymorphisms may result, for instance, from altered expression levels 
or altered function due to amino acid substitutions. Variations in immune response 
genes such as IL10, IL6 and IL4 have been associated with altered cytokine expression 
levels.(19-21) An altered function because of amino acid substitutions has been 
reported for polymorphisms in TLR4 and poly (ADP-ribose) polymerase (PARP). 
(22, 23) The PARP 762A variant was found recently to be associated with reduced 
activity after H2O2 exposure, which is known to be present in inflammation.(23) Other 
polymorphisms were selected in this study because of previous associations with 
infectious or inflammatory diseases such as the IL8 C781T polymorphism, which 
was reported recently to be associated with bronchiolitis caused by the respiratory 
syncytial virus.(24)
In this study, we investigated whether polymorphisms in selected immune response 
genes may contribute to recurrence of otitis media and to clinical and immunologic 
response to pneumococcal vaccination.
Methods
Participants. Patients who initially participated in a randomized, controlled study 
on prevention of recurrent AOM by pneumococcal vaccinations were included.(25) 
Children were enrolled in the study after obtaining approval of the medical ethical 
committee of the participating hospitals and informed consent from the parents or 
guardians. DNA was available from 348 Dutch Caucasian children, 1 to 7 years of 
age, who suffered from ≥ 2 AOM episodes in the preceding year. The number of 
AOM episodes prior to vaccination was based both on parental report (AOM defined 
as having ≥ 1 of these symptoms: acute earache, new-onset otorrhea, irritability, and 
fever) and on clinical information of the diagnosis by a physician. Children who did 
not have AOM episodes were not included, because they were not likely to benefit 
from vaccination. In the present study cohort, 122 children suffered from 2 to 3 otitis 
media episodes whereas 226 children suffered from ≥ 4 episodes (defined as otitis-
prone condition) (Table 1).(26) Children received either pneumococcal vaccinations 
(n = 168) or control vaccines i.e. hepatitis A (2 years or older) or hepatitis B (younger 
than 2 years) (n = 180) vaccines. In the pneumococcal vaccine group 1 dosage of 
7-valent conjugate vaccine (Prevnar®, Wyeth, Rochester, NY, USA) was administered
to children 2 to 7 years of age, whereas 2 dosages were given with a 1-month 
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Table 1. Characteristics of patients with 2 or more AOM episodes.
1Fisher’s Exact test, Mann-Whitney U test, and t test were performed when appropriate.
2Atopy was defined as having eczema, hay fever, or recurrent wheezing or asthma.
interval to children of 1 to 2 years. In both groups, this procedure was followed after 
6 months by 1 dose of the 23-valent polysaccharide vaccine (Pneumune®, Wyeth). 
Childrens’ progress was followed until 18 months after completion of the vaccine 
scheme to check for the recurrence of physician-diagnosed AOM.(25)
Dutch Caucasian controls (n = 463) were derived from the Dutch blood bank Sanquin, 
after informed consent was obtained and represented healthy adult donors. No records 
of prior history regarding AOM were available for these adult controls; however, in the 
general population a total number of ≤ 3.2 AOM episodes is expected in childhood. 
(26) For children aged 0 to 13 years had an estimated number of 120 episodes of 
physician diagnosed AOM per 1000 person-years in the Netherlands in the period 
1995-2003.(27) This infers that controls will have experienced, on average, fewer 
AOM episodes per year than the patients.
Genotyping. Single base extension analysis was used to genotype inducible nitric 
oxide synthase (NOS2A) S608L (rs2297518), PARP V762A (rs1136410), complement 
component inhibitor-1 (C1INH) V480M (rs4926), IL4 C-524T (rs2243250), IL10 
G-1082A (rs1800896), IL10 C-819T (rs3021097), IL1B C-31T (rs1143627), TNFA 
A-863C (rs1800630), TNFA T-857C (rs1799724), TNFA G-376A (rs3093659), TNFA 
G-308A (rs1800629), TNFA G-238A (rs361525), IL6 G-174C (rs1800795), IL8 C781T 
(rs2227306), TLR4 D299G (rs4986790) and TLR4 T399I (rs4986791) (http://www.
ncbi.nlm.nih.gov/SNP). 
In short, the genomic region of interest was amplified using polymerase chain 
reaction. After purification, a single base extension was performed using a primer 
ending 1 nucleotide prior to the single nucleotide polymorphism (SNP) location. 
Up to seven SNPs were analyzed in one multiplex assay. A poly-T-tail attached 
to the primer combined with the use of a Liz size marker served to distinguish 
Table 1. Characteristics of patients with 2 or more AOM episodes.
 Characteristics 2-3 AOM episodes   4 AOM episodes p-value
1
n=122 n=226
Male gender, n (%) 84 (69) 128 (57) 0.03
Median age (min-max), y 2.42 (1.0-6.3) 2.10 (1.0-7.0) 0.40
Age group (12-48 months), n (%) 84 (69) 180 (80) 0.03
Geometric mean age at first AOM (SD), months 10.1 (2.0) 7.7 (2.1) 0.001
Breastfeeding ! 3 months, n (%) 57 (47) 96 (43) 0.50
Tobacco smoke exposure indoors, n (%) 41 (34) 70 (31) 0.63
Day care
At age 12-24 months, n/N (%) 22/44 (50) 42/99 (42) 0.47
At age 25-48 months, n/N (%) 70/78 (90) 113/127 (89) 1.00
Median number of siblings (min-max), (mean) 1.0 (0-3)
(0.93)
1.0 (0-7)
(1.17)
0.02
Family history positive for AOM
Parents (121/225), n (%) 79 (65) 131 (58) 0.21
Siblings, n/N (%) 48/86 (56) 98/182 (54) 0.79
Atopy, n (%)
2
54 (44) 117 (52) 0.22
Fisher’s Exact test, Mann-Whitney U test, and t test were performed when appropriate.
2
Atopy was defined as having eczema, hay fever, or recurrent wheezing or asthma.
r
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SNPs in the multiplex analysis (Tables 2 and 3). The TLR2 R753Q polymorphism 
(rs5743708) was determined using Taqman analysis using primers, TLR2-753F 
CCATTCCCCAGCGCTTCT and TLR2-753R CCAGGTAGGTCTTGGTGTTCATT 
and probes TLR2-753V1 VIC-AAGCTGCAGAAGAT and TLR2-753M1 FAM-
AAGCTGCGGAAGAT. A subset of polymerase chain reaction samples was sequenced 
to confirm genotypes. All genotypes were annotated independently by 2 investigators 
who were blinded for the clinical data.
Table 2. Polymerase chain reaction primer sequences.
Antibody measurements. In children with ≥ 2 AOM episodes, a blood sample was 
taken for immunologic assessment before and 1 month after complete vaccination. 
Prevaccination and postvaccination immunoglobulin G (IgG) levels to the 7 
pneumococcal serotypes included in the conjugate vaccine were measured in serum 
by enzyme-linked immunosorbent assay (ELISA) as described previously.(28, 29)
Statistical analysis. Statistical analysis was performed using SPSS 11.0 (SPSS 
Inc., Chicago IL) and Stata 8 (Stata Corp, College Station, TX). Verification of Hardy-
Weinberg equilibrium of genotypes was performed using the c2 test (1df). Binomial 
variables were analyzed using Pearson’s c2 test (2df) or Fisher’s exact test when 
appropriate. Continuous variables were compared for the different genotypes using 
the Mann-Whitney U test. When necessary, variables were log-transformed to 
2
Table 2. P l rase chain reaction primer s quences.
Pool 1 Upper 5’! 3’ Lower 5’ ! 3’ rs No. Change
NOS2A GCAGGGCTAGGAGTAGGA AGCCCCATATGTAAACCAA rs2297518 608 S/L
PARP CTGCCCCTGTTCTACCA ACTGTAGGCCACCTCGAT rs1136410 762V/A
Pool 2
C1INH CCTCCGCCATCTCTGT GCTCGCCCTAACCTGA rs4926 480 V/M
IL4 CTTGCCAAGGGCTTCCTTAT TGGAAACTGTCCTGTCATGG rs2243250 C-524T
Pool 3
IL10 TCCCCTTACCTTCTACACAC GACCCCTACCGTCTCTATTT rs1800896 G-1082A
IL1B CTTGCCCTTCCATGAAC TGCCTCGAAGAGGTTTG rs1143627 C-31T
TNFA.1 CCCCTCCCAGTTCTAGTT GGGACACACAAGCATCA rs361525
rs1800629
rs3093659
G-238A
G-308A
G-376A
TNFA.2 GGAGAATGTCCAGGGCTATG AAAATCAGGGACCCCAGAGT rs1800630
rs1799724
A-863C
T-857C
Pool 4
TLR4 ATGCCCCTACTCAATCTCTCT GCCAGCCATTTTCAAGACT rs4986790
rs4986791
299 D/G
399 T/I
IL6 TTGTCAAGACATGCCAAGTGCT GCCTCAGAGACATCTCCAGTCC rs1800795 G-174C
IL8 AGCTTGCCTACTATAAATAACA CTAGCCCTTGACCTCAG rs2227306 C781T
Pool 5
IL10 TCCCCTTACCTTCTACACAC GACCCCTACCGTCTCTATTT rs3021097 C-819T
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Table 3. Primer sequences for single base extension reactions.
obtain an approximately normal distribution.
A comparison of genotype frequencies was made between patients and the reference 
control group. In addition, genotype frequencies in children suffering from 2 to 3 
episodes per year were compared with those of patients having ≥ 4 episodes after 
correction for gender, number of siblings, age, log-transformed age at the time of 
the first AOM episode, and the interaction term between the latter 2 by using binary 
logistic regression. Log-transformed age at the first AOM episode was included in 
the analysis because an early first infection predisposes to a second AOM episode. 
A child who has had a first AOM episode at a younger age has had a longer period 
of time to develop multiple AOM episodes than a child of the same age who suffered 
from the first infection at a later age. Since the interaction between the age at the 
first AOM episode and the age of inclusion was significant, it was accounted for in 
the analyses. Log-transformed antibody levels were compared between individuals 
with different genotypes. Age, number of AOM episodes (2-3 vs. ≥ 4) and the number 
of conjugate vaccinations (1 or 2), were included in the analyses that assessed the 
effect of the different genotypes. Only when genotypes were consistently associated 
with different serotype-specific antibodies was this association considered relevant.
To determine the involvement of SNPs on occurrence of AOM after complete 
vaccination, negative binomial regression was used, because it allows for extra 
variation (overdispersion). The time of follow-up was measured from one month after 
3
Table 3. Primer sequences for single base extension reactions.
Primer sequence Primer
length
(bases)
Pool 1 5’ ! 3’
PrNOS2A_U TTTTGCTCTTTCAGCATGAAGAGC 24
PrPARP_L TTTTTTTTTTGCAGGTTGTCAAGCATTTCC 30
Pool 2
PrIL4_U TAAACTTGGGAGAACATTGT 20
PrC1INH_U TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCAGCAGCCCTTCCTCTTC 66
Pool 3
PrTNFA_2863U AGTCGAGTATGTGGACCCCC 20
PrIL10_1082L TTTTTTTTTTTTACCTATCCCTACTTCCCC 30
PrTNFA1238U TTTTTTTTTTTTTTTTTTTTTTAGAAGACCCCCCTCGGAATC 42
PrIL1B_L TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTCCCTCGCTGTTTTTAT 48
PrTNFA_1308L TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTAGAGGCTGAACCCCGTCC 54
PrTNFA_1376U TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCCTGCATCCTGTCTGGAA 66
PrTNFA_2857L TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTCTACATGGCCCTGTCTTC 72
Pool 4
PrIL6_L AATGTGACGTCCTTTAGCAT 24
PrIL8_L TTTTTTTTTTCATAACTGACAACATTGAAC 30
PrTLR4_299U TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTTAGACTACTACCTCGATG 60
PrTLR4_399L TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGATCTAAATACTTTAGGCTG 72
Pool 5
PrIL10_819U TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCCTTGTACAGGTGATG
TAA
82
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complete vaccination until the end of the study. Effects were corrected for treatment 
(anti pneumococcal vaccinations or hepatitis vaccinations) and the number of 
AOM episodes in the year preceding vaccinations (2-3 vs. ≥ 4). P values ≤ 0.05 
were considered to be statistically significant. No correction was made for multiple 
testing.
Results
We investigated the association between variations in genes listed in Table 2 and 
occurrence of ≥ 2 episodes of AOM, the number of AOM episodes before vaccination, 
specific anti-pneumococcal IgG levels after vaccination and AOM after complete 
vaccination, respectively. Only significant associations will be discussed. SNPs not 
mentioned in the results section showed no significant associations.
Genotype distribution for all SNPs but the IL10 G-819A polymorphism reached Hardy 
Weinberg equilibrium in controls. To rule out technical problems, 14 individuals were 
typed using both the reverse and forward primer in the single base extension reaction. 
Results for both strands were identical. Sequencing of 13 random controls also 
showed identical genotypes, excluding technical errors (data not shown). Genotype 
distributions in controls are listed in Table 4.
IL6 -174 G/G genotype is associated with susceptibility to AOM. The number 
of individuals with the IL6 -174 C/C, C/G and G/G genotypes in the total cohort of 
AOM patients were 49 (14.1%), 156 (45%), and 142 (40.9%), respectively. The 
corresponding frequencies in controls were 82 (17.8%), 232 (50.4%) and 146 
(31.7%), respectively. The IL6 -174 G/G genotype was found more frequently in AOM 
patients compared with controls than the C/G genotype (OR 1.45, p=0.02) and the 
C/C genotype (OR 1.64, p=0.02).
TNFA promoter genotypes -238 G/G and -376 G/G and TLR4 299 D/D genotype 
are associated with an otitis-prone condition. Similar to other otitis studies, in our 
study, population risk factors for AOM such as a high number of siblings and low age 
at first AOM are related to an otitis-prone condition (Table 1) (13, 30, 31). Females 
were overrepresented in the group of children suffering from ≥ 4 AOM episodes 
when compared with the children who had 2 to 3 AOM episodes. Children under 
the age of 4 were more likely to have had ≥ 4 AOM episodes in the previous year 
than older children. The interaction of age and age at the first AOM episode was 
significantly associated with AOM recurrence rate (p<0.01). Therefore, the effect of 
the polymorphisms on recurrence rate of AOM was corrected for these factors (Table 
5). 
The TNFA -238 G/G genotype was overrepresented in the otitis-prone children 
compared with the children with 2 to 3 AOM episodes (crude OR 2.13, p=0.03, 
adjusted OR 2.29, p=0.03). Because a difference was observed in recurrence-rate 
distribution in children over and under the age of 4 years, these were also analyzed 
separately. The association was mainly attributable to children under the age of 4 
years. The TNFA -376 G/G genotype was associated with the otitis-prone condition
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Table 4. Genotype distribution of polymorphisms in Dutch Caucasian controls.
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Table 4. Genotype distribution of p lymorphisms in Dutch C u asian controls.
SNP Genotype frequency SNP Genotype frequency
 Controls Controls
 n (%) n (%)
NOS2a 608 IL4 -524
G/G 302 (65.2) C/C 340 (73.8)
G/A 140 (30.2) C/T 112 (24.3)
A/A 21 (4.5) T/T 9 (2.0)
PARP 762 IL1B -31
T/T 300 (66.7) C/C 57 (12.5)
T/C 140 (31.1) C/T 215 (47)
C/C 10 (2.2) T/T 185 (40.5)
C1INH 480 IL10 -1082
G/G 256 (55.5) G/G 123 (26.7)
G/A 176 (38.2) G/A 219 (47.6)
A/A 29 (6.3) A/A 118 (25.7)
TNFA -863 IL10 -819
C/C 330 (71.4) C/C 284 (61.6)
C/A 117 (25.3) C/T 145 (31.5)
A/A 15 (3.2) T/T 32 (6.9)
TNFA -857 IL6 -174
C/C 387 (84.5) C/C 82 (17.8)
C/T 66 (14.4) C/G 232 (50.4)
T/T 5 (1.1) G/G 146 (31.7)
TNFA -376 IL8 781
G/G 447 (96.8) C/C 152 (32.8)
G/A 15 (3.2) C/T 235 (50.8)
A/A T/T 76 (16.4)
TNFA -308 TLR4 299
G/G 301 (65.2) A/A 374 (86.4)
G/A 147 (31.8) A/G 58 (13.4)
A/A 14 (3.0) G/G 1 (0.2)
TNFA -238 TLR4 399
G/G 415 (89.8) C/C 379 (87.1)
G/A 47 (10.2) C/T 54 (12.4)
A/A T/T 2 (0.5)
264
C
h
a
p
te
r 
4
.2
Table 5. Genotype distribution of TNFA and TLR4 polymorphisms in children with AOM.
Data are from the crude and adjusted logistic regression analysis.
1OR adjusted: effect of SNP adjusted for gender, number of siblings, age, log (age at first AOM episode) 
and the interaction of the latter two.
 
in children (crude OR 3.10, p=0.05, adjusted OR 3.06, p=0.07). No significant 
association was found when older and younger children were analyzed separately.
In addition, carriage of the TLR4 299 G allele was associated with a lower number 
of AOM episodes (OR 0.5, p=0.04). This finding, however, remained significant only 
5
Table 5. notype distribution of TNFA and TLR4 polymorphis s in children with AOM.
SNP controls 2-3 episodes of
AOM
! 4 episodes of
AOM
2-3 vs ! 4
OR (p)
All patients Crude Adjusted
1
TNFA G-238A n = 462
n (%)
n = 120
n (%)
n = 222
n (%)
G/G vs G/A
G/G 415 (89.8) 101 (84.2) 204 (91.9) 2.13 (0.03) 2.29 (0.03)
G/A 47 (10.2) 19 (15.8) 18 (8.1)
A/A 0 (0) 0 (0) 0 (0)
Patients < 4 years
G/G 68 (82.9) 162 (92.0) 2.38 (0.03) 3.06 (0.01)
G/A 14 (17.1) 14 (8.0)
A/A 0 (0) 0 (0)
Patients > 4 years
G/G 33 (86.8) 42 (92.3) 1.59 (0.51) 1.41 (0.66)
G/A 5 (13.2) 4 (8.7)
A/A 0 (0) 0 (0)
All patients
TNFA G-376A n = 462
n (%)
n = 120
n (%)
n = 222
n (%)
G/G vs G/A and A/A
G/G 447 (96.8) 112 (93.3) 217 (97.7) 3.10 (0.05) 3.06 (0.07)
G/A 15 (3.2) 8 (6.7) 4 (1.8)
A/A 0 (0) 0 (0) 1 (0.5)
Patients < 4 years
G/G 77 (93.9) 172 (97.7) 2.79 (0.13) 3.05 (0.12)
G/A 5 (6.1) 3 (1.7)
A/A 0 (0) 1 (0.6)
Patients > 4 years
G/G 35 (92.1) 45 (97.8) 3.85 (0.25) 2.74 (0.44)
G/A 3 (7.9) 1 (2.2)
A/A 0 (0) 0 (0)
All patients
TLR4 299 D/G n = 433
n (%)
n = 121
n (%)
n = 216
n (%)
D/D vs D/G and G/G
D/D 374 (86.4) 99 (81.8) 194 (89.8) 1.96 (0.04) 1.66 (0.14)
D/G 58 (13.4) 20 (16.5) 22 (10.2)
G/G 1 (0.2) 2 (1.7) 0 (0)
Patients < 4 years
D/D 67 (80.7) 157 (91.3) 2.50 (0.02) 2.49 (0.03)
D/G 14 (16.9) 15 (8.7)
G/G 2 (2.4) 0 (0)
Patients > 4 years
D/D 32 (84.2) 37 (84.1) 0.99 (0.99) 0.65 (0.54)
D/G 6 (15.8) 7 (15.9)
G/G 0 (0) 0 (0)
Data are fr  the crude and adjusted logistic regression analysis.
1
OR adjusted: effect of SNP adjusted for gender, number of siblings, age, log (age at first AOM episode) and the
interaction of the latter 2.
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after correction for confounding factors when the children under the age of 4 years 
were analyzed separately (crude OR 2.50, p=0.02, adjusted OR 2.49, p=0.03). 
TNFA -863 C/C genotype and carriage of the TNFA -238 A allele are associated 
with higher specific anti-pneumococcal IgG levels after complete vaccination. 
IgG anti-pneumococcal antibody levels were evaluated in 80 children of the 
pneumococcal vaccine group; 34 aged 12 to 24 months and 46 were aged 25 to 84 
months. Four or more AOM episodes in the year preceding inclusion were observed 
in 36 children, whereas 44 had 2 to 3 episodes of AOM. Before vaccination, all IgG 
anti-pneumococcal antibody levels were low for patients with 2 to 3 AOM and ≥ 4 
AOM episodes (Table 6). 
Table 6. Geometric mean (95% Confidence Interval) of specific anti-pneumococcal IgG in children 
with 2 to 3 and children with ≥4 AOM episodes, before vaccination and one month after complete 
vaccination.
1P values were corrected for age, by using regression analysis.
Serum IgG anti-pneumococcal antibody levels against all serotypes were lower in 
the children with an AOM recurrence rate of ≥ 4 compared with those with only 2 
to 3 AOM episodes after complete vaccination. This was significant for all except 
the anti-serotype 6B and 23F antibody levels. Age, independent from the number 
of AOM episodes (2-3 or ≥ 4), had a significant effect on specific IgG levels against 
serotype 14 at baseline, and on anti-serotype 4 antibody levels after vaccination. By 
using a logistic regression model adjusting for age, number of AOM episodes and 
number of conjugate vaccinations, a significantly lower anti-pneumococcal serotype 
23F antibody level was observed for the carriers of the TNFA -863 A allele compared 
with children homozygous for the C allele (p<0.001). Furthermore, a trend for lower 
specific IgG levels was observed against 5 of 7 vaccine serotypes (p=0.05-0.10) in 
the carriers of the -863A allele. The TNFA -238 A allele carriers had higher geometric 
mean specific IgG levels against all serotypes (Table 7). This was, however, only 
significant for antibodies against pneumococcal serotypes 18C and 19F without 
correction for confounding factors (p=0.04 and p=0.04, respectively).
No significant differences in specific IgG levels were observed for the IL6 -174 G/C 
and the IL10 -1082 G/A and -819 C/T genotypes (data not shown).
6
Table 6. Geometric mean (95% Confidence Interval) of specific anti-pneumococcal IgG in children with 2 to 3
and childre  with !4 AOM episodes, before vaccination and one month after complete vaccination.
Prior to vaccination One month after complete vaccination
Total IgG against
capsular type
2-3 AOM episodes
n = 36
! 4 AOM episodes
n = 44
1
2-3 AOM episodes
n = 36
! 4 AOM episodes
n = 44
1
4 0.05 (0.04-0.07) 0.05 (0.04-0.06) 0.61 5.91 (4.6-7.6) 3.55 (2.6-4.8) <0.01
6B 0.04 (0.03-0.05) 0.04 (0.04-0.05) 0.74 1.39 (0.7-2.7) 0.75 (0.4-1.4)   0.20
9V 0.22 (0.16-0.31) 0.18 (0.13-0.25) 0.37 43.48 (31-61) 20.18 (14-30) <0.01
14 2.20 (1.27-3.82) 1.17 (0.84-1.61) 0.05 117.84 (85-164) 59.94 (47-77)   0.001
18C 0.27 (0.18-2.50) 0.20 (0,14-0.28) 0.29 12.80 (9.9-17) 7.79 (6.0-10) <0.01
19F 0.43 (0.26-0.71) 0.23 (0.18-0.30) 0.02 25.81 (18-36) 8.16 (5-12) <0.001
23F 0.53 (0.40-0.71) 0.57 (0.43-0.75) 0.65 4.91 (3.6-6.7) 3.28 (2.3-4.8)   0.12
p values were corrected for age, by using regression analysis.
pp
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Table 7. Geometric mean (95% Confidence Interval) of specific anti-pneumococcal antibodies 1 
month after complete vaccination for different TNFA -863 and TNFA -238 genotypes.
Data are from the crude and adjusted logistic regression analysis.
1P (adjusted): indicates the effect of SNP adjusted for age, AOM rate (2-3 vs ≥ 4) and number of conjugate 
vaccinations (1 or 2).
IL10 -1082 A/A genotype is associated with protection from AOM recurrence 
after vaccination. Previously, we have reported that the number of AOM episodes 
in the per-protocol analysis was higher in the pneumococcal vaccine group than in 
the control vaccine group, in particular among children who suffered from ≥ 4 AOM 
episodes in the year preceding inclusion.(25) We corrected for this feature to assess 
whether the polymorphisms were correlated to the number of AOM episodes after 
complete vaccination. Patient characteristics did not differ between the pneumococcal 
and control vaccine group.(25) We observed that the IL10 -1082 A/A genotype protects 
patients from AOM recurrence during follow-up after vaccination (IRR 0.63, p=0.01).
No significant differences were observed for polymorphisms in TNFA or IL6 (data not 
shown).
Discussion
In this study, we found an association between TNFA promoter polymorphisms and 
otitis-prone condition and specific IgG production after pneumococcal vaccination. The 
TNFA -238 G/G genotype was associated with the otitis-prone condition and a trend 
for lower specific anti-pneumococcal antibody levels after vaccinations compared 
with carriers of the A allele. The TNFA -863 A allele was also associated with a trend 
for lower specific anti-pneumococcal IgG levels compared with children with the 
-863 C/C genotype. The TNFA -376 G/G genotype was also associated with an otitis 
prone condition. Similar to the study of Joki-Ekkila et al., we found no association 
between the TNFA -308 promoter polymorphism and recurrent AOM.(32) In a recent 
study, an association was reported between carriage of the rare TNFA -308 allele 
and susceptibility to AOM. The allele frequencies of the TNFA -308 polymorphism, 
however, differed from what is usually reported for this polymorphism.(33) Differences 
7
Table 7. Geometric mean (95% Confidence Interval) of specific anti-pneumococcal antibodies 1 month after
complete vac ination for different TNFA -863 and TNFA -238 genotypes.
IgG against pneumococcal capsular type
4 6B 9V 14 18C 19F 23F
TNFA -863
C/C
(n = 54)
5.00
(3.9-6.4)
1.27
(0.8-2.1)
33.29
(24-45)
90.11
(69-118)
10.12
(8.0-13)
16.00
(11-23)
5.22
(4.0-6.8)
C/A and A/A
(n = 26)
3.52
(2.3-5.3)
0.60
(0.3-1.4)
20.66
(12-36)
65.52
(47-92)
8.99
(6.4-13)
9.93
(6.0-17)
2.19
(1.4-3.5)
p (crude) 0.12 0.10 0.10 0.16 0.80 0.13 0.001
p (adjusted)
1
0.05 0.10 0.06 0.10 0.42 0.05 <0.001
TNFA -238
G/G
(n = 66)
4.53
(3.7-5.5)
0.93
(0.6-1.5)
27.36
(21-36)
76.22
(61-95)
8.87
(7.4-11)
11.86
(8.6-16)
3.74
(2.9-4.9)
G/A
(n = 12)
4.17
(1.6-11)
1.89
(0.5-6.7)
34.88
(9.7-125)
125.04
(61-257)
15.54
(6.9-35)
27.83
(12-67)
5.03
(2.1-12)
p (crude) 0.78 0.23 0.54 0.10 0.04 0.04 0.41
p (adjusted)
1
0.70 0.46 0.77 0.21 0.06 0.07 0.39
Data r  from the crude and djusted logistic re ression analysis.
1
p (adjusted): indicates the effect of SNP adjusted for age, AOM rate (2-3 vs !4) and number of conjugate vaccinations (1 or 2).
  
 Polymorphisms in recurrent otitis media 267
in the observed associations between the TNFA promoter polymorphisms may, 
indeed, result from differences in allele frequency in the population and the effect 
of haplotypes. This finding may be specifically true for rare polymorphisms like the 
TNFA -376 G/A polymorphism. For our study, however, the limited number of patients 
prohibited haplotype analysis. 
TNF-α levels in nasopharyngeal secretions are decreased in children with recurrent 
otitis media compared with healthy children.(9) TNF-α stimulates immunoglobulin 
and mucin production, and low TNF-α concentrations may compromise these 
defence mechanisms.(7) The association between various TNFA polymorphisms and 
otitis media parameters found in our study may indicate that, indeed, there is a role 
for these polymorphisms in TNF-α production in vivo. In the recent past, numerous 
studies have been performed to investigate the association of TNFA promoter 
polymorphisms and TNF-α levels in different inflammatory and infectious diseases, 
and contradictory results have been reported.(34) TNF-α expression is probably not 
determined by one polymorphism, but, rather, by a combination of polymorphisms 
in TNFA and TNFA-associated genes. Different pathogens may induce a variety of 
cytokine responses, and because numerous pathogens, both bacterial and viral, 
are known to cause otitis media, unravelling the role of polymorphisms on TNF-α 
production in the human setting is very difficult. Because TNF-α levels are expected 
to change during the course of infection, the timing of sampling is likely to be a very 
important determinant of the results.
In addition, the IL6 -174 G/G promoter genotype was found more frequently in 
patients with AOM than in healthy adult controls in our study. Our findings support the 
findings of others (e.g., the study by Nieters et al.) who found homozygosity of the IL6 
-174 C allele to be associated with a lower frequency of reported common colds.(35) 
Common colds are known to predispose for recurrent otitis media. In addition, Patel 
et al. reported IL6 -174 G allele carriage to be increased in otitis media susceptible 
children.(33) The IL6 G/G genotype was shown previously to be associated with 
high IL-6 levels compared with the C/C genotype.(21) This association, however, 
is not consistent, however, and a more complex regulation of IL-6 production that 
depends on multiple polymorphisms in the IL6 promoter region appears to play a 
role.(36, 37) Furthermore, IL-6 expression is influenced by TNF-α, and interaction of 
polymorphisms in these and other genes may co-determine the phenotype.
Carriage of the TLR4 299 G allele was associated with a lower number of AOM 
episodes, but was significant only in children younger than 4 years after corrections for 
confounding factors. Possibly, a low allele frequency in our population (G allele 10% 
in the group with 2-3 AOM episodes versus 5% in the otitis-prone group) hampered 
identification of an association. TLRs recognize microbial patterns in a specific 
way. It is thought that, depending on the micro-organism involved, a combination 
of TLRs is triggered, which determines the direction of the immune response.(38) 
Detailed information on the causative pathogens in each disease episode is needed 
to elucidate the precise role of TLRs and their genetic variation in AOM and other 
diseases. Unfortunately, these data are not available in the current study.
The IL10 -1082 A/A genotype was associated with protection from AOM after 
vaccination. The IL10 promoter haplotype that includes the -1082 A/A genotype is 
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associated with low IL-10 production.(19, 39, 40) For the IL10 -819 C/C genotype, 
which is in the same haplotype, a similar trend was observed (data not shown). In 
IL-10 deficient mice immunized with non-virulent unencapsulated S. pneumoniae 
(strain R36A), elevated induction of proinflammatory cytokines was observed, which 
supports the hypothesis that low IL-10 producers confer better response upon 
vaccination. Antibody titers against pneumococcal proteins were increased compared 
with those in  wild-type mice.(41) Although no association was observed between the 
IL10 polymorphism and specific antibody levels in our population, one might expect 
a similar effect. Possibly, the concentration of IL-10 in low producers is sufficient to 
preclude finding differences in antibody titers.
Because otitis media is a multi-factorial disease, the effect of each polymorphism 
on its own is expected to be limited. In addition, we are aware that most of these 
associations are expected to lose significance after correction for multiple testing. 
However, because no consensus has been reached on what method to use to correct 
for multiple testing in genetic association studies, we felt it most appropriate to provide 
p-values as they are.
The associations in our study were attributable mainly to children younger than 4 
years.  Several factors may explain this finding. First, a selection for children suffering 
from ≥ 2 episodes of otitis media for the vaccination trial may have resulted in a biased 
group in the older children, including those children with the highest recurrence rates 
or ongoing infection. Second, the immune system and anatomy, like the Eustachian 
tube, of young children are both still developing and differ from older children and 
adults, which likely results in a more prominent role for innate immunity at younger 
age. In contrast to previous studies, our study only included patients with recurrent 
AOM and no age-matched controls without otitis were included.(30, 42)  
In conclusion, several polymorphic variants in immune response genes (ie, IL6 -174 
G/C, TNFA -863 A/C, TNFA -376 G/A, TNFA -238 G/A, TLR4 D/G and IL10 -1082 
G/A) are suggested to have a potential influence on middle ear infections. Because 
the various genotypes are expected to interact with each other and numerous 
environmental and host factors, additional functional and genetic studies are 
warranted to elucidate their individual contributions to recurrence of AOM.
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5Chapter 5Genetic variability and nasal carriage of S. aureus

Chapter 5.1 
Association between nasal carriage of 
Staphylococcus aureus and the human 
complement cascade activator serine protease 
C1 inhibitor (C1INH) valine vs. methionine 
polymorphism at amino acid position 480
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Abstract
Objective. Staphylococcus  aureus  produces compounds that interfere with 
complement deposition. We hypothesized that humans have developed 
countermeasures to staphylococcal complement evasion.
Methods. We screened for single nucleotide polymorphisms in the serine protease 
C1 inhibitor (C1INH) gene at amino acid position 480 (valine vs. methionine) and 
nasal carriage of S. aureus. 
Results. In our study cohort, 38 individuals were persistently colonized by S. aureus, 
whereas 50 were invariably culture-negative. A trend was observed towards an 
increased prevalence of the Val/Val genotype in non-carriers compared to persistent 
carriers (OR 0.50, p=0.07). The Val/Val genotype was significantly overrepresented 
in non-carriers compared to 463 Caucasian blood donors (OR 0.52, p=0.02).
Conclusion. These findings suggest that susceptibility to S. aureus nasal carriage is 
associated with the C1INH V480M polymorphism.
Introduction
Staphylococcus aureus uses various mechanisms that facilitate escape from the 
human innate immune response.(1-3) This will probably contribute significantly to 
bacterial survival in the hostile host environment, although it is currently unclear how 
nasal colonization is affected by for instance anti-complement features. A central 
molecular regulator of the human complement system is the serine protease C1 
inhibitor (C1-Inh), which prevents over-activation of the complement cascade. C1-Inh 
is a possible candidate that might facilitate host circumvention of the staphylococcal 
‘anti-complement’ activity. C1-Inh harbours a serpine or serine protease domain that 
has proteolytic capacities and is essential for the inhibitory capacity of C1-Inh.(4) C1-
Inh also inhibits contact system proteases, such as kallikrein and blood coagulation 
factor XII, and is involved in endothelial binding of leukocytes.(5-7) A polymorphism 
in this protein has not yet been linked to infectious disease susceptibility. However, 
considering the important role of C1-inh in complement regulation and the observation 
that about 25% of the general population carries S. aureus persistently in the nasal 
cavity, we hypothesized that genetic variation in the protease domain of C1INH might 
be associated with nasal carriage of S. aureus. 
Methods
A total number of 111 Caucasian volunteers were included in the current analysis. 
Volunteers were co-workers from the Department of Medical Microbiology & 
Infectious Diseases, Erasmus MC, Rotterdam (n = 19), participants of an ongoing 
epidemiology cohort study in the elderly in Rotterdam (n = 36), and medical students 
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of the Erasmus MC (n = 56). Seven (36.8%) of the co-workers from the Department of 
Medical Microbiology & Infectious Diseases were male, and the median age (range) 
was 29 (20-52) years. 
The median age (range) of the elderly participants was 71 (61-101) years; 15 (41.7%) 
were male. Among the medical students 26 (46.4%) were male, and the median age 
(range) was 19 (18-22) years. In addition, blood samples from Caucasian controls 
representing the general Dutch adult population (n = 463) were provided by the 
Sanquin Blood Bank South West Region. In the control cohort, 233 (50.3%) were 
male and the mean age was 39.1 years (SD 8.5). No records regarding S. aureus 
carriage were available for the controls. However, previous studies in both children 
and elderly from the same geographical region revealed that carriage rates for these 
and other groups are similar.(8, 9) We therefore assume that the groups that we 
compare in the present study are not significantly different with respect to carriage 
rates. Both controls and volunteers originated from the South West area of the 
Netherlands and their S. aureus carriage rates are expected to be similar. Numbers 
of individuals in test and control groups allow significant differences to be detected at 
4-10% change in allele frequencies at 80% power and p<0.05. All participants gave 
written informed consent and the study protocol was approved by the Medical Ethics 
Committee of Erasmus MC.
Serial nasal swab cultures were performed as described previously.(9, 10) Persistent 
carriers were defined as those having at least 80% of their nasal cultures positive for 
S. aureus. Intermittent carriers are positive in between 20% and 80% of all culture 
efforts. Non-carriers were defined as those being repeatedly culture-negative for S. 
aureus.
Blood samples were used for DNA extraction and genotyping. DNA was extracted 
from peripheral blood leukocytes using standard protocols (DNA minikit; Qiagen). 
The C1INH valine to methionine substitution at amino acid position 480 (V480M) 
(rs4926) genotype was determined using single base extension analysis (ABI 
PRISM SNaPshot multiplex kit, Applied Biosystems, Warrington, UK). The genomic 
region of interest was amplified in 10 μl containing 0.2 mM dNTPs, 1x PCR buffer, 
1.5 mM MgCl2, 0.1 U of Taq (Integro BV, Leuvenheim, the Netherlands), 2 pmol of 
each primer (5’-CCTCCGCCATCTCTGT-3’ and 5’-GCTCGCCCTAACCTGA-3’) 
and 5 ng of DNA. Cycle conditions were 95oC for 5 min, followed by 36 cycles of 
95oC for 30 s, 58oC for 30 s and 72oC for 1 min and 1 cycle of 72oC for 5 min. The 
C1INH V480M genotype was determined by single base extension of the primer 
5’-(T)47GCAGCAGCCCTTCCTCTTC-3’, ending one nucleotide prior to the SNP 
location. To confirm accuracy of the genotyping analysis, 11 controls covering all 
sequence variants were sequenced. The sequences and genotypes assessed by 
SNaPshot were in concordance.
Statistical analysis was performed using SPSS 11.0. Verification of Hardy-Weinberg 
equilibrium of genotypes was performed using the c2 test (1 df). A comparison of 
genotype frequencies was made between persistent carriers or non-carriers and 
controls using binary logistic regression. Additionally, genotype frequencies were 
compared between non-carriers and persistent carriers, the latter categories 
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representing the extremes of the phenotype tested.(9) Probability (P) values ≤ 0.05 
were considered to be statistically significant. Since no consensus exists on what 
methods to use in genetic association studies, no correction was made for multiple 
testing.
Results and discussion
In the test group, 38 individuals were persistently colonized by S. aureus, whereas 50 
were invariably culture-negative; 23 were intermittent carriers. The C1INH Val480Met 
genotype distributions for the V/V, V/M and M/M genotypes in the total cohort of 
microbiologically assessed individuals were 72 (64.9%), 33 (29.7%), and 6 (5.4%), 
respectively. The corresponding frequencies among bloodbank controls were 256 
(55.5%), 179 (38.2%) and 29 (6.3%), respectively. Genotype distribution in both 
groups reached Hardy-Weinberg equilibrium (p=0.40 and 0.86, respectively). A trend 
was observed towards a higher prevalence of the V/V genotype in the non-carriers 
compared to persistent carriers (OR 0.50, p=0.07) (Table 1). 
Table 1. C1INH V480M genotype frequency compared between S. aureus persistent carriage or 
non-carriage groups and controls.
1NC, non-carrier; CO, controls.
2PC, persistent carrier.
3OR, Odds ratio.
Comparing non-carriers to the controls, the log(OR) of the C1INH 480 V/V versus M/M genotype was two 
times the log(OR) of the V/M versus M/M genotype (0.6 and 0.3, respectively). Hence, the relation between 
the G allele and S. aureus carriage is probably additive and the C1INH genotype was therefore included 
in the binary logistic regression analysis as a linear factor (SPSS 11.0).
The V/V genotype was overrepresented among non-carriers when compared to the 
general population (72.0 vs. 55.5%, respectively, OR 0.52, p=0.02). The fact that the 
association between C1INH polymorphism and nasal carriage of S. aureus is not 
absolute is considered likely because the interaction between bacteria in general and 
man is thought to be complex and dependent on a large variety of both human and 
bacterial factors.(11)
As the functional relevance of the V480M substitution remains to be determined, the 
role of this polymorphism in staphylococcal colonization is unknown.(12) Previously, 
no differences between the V480 C1-Inh and the M480 C1-Inh were observed with 
regard to structure, protein stability, serum concentration or inhibition of C1.(13) It is 
7
n (%) NC v CO
1
PC vs CO
2
NC vs PC
C1INH
V480M
Non-carrier Persistent
carrier
Controls OR
3
 (p)
(95% CI)
OR (p)
(95% CI)
OR (p)
(95% CI)
Total (n) 50 38 461
V/V 36 (72.0) 21 (55.3) 256 (55.5) 0.52 (0.02) 1.05 (0.86) 0.50 (0.07)
V/M 13 (26.0) 14 (36.8) 176 (38.2) (0.29-0.92) (0.62-1.79) (0.24-1.07)
M/M 1 (2.0) 3 (7.9) 29 (6.3)
1
NC, n - arrier; CO, controls.
2
PC, persistent carrier.
3
OR, Odds ratio.
Comparing non-carriers to the controls, the log(OR) of the C1INH 480 V/V versus M/M genotype was two times the
l g(OR) of the V/M versus M/M genotype (0.6 and 0.3, respectively). Hence, the relation between the G allele and S.
aureus carriage is probably additive and the C1INH genotype was therefore included in the binary logistic regression
analysis as a linear factor (SPSS 11.0).
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therefore unlikely that there is a difference in the direct interaction between S. aureus 
and C1-Inh.(14) It might very well be that the polymorphism has an effect on one 
of the other functions of C1-Inh.(6, 13) Future opsonophagocytosis experiments or 
characterization of complement deposition on bacterial cells using serum samples 
from donors with different C1INH genotypes may help to elucidate the molecular basis 
of S. aureus - C1-Inh interactions. To perform such experiments, serum is needed 
from individuals with the different C1INH genotypes, multiple S. aureus strains need 
to be tested and the influence of antibodies against S. aureus needs to be assessed.
(15, 16) We here demonstrate that a genetic polymorphism in a complement gene 
seems to be associated with staphylococcal colonization of the nose. This observation 
suggests that human complement gene variability is relevant in counterbalancing the 
complement-interfering abilities of S. aureus, although nothing is as yet known on the 
mechanistic aspects of this host-pathogen interaction. 
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Abstract
Objective. Staphylococcus aureus colonization of the human nares predisposes to 
sometimes severe auto-infection. We investigated whether genetic polymorphisms 
affect the S. aureus carriage status.
Methods. Sequence variation in α-defensin and β-defensin, and mannose-binding 
lectin (MBL) genes were determined for a group of volunteers (n = 109) with known 
S. aureus nasal carriage status. DEFA1/3 expression was measured in a subset of 
the volunteers (n = 32).
Results. None of the single nucleotide polymorphisms studied could clearly 
distinguish the (non) carriage groups. S. aureus carriers differed from non-carriers 
in baseline level of HNP1-3 peptide production (median: 218 vs. 89 μg/ml, p=0.016). 
No association between HNP1-3 levels and the individual sequence polymorphisms 
was documented. The combined copy numbers of DEFA1/A3 genes ranged from 
5 to 23 per diploid genome. A linear correlation between combined copy numbers 
and HNP1-3 peptide concentrations in nasal secretions of non-carriers was noted (r2 
=0.8991). DEFA3 gene was absent in 25% of the individuals. MBL haplotype A was 
overrepresented in persistent S. aureus carriers (87% vs 67%; p=0.038). 
Conclusion. Defensin gene polymorphism, both in sequence and in gene copy 
numbers, does not seem to be involved in S. aureus carriage predisposition. 
However, MBL haplotypes do so significantly. Baseline HNP1-3 production is more the 
consequence of S. aureus colonization than a reason for the (non) carrier status.
Introduction
Despite of a variety of antimicrobial substances secreted by the human nasal mucosae, 
Staphylococcus aureus is still capable of persistently colonizing the vestibulum nasi 
in approximately 1 out of 4 individuals.(1) Nasal carriage of S. aureus provides an 
important source for blood-borne, surgical site and other nosocomial infections.(1, 
2) Conversely, persistent nasal S. aureus carriage seems to protect against a more 
severe course of staphylococcal disease especially bacteraemia.(1) Consequently, 
it is important to elucidate the immunological mechanisms prohibiting or leading 
to S. aureus nasal carriage. It has been suggested that persistent S. aureus nasal 
carriers may suffer from dysregulation of innate humoral factors present in their nasal 
secretions.(3-5) In addition, polymorphisms in innate immune-response genes are 
known to be associated with susceptibility to other infectious diseases.(6, 7) We 
hypothesized that single nucleotide polymorphisms (SNPs) previously reported in 
defensin- and mannose-binding lectin (MBL) genes, encoding for proteins produced 
at the nasal mucous lining, might play a role in S. aureus carriage.(7, 8) It has been 
demonstrated that defensin gene transcription can be strongly enhanced upon 
stimulation with bacterial cell wall associated lipopolysaccharide (LPS).(9)  
We here present a comparative sequence and SNP analysis of the DEFA1/3, 
284
C
h
a
p
te
r 
5
.2
DEFA4, DEFB1 and MBL genes for a group of volunteers with known S. aureus 
nasal carriage status. A variety of SNPs was identified and the frequency of those 
SNPs within a validation cohort of persistent carriers and non-carriers of S. aureus 
was determined. Furthermore, we measured the expression of DEFA1/3 in nasal 
secretions of individuals with different S. aureus carriage phenotypes, before and 
after mupirocin treatment and after active in vivo re-colonization with S. aureus. We 
also performed quantitative PCR analysis to determine both the gene copy number 
variability and presence of the DEFA1 and DEFA3 genes.
Methods
Study population. A total number of 109 volunteers were included in the current 
analysis: 37 were demonstrated to be persistently colonized by S. aureus, 22 were 
colonized intermittently, whereas 50 were continuously culture-negative. Volunteers 
were co-workers from the Department of Medical Microbiology & Infectious Diseases, 
Erasmus MC, Rotterdam (n = 19), elderly people taking part in an ongoing clinical-
epidemiology cohort study in Rotterdam (n = 35), and medical students of the Erasmus 
MC (n = 55). Blood samples were used for DNA extraction prior to genotyping. S. 
aureus nasal carriage status was determined by longitudinal culturing of nasal swabs 
of each individual as described previously.(10, 11) Persistent carriage was defined 
as having at least 80% of the cultures testing positive for S. aureus. Non-carriers 
were those individuals having no positive cultures, whereas intermittent carriers had 
at least one but less than 80% of positive cultures.(10, 11) All participants provided 
written informed consent and the study protocol was approved by the Medical Ethics 
Committee of the Erasmus MC.
Collection of nasal secretions. Nasal secretions were collected from a subset 
(n = 32) of the abovementioned volunteer group, participating in another study.
(11) Nasal secretions were collected from 11 non-carriers, 13 intermittent carriers 
and 8 persistent carriers. These volunteers were also treated with mupirocin nasal 
ointment to eliminate S. aureus from the nose. Ten weeks later, with nasal swab 
cultures being still negative, both nostrils of all participants were inoculated with a 
109 CFU/ml combination of S. aureus strains: the laboratory S. aureus 502a strain, 
2 strains obtained from persistent S. aureus nasal carriers and 1 strain originated 
from an intermittent carrier of S. aureus in the nose. Moreover, the intermittent- and 
persistent carriers in this study population were also reinoculated with their own 
strain. At base line, before and after inoculation, nasal secretions were obtained from 
the volunteers. The materials were processed as described before.(3) The nasal 
secretions were collected by vacuum-aided suction, without chemical stimulation. 
The secretion volume varied from 0.4 to 2 ml per donor per occasion. The secretions 
were sonicated briefly (3 times 10 sec bursts at low power) to disrupt the mucoprotein 
aggregates and to facilitate reproducible handling. The secretions were stored in 
aliquots at -20oC until use.
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DEFA 1/3 quantitative dot-blotting. Sonicated whole nasal fluid was diluted 1:10 in 
10% acetic acid, vortexed for 20 min, and centrifuged at 13,000 rpm for 10 min, all 
at 4oC. The supernatant was collected and kept on ice. The pellet was re-extracted 
with 400 μl of 10% acetic acid for another 20 min. Following centrifugation, both 
supernatants containing acid-soluble proteins were pooled and vacuum dried using 
a ThermoSavant SPD1010 SpeedVac system. Protein pellets were resuspended to 
the original fluid volume in 1% acetic acid and stored at -20oC. The immuno-dotblot 
technique was performed as described previously.(12) In short, DEFA1/3 standards 
and extracted nasal fluid samples were dotted onto Immobilon-P PVDF membranes 
that were pre-wet with Tris-buffered saline (500 mM NaCl, 20 mM Tris-HCl pH 7.4, 
TBS). After dotting, the proteins were fixed to the membranes by TBS (150mM NaCl 
and 10mM Tris-HCl, pH 7.5) containing 0.05% glutaraldehyde. Blots were blocked 
using Superblock (Pierce, Rockford, USA) containing 0.05% Tween-20 for 30 min 
at 37oC in an environmental shaker at 30 rpm. Primary antibody incubation was 
carried out overnight at room temperature using 1:3000 diluted rabbit anti-DEFA1/3 
antisera. The secondary antibody, goat anti rabbit IgG complexed to horse radish 
peroxidase, was diluted 1:20,000 and incubated for 1 h at room temperature. Blots 
were blocked again and developed using Immun-Star reagent (BioRad) according to 
the manufacturer’s protocol. Blots were visualized using a ChemiDoc XRS Imaging 
System (BioRad, Hercules, USA) and quantitative analysis was performed by fitting 
unknown values to the standard curve using Quantity One Software (BioRad).
Sequence analysis of DEFA1/3 genes. Human genomic DNA was extracted 
from peripheral blood leukocytes with the Magna-Pure Large Volume protocol 
(Roche, Almere, the Netherlands). In a pilot experiment, using genomic DNA from 
2 persistent carriers, 2 non-carriers and 1 intermittent carrier, the complete human 
α-1/3 (DEFA1/3) and β-defensin-1 (DEFB1) genes (Genebank accession numbers 
L12690 and U50930/U50931, respectively) were amplified using overlapping 
amplicons, synthesized while employing the oligonucleotides described in Table 1. It 
has to be emphasized that these are all general primers, incapable of distinguishing 
between the various DEFA1/3 (pseudo)genes. Amplification of the genes was 
achieved with a straightforward thermocycling program (Table 1). Double stranded 
DNA sequencing using the PCR primers, dideoxy terminator technology and capillary 
ABI sequencing machines were performed at BaseClear (Leiden, the Netherlands). 
Sequences were aligned using MEGALIGN (DNA Star Software, Michigan, USA) 
and homo- and heterozygous mutations were verified by visual examination of the 
electropherograms. Based on the sequence results, an adapted sequence protocol 
for DEFA1/3 intron 2 was designed to determine the G1623T and the C1748T SNPs 
within the DEFA1/3 genes (GenBank Accession No. L12690) for the whole group of 
volunteers (n = 109). 
Gene copy number assessment by quantitative PCR. The cumulative copy 
numbers of the DEFA1/3 genes were determined for a subset of volunteers (n = 32, 
see nasal secretion) as described by Linzmeier and Ganz.(13) In short, fivefold serial 
dilutions were made to generate initial DNA concentrations of 50, 10 and 2 ng for 
target and reference amplifications. For accurate control measurement, the genes for 
TATA box-binding protein (TBP) and myeloperoxidase were selected as references. 
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Both genes do not have pseudogenes and are present on the haploid genome as a 
single copy. Quantitative real-time PCR was performed on a MiniOpticon instrument 
(BioRad, Veenendaal, the Netherlands) in a 48-well plate format. 
Table 1. Sequences for the primers used for the amplification of the α- and β-defensin and mannose-
binding lectin genes.
For every DNA sample, target and both reference genes were amplified simultaneously 
in separate wells. PCR was performed independently in triplicate. The average of the 
results obtained from the three different DNA concentrations formed the given gene 
copy number.
The copy numbers (CN) of the target genes were calculated as follows: 
Δ Ct = Ct reference – Ct target
CN target = 2 
Δ Ct x CN reference
CN reference is known to be 2 per diploid genome and Ct, the threshold cycle, is the 
PCR cycle number at which the fluorescent signal emitted by the PCR products 
significantly exceeds the background fluorescence level.
DEFA1 and DEFA3 allele discrimination by real-time PCR. The protocol was 
described before.(13) In short, two sets of PCR primers were designed to detect the 
presence and absence of the DEFA1 and DEFA3 genes, based on the detection of 
the C3400A SNP. Each allele-specific PCR was performed in duplicate. PCRs using 
allele-specific primer sets were performed separately. Real-time PCR was carried 
1
Table 1. Sequences for the primers used for the amplification of the _- and _-defensin and mannose-binding lectin
genes.
Amplified region Oligo name Nucleotide sequence
(5’ to 3’)
Annealing
temperature (˚C)
Reference
1
DEFA1/3 5’UTR 963 (F) gaa.ttc.cct.gta.agc.cct.gt 57 This study
964 (R) aca.att.gtc.tag.gat.cat.ct
DEFA1/3 5’UTR 963 (F) gaa.ttc.cct.gta.agc.cct.gt 58 This study
966 (R) ggt.gag.gtt.aaa.gta.gaa.ct
DEFA1/3 exon-1 967 (F) gac.caa.ggt.aga.tga.gag.gt 59 This study
968 (R) aga.cca.agg.acc.taa.ata.gg
DEFA1/3 intron-1 969 (F) act.atc.aca.ggt.ctt.tgg.aa 57 This study
970 (R) gtg.aca.cag.agt.ggt.tta.ag
DEFA1/3 intron-1/exon-2 971 (F) gtc.taa.gta.gag.gtg.gaa.at 57 This study
972 (R) cag.tga.gag.agg.agg.tgt.gca.t
DEFA1/3 exon-2, 3 HHNP (F) aga.cat.taa.agg.tac.aga.tgt 56 This study
HHNP (R) ttg.gta.gct.gta.tcc.caa.gtg
DEFA4 3’UTR U2 (F) ccc.agc.atg.aca.ttc.tgg.a 50 This study
U2 (R) gtg.ttg.gga.act.gcc.tca.ttg
U2 VIC probe agc.aga.acg.tta.atc
U2 FAM probe cag.cac.aat.gtt.aat
DEFB-1 promot r P44 (F) cga.ctg.gca.ggc.aac.ac 50 (29)
P44 (R) tgt.cag.ctc.agc.ctc.caa.ag
P44 VIC probe cca.gcg.tct.ccc.cag
P44 FAM probe cca.gcc.tct.ccc.cag
MBL codon 54/57 1731 (F) gta.gga.cag.agg.gca.tgc.tc 58 (29, 30)
1732 (R) cag.gca.gtt.tcc.tct.gga.agg
MBL promoter -221 1729 (F) gtt.tcc.act.cat.tct.cat.tcc.cta.ag 60 (29, 30)
1720 (R) gaa.aac.tca.ggg.aag.gtt.aat.ctc.ag
1
The DEFA1/3 and DEFA4 primers are homologous to GenBank accession L12960 and U18745, respectively. The DEFB-1
primers correspond to U50930.
e
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out according to the protocol used for gene copy number assessment, except for the 
primer annealing temperatures. Those were adapted to 70°C and 68°C for primer 
sets 1 and 2, respectively.
Taqman assay for DEFA and DEFB-1. The allele frequency of SNP rs736227 (NCBI, 
SNP database) in the 3’ UTR region of DEFA4 and of rs1800972 in the promoter 
region of DEFB-1 were examined with real time tests using a 7900 HT thermocycler 
(Applera, Nieuwerkerk a/d IJssel, the Netherlands). Primers and FAM- and VIC-dye 
probes were designed by ABI (Table 1) in such a way that pseudogenes were not 
co-amplified.
PCR-RFLP analysis of MBL. SNPs were detected for the MBL codons 54 and 
57 in exon1, and for promotor position -221 using PCR restriction fragment length 
polymorphism (RFLP) analysis with restriction endonucleases BanI, MboII and BsaJI, 
respectively (Table 1).(7) BanI reveals a restriction site in codon 54 of the MBL exon1, 
that results in discrimination between homozygous wild-type (GGC/GGC), wild-type/
mutant GGC/GAC and homozygote mutant (GAC/GAC) genotypes. MboII restriction 
analysis detects polymorphism in codon 57 of MBL exon 1 and distinguishes between 
wild-type (GGA) and mutant (GAA) alleles. BsaJI discriminates the wild-type (G) and 
mutant (C) alleles in the promoter sequence position -221. The MBL haplotypes 
are defined as described previously.(7) Haplotype A combines wild-type alleles in 
both codon 54 and 57 (W54, W57), haplotype B (m54, W57) and haplotype C (W54, 
m57).
Statistical analysis. Association between S. aureus nasal carriage status and the 
presence of a polymorphism in the various genes was assessed by the Fisher’s Exact 
test. The persistent S. aureus carriage group was compared to the combined non-
carrier and intermittent S. aureus carrier group. The latter two groups were combined 
because only persistent S. aureus carriage, characterized by a high bacterial load, 
is associated with an increased risk for infections.(1, 14) The odds ratio (OR) was 
defined as the cross-product ratio of the numbers shown in the 2 x 2 table. Means 
were compared using paired and unpaired tests. P values less than 0.05 were 
considered significant.
Results
Analysis of polymorphisms in the defensin genes. Defensin genes have been 
mapped to chromosome 8p22/p23 and DEFA1 has been noted to display copy number 
polymorphism with two to five copies per haploid genome. In a pilot experiment, 
DEFA1/3 genes of five volunteers (known carrier status) were sequenced in full. This 
was done to determine the presence of relevant SNPs in the defensin genefamily 
with the ultimate intention to distinguish S. aureus nasal carriers from non-carriers. 
The PCR primers of the overlapping amplicons (Table 1) appeared to be adequately 
selective and the amplified products all had the expected size. Sequencing revealed 
near identity with GeneBank Accession reference sequence number L12960. The 
results of our sequence analysis revealed two SNPs in the DEFA1/3 genes. 
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Notably, these polymorphisms are located in non-coding regions of the genes only. 
Based on the sequence data obtained during the pilot experiment, the amplified 
intron 2 region of DEFA1/3 was sequenced for the entire volunteer group (n = 109) 
to detect the different allelic profiles of the various DEFA1/3 (pseudo)genes. Table 2a 
summarizes the comparison of the allelic frequencies among the S. aureus carrier and 
the non-carrier group. The latter group includes the intermittent S. aureus carriers. 
Variability in allelic frequencies in which the SNPs occurred could not distinguish 
between the S. aureus carriage phenotypes.
The DEFA1/3 gene copy numbers ranged from 7 to 22 for the non-carrier group 
(average of 13 copies) and from 5 to 23 for the carrier group (average of 13 copies). 
Again, different S. aureus carriage profiles could not be distinguished on the basis of 
these quantitative data.
The presence of DEFA1 and DEFA3 genes was achieved by robust amplification 
compared to non amplification. The DEFA1 gene was detected in every individual, 
while the DEFA3 gene is absent in 10% of the non carrier group and in 15% of the carrier 
group. The absence of DEFA3 was unrelated to the S. aureus carriage phenotype 
(p=1.000). The TaqMan tests did not reveal polymorphisms in the promoter region 
of DEFB1 and in the 3’- UTR domain of DEFA4 that could discriminate effectively 
between both carriage groups (Tables 2a and 2b). 
The frequency of the different restriction patterns of the codon 54 and 57 of exon 1 
resulting in classification of 3 MBL alleles A (wild-type 54 and 57), B (mutant 54 and 
wild-type 57), and C (wild-type 54, mutant 57), did not show significant differences 
between the allelic profiles of the MBL gene between the carrier groups. However, 
analysis of the genotypes documented a slight haplotype A overrepresentation in 
the persistent carrier group (p=0.038, Table 2c). The genotypes were proportionally 
distributed according to the Hardy-Weinberg Equilibrium analysis (codon 54, HWE 
p=0.59 and codon 57, HWE p=0.77).
Table 2c. Association of MBL haplotypes and S. aureus carriage status.
1NC, non-carrier; IC, intermittent carrier; PC, persistent carrier.
HNP1-3 level in nasal secretions. The overall results are presented in Figure 1 and 
show an apparent increase in the HNP1-3 levels (i.e. DEFA1/3 expression) in nasal 
secretions during the elimination-recolonization studies. Starting at baseline values, 
going through decolonization and re-colonization, the HNP1-3 values demonstrated 
a decreased level after S. aureus elimination which increased again to a higher level 
after re-colonization of the nares with S. aureus. This differential expression did not 
reach statistical significance. It is interesting to note that large variations in the local 
production of HNP1-3 were documented, ranging from borderline positive (50μg/mL) 
to values of more than 2 mg/mL. 
Table 2c. ssociation of MBL haplotypes and S. aureus carriage status.
Haplotype Non-carrier
(%)
Intermittent carrier
(%)
Persistent carrier
(%)
Fisher’s exact
Test  value
NC+IC vs. PC
1
MBL2 A 32 (64.0) 16 (72.8) 32 (86.5) 0.038
MBL2 B 14 (28.0) 5 (22.7) 4 (10.8) 0.080
MBL2 C 4 (8.0) 1 (4.5) 1 (2.7) 0.662
NC, non-carrier; IC, intermittent carrier; PC, persistent carrier.
Table 3. Association of the DEFA1/3 copy numbers and the DEFA1/3 expression (HNP1-3) at baseline level in
nasal secretions of 32 volunteers.
S. aureus carriage status
Non-carrier (n=11) Intermittent carrier (n=13) Persistent carrier (n=8)
HNP
1
CN
2
HNP CN HNP CN
19 10 223 9 81 15
240 18 188 15 51 23
246 22 79 13 321 14
36 11 241 12 566 13
145 15 182 18 218 14
7 9 3 5 52 12
89 13 189 11 113 11
89 12 181 10 295 9
66 14 343 22
3 7 28 5
89 14 118 14
128 9
32 7
r
2
0.8991 0.5626 0.1115
Correlation coefficient (r
2
) displays the linear correlation between HNP1-3 peptide concentration in nasal secretions
and the number of DEFA1-3 gene copies of the individuals within each S. aureus carriage group.
1
HNP; HNP1-3 concentration (_g/ml) in nasal secrete.
2
CN; copy number of DEFA1/3 genes.
*
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Figure 1. Quantitative box-plot analysis (median, minimum-, maximum value, 25% and 75% percentile) of 
DEFA1/3 production in various groups of defined S. aureus (non)carriers in various states of colonization. 
The carrier status is shown on the X-axis; NC, non-carrier plus intermittent carrier group (n = 23); PC, 
persistent carrier group (n = 7). The abbreviations base, elim and recol indicate the state of colonization: 
base line level, after elimination of S. aureus from the nasal cavity with mupirocin and after recolonization 
with 109 CFU/mL S. aureus, respectively.
* indicates the significant difference in HNP 1-3 level in both groups (p=0.016).
Only for those samples that were positive for S. aureus as determined by culture 
at baseline, higher median HNP1-3 values were scored than for culture negative 
samples (218 versus 89 μg/mL; p=0.016, data not shown). No significant differences 
were found in the baseline expression levels of HNP1-3 peptides in nasal secretions 
between the two different genotypes (G-1623-T). Good correlation was found between 
the DEFA1/3 copy number in non-S. aureus nasal carriers and the HNP1-3 baseline 
expression level (r2 = 0.8991, Table 3).
Discussion
Our data show that genetic polymorphism in the defensin genes are not associated 
with nasal carriage of S. aureus. This lack of association contradicts an apparent 
difference in the expression of DEFA1/3 at the protein level, irrespective of the 
fact that colonized individuals show elevated DEFA1/3 levels in nasal secretions. 
Also, there is no apparent difference in the physiological response upon mupirocin-
mediated elimination of S. aureus. Interestingly, an increase in the DEFA1/3 levels 
is found after recolonization of the nose with S. aureus. This suggests an ineffective 
local inflammatory response to the presence of S. aureus.
Presence of SNPs in the 3’UTR region and promotor regions may lead to instability 
of the transcript, possibly resulting in variability of translation. We have not tested this 
hypothesis. We observed no association between S. aureus nasal carrier status and 
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Table 3. Association of the DEFA1/3 copy numbers and the DEFA1/3 expression (HNP1-3) at 
baseline level in nasal secretions of 32 volunteers.
Correlation coefficient (r2) displays the linear correlation between HNP1-3 peptide concentration in nasal 
secretions and the number of DEFA1-3 gene copies of the individuals within each S. aureus carriage group.
1HNP; HNP1-3 concentration (μg/mL) in nasal secrete.
2CN; copy number of DEFA1/3 genes.
allelic polymorphism of DEFA4 and DEFB1 genes. 
Transcription of some members of the α and β defensin gene families is strongly 
enhanced upon tissue damage or stimulation with bacterial lipopolysaccharide, 
although the latter is still controversial.(9, 15, 16) The question whether defensin 
insufficiency predisposes towards nasal colonization by S. aureus is an obvious 
one. It has been shown that the colonized state is characterized by increased 
local concentrations of defensins, which is in agreement to our findings.(4) Nasal 
secretions display antimicrobial activity and this effect was found to vary strongly 
among donors, suggesting differential effects on the expression regulation of genes 
encoding for the secreted peptides by staphylococcal products, environmental factors 
or genetic host factors. Bactericidal activity of nasal secretions from persistent nasal 
carriers of S. aureus was very low in relation to those of non-carriers.(3, 4) Genetic 
variation but also individual differences between post-translational modification of the 
defensin propeptides within neutrophils or regulation of defensin gene expression 
by cytokines could be important mediators.(17) Besides host factors, variation in 
pathogenicity between different S. aureus strains is likely to play a role. Resistance 
to cationic antimicrobial peptides of S. aureus strains colonizing the nose has been 
noted before.(18, 19) Also, diverse pathogenic factors, such as (lipo)teichoic acid 
or staphylokinase have an effect on the bactericidal activity of defensins and are 
probably prerequisites for colonization by S. aureus strains.(18, 19) Our current 
protein data confirm that S. aureus nasal carriage is a low grade infectious process 
triggering variable innate host responses.(20, 21) This implies that colonization by S. 
aureus may result in tissue damage.(22) Therefore, it is important to study the role of 
major staphylococcal macromolecules, such as peptidoglycan or lipoteichoic acid, in 
the process of neutrophil recruitment.(23, 24)
4
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Table 3. Association of the DEFA1/3 copy numbers and the DEFA1/3 expression (HNP1-3) at baseline level in
na a  secr tions of 32 volunte rs.
S. aureus carriage status
Non-carrier (n = 11) Intermittent carrier (n = 13) Persistent carrier (n = 8)
HNP
1
CN
2
HNP CN HNP CN
19 10 223 9 81 15
240 18 188 15 51 23
246 22 79 13 321 14
36 11 241 12 566 13
145 15 182 18 218 14
7 9 3 5 52 12
89 13 189 11 113 11
89 12 181 10 295 9
66 14 343 22
3 7 28 5
89 14 118 14
128 9
32 7
r
2
0.8991 0.5626 0.1115
Correlation coefficient (r ) displays the linear correlation between HNP1-3 peptide concentration in nasal secretions
and the number of DEFA1-3 gene copies of the individuals within each S. aureus carriage group.
1
HNP; HNP1-3 concentration (_g/ml) in nasal secrete.
2
CN; copy number of DEFA1/3 genes.
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Defensin gene copy number is related to effective expression. In a recent study, the 
HBD-2 gene copy number predisposes to colonic Crohn Disease, perhaps leading to 
a decreased beta-defensin 2 production. Linzmeier and Ganz showed that the HNP1-
3 peptide levels in human neutrophils are proportional to the copy number of the 
DEFA1 and DEFA3 genes.(13) The authors hypothesize that the variation in defensin 
gene copy number could underlie variability in individual resistance to infection. Large 
numbers of gene copies would generate increased amounts of the antimicrobial 
peptides HNP1-3 and may have an influence on the S. aureus colonization status 
in the human nose. However, in our study, no significant variation in defensin gene 
copy number between S. aureus non carrier- and carrier groups could be detected. A 
good correlation was found between DEFA1/3 gene copy number and baseline level 
of HNP1-3 expression in nasal secretions of non-carriers. It seems that the HNP1-3 
concentration in the nasal mucous is a combined effect of the number of defensin 
gene replicates and the presence of S. aureus in the nose. The number of DEFA1/3 
gene copies per diploid genome in our study group seems higher than in Linzmeier’s 
study population.(13) The frequent absence of the DEFA3 gene, which encodes for 
the HNP3 peptide, is likely to have an effect on effectiveness of innate immunity. 
Again, in our study no significant difference in the DEFA3 absence was measured 
for the S. aureus carrier- and non-carrier groups. The percentage DEFA3 loss in our 
study population was similar to the observation of Linzmeier and Ganz.(13) 
The MBL haplotype A was overrepresented in the S. aureus persistent carrier group. 
This MBL type is associated with normal levels and good opsonisation activity of the 
MBL protein.(25) Genetic polymorphism in the MBL gene is known to be associated 
with infectious disease susceptibility. The lectin-dependent complement activation 
pathway contributes significantly to the opsonophagocytosis of S. aureus.(26) 
Genetic polymorphism in MBL is associated with increased numbers of infections 
during childhood.(27) A recent study provides evidence that MBL plays a key role in 
restricting the complications associated with S. aureus infection in mice and raises 
the hypothesis that the MBL gene may act as a disease susceptibility gene in relation 
to staphylococcal infections in humans.(28) We here present data that suggest that 
MBL haplotypes are also associated with S. aureus nasal colonization.
Although the sample size used in our study is limited, the results are obvious. Our 
current data show that genetic predisposition towards staphylococcal carriage exists. 
It has been shown recently that genotype-dependent variability in the sensitivity to 
glucocorticoids is associated with tolerance towards staphylococcal nasal colonization.
(5) Although we could not find a difference in gene expression, a possible role of this 
polymorphism in the translational or post-translational maturation of the α-defensins 
could not be excluded and needs to be investigated further. The results obtained from 
this study suggest that genetic polymorphism in genes encoding defensins does not 
predispose to S. aureus carriage. Our future research will be focussed on genome 
wide SNP analysis, involving all innate immunity factors. Secondly, expression profiles 
of those genes and (post-)translational proteomic screening (e.g., 2D electrophoresis) 
should be performed to measure the relevance of innate immunity factors in the S. 
aureus nasal carriage status.
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The current working hypothesis that staphylococcal colonization of the vestibulum 
nasi is a complex, multi-factorial process, depending on both host and microbe 
capacities still holds and deserves additional research. 
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Abstract
Objective. Staphylococcus aureus is capable of persistently colonizing the vestibulum 
nasi. We hypothesized that polymorphisms in host inflammatory response genes and 
genetic variation of S. aureus contribute to the susceptibility to S. aureus carriage and 
infection. 
Methods. The prevalence of persistent S. aureus nasal carriage in 3851 participants 
aged 61-101 years was 18% (678 of 3851 participants), whereas 73% of volunteers 
(2804 of 3851) were not colonized. A total of 1270 individuals had boils. Polymorphisms 
in TNFA (C-863T), IL4 (C-542T), CFH (Tyr402His), and CRP (C1184T, C2042T and 
C2911G) were determined. Genetic similarity among 428 S. aureus strains was 
determined by use of amplified fragment length polymorphism analysis (AFLP)-
mediated genotyping.
Results. The IL4 -524 C/C host genotype was associated with an increased risk of 
persistent S. aureus carriage, irrespective of S. aureus AFLP genotype. The CRP 
haplotype 1184C; 2042C; 2911C was overrepresented in individuals who were not 
colonized. In individuals with boils, carriers of the CFH Tyr402 variant and the CRP 
2911 C/C genotype were overrepresented. 
Conclusion. Persistent carriage of S. aureus is influenced by genetic variation in host 
inflammatory response genes. As would be expected in multifactorial host-microbe 
interactions these effects are limited. Interestingly, host genotype was associated with 
the carriage of certain S. aureus genotypes. Apparently, a close interaction between 
host and bacterial determinants are prerequisites to long term colonization.
Introduction
The nasal mucous membrane secretes inflammatory mediators such as complement 
and cytokines.(1) Together with anti-microbial agents such as defensins, lysozyme, 
lactoferrin, and mucin these seem to protect the host from microbial infections.(2) 
Despite these local defence mechanisms, Staphylococcus aureus is capable of 
persistently colonizing the vestibulum nasi in approximately one out of four to five 
individuals.(3-5) Because nasal carriage of S. aureus is associated with an increased 
risk of infection, particularly in patients who have undergone surgery or who are 
immunocompromised, identification of the determinants of S. aureus colonization 
is important.(4) The prevalence of nasal carriage of S. aureus is increased in 
individuals who produce nasal secretions that are deficient in anti-microbial activity.
(6, 7) Genetic polymorphisms in immune response genes are known to influence 
individuals’ susceptibility to infectious diseases and the severity of those diseases. 
Likewise, polymorphisms may be involved in determining S. aureus nasal carriage 
and S. aureus infections such as boils.(8, 9)
Major pathways in S. aureus colonization are the activation of cytokines and interaction 
with the complement system upon interaction with S. aureus.(10-12) Lipoteichoic 
acid and protein A of S. aureus induce TNF-α, IL-6, IL-8 and IL-1β, which indicates 
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that these inflammatory mediators play a role in the defence against staphylococcal 
colonization and infection.(10) TNF-α, IL-4 and IL-1β are known to stimulate the 
production of mucin, IL-6 and IL-8.(1, 13) Several variants in the TNFA promoter region 
have been associated with differences in concentrations of its protein.(14) In addition, 
genetic polymorphisms in TNFA, IL1B and IL6 have previously been associated 
with meningococcal infection, while IL4 polymorphisms have been associated with 
atopy, asthma and severe respiratory infections.(15-17) The IL4 -524 T allele has 
previously been associated with atopy and asthma, possibly due to an increased 
immunoglobulin class switch to the IgE type.(18) The IL4 -524 C allele was found to 
be associated with decreased transcriptional activity in reporter gene studies, and 
carriage of the C allele is associated with a significantly lower serum concentration 
of IL-4.(18, 19) IL-4 skews the immune response towards the Th2 response and was 
shown to stimulate mucin production.(20) Although IL-4 deficiency is associated with 
aggravated S. aureus infection in a mouse model, no data are available on its role in 
carriage of S. aureus.(21)
C-reactive protein (CRP) is another major acute phase protein that influences 
complement activation through opsonisation, which increases the clearance of 
microbes.(22, 23) Recently, it has been shown that CRP can bind staphylococcal 
protein A and it may, therefore, be expected that differences in basal CRP expression 
levels might influence colonization with S. aureus.(24) Genetic polymorphisms in the 
CRP gene are known to influence basal CRP levels.(25-27) In addition to cytokines 
and CRP, factors of the complement system itself are important in the first line defence 
against microbes. An important regulator of the complement system is complement 
factor H (CFH), which inhibits excess activation of C3 and metabolizes activated 
C3.(28) We therefore hypothesize that a polymorphism resulting in an amino acid 
substitution in the CRP- binding region (Tyr402His) of CFH may affect the innate 
immune response upon colonization with S. aureus. Recently, it has been shown 
that S. aureus can evade the immune response by inhibiting C3 convertases, which 
indicates the importance of direct host and pathogen interaction.(12) The possibility 
of S. aureus counteracting host immune responses likely depends on the capability of 
S. aureus to express specific proteins in variable quantities. This implies that genetic 
variation in both the host and the microbe may contribute to the S. aureus carriage 
phenotype. Recently, amplified fragment length polymorphism (AFLP) analysis, used 
to assess genetic variability in S. aureus strains, revealed that certain genetic clones 
are more virulent than others.(29) 
In this study we investigated if genetic polymorphisms in IL4, TNFA, CFH and CRP 
are associated with nasal carriage of S. aureus and the occurrence of boils in a large, 
well-characterized cohort of 3851 men and women aged 61 years and over from the 
Netherlands.(30) In addition, we studied the effect of genetic variation of S. aureus 
itself on the likelihood of colonization in a subset of 428 subjects of this cohort.
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Methods
Study cohort. This analysis was conducted as part of a prospective, population-
based study on the occurrence and determinants of disease in elderly individuals, 
known as the Rotterdam Study. This longitudinal study commenced in 1990 and was 
approved by the Medical Ethics Committee of the Erasmus University.(30) Informed 
consent was obtained from all participants. The second follow up -between April 1997 
and December 1999- involved 4797 participants that remained of the initial 7983 
individuals. Of these 4797, there were 3882 (81%) participants who were able to visit 
the study centre. A complete bacteriological assessment was obtained from 3851 
participants. An incomplete set of nasal swab cultures was obtained for 31 persons, 
hence these individuals were excluded. The median age in this study population 
was 71 years (range, 61-101 years), and 58% were female. Medical information 
(including age, sex, smoking behaviour, diabetes, and history of eczema or boils, 
defined as an acute folliculitis with a diameter of more than 1 cm) was obtained from 
questionnaires and medical records at baseline and during the two follow-up visits 
that were performed thus far. In addition, laboratory assessments, including fasting 
glucose level and serum CRP level, were obtained at baseline. Serum CRP levels at 
baseline were determined as described previously.(27)
Definition of S. aureus carriage status. S. aureus carriage status was assessed 
for all participants by two quantitative nasal swab cultures separated by a one-week 
interval, as described previously.(31) Persistent carriers (n = 678) were defined as 
individuals for whom both cultures were positive for S. aureus. Non-carriers were 
defined as those who had no positive culture results (n = 2804), whereas intermittent 
carriers were those who had only one culture positive for S. aureus (n = 369).(31)
Genotyping. The TNFA A-863C (reference single nucleotide polymorphism accession 
number rs1800630) genotype was determined by use of single base extension 
analysis (SNaPshot, Applied Biosystems) (Table 1). 
Table 1. Primers and probes for TNFA A-863C and IL4 C-542T.
1SNP, single nucleotide polymorphisms; rs number, reference SNP accession number; SBE, single base 
extension.
Bi-allelic discrimination with Taqman analysis was used to determine the IL4 C-524T 
(rs2243250) genotype. Primers were ordered from the Applied Biosystems Assay-
by-Design service (www.appliedbiosystems.com). The CFH C402T (rs1061170), 
CRP C1184T (rs1130864), CRP C2042T (rs1205) and CRP C2911G (rs3093068) 
genotypes were determined using Taqman analysis (Applied Biosystems), as 
described previously.(27, 32)
Table 1. Primers and probes for TNFA A-863C and IL4 C-542T.
Gene SNP
1
rs number
1
Method Primer or probe
TNFA A-863C rs1800630 SBE
1
F5’GGAGAATGTCCAGGGCTATG3’
R5’ACTCTGGGGTCCCTGATTTT3’
SBE 5’TTTTTTGAAGTCGAGTATGTGGACCCCC3’
IL4 C-524T rs2243250 Taqman F5’GGCAGAATAACAGGCAGACTCT3’
R5’GACCTGTCCTTCTCAAAACACCTAA3’
C VIC-CATTGTCCCCCAGTGCT
T FAM-CATTGTTCCCCAGTGCT
NP, single nucleotide polym rphisms; r  number, reference SNP ac ssion numb r; SBE, single base extension.
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Molecular typing of S. aureus. Using AFLP analysis, the presence or absence 
of 147 markers was determined for a subset of S. aureus isolates recovered from 
428 (41%) of 1047 culture positive subjects, as described elsewhere.(29) In short, 
by use of the predictive software package Recomb, optimal enzyme and primer 
combinations were selected. Bacterial DNA was digested with the enzymes MboI and 
Csp6I and the linker oligonucleotide pair for MboI (5’-CTCGTAGACTGCGTACC-3’ 
and 5’-GATCGGTACGCAGTCTAC-3’) and for Csp6I (5’-GACGATGAGTCCTGAC-3’ 
and 5’-TAGTCAGGACTCAT-3’) was ligated. Subsequently, a non-selective pre-
amplification was performed using the MboI primer (5’-GTAGACTGCGTACCGATC-3’ 
and Csp6I primer: 5’-GACGATGAGTCCTGACTAC-3’). In the final amplification, a 
33P-labeled MboI primer containing one selective nucleotide (either +C or +G) and a 
Csp6I primer containing two selective nucleotides (+TA) were used. Amplified material 
was analyzed using standard polyacrylamide slab gels and autoradiography. Marker 
fragments were scored and a binary table that scored marker fragment absence (0) 
or presence (1) was constructed.
The 428 S. aureus isolates were obtained from 103 individuals with intermittent 
nasal carriage and 325 individuals with persistent nasal carriage who were randomly 
selected from our cohort. Of these 428 carriers, 225 (53%) were female. A total of five 
phylogenetic clusters (I, II, III, IVa, and IVb) were defined combining these markers.
(29) 
Statistical analysis. Statistical analysis was performed using SPSS (version 11.0, 
SPSS). The verification of Hardy-Weinberg equilibrium of genotypes was performed 
using Pearson’s c2 test. Binomial variables were analyzed using Pearson’s c2 test or 
Fisher’s exact test, as appropriate. Continuous variables were analyzed using the 
students’ t-test or the Mann-Whitney U test, as appropriate. Initially, a comparison of 
host genotype frequencies was made between the non-S. aureus carriers and the 
group with persistent carriage. Individuals with intermittent carriage were excluded 
from this host genetics analyses because they represented a group that was 
considered less likely to enable discrimination between the features of individuals 
with persistent carriage and those with no carriage.(31, 33) Because age, sex, active 
smoking, eczema and fasting glucose were previously reported to be associated 
with S. aureus carriage, risk estimates were adjusted for these parameters in the 
logistic regression analyses to determine their influence.(9) Genotype distributions 
were compared between individuals who reported having had boils at least once in 
their life and individuals who had not had boils. Because the occurrence of boils was 
associated with age, sex and smoking, these factors were included in the logistic 
regression analyses to determine their influence. CRP haplotypes were determined 
using Haplo Stats (CRAN).(34)
In a subset of 428 individuals (41% of 1047) with persistent and intermittent nasal 
carriage of S. aureus the effect of genetic variation in S. aureus strains on carriage 
phenotype (intermittent or persistent) was assessed using Pearson’s c2 test and 
logistic regression analysis. Both S. aureus phylogenetic clusters and individual 
AFLP markers were analyzed. In a logistic regression model the effect of host 
polymorphisms on carriage phenotype (intermittent or persistent) was corrected for 
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eczema and for AFLP markers found to contribute significantly to carriage phenotype 
in a univariate analysis. In this last analysis, comparison is only possible between 
intermittent and persistent carriers, because S. aureus genotypes were included in 
the model, which, of course, is only possible when an isolate is cultured. Probability 
(P) values ≤ 0.05 were considered to be statistically significant. No correction was 
performed for multiple testing.
Results
S. aureus nasal carriage. Persistent carriage of S. aureus was observed in 678 
(18%) of 3851 participants. Median age, gender, smoking behaviour, presence of 
eczema, and median fasting glucose level were independently significantly different 
between S. aureus non-carriers and persistent carriers (Table 2). 
Table 2. Characteristics of the study population.
13
Table 2. Chara ristics of the study population.
S. aureus carriage status
n = 3482
Presence of boils
n = 3815
Characteristic None Persistent p No Yes p
otal 2804 678 2545 1270
Median age (range) years 72 (61 -101) 71 (61-95) 0.11
1
72 (61-101) 70 (61-95) <0.001
Male sex 1121 (40) 333 (49) <0.001 868 (34) 744 (59) <0.001
Smoking history
Non smoker 945 (34) 230 (34) 0.046 979 (39) 309 (24) <0.001
Past smoker 1326 (48) 348 (52) 0.007 1147 (45) 712 (56) 0.66
Current smoker 515 (19) 96 (14) 1 418 (16) 249 (20) 1
Eczema 231 (8) 100 (15) <0.001 233 (9) 130 (10) 0.29
Fasting glucose level
median (range), mmol/L 5.6 (1.6-18.9) 5.6 (4.0-19.8) 0.001 5.6 (1.6-19.8) 5.6 (3.0-20.5) 0.31
C-reactive protein, mg/L
(95% CI) 1.53 (1.47-1.58) 1.64 (1.51-1.78) 0.09 1.54 (1.48-1.60) 1.60 (1.51-1.69) 0.47
Gene SNP allele
IL4
2
-524 C 1478 (85) 366 (91) 0.008 1360 (87) 674 (85) 0.28
T 252 (15) 38 (9) 204 (13) 116 (15)
TNFA
2
-863 C 1450 (83) 336 (83) 0.78 1298 (83) 672 ((84) 0.26
A 290 (17) 70 (17) 274 (17) 124 (16)
CFH 402 T 3272 (64) 784 (63) 0.46 2913 (63) 1524 (65) 0.22
C 1812 (36) 456 (37 1675 (37) 820 (35)
CRP 1184 C 3406 (69) 823 (68) 0.86 3087 (69) 1551 (68) 0.34
T 1550 (31) 379 (32) 1387 (31) 735 (32)
CRP 2042 C 3414 (68) 798 (66) 0.10 3055 (67) 1565 (68) 0.66
T 1610 (32) 420 (34) 1489 (33) 745 (32)
CRP 2911 C 4698 (94) 1129 (93) 0.30 4225 (94) 2168 (95) 0.11
G 294 (6) 81 (7) 285 (6) 122 (5)
Data are no. (%) of participants, unless otherwise indicated. CI, confidence interval; CRP, C-reactive protein; SNP,
single nucleotide polymorphism. Data on intermittent carriers were omitted from S. aureus carriage analysis, and
data were missing for 36 individuals for the analysis regarding boils.
1
In multivariate analysis, after correction for sex, smoking history, eczema, serum glucose and serum CRP level, the
median age was significantly different (p=0.02).
2
IL4 and TNFA polymorphisms were determined in a subset of ~ 34% of the total population for whom S. aureus
carriage information was available (1186 and 1192 participants, respectively; intermittent S aureus nasal carriers (n=
119) included).
T
  
Data are no. ( ) of participants, unless otherwise indicated. CI, confidence interval; CRP, C-reactive 
protein; SNP, single nucleotide polymorphism. Data on intermittent carriers were omitted from S. aureus 
carriage analysis, and data were missing for 36 individuals for the analysis regarding boils.
1In ultivariate analysis, after correction for sex, smoking history, eczema, serum glucose and serum CRP 
level, the median age wa  significantly different (p=0.02).
2IL4 and TNFA polymorphisms were determined in a subset of ~ 34% of the total population for whom S. 
aureus carriage information was available (1186 and 1192 participants, respectively; intermittent S aureus 
nasal carriers (n = 119) included).
302
C
h
a
p
te
r 
5
.3
Table 3. Frequency of S. aureus carriage, according to host genotype.
14
 SNP P for HWE
1
Persistent S. aureus carrier/
(non and persistent carrier) (%)
OR for persistent carriage
of S. aureus (95% CI)
2
IL4 -524 0.15 C/T and T/T vs C/C
C/C 167/802 (20.8) 0.58 (0.4-0.8)
C/T 32/240 (13.3)
T/T 3/25 (12.0)
TNFA -863 0.90 C/C vs C/A and A/A
C/C 138/744 (18.5) 0.93 (0.7-1.3)
C/A 60/298 (20.1)
A/A 5/31 (16.1)
CFH 402 0.22
T/T 246/1324 (18.6) 0.97 (0.7-1.3)
T/C 292/1408 (20.7) 1.11 (0.8-1.5)
C/C 82/430 (19.1) 1
CRP 1184 0.85
C/C 279/1447 (19.3) 1.01 (0.7-1.4)
C/T 265/1335 (19.9) 1.04 (0.8-1.4)
T/T 57/297 (19.2) 1
CRP 2042 0.26
C/C 250/1405 (17.8) 0.90 (0.7-1.2)
C/T 298/1402 (21.3) 1.12 (0.8-1.5)
T/T 61/314 (19.4) 1
CRP 2911 0.04 C/G and G/G  vs C/C
C/C 530/2744 (19.3) 1.11 (0.8-1.5)
C/G 69/339 (20.4)
G/G 6/18 (33.3)
CRP Haplotype Haplotype frequency, %
Haplo 1 CTC 32.7
0 copy 243/1354 (17.9) 1
1 copy 287/1363 (21.1) 1.22 (1.0-1.5)
2 copies 60/307 (19.5) 1.11 (0.8-1.5)
Haplo 2 CCC 29.8
0 copy 309/1483 (20.8) 1
1 copy 243/1278 (19.0) 0.89 (0.7-1.1)
2 copies 38/263 (14.4) 0.64 (0.4-0.9)
Haplo 3 CCG 6
0 copy 516/2677 (19.3) 1
1 copy 68/331 (20.5) 1.08 (0.8-1.4)
2 copies 6/16 (37.5) 2.51 (0.9-6.9)
Haplo 4 TCC 31.4
0 copy 273/1419 (19.2) 1
1 copy 260/1311 (19.8) 1.04 (0.9-1.3)
2 copies 57/294 (19.4) 1.01 (0.7-1.4)
Haplotypes of CRP single nucleotide polymorphisms (SNPs) could be determined for only 3024 individuals.
Differences in denominators reflect differences in the number of individuals for whom the SNP was successfully
genotyped. CI, confidence interval; OR, odds ratio.
1
Hardy-Weinberg equilibrium, for all individuals for whom S. aureus carriage was determined.
2
Univariate analysis, binary logistic regression; OR, Odds ratio.
Haplotypes of CRP single nucleotide polymorphisms (SNPs) could be determined for only 3024 individuals. 
Differences in denominators reflect differences in the number of individuals for whom the SNP was 
successfully genotyped. CI, confidence interval; OR, odds ratio.
1Hardy-Weinberg equilibrium, for all individuals for whom S. aureus carriage was determined.
2Univariate analysis, binary logistic regression; OR, Odds ratio. 
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Genotype distribution for all single nucleotide polymorphisms (SNPs) followed 
Hardy-Weinberg equilibrium (HWE), but was borderline significantly deviant for CRP 
C2911G (p=0.04).
Individuals who had the IL4 -524 T allele were less frequently had persistent S. 
aureus carriage compared to those who did not have this allele (Tables 2 and 3). 
Although individual SNPs in CRP were not associated with S. aureus carriage, we 
observed a 1.4-1.5 times overrepresentation of the CRP (1184-2042-2911) C-C-C 
haplotype 2 (one or two copies vs. no copies) in S. aureus non-carriers, whereas 
an opposite effect was observed for the C-C-G haplotype 3 (Table 3). The T-C-G 
haplotype was too rare (0.1% of participants) for meaningful analyses. It seemed that 
the polymorphism at position 2911 was driving the association, but only for a particular 
haplotype background (haplotype 2 versus 3). Serum CRP levels were slightly but 
not significantly increased in persistent S. aureus carriers compared to non-carriers 
(Table 2). Similar results were obtained in a multivariate analysis adjusted for for age, 
sex, smoking behavior, eczema and serum glucose level (data not shown).
Skin infections. A total of 1270 (33%) of 3815 participants reported having had boils 
had at least once (data were missing for 36 of 3851 individuals, Table 2). Participants 
with a history of boils were on average 1.5 years younger and 2.7 times more likely 
to be male than those without a history for boils (Table 2). Non-smoker status was 
associated with protection from the occurrence of boils, compared with current 
smokers (odds ratio (OR) 0.53 (95% CI 0.43-0.65), p<0.001). Geometric mean CRP 
levels were similar in individuals with and without boils. Eczema and fasting glucose 
levels were not associated with occurrence of boils.
The TNFA -863 polymorphism was not associated with nasal carriage of S. aureus or 
the occurrence of boils (Tables 3 and 4). Homozygosity for the CFH 402 C (His) allele 
and carriage of the CRP 2911 G allele were associated with decreased occurrence of 
boils. The occurrence of boils was decreased in carriers of the CRP C-C-G haplotype 
3 (n = 109 participants (29%)), compared to individuals who did not have the C-C-G 
haplotype (n = 1008 participants (34%) (OR crude 0.78 (95% CI 0.6-1.0); p=0.03). If 
nasal carriage was introduced into the logistic regression analysis, identical results 
were obtained. Other CRP haplotypes were not associated with occurrence of boils 
(data not shown).
S. aureus phylogenetic clusters and S. aureus nasal carriage. Subsequently, in 
a random subgroup of 428 (41%) of 1047 participants with cultures positive for S. 
aureus, we assessed the effect of genetic variation in S. aureus strains on S. aureus 
carriage phenotype. We had previously found that analysis of the AFLP markers 
revealed the presence of five S. aureus phylogenetic clusters.(29) The frequency 
of the clusters among isolates recovered from 103 individuals with intermittent 
carriage and 325 individuals with persistent carriage strains are depicted in Table 
5. Individual clusters were not differentially distributed between S. aureus carriage 
phenotypes (data not shown). We assessed the incidence of S. aureus carriage 
status (intermittent or persistent) for each AFLP cluster by genotype for each human 
SNP. Individuals with the IL4 -524 C/C genotype from whom an S. aureus isolate 
belonging to cluster I was recovered, were 3.2 times (95% CI 1.0-10.1 times) more
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Table 4. Distribution of genotype in individuals with and without a history of boils.
1Univariate analysis, binary logistic regression. Similar results were obtained after adjusting for age, gender 
and smoking history. OR, Odds ratio.
likely to have persistent S. aureus carriage, compared with individuals with the C/T 
and T/T genotypes combined (Table 5). Individuals with the CRP 2042 C/C genotype 
from who a cluster II isolate was recovered were 5.5 times (95% CI 1.1-28.2 times) 
more likely to have persistent S. aureus carriage, compared with participants with the 
T/T genotype, indicating minor contributions as expected. No significant differences 
in individual clusters were observed for the SNPs in TNFA or CFH or for the CRP 
1184 and 2911 polymorphisms (data not shown).
Individual S. aureus AFLP markers and S. aureus nasal carriage. By use 
of univariate logistic regression only the presence of eczema was significantly 
associated with persistent S. aureus carriage as compared with intermittent S. aureus 
carriage (OR 1.77, p=0.007). Age, sex, smoking, and fasting glucose levels were not 
significantly different between intermittent and persistent carriers (data not shown).
No significant difference was observed for the distribution of host genotypes 
between
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Table 4. Distribution of genotype in individuals with and without a history of boils. 
 
SNP 
Genotype frequency,  
particpants with a history of boils/all particpants (%) 
Crude OR for presence of boils  
(95% CI)
1
 
IL4 -524  C/C vs C/T and T/T 
C/C 290/884 (23.6) 0.87 (0.7-1.2) 
C/T 94/266 (35.3)  
T/T 11/27 (40.7)  
TNFA -863  C/C vs C/A and A/A 
C/C 138/673 (20.5) 1.18 (0.9-1.5) 
C/A 102/330 (30.9)  
A/A 11/34 (32.4)  
CFH 402  C/C vs T/T and T/C 
T/T 490/1436 (34.1) 0.83 (0.67-1.0) 
T/C 544/1565 (34.8)  
C/C 138/465 (29.7)  
CRP 1184   
C/C 528/1593 (33.1) 0.89 (0.7-1.1) 
C/T 495/1452 (34.1) 0.93 (0.7-1.2) 
T/T 120/335 (35.8) 1 
CRP 2042   
C/C 528/1543 (34.2) 1.02 (0.8-1.3) 
C/T 509/1534 (33.2) 0.98 (0.8-1.2) 
T/T 118/350 (33.7) 1 
CRP 2911  C/G and G/G vs C/C  
C/C 1032/3012 (34.3) 0.79 (0.6-1.0) 
C/G 104/369 (28.2)  
G/G 9/19 (47.4)  
CRP Haplo 3 CCG  1 or 2 vs 0 copies 
0 copy 1008/2937 (34.3) 0.78 (0.6-1.0) 
1 copy 102/361 (28.3)  
2 copies 7/17 (41.2)  
Univariate analysis, binary logistic regression. Similar results were obtained after adjusting for age, gender and smoking history. 
OR, Odds ratio. 
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Table 5. Host genotype frequencies in S. aureus carriers stratified by amplified fragment length 
polymorphisms analysis clusters.
individuals with intermittent and persistent carriage with or without adjustment for 
eczema and bacterial genotype clusters.
Because most markers were not 100% specific for one of the clusters (data not 
shown), which were also not differentially distributed among individuals with 
intermittent carriage and persistent carriage, we assessed the prevalence of the 147 
individual S. aureus AFLP markers in the carriage groups. Five of the 147 markers 
were differentially distributed between isolates from individuals with intermittent 
carriage and individuals with persistent carriage in a univariate analysis (Table 6). 
When we analyzed these five markers simultaneously in a logistic regression model 
or after correction for multiple testing, none of them remained statistically significant. 
When we analyzed the effect of human genetic polymorphisms, no significant
Table 6. Distribution of S. aureus amplified fragment length polymorphisms (AFLP) analysis 
markers in isolates recovered from participants with intermittent and persistent colonization.
16
Table 5. Host genotype frequencies in S. aureus carriers stratified by amplified fragment length
polymorphism  nalysi  cluster .
Strains from persistent carriers/ all carriers (%)
1
All I II III IVa IVb
S. aureus carriage status
2
Intermittent 56/103 (54) 20/103 (19) 22/103 (21) 4/103 (4) 1/103 (1)
Persistent 105/325 (46) 92/325 (28) 68/325 (21) 10/325 (3) 5/325 (2)
By host genotype
IL4 -524
C/C 84/111 (76) 45/59 (76) 19/24 (79) 14/19 (74) 4/6 (67) 2/3 (67)
C/T and T/T 18/30 (60) 8/16 (50) 6/8 (75) 3/5 (60) 1/1 (100) 0/0
OR  C/C vs. CT and T/T 3.21 (1.0-10.1) 1.27 (0.2-8.3) 1.87 (0.2-14.6) - -
CRP 2042
C/C 120/157 (76) 52/75 (69) 33/37 (89) 26/35 (74) 6/7 (86) 3/3 (100)
C/T 151/199 (76) 69/93 (74) 48/59 (81) 29/40 (73) 3/4 (75) 2/3 (67)
T/T 28/38 (74) 11/14 (79) 6/10 (60) 10/12 (83) 1/2 (50) 0/0
OR C/C vs T/T 0.49 (0.2-2.4) 5.50 (1.1-28.2) 0.58 (0.1-3.2) 6 (0.2-196) -
OR, Odds ratio (95% CI).
1
Data are isolates recovered from individuals with persistent carriage/isolates recovered from all individuals with
carriage (%).
2
P=0.43.
Table 6. Distribution of S. aureus amplified fragment length polymorphisms (AFLP) analysis markers in
isolates recovered from participants with intermittent and persistent colonization.
Marker Percentage of isolates positive for the marker,
by S. aureus AFLP cluster
Carriage group no. (%) of isolates
n strains
I
206
II
112
III
90
IVa
14
IVb
6
Intermittent
(n = 103)
Persistent
(n = 325)
 OR
(95% CI)
1
F2115.628
2
87.3
(205)
5.5
(109)
97.5
(80)
92.9 83.3 77/101 (76.2) 204/313 (65.2) 0.58 (0.3-1.0)
F2217.206 1 99 1 50 0 20 (19.4) 101 (31.1) 1.87 (1.1-3.2)
F2340.870 2 100 0 29 100 21 (20.4) 104 (32.0) 1.84 (1.1-3.1)
F2386.357 0 0 8 0 0 5 (4.9) 2 (0.6) 0.12 (0.0-0.6)
F2305.620 0 0 9 0 33 6 (5.8) 4 (1.2) 0.20 (0.1-0.7)
Odds ratio (OR) for persistent versus intermittent carriage. Only those markers differentially distributed in univariate
analysis without correction for multiple testing are included in the table.
2
A total of 414 isolates were successfully typed for the F2115628 AFLP marker: 205 isolates for cluster I, 109 for
cluster II, 80 for cluster III, 14 for cluster Iva and, 6 for cluster IVb.
16
Table 5. Host genotype frequencies in S. aureus carriers stratified by amplified fragment length
polymorphisms analysis clusters.
Strains from persistent carriers/ all carriers (%)
1
All I II III IVa IVb
S. aureus carriage status
2
Intermittent 56/103 (54) 20/103 (19) 22/103 (21) 4/103 (4) 1/103 (1)
Persistent 105/325 (46) 92/325 (28) 68/325 (21) 10/325 (3) 5/325 (2)
By host genotype
IL4 -524
C/C 84/111 (76) 45/59 (76) 19/24 (79) 14/19 (74) 4/6 (67) 2/3 (67)
C/T and T/T 18/30 (60) 8/16 (50) 6/8 (75) 3/5 (60) 1/1 (100) 0/0
OR  C/C vs. CT and T/T 3.21 (1.0-10.1) 1.27 (0.2-8.3) 1.87 (0.2-14.6) - -
CRP 2042
C/C 120/157 (76) 52/75 (69) 33/37 (89) 26/35 (74) 6/7 (86) 3/3 (100)
C/T 151/199 (76) 69/93 (74) 48/59 (81) 29/40 (73) 3/4 (75) 2/3 (67)
T/T 28/38 (74) 11/14 (79) 6/10 (60) 10/12 (83) 1/ 50) 0/0
OR C/C vs T/T 0.49 (0.2-2.4) 5.50 (1.1-28.2) 0.58 (0.1-3.2) 6 (0.2-196) -
OR, Odds ratio (95% CI).
1
Data are isolates recovered from individuals with persistent carriage/isolates recovered from all individuals with
carriage (%).
2
P=0.43.
Table 6. Distribution of S. aureus amplified fragment length polymorphisms (AFLP) analysis markers in
isolates recovered from participants with intermittent and persistent colonization.
Marker Percentage of isolates positive for the marker,
by S. aureus AFLP cluster
Carriage group no. (%) of isolates
n strains
I
206
II
112
III
90
IVa
14
IVb
6
Intermittent
(n = 103)
Persistent
(n = 325)
 OR
(95% CI)
1
F2115.628
2
87.3
(205)
5.5
(109)
97.5
(80)
92.9 83.3 77/101 (76.2) 204/313 (65.2) 0.58 (0.3-1.0)
F2217.206 1 99 1 50 0 20 (19.4) 101 (31.1) 1.87 (1.1-3.2)
F2340.870 2 100 0 29 100 21 (20.4) 104 (32.0) 1.84 (1.1-3.1)
F2386.357 0 0 8 0 0 5 (4.9) 2 (0.6) 0.12 (0.0-0.6)
F2305.620 0 0 9 0 33 6 (5.8) 4 (1.2) 0.20 (0.1-0.7)
Odds ratio (OR) for persistent versus intermittent carriage. Only those markers differentially distributed in univariate
analysis without correction for multiple testing are included in the table.
2
A total of 414 isolates were successfully typed for the F2115628 AFLP marker: 205 isolates for cluster I, 109 for
cluster II, 80 for cluster III, 14 for cluster Iva and, 6 for cluster IVb.
OR, Odds ratio (95% CI).
1Data are isolates recovered from individuals with persistent carriage/isolates recovered from all individuals 
with carriage (%).
2P=0.43.
1Odds ratio (OR) for persistent versus intermittent carriage. Only those markers differentially distributed in 
univariate analysis without correction for multiple testing are included in th  table.
2A total of 414 isolates were uccessfully typed for the F2115628 AFLP marker: 205 isolates for cluster I, 
109 for cluster II, 80 for cluster III, 14 for cluster IVa and, 6 for cluster IVb.
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differences were observed between individuals with intermittent and persistent 
carriage when polymorphisms were individually included in the model or when the 
effect was adjusted for eczema. A trend was observed for the IL4 C-524T and CRP 
C1184T polymorphisms (Table 7). When the effect of human polymorphisms was 
corrected for eczema and the five relevant AFLP markers, a significant association 
between the IL4-524 C/C genotype and persistent carriage was observed (OR 2.52, 
95% CI 1.0-6.2), indicating that interaction between S. aureus and human genetic 
variation may codetermine S. aureus carriage phenotype. It must be noted however, 
that after correction for multiple testing, these associations would no longer be 
significant.
Table 7. S. aureus carriage status, according to host genotypes.
17
Table 7. S. a reus c rriage status, according to host genotypes.
Binary logistic regression
Genotype frequency Crude Adjusted Adjusted
SNP Total Persistent/all carriers (%)
1
OR (95% CI)
2
OR (95% CI)
3
OR (95% CI)
4
IL4 -524 141 C/C vs C/T and T/T
C/C 84/111 (75.7) 2.07 (0.9-4.9) 2.06 (0.9-4.8) 2.52 (1.0-6.2)
C/T and T/T 18/30 (60.0)
TNFA -863 142 C/C vs C/A and A/A
C/C 64/93 (68.8) 0.57 (0.2-1.3) 0.56 (0.2-1.3) 0.61 (0.3-1.5)
C/A 34/43 (79.1)
A/A 5/6 (83.3)
CFH 402 401
T/T 120/158 (75.9) 0.96 (0.5-2.0) 0.98 (0.5-2.0) 0.84 (0.4-1.8)
T/C 143/187 (76.5) 0.98 (0.5-2.0) 0.97 (0.5-2.0) 0.80 (0.4-1.7)
C/C 43/56 (76.8) 1 1 1
CRP 1184 390
C/C 132/177 (74.6) 0.43 (0.2-1.2) 0.43 (0.2-1.2) 0.43 (0.2-1.2)
C/T 131/174 (75.3) 0.45 (0.2-1.2) 0.46 (0.2-1.2) 0.43 (0.2-1.2)
T/T 34/39 (87.2) 1 1 1
CRP 2042 394
C/C 120/157 (76.4) 1.16 (0.5-2.6) 1.12 (0.5-2.5) 1.22 (0.5-2.8)
C/T 151/199 (75.9) 1.12 (0.5-2.5) 1.09 (0.5-2.4) 1.13 (0.5-2.6)
T/T 28/38 (73.7) 1 1 1
CRP 2911 390 C/C vs C/G and G/G
C/C 263/343 (76.7) 1.13 (0.6-2.3) 1.18 (0.6-2.4) 1.17 (0.6-2.4)
C/G 35/47 (74.5)
G/G
Data are individuals with persistent carriage/all individuals with carriage (%). “All individuals with carriage” 
indicates both those with intermittent and those with persistent carriage.
2
Univariate analysis, binary logistic regression; OR, Odds ratio.
3
Adjusted for eczema.
4
Adjusted for eczema and S. aureus AFLP markers F2115.628, F2217.206, F2340.870, F2386.357,
 and F2305.620.
1Data are individuals with persistent carriage/all individuals with carriage (%). “All individuals with carriage” 
indicates both those with intermittent and those with persistent carriage.
2Univariate analysis, binary logistic regression; OR, Odds ratio.
3Adjusted for eczema.
4Adjusted for eczema and S. aureus AFLP markers F2115.628, F2217.206, F2340.870, F2386.357, and 
F2305.620.
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Discussion
We documented an association between the -524 promoter polymorphism in IL4 and 
nasal carriage of S. aureus. In elderly participants with the IL4 -524 C/C genotype 
persistent S. aureus carriage was more often observed than in individuals with the 
IL4 -524 T allele, even after adjustment for confounding factors. The C-allele, with 
lower IL-4 serum concentration and, therefore, lower mucin production, is associated 
with carriage of S. aureus, which suggests that decreased mucociliary clearance 
might play a role here.(35) This refutes the possibility that a higher mucin production 
promotes carriage by improving bacterial adherence.(8, 36) Most of the studies on 
IL-4 have been performed during infection rather than during colonization. The role of 
IL-4 in systemic infection seems crucial since IL-4 deficient mice are more susceptible 
to shock induced with staphylococcal enterotoxin B and D-galactosamine than wild 
type mice.(37) In addition, IL-4, in combination with IL-10, seems to protect mice from 
aggravation of the pro-inflammatory immune response in S. aureus infection.(21) The 
outcome of S. aureus sepsis in IL-4 deficient mice, however, is dependent on the 
genetic background of the mouse strain in which where IL-10 deficiency leads to an 
aggravated course of infection, possibly due to impaired bacterial clearance.(38) It 
must be noted that most sepsis models use staphylococcal superantigens, whereas 
these are not always present in S. aureus, and moreover, these superantigens 
are accompanied by different antigens, which may elicit either predominant Th1 
or Th2 responses.(39-43) Besides IL-4, IL-1β, TNF-α and IL-13 also stimulate 
mucin production.(1, 44) The TNFA C-863A polymorphism was not associated 
with S. aureus nasal carriage. Although TNF-α was shown to be involved in the 
pathogenesis of staphylococcal sepsis, we now presume that its role in colonization 
is less pronounced.(10)
When assessing the possible association of host genetic polymorphisms between 
intermittent and persistent carriers, we observed a significant difference for the IL4 
C-524T polymorphism when S. aureus AFLP markers, significantly associated with 
carriage phenotype, were included in the model. This difference was not significant 
when S. aureus genotype was not taken into account or when S. aureus  AFLP clusters, 
instead of individual markers, were included in the model. Not all individual AFLP 
markers are specific for a single cluster. Remarkably, the two markers associated with 
increased risk for persistent carriage, were present in the vast majority of cluster II S. 
aureus strains (99-100%). Although cluster II strains were recovered more frequently 
from individuals with persistent carriage, compared to with isolates recovered from 
individuals with intermittent carriage, this difference was not significant. It should be 
noted that if correction for multiple testing was applied when analyzing the individual 
markers, these would no longer have been significant, and assessing their true effect 
and functional relevance requires further research. 
Individual SNPs in CRP were not consistently associated with S. aureus carriage, 
but when the effect of haplotypes was assessed, overrepresentation of the CRP 
C-C-C haplotype 2 was observed in non-carriers. CRP haplotypes have been shown 
to be associated with differences in basal CRP expression levels.(27) However, 
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the C-C-C (haplo 2) haplotype is associated with intermediate levels whereas the 
C-T-C (haplo 1) haplotype is associated with a lower CRP level and the T-C-C (haplo 
4) haplotype with higher CRP levels.(27) This renders interpretation of the current 
results difficult. In addition, the CRP level itself was not significantly associated with 
S. aureus colonization. A possible explanation could be that this single time point 
of CRP measurement may not be relevant, whereas the CRP haplotypes reflect 
lifelong exposure. Alternatively, this haplotype may be linked to another unknown 
polymorphism which is associated with S. aureus colonization. In addition, carriage 
of one or two copies of the CRP C-C-G haplotype 3, previously associated with the 
highest basal CRP levels, was associated with a decreased occurrence of boils in 
our study, although CRP levels were not associated with boils.(27) Because CRP 
levels were measured as a baseline value, irrespective of the presence of boils, no 
conclusion can be drawn about the possible effect of the haplotype on CRP level 
upon infection.
Because the complement system is involved in the defence against microbes we 
expected that the CFH Tyr402His variant might play a role in colonization with 
S. aureus. Although we did not find an association with S. aureus carriage in our 
population, the occurrence of boils was associated with presence of the CFH 402Tyr 
variant. The functional relevance of the Tyr to His substitution is not known, but since 
the polymorphism is located in the CRP binding region of CFH, it may affect the 
innate immune response. Moreover, recent findings underline the importance of the 
S. aureus immune evasion strategy that relies on the  inhibition of C3 convertases.
(12)
Although the IL4, CFH and CRP variants appear to be involved in susceptibility to 
nasal carriage of S. aureus, the exact role that the individual polymorphisms we 
studied play in colonization and occurrence of boils remains unclear.
Besides environmental and genetic host factors that can influence carriage, S. aureus 
bacteria themselves are considered to be responsible due to different mechanisms 
that facilitate escape from the human immune response.(11) Recently, the importance 
of staphylococcal proteins such as staphylococcal complement inhibitor and 
staphylokinase, in the evasion of the complement system, and thereby the innate 
immune system, has become evident.(45)
The present study involved a large number of participants. Although this decreases 
the risk of finding false-positive or false-negative associations, replication in an 
independent similar population, in populations involving other age groups, and/or 
complementing functional studies are still warranted. This is specifically important 
for the assessment of the effect of AFLP markers, because multiple testing very 
likely contributed to finding the associations. In addition, the presence of boils was 
defined as ever having had boils. This information was derived from medical records, 
but information also came from questionnaires, which may have resulted in a recall 
bias.
In conclusion, the CRP C-C-C haplotype was associated with negative nasal swab 
cultures for S. aureus. Carriage of the CFH 402 Tyr allele were overrepresented 
in individuals with boils, while boils were observed less frequently among carriers 
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of the CRP (1184-2042-2911) C-C-G haplotype. The IL4 -524 C/C genotype was 
overrepresented in among individuals with persistent nasal carriage of S. aureus, 
compared with non-carriers. When accounting for the effect of S. aureus  AFLP markers 
that were differently distributed between isolates recovered from individuals with 
intermittent carriage and those with persistent carriage, an independent association 
between the IL4 -524 C/C genotype and persistent carriage was observed. Additional 
genetic and functional studies in large populations are warranted to further clarify the 
contribution of these individual factors in staphylococcal nasal carriage and infections 
in humans.
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Introduction
This thesis is the result from a collaboration between a series of clinical and preclinical 
departments at the Erasmus MC, as well as selected other national and international 
centres that was started because of a mutual interest in the role of genetic variation in 
inflammatory disease susceptibility and pathogenesis. The diseases of interest were 
considered to have similarities in at least a part of their pathogenesis. All diseases 
included had inflammatory components, thought to be elicited by common (innate) 
immune response pathways. These immune response pathways could be initiated 
by infection or colonization with bacteria or viruses, or be an effect of autoimmune 
response. The availability of well described, homogenous patients was a prerequisite 
for the inclusion of a cohort into the study, to minimize the chance of introducing bias 
as seen in poorly defined heterogeneous cohorts.
In this chapter the findings in the diseases described in this thesis are summarized. 
Genetic polymorphisms were analyzed in patient cohorts with inflammatory diseases: 
meningococcal infection, chronic hepatitis C virus (HCV) infection and recurrent 
acute otitis media (AOM) being infectious diseases; rheumatoid arthritis (RA) from 
the group of autoimmune diseases; and Guillain Barré syndrome (GBS) and Barrett 
oesophagus as intermediates between infectious and autoimmune disease. In 
addition, we investigated S. aureus nasal carriage as a risk factor for infection, and 
sepsis after severe multiple trauma as an inflammatory condition.
Table 1 summarizes the positive results in the studies. Polymorphisms in IL4, 
PAI1, TNFA, IL6, IL10 and C1INH were associated with more than one of the 
studied diseases. This shows that our strategy, assessing what could be common 
denominators in inflammatory diseases based on the literature available at that time 
appears accurate. It must be noted that some polymorphisms were only studied in one 
or two, but not all patient cohorts (CRP, CFH, MBL, CD14, IL1RN, TAFI, and MMP9). 
This resulted from a specific interest in these genes by the different collaborators.
IL4 -542 C/T polymorphism in meningococcal infection and nasal 
colonisation with S. aureus
The IL4 -524 C allele was transmitted more often from parents to patients with 
meningococcal disease than expected under Mendelian inheritance (Chapter 2.4). In 
elderly individuals with the IL4 -524 C/C genotype persistent S. aureus carriage was 
more often observed than in individuals with the IL4 -524 T allele even after adjustment 
for confounding factors (Chapter 5.3). Previously, IL4 high producer genetic variants 
have been associated with atopy, asthma and severe respiratory infections.(1-3) The 
IL4 -524 C/C genotype is associated with lower IL4 expression, while low IL-4 serum 
concentrations are associated with low mucin production.(4-6) This indicates that an 
increased susceptibility to both meningococcal infection and S. aureus colonization 
might result from a decreased mucociliary clearance.
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Table 1. Positive gene/SNP-disease associations identified in this thesis.
NA, not addressed thus far.
1The DEFB1 polymorphism was genotyped in meningococcal infection and for S. aureus carriage only.
2TAFI polymorphisms were determined in meningococcal sepsis patients only. DIC, disseminated 
intravascular coagulation; tdt, transmission disequilibrium test.
3MMP9 was genotyped only in patients with Guillain Barré syndrome and controls.
4IL1RN and CD14 polymorphisms were genotyped in Barrett oesophagus patients and controls only.
5ETR, end of treatment response.
6MBL, CFH and CRP polymorphisms were determined for S. aureus carriage analysis only.
Mainly recent, but not long-lasting colonization results in increased risk for infection. 
Colonization with microbes will elicit specific antibody response. This however takes 
time. For recently acquired microbes there has not been enough time for the host 
to produce specific antibodies, and the lack of these specific antibodies results 
in an increased risk of infection.(7) The role of IL-4 in systemic infection is crucial 
since IL-4 deficient mice are more susceptible to shock induced with a combination 
12
Table 1. tive gene/SNP-disease associations identified in this thesis.
Disease Susceptibility Severity Treatment response
Meningococcal infection DEFB1
1
 G/G > UK
IL4 -542 C >, tdt
C1INH 480 Val >, tdt
DEFB1 G/G > DIC, UK
1
DEFB1 C/C > mortality,
UK
1
IL4 -524 T/T > mortality,
Dutch
TAFI 325Ile/Ile > DIC,
Dutch
2
NA
Sepsis in trauma patients PAI1 4G/4G > - NA
Guillain Barré syndrome - MMP9 -1562 T > severe
3
TNFA -863 A/A > severe
NA
Rheumatoid arthritis IL6 -174 G/G >
IL8 781C/C >
PAI1 5G/5G >
TNFA -308 G/G > severe
TNFA -238 A/A > severe
NA
Barrett oesophagus IL1RN 2018C >
4
CD14 -260 T/T <
 4
CD14 -260 T/T and TLR4
+896 A/A combined <
IL1B -511 C/C + IL1RN
2081 T/T + CD14 -260
T/C+TLR4 896 A/G
combined <
NA NA
Chronic HCV infection IL6 -174 G/G >
TNFA -857 T >
- IL10 -819 T
IL10 -1082A;-819T > viral
response
PAI1 5G/5G SVR
PARP 762 A < ETR
5
Recurrent acute otitis
media
IL6 -174 G/G > PAI1 4G/4G >
TNFA -238 G/G >
TNFA -376 G/G >
TLR4 299 A/A >
TNFA -238 G/G
TNFA -863 A lower
specific antibody response
upon vaccination
IL10 -1082 A/A: protection
from more recurrent AOM
upon complete vaccination
Staphylococcus aureus
nasal colonization
Staphylococcus aureus
infection: boils
C1INH 480 Val >
MBL haplotype A >
6
IL4 -524 C/C >
CRP haplotype 1184C;
2042C; 2911C <
CFH Tyr402 >
CRP 2911 C/C >
- NA
NA, not addressed thus far.
1
The DEFB1 polymorphism was genotyped in meningococcal infection and for S. aureus carriage only.
2
TAFI polymorphisms were determined in meningococcal sepsis patients only. DIC, disseminated intravascular
coagulation; tdt, transmission disequilibrium test.
3
MMP9 was genotyped only in patients with Guillain Barré syndrome and controls.
4
IL1RN and CD14 polymorphisms wer  genotyped in Barrett oesophagus patients and controls only.
5
ETR, end of treatment response.
6
MBL, CFH and CRP polymorphisms were determined for S. aureus carriage analysis only.
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of staphylococcal enterotoxin B and D-galactosamine than wild type mice.(8) In 
addition, IL-4, in combination with IL-10, protects mice from aggravation of the pro-
inflammatory immune response in S. aureus infection.(9) In adult sepsis patients 
IL-4 mRNA levels were decreased when compared to patients with bacteraemia or 
controls.(10)
One might expect that given these results co-colonization of N. meningitidis and S. 
aureus is likely to occur in susceptible individuals. Although a positive correlation 
was observed in children between N. meningitidis and S. pneumoniae colonization, 
no correlation exists between S. aureus and meningococcal carriage.(11) Possibly 
only limited interaction between S. aureus and meningococci exists allowing co-
colonization of these two microbes without favouring or inhibiting colonization of the 
other in the presence of one. The interaction of the microbes and the host in a given 
environmental context, for example the nasopharynx, will determine the outcome after 
exposure of the host to the microbe: asymptomatic colonization, infection, severity of 
infection, and outcome of infection.(12)
IL-4 is a typical Th2 cytokine.(6) We observed an increased susceptibility for microbial 
colonization and infection in IL-4 low producers, while high IL-4 production genotypes 
were associated with asthma and atopy. This underlines the importance of the 
adequate regulation of both Th1 and Th2 responses, to prevent either phenotype. 
PAI1 4G/5G polymorphism important in tissue integrity
PAI-1 inhibits cellular migration and invasion, processes essential in tissue repair 
in inflammatory disease.(13, 14) Hence, higher PAI-1 levels might result in longer 
persistence of tissue inflammation, or abnormally repaired tissue, prone to bacterial 
colonization and new infections. The -675 4G/4G promoter genotype is associated 
with high PAI-1 expression.(15, 16) The high production genotype is associated with 
poor outcome in meningococcal disease.(17)
Children with the PAI1 4G/4G genotype had an increased risk of more frequent AOM 
episodes compared with those who were homozygous for the 5G variant, also after 
correction for cofactors (p=0.03, OR 2.31). This finding was attributable to children 
< 4 years of age (p=0.02, OR 2.97) (Chapter 4.1). In addition, homozygosity for 
the PAI1 4G allele in patients with HCV infection associated with non-sustained 
response to therapy (Chapter 3.4), while in multiple trauma patients it associated 
with susceptibility to sepsis (Chapter 2.9). The PAI1 5G homozygous variant was 
associated with increased RA susceptibility (Chapter 3.2).
Two possible mechanisms for PAI-1 interaction and inhibition of tissue repair have 
been proposed. First, PAI-1 may inhibit a proteolytic cascade at the cell surface 
that results in matrix destruction, allowing cellular migration and invasion for tissue 
repair. The proteolytic cascade mechanism involves the activation of surface-bound 
plasminogen by surface bound urokinase plasminogen activator (uPA). PAI-1 can bind 
to uPA on the cell surface and inhibit its proteolytic activity and hence tissue repair.(18-
20) A second proposed pathway involves competitive binding of PAI-1 and integrin 
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to vitronectin. Both share the same binding site region on vitronectin. Vitronectin/
integrin interaction is needed for cell migration and adhesion. The inhibiting effect of 
PAI-1 is negated when excess non-surface bound uPA forms a complex with PAI-1 
resulting in a release of PAI-1 from vitronectin, which is then available for interaction 
with integrin, favouring cell adhesion.(21)
A possible role for high PAI-1 concentrations in the stronger inhibition of healing 
of inflamed otolaryngeal tissue that may thus favour an otitis prone condition is 
supported by the results of Hellström and co-workers that imply a further role for 
PAI-1 and plasminogen in tissue repair. They have shown that perforated tympanic 
membrane of plasminogen deficient mice exhibits reduced healing 15 days after 
myringectomy compared with TM from wild type mice.(22) Intravenous administration 
of plasminogen, in plasminogen deficient mice, resulted in restored TM healing 
even if plasminogen was administered 30 days after perforation. The distribution of 
inflammatory cells in the perforated TM differed significantly between plasminogen 
deficient and wild type mice in vivo. Plasminogen deficient mice with initially normal 
tympanic membranes showed spontaneous development of middle ear effusion. In 
addition, uPA expression is increased upon infection with Streptococcus pneumoniae 
in an otitis media model in the rat.(23) S. pneumoniae is one of the major causative 
microbes of otitis media in humans.(24-26)
Interaction of PAI-1 with uPA prohibits catalytic activation of plasminogen to plasmin. 
High PAI-1 levels might therefore result in similar clinical findings as seen in 
plasminogen deficiency. Furthermore, in skin wound healing, PAI-1, uPA and uPA-
Receptor are expressed at the site of regenerative epithelial outgrowths at the edge 
of the wound.(27, 28) Plasminogen deficient mice showed impaired wound healing.
(29)
The pleiotropic PAI-1 molecule is also involved in fibrosis.(30) Additionally, PAI-
1 deficiency protects against fibrosis formation in diverse animal disease models.
(31) Furthermore, plasminogen deficiency interferes with clearance of debris after 
acute injury, and results in activation of hepatic stellate cells known to be involved in 
fibrosis progression.(32, 33) Since increased PAI-1 levels inhibit wound healing and 
induce fibrosis, it is reasonable to assume that this mechanism contributes to the 
nonsustained response to treatment with peginterferon alfa-2a and ribavirin in PAI1 
4G homozygous HCV infected patients (Chapter 3.4). 
Whether the role of PAI-1 in pathophysiologic processes proposed in otitis media and 
HCV infection is similar for susceptibility to sepsis in multiple trauma patients is not yet 
clear, but plausible. PAI-1 concentrations are increased in multiple trauma patients.
(34) This was thought to result in a decreased fibrinolysis and the occurrence of 
microthrombi in disseminated coagulation as in meningococcal sepsis. Additionally, 
the high producer PAI1 4G/4G promoter genotype was associated with increased 
mortality.(34) The latter could not be confirmed in our study, possibly due to less 
severe disease and improved treatment regimes of the current study population.
The role for PAI-1 in rheumatoid arthritis seems to differ from the mechanisms 
proposed above for otitis media, HCV infection and sepsis in trauma patients. The 
PAI1 5G homozygous variant, related to low PAI-1 levels and therefore decreased 
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inhibition of plasminogen activator was associated with RA when compared with 
controls. No link was observed with severity of disease. Plasminogen deficiency is 
associated with decreased susceptibility to and or severity of arthritis in mice models.
(35) PAI-1 deficiency, however, has also been associated with decreased severity in 
murine antigen-induced arthritis.(36)
In general, the role of factors involved in tissue repair and integrity, such as filaggrin 
and myosin became more evident in the past few years, as illustrated in celiac 
disease and atopic dermatitis.(37-39) This underlines the importance of tissue repair 
and integrity in the pathogenesis of inflammatory diseases.
IL6 and increased susceptibility to inflammatory disease
The IL6 -174 G/G genotype was overrepresented in rheumatoid arthritis patients 
(Chapter 3.2), and individuals with hepatitis C infection (Chapter 3.4) when compared 
to healthy controls. In addition, the IL6 -174 G/G promoter genotype was found more 
frequently in AOM patients in our study (Chapter 4.2). This is consistent with the 
increased expression of IL-6 during experimental otitis media in animals.(40, 41) 
The IL6 G/G genotype is associated with increased IL-6 levels compared to the 
C/C genotype. This SNP therefore contributes to the complex regulation of IL-6 
production involving multiple polymorphisms.(42-45) Furthermore, IL-6 expression is 
influenced by TNF-α, and interaction of polymorphisms in these and other genes may 
co-determine the disease phenotype.
Barrett et al. found the high producer variant to be more prevalent in persistent HCV 
infection compared with spontaneous viral clearance.(46) Patients with chronic 
hepatitis C have increased IL-6 expression when compared to healthy controls. 
Whether this is secondary to infection or reflects increased susceptibility to or reduced 
clearance of infection with HCV in high IL-6 producers is not clear.(47)
The substantial improvement of RA upon treatment with anti-IL-6 receptor antibody 
underscores the importance of this pleiotropic cytokine in the pathogenesis. (48) 
The exact functional role of the pleiotropic pro-inflammatory IL-6 increasing the 
susceptibility in these diseases is not yet known. Experimental models assessing 
early disease in normal and IL-6 deficient animals could provide further insight into 
the role of IL-6 in susceptibility to RA.
IL10 low producer variants enable enhanced proinflammatory 
responses
IL-10 is a well-known anti-inflammatory cytokine, which serves with other cytokines, 
such as IL-4, to counterbalance the pro-inflammatory response elicited in infection. 
The promoter -1082A;-819T haplotype was previously associated with decreased 
expression of IL-10.(49-51)
In our study carriage of the IL10 -819T allele was associated with rapid viral response 
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(a decrease or disappearing in viral titers) in HCV patients at 6 weeks of treatment 
with peginterferon alfa-2a and ribavirin (Chapter 3.4). The IL10 promoter low producer 
haplotype was associated with end of treatment viral response and sustained viral 
response 24 weeks after the termination of the treatment. 
In addition, the IL10 -1082 A/A genotype was associated with protection from AOM 
after vaccination (Chapter 4.2). These observations point towards an improved 
pro-inflammatory response in low IL-10 producers in patients with recurrent AOM 
vaccinated against pneumococci and patients treated for HCV infection. The first 
concept is supported by observations in animal studies. In IL-10 deficient mice 
immunized with non-virulent unencapsulated S. pneumoniae (strain R36A) elevated 
induction of pro-inflammatory cytokines was observed, supporting the hypothesis 
that low IL-10 producers confer better response upon vaccination. Moreover, 
antibody titers against pneumococcal proteins were increased in IL-10 deficient 
mice compared to wild type mice.(52) Our results indicate that it may be possible to 
identify individuals who are more likely to fail a proper response to vaccination. These 
individuals could in the future possibly be selected for adjusted vaccination regimes 
providing optimized vaccination response for everybody.
C1INH polymorphism in meningococcal infection and nasal 
colonization with S. aureus
The C1INH 480 Val variant was associated with increased susceptibility for 
meningococcal infection and also with nasal carriage of S. aureus (Chapters 2.4 and 
5.1).
The complement system is important in the defence against bacterial infections 
evidenced by the increased susceptibility to infection with meningococci in patients with 
deficiencies of complement factors, and the mechanisms S. aureus has developed to 
evade the complement system.(53, 54) Over-activation of the complement cascade is 
prevented by the serine protease C1 inhibitor (C1-Inh), which is an important molecular 
regulator of the human complement system. This multifunctional protein also inhibits 
activity of contact system proteases, such as kallikrein and blood coagulation factor 
XII, and is involved in endothelial binding of leukocytes.(55-57)
As the functional relevance of the V480M substitution remains to be determined, 
the role of this polymorphism in staphylococcal colonization and the pathogenesis 
of meningococcal infection is unknown.(58) Previously, no differences between the 
V480 C1-Inh and the M480 C1-Inh were observed with regard to structure, protein 
stability, serum concentration or inhibition of C1.(59) It is therefore unlikely that there 
is a difference in the direct interaction between microbes and C1-Inh.(60) It might very 
well be that the polymorphism has an effect on one of the other functions of C1-Inh.
(56, 59) Future opsonophagocytosis experiments or characterization of complement 
deposition on bacterial cells using serum samples from donors with different C1INH 
genotypes are required to elucidate the molecular basis of (indirect) microbe- C1-Inh 
interactions.
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TNFA expression: too much, too little? 
The TNFA -863 A variant was associated with increased severity of GBS and a 
decreased specific antibody response upon anti-pneumococcal vaccination (Chapters 
3.1 and 4.2). A previous study showed that the A-allele at position -863 of TNFA was 
associated with higher TNF-α concentration due to an inadequate down regulation 
of its production.(61) Previous reports also showed that high serum levels of TNF-α 
were associated with severity of GBS.(62-66) This is possibly mediated by the extent 
of macrophage activation, resulting in an insufficiently controlled pro-inflammatory 
response.
In addition, the TNFA -238 G/G genotype was associated with more recurrent AOM, 
while the -238 A/A genotype was associated with more severe RA (Chapters 3.2 and 
4.2).
The interpretation of these findings is more complex. Both an excess and insufficient 
TNFA expression may explain more severe disease in AOM. An excess of TNF-α 
may result in increased tissue damage, prone to recurrent infection while a decreased 
TNF-α response may prevent adequate clearance or inactivation of the microbes 
resulting in (ongoing) infection. The effect of the TNFA -238 polymorphism on TNF-α 
expression is unclear. In the recent past numerous studies have been performed 
to investigate the association of TNFA promoter polymorphisms and TNF-α levels 
in different inflammatory and infectious diseases, reporting contradictory results.
(67) TNF-α expression is probably not determined by one but by a combination 
of polymorphisms in TNFA and -associated genes. This is further complicated by 
the low minor allele frequency. Small changes in numbers are likely to substantially 
influence the results, which increases the risk of false positive and false negative 
associations.
Furthermore, and specifically in AOM, different pathogens may induce a variety 
of cytokine responses, and since numerous pathogens, both bacterial and viral, 
are known to cause otitis media, unravelling the role of polymorphisms on TNF-α 
production in the human setting is very difficult. Moreover, since TNF-α levels are 
expected to change during the course of infection, timing of sampling is likely to 
be a very important determinant of the results. Differential expression of TNF-α is 
very likely to influence disease susceptibility and severity due to its pleiotropic pro-
inflammatory actions. TNF-α stimulates, for example, immunoglobulin and mucin 
production and low TNF-α concentrations compromise these defence mechanisms.
(68) TNF-α levels in nasopharyngeal secretions are decreased in children with 
recurrent otitis media compared with healthy children.(69) 
The association between various TNFA polymorphisms and AOM, RA, and GBS 
described in this thesis indicate that indeed there is a role for these polymorphisms 
in TNF-α production in vivo. Analyzing TNF-α expression in our patient cohorts in 
relation to the TNFA haplotypes, could clarify the effect of the polymorphisms tested 
in these patients.
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Conclusion
The above shows that several of the polymorphisms included in this thesis were indeed 
associated with two or more phenotypes. This phenomenon of pleiotropy supports 
the hypothesis that similar pathogenic processes are likely to be involved in different 
diseases. While observations were consistent in some, others like for the SNPs in 
TNFA in the different diseases appeared contradictory. Low minor allele frequency, 
relatively small patient populations still, and therefore increased risk of finding false 
positive or false negative findings may have contributed to these findings. This is also 
reflected by the loss of significance for some of the associations after correction for 
multiple testing. One must however consider that the effect of genetic polymorphisms 
is expected to be limited at most, and multiple SNPs are expected to be involved 
besides other host and environmental factors.
Observational studies but also controlled (in vitro/animal model) experiments, 
assessing protein levels, such as those for TAFI, ADAMTS13, VWF, and MIF in 
meningococcal disease (Chapters 2.5 to 2.7) are required to elucidate the relevance 
of SNPs associated with disease. In addition, RNA expression profiling studies as 
described in chapter 2.8 can support genetic association, and they can also provide 
new insights and point toward other candidate genes possibly involved in the 
pathogenesis of inflammatory diseases.
The emerging interest in tissue integrity is further supported by our observations 
for PAI1 polymorphism in AOM, HCV infection, and possibly sepsis in multi trauma 
patients. In addition, the role of IL4 and C1INH in susceptibility to S. aureus nasal 
carriage and susceptibility to meningococcal infection deserves further attention. 
Functional studies elucidating the contribution of these molecules to the pathogenesis 
are required.
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Chapter 6.2 
Genotyping studies: Future perspectives
A personal view
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Introduction
In this chapter I will discuss the strategies that are being used or should in my opinion 
be implemented when assessing the effect of single nucleotide polymorphisms (SNPs) 
in multifactorial (complex) traits and diseases. Complex diseases are conditions that 
are influenced by the actions of multiple genes, their interactions with each other and 
with the environment.
Genetic variants, including di-, tri- or multiple-nucleotide repeats (microsatellite 
regions), and copy number variation, although diverse and relevant, fall outside the 
scope of this overview. 
Since the discovery of the double helix structure of DNA by Watson and Crick in 
1953 the knowledge about this coding structure has expanded and is still expanding 
with great speed including the sequencing of the complete genome of Jim Watson.
(1-3) Although heritability had been a recognized phenomenon long before that, 
understanding the DNA structure made it possible to determine the molecular origin 
of the features observed. The search for mutations in single gene diseases such 
as Huntingtons disease and cystic fibrosis has been very successful using linkage 
analysis in large multigenerational families.(4)
The idea that all diseases and traits can be explained by single mutations has however 
been proven wrong long ago. In single gene diseases it was observed that many 
different mutations in the same gene result in similar phenotypes. In cystic fibrosis for 
instance, over 1000 mutations and 200 polymorphisms have been described in the 
cystic fibrosis transmembrane conductance regulator gene, although their individual 
functional effects are not yet all known.(5) And, especially for complex traits and 
diseases, in which not only genetic but also environmental factors can be involved, 
this simplified view was found to be erroneous. Most likely multiple variations in 
different genes will co-determine the phenotype in interaction with environmental 
factors. This implies that most of these common variants are expected to have only 
a modest effect.
Inflammatory diseases can be included in the category of complex diseases. 
Inflammation is a process by which the white blood cells and chemicals protect 
the body from infection, irritation or other injury. Autoimmune diseases in which the 
inflammation is directed against ‘self’ and causes tissue damage are also part of the 
inflammatory diseases. Multifactoriality of these complex diseases is illustrated by an 
increased susceptibility to certain infectious diseases, which will have no immediate 
consequences, unless one is exposed to the causative micro-organism. 
Replication of genetic associations
In the recent past numerous associations have been published between SNPs 
and complex traits. Some of these have been confirmed in independent (patient) 
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cohorts.(6) For most however, replication has been proven difficult. Numerous 
factors are likely to have contributed to the discrepancies observed (Table 1). First 
of all disease definition, or subgroup classification often differs between studies. 
Assessing subtle clinical differences on a greyscale rather than looking at black 
and white differences may result in different findings, especially since the expected 
contribution of each of the genetic factors is small and the observed phenotype is 
the result of the combination of these factors. The use of internationally standardized 
diagnostic criteria helps to deal with this issue. Although such criteria are available 
for an increasing number of diseases, still usually several similar, but not identical, 
internationally recognized standards exist and are being used simultaneously. 
Examples include severity scores used in paediatric meningococcal disease patients, 
for whom a.o. sequential organ failure assessment (SOFA) score, Rotterdam score, 
paediatric index of mortality (PIM) score, different paediatric risk of mortality (PRISM) 
scores, and organ system specific severity scores have been used.(7-12) The use 
of multiple different scoring systems limits comparison of different study populations. 
Table 1. Factors involved in non replication of genetic associations.
Furthermore, with increased knowledge of complex diseases, more clinical subgroups 
are being identified. Disregarding the existence of subgroups, would bias the results, 
since the distribution of these subgroups may differ between different study populations 
examined. Since existence of subgroups is not always acknowledged at the time of 
the study, it is not surprising that associations now considered to be true, may in the 
future be determined to be actually false based on increased knowledge of disease 
definition. Moreover, the choice of the control group also determines what can and 
cannot be analyzed. When assessing the contribution of a given SNP to disease 
susceptibility one should - if possible - correct for (confounding) factors that may 
codetermine disease. For example, when the effect of SNP A on the susceptibility to 
diabetes mellitus is assessed in an obese patient cohort, one should preferably use 
a matched control population. Since an increased body mass is a known risk factor 
for diabetes, this infers including individuals that are of the same ethnic origin, not 
diabetic, but do have an increased body mass index, which is not significantly different 
from the diabetes patients. This was demonstrated by the differences observed when 
analyzing a genetic variant in FTO in type 2 diabetes and obesity.(13) When the 
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Table 1. Fact i volved in on replication f genetic associati ns.
Factors involved in non-replication Explanation
Disease definition Existence of (unidentified) clinical subgroups
Ethnic heterogeneity Applicability limited to a single specific population
Winners curse Initial positive findings are not often replicated
Lack of statistical power Small sample sizes
Genotyping of other SNPs in the gene of interest SNPs may or may not be in linkage disequilibrium
Using different genome wide genotyping platforms There is no 100% overlap of SNPs included in the
platforms
Table 2. Populations genotyped for HapMap.
Populations Number of individual DNA samples
Yoruba in Ibadan, Nigeria 180
Han Chinese in Beijing, China 90
Japanese in Tokyo, Japan 91
CEPH collection (NIGMS human genetic cell repository)
(Utah residents with ancestry from northern and western
Europe)
90
Additional populations being genotyped
Maasai in Kinyawa, Kenya 90
Luhya in Webuye 100
Chinese in Metropolitan Denver, CO, USA 100
Gujarati Indians in Houston, TX, USA 100
Toscani in Italy 100
Mexican ancestry in LA, CA, USA 90
African ancestry in SW, USA 90
CEPH, Centre d'Etude du Polymorphisme Humain; NIGMS, National Institute of General Medical Sciences, USA.
 Future perspectives 333
FTO variant was compared between patients with diabetes and controls matched for 
body mass index, no association was observed, while the FTO variant was reported 
to be associated with diabetes when a lean healthy control cohort was used. Given 
these differences it was noted that the FTO variant was actually not associated with 
diabetes, but with obesity, and through that, with diabetes.(14, 15)
Additionally, positive findings are easier to publish than negative results, resulting 
in publication bias. And since small sample sizes are more prone to obtain false 
positive associations than large sample sizes, it is not unexpected that initial positive 
results have not been replicated in subsequent larger studies.(16) This has several 
implications. First, sample sizes should be large enough to ensure statistical power, 
and second it should be made easier to publish negative results. While until recently 
cohort sizes of several hundreds of individuals were considered sufficient, now the 
call has been placed to include at least several (ten)thousands.(13, 17-19) Single 
centres usually do not have sufficient numbers of patients to meet this criterion. This 
implies the need for collaboration and an (international) multicentre approach, and as 
mentioned above, further standardization of diagnostic criteria and severity scores. 
Recently, several consortia have been formed like the Wellcome Trust Case Control 
Consortium (WTCCC GWA) in the United Kingdom that has collected ~2,000 patients 
per diagnosis (Crohn’s disease, diabetes type I and II, bipolar disorder, rheumatoid 
arthritis, coronary artery disease) and ~3,000 controls, consisting of a birth cohort 
and healthy blood donors.(17) Yet other more recent initiatives have collected or are 
still collecting over 100,000 individuals.(17, 18) 
Collaboration sounds easy. One must however not forget that this requires another 
way of thinking in the scientific community. For decades competition has been 
the key word. And even now, researchers are rewarded for the number of top 10-
25% publications in which their name is either first or last in the author list. Even 
more, financial support is at least partially determined based on these criteria. The 
collaborative effort needed to enable the collection of thousands of patients per 
disease or trait and an equal number of controls sometimes requires, however, giving 
up these prominent authorship positions. While the need for collaboration is clear 
and progress is being made towards the formation of multiple collaborative efforts, 
scientists are sometimes still reluctant, given the importance of authorship. Reforming 
the system toward scientists being rewarded for collaborative efforts would positively 
contribute to improvement of genetic association studies.
Relevance of biobanks
Large patient sample collections require a structured organization, managing the 
storage and use of samples and associated information, for instance in the form 
of a biobank. Besides ‘sacrifices’ from scientists, sharing collections and giving 
up first or last authorship for ‘the good cause’, this implies further thinking about 
legislation and medical ethical considerations. For example, who owns the samples 
and, anonimized, clinical information: The individual patient, the researcher, the 
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consortium, the institutes involved, or the biobank? And how long can samples be 
stored before they need to be destroyed. Medical ethical committees now ask for 
destruction of patient materials after a maximum of 15 and sometimes 30 years. 
Collection of these large numbers of samples, especially for the more rare diseases, 
however, may require a long period of time. In my view it is ethically not justifiable 
to have to ask a patient for a new sample when material would still be available if 
legislation had not required its destruction. Even more, in diseases associated with 
increased mortality, like meningococcal disease or multiple trauma, it is impossible 
to obtain new samples. Hence, I hereby plead for an increased storage time that 
may be even indefinite for some very rare diseases. For the same reasons, while not 
disregarding the rights of the donors of the material, so only if samples and clinical data 
are anonimized, I suggest for genetic studies to allow additional genes to be screened 
without additional explicit informed consent of the donor. For initial recruitment of 
individuals, of course informed consent to perform genetic association studies is still 
required. One of the goals of biobank formation is to create large patient cohorts from 
national and international collaborating research teams. Current legislation, however, 
differs between countries. Uniformity of (inter)national legislation is therefore required 
to avoid hindrance of these collaborative efforts.(20) 
These biobanks may through registration of studies also serve as a control system to 
ensure public (online) availability of results, whether positive or negative. This would 
contribute to a decrease in publication bias.
The power of quantitative trait loci (QTL)
Most genetic association studies focus on binomial outcome variables such as 
patient or control, complication or no complication, and death or survival. The reason 
for this is most likely clinical routine, convenience, and relatively easy statistics. 
Figure 1. Endophenotypes. 
Factors that can be used as quantitative trait loci, increasing the statistical power compared to only 
analyzing dichotomous clinical endpoints. 
SNP in DNA
RNA
Protein
Pathway
Expression level
Levels in circulation
Intermadiate phenotype
Clinical endpoint
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While some outcomes are clearly dichotomous, others, like complications can, 
however, also be subdivided into categories from “no” via “mild” to “severe” 
complications. Moreover, outcomes are usually determined by multiple factors of which 
some (if not most) may be quantitative like levels of C-reactive protein, plasminogen 
activator inhibitor type 1, or viral load. Instead of assessing dichotomous endpoints 
of phenotypes, one could also focus on quantitative trait loci (QTL). These provide 
the advantage of increased statistical power compared to dichotomous outcome 
parameters. In addition, SNPs if having an influence will do so most likely on one of 
the quantitative traits that codetermine the disease phenotype. Focusing on the more 
direct link, endophenotypes (Figure 1), instead of the indirect disease phenotype, 
also eliminates confounding factors that influence clinical traits but not the QTL. 
 
Genome wide approaches
Efficient genotyping of the extended cohorts now required in genetic association 
studies would not have been feasible without the progress that has been made in 
the techniques for genotyping. High throughput genotyping platforms (in terms of 
number of samples) such as Taqman and Sequenom approaches, analyzing up to 
384 or even more individuals in one assay simultaneously, and the availability of high 
density microarray techniques, genotyping up to 1 million SNPs in a single experiment, 
enable the scientific world to obtain enormous amounts of data in a short time frame. 
Nearly 12 million unique reference SNPs are known today, of which approximately 
6 million have been validated, and this number is still expanding on a daily basis. 
Approximately 4.6 million of the SNPs are located in genes, of which most (3.8 million) 
are located in intronic regions, while 80,000 SNPs result in an amino acid substitution.
(21, 22) Additionally, other types of genetic variation such as variable number of 
tandem repeat polymorphisms, restriction fragment length polymorphisms, different 
numbers of pseudogenes, and large structural variations, potentially influencing gene 
function, are present in the human genome.(23-25) Only part of the polymorphisms 
has been genotyped thus far. However, since SNPs located at close proximity are 
known to form haplotype blocks that are inherited together, there is no need to type 
all possible SNPs. Since the completion of the human genome much effort is put 
into documentation of existing haplotypes in diverse populations by the Hapmap 
project (Table 2).(26) Using the Tagger program developed by de Bakker et al., one 
can select SNPs that tag one or more other SNPs and only genotype the tagging 
SNPs.(27) This enables efficient genotyping of SNPs. However, it must be noted that 
coverage of SNPs throughout the genome using this approach differs for different 
ethnic populations. Using the first human haplotype map (2005), coverage ranged 
from 71% in African Americans to 84% in European Americans.(28) This results from 
the fact that haplotype blocks in African Americans are smaller and have different 
allelic structure than in European Americans. Using high density oligonucleotide 
arrays it was estimated that in Chinese approximately 250,000 SNPs are needed to 
obtain reasonable coverage, while in European Americans and African Americans 
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these numbers are approximately 300,000 and 550,000, respectively.(26, 28) This 
difference is illustrated by Nicolae at al. who reported that using the Affymetrix 100k 
SNP array, coverage in phase I was less in the African HapMap samples than in the 
European HapMap samples.(29) Taking an r2 of 0.8 about 60% of SNPs are covered 
in Europeans using the Affymetrix 500k SNP microarray. Using specific multimarker 
tests, combining two SNPs to be minimally involved in the haplotype, an additional 20% 
is covered. With an r2 of 0.95, 72% of SNPs is covered using the Illumina 300k array. 
None of the platforms has a 100% coverage. In general coverage is less in regions 
near telomeres and in GC-rich regions since here recombinations occur more often. 
Recently the second generation human haplotype map was published covering ~3.1 
million SNPs. Currently available genome wide platforms cover the phase II SNPs 
with an r2 of up to 0.8 in African and up to 0.95 in non-African populations.(30) Taking 
an r2 of 0.8, 1.1 million tag SNPs are needed to capture phase II SNPs in African 
populations, while ~550,000 and ~520,000 tag SNPs are needed in populations from 
European descent and Chinese and Japanese populations combined, respectively.
(30) Using an r2 of 1 would require a double number of tag SNPs since most SNPs 
are already captured using r2 of 0.8, while the remaining SNPs have lower minor 
allele frequencies or are even untaggable. The small although substantial increase in 
coverage is also illustrated by the fact that with the phase II HapMap taking an r2 of 
≥ 0.8, about 68% of SNPs are covered in Europeans using the Affymetrix 500k SNP 
microarray, while 77% is covered using the Illumina 300k array.(30) Only recently 
other types of polymorphisms, such as structural variants have been included in 
the Hapmap project. Moreover, a high-resolution sequencing map of these human 
structural variants has been published recently.(31) 
From the above it is clear that there are differences in genetic variation between ethnic 
populations. However, 85-90% of the variation is present between individuals within a 
population, while 1-2% of the variation occurs between populations within a continent 
and 10-12% between continents.(32, 33) To improve coverage of the HapMap, 
additional populations are currently being genotyped allowing implementation of the 
HapMap in genetic association studies regarding populations world wide (Table 2).
Table 2. Populations genotyped for HapMap.
CEPH, Centre d’Etude du Polymorphisme Humain; NIGMS, National Institute of General Medical Sciences, 
USA.
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Table 2. Populations genotyped for HapMap.
Populations Number of individual DNA samples
Yoruba in Ibadan, Nigeria 180
Han Chinese in Beijing, China 90
Japanese in Tokyo, Japan 91
CEPH collection (NIGMS human genetic cell repository) (Utah
residents with ancestry from northern and western Europe)
90
Additional populations being genotyped
Maasai in Kinyawa, Kenya 90
Luhya in Webuye 100
Chinese in Metropolitan Denver, CO, USA 100
Gujarati Indians in Houston, TX, USA 100
Tuscany in Italy 100
Mexican ancestry in LA, CA, USA 90
African ancestry in SW, USA 90
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Candidate gene approach revisited
Does this massive genome wide association approach mean that candidate gene 
studies are no longer needed? On the contrary. Finding an association of a tagging 
SNP with disease can be interpreted in different ways. The SNP itself can be associated 
with disease (direct association), but most likely the SNPs is a marker that is linked 
to the true disease allele that still needs to be determined (indirect association). 
Finding the association with the tagging SNP thus narrows the search region. It is still 
needed to identify the candidate gene and the disease or phenotype codetermining 
SNP(s) in the region covered by the SNP. A candidate gene approach based on 
the association with a marker SNP can then be conducted. This includes not only 
genotyping but preferably also functional studies to establish functional relevance 
of polymorphisms. These functional studies could be observational, but should 
ideally also include controlled (in vitro) studies, while at the same time recognizing 
the limitations of this approach in complex diseases where multiple genetic, both 
from the host as well as the microbe, and other environmental factors codetermine 
the phenotype. The logistic obstacles encountered in a disease like meningococcal 
infection, with its acute and rapidly evolving pathogenesis (a few hours to one day) for 
example, are well recognized. Another limitation of functional studies, specifically in 
paediatric populations is the relatively small number of patients available for inclusion 
and the limited volume of blood that can be drawn, allowing only few assays to be 
performed. Nonetheless, research in these populations is important to elucidate 
pathophysiological processes in a disease which still has a high mortality and 
morbidity. Furthermore, functional studies using RNA expression profiling provide 
additional information on the pathways involved in the pathogenesis of disease. This 
may direct the search for candidate genes. For example, myosin associated with 
celiac disease, rheumatoid arthritis, and systemic lupus erythematodes (SLE), also 
seems a good candidate for other inflammatory diseases.(34, 35) The MYO9B AAA 
haplotype was consistently associated with autoimmune disease. In celiac disease 
the aberrant myosin is thought to result in a compromised intestinal barrier enabling 
gluten peptides to enter the deeper mucosal layers where an inflammatory reaction 
can be elicited.(34) 
Developments in genetic epidemiology
The requirement of large numbers of individuals has not always been met in past 
studies. Results of genetic association studies were contradicted, or at least the 
initially estimated odds ratio decreased in subsequent studies.(36, 37) This is not 
surprising given the large number of available SNPs in the human genome, and the 
extensive number of phenotypes that can be tested resulting in a low a-priori chance of 
a true association. Using meta-analysis a more realistic odds ratio can be estimated.
(37) It must be taken into account, however, that special care has to be taken with 
regard to disease definition in pursuing this approach.(38) Outcome/phenotype 
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definition should be equal to or at least very similar to the original population, and 
at least the SNP that was observed to be associated with the phenotype studied 
should be included in the analysis to allow comparison. Additionally, for replicability, 
using the same genotyping platform in genome wide approaches facilitates 
comparison, in particular when raw data is made available. Furthermore, populations 
of different ethnic background should be tested to be able to generalize findings. 
Others, however, question whether replication makes sense at all. They argue that 
subdividing populations to meet the replication criteria results in a loss of power, and 
besides a reduced probability of finding false positives, also in a reduced opportunity 
to find true or universal associations.(39) Even despite the use of large populations 
and minimizing of between-study heterogeneity, a considerable portion of genuine 
associations may be found to be non-replicable.(13) Recently interim guidelines 
have been published to improve and assess quality of genetic association studies.
(40) These provide a preliminary key for determining credibility of observed positive 
and negative observations, with regard to epidemiologic evidence. No consensus yet 
exists on guidance for rating clinical relevance and biological plausibility.(40)
Larger number of statistical tests performed, especially in the genome-wide microarray 
approach required the development of statistical methods capable of dealing with 
these massive amounts of data and to correct for multiple testing.(41) Bonferroni 
correction, the usually applied method is overly conservative and has already been 
rejected, since it assumes that all tests performed are independent, while in genetic 
association studies this is not the case, for example for tightly linked SNPs or for 
related phenotypes. Since it may be that not so much the number of analyses but the 
low a-priory probability of a true SNP-disease association is the problem, Bayesian 
methods may be more appropriate to determine the posterior probability of an 
association.(42)
Although different methods to correct for multiple testing have been compared by 
Tyrer et al. suggesting the use of a novel admixture maximum likelihood approach, 
no definite answer has been given so far.(43) The search continues for a test that 
allows correction for multiple testing, without substantial loss of statistical power. For 
now it is thought best to give p values as they are. This means that some findings that 
are now considered positive may in the future be regarded as false positives. A way 
to circumvent this is to use smaller p-values than 0.05 to be considered statistically 
significant. The size of p will then of course depend on the number of SNPs and 
the number of analyses performed. In addition, new insights, and the availability of 
increased computational capacity, resulted in progressively more stringent p values 
being accepted. For genome wide association studies (GWAS) a P value of 5*10-8 is 
currently considered genome wide statistically significant. Many different statistical 
packages have been developed and are currently being developed and used, some 
easier to use than others.(44). Usually, the application of one package is not sufficient 
requiring data transformation for use in other relevant packages. In this thesis, SPSS, 
Stata, Thesias, Genehunter, Haplostat, and R program were used. Construction of a 
package that would incorporate different statistical approaches is therefore expected 
to ease the work of scientists markedly.
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As mentioned before, complex diseases are considered to have a multifactorial 
origin and two of the issues that arise are first, that it is statistically challenging 
even given the large number of samples in consortia, and, second, the expected 
interaction between individual SNPs and between SNPs and environmental factors. 
This is usually considered too difficult for current computer systems, and adds to the 
problems with multiple testing. Tackling of these problems will most likely improve our 
understanding of the pathogenesis of diseases and possibly even explain differences 
observed with regard to the effect of SNPs in different populations. 
Differences in populations may in their turn also result in a form of confounding, 
known as population stratification. This is defined by the fact that disease risk is more 
similar in related individuals, particularly when they are from the same ethnic group, 
when compared to less or even unrelated individuals. Ethnicity itself does not per se 
explain the risk but may be a marker for lifestyle or socioeconomic status determining 
access to healthcare.(45) This may result in both false positive but also false negative 
findings. The role of population stratification is debated and is thought to cause real 
problems not when present, but only when the magnitude of its effect is essential.
(45, 46) The potential impact of population stratification was demonstrated by Kidd 
et al. who reported a deletion in the APOBEC3A and APOBEC3B genes that was 
differentially distributed amongst Europeans and Africans when compared to East 
Asians and Amerindians or Oceanic populations.(47) No single SNP in the HapMap 
project tagged the deletion, which may result in false negative results in association 
studies. 
Ways to approach this problem take into account that allele frequencies can differ 
between populations.(32, 33) Ideally an outbred population is used as a representative 
for the general population; however, this requires very large numbers of individuals. 
Another strategy is to use ethnically matched controls. In addition genomic control 
can be used to control for ethnic differences in subgroups. This method uses null 
SNPs (> 100), expected not to be involved in disease, genotyped in both cases and 
controls, to confirm descent of individuals, and to determine if population stratification 
or admixture plays a role. This method also provides ways to correct for population 
stratification or admixture: If a population is composed of a recent admixture of different 
ethnic groups that differ in marker allele frequencies and disease frequencies (or 
the quantitative trait means), spurious associations may result between the marker 
genotypes (or alleles) and the complex traits. However, it does not control for cultural 
or socio-economic aspects of ethnicity, which may result in differential penetrance of 
the disease associated allele.(45)
Implementation of polymorphisms in treatment and diagnosis
Genetic association studies are currently directed towards understanding disease 
susceptibility and severity in populations. Since multiple factors, both genetic and 
environmental are involved in codetermining the phenotype, the contribution, if 
present, of each individual SNP will be small as outlined above. Presence of a certain 
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allele will increase or decrease risk or chance for a certain phenotype but does not 
automatically result in disease. Application of the results to individual patients is still 
rare and currently restricted to less common diseases such as adapted therapy in AML 
patients or dosage adaptations of drugs such as warfarin in pharmacogenomics.(48-
50) If any association is observed, specific therapy is not yet possible and intervention 
is usually directed at prevention and behaviour modification, a measure that is likely 
to benefit all individuals and not just those at increased risk for diseases like diabetes 
or cardiovascular disease.
SNPs can identify groups of patients at increased risk for severe disease and may 
assist in selecting patients for experimental therapeutic trials. Especially for rapid onset 
diseases, such as meningococcal disease this, however, requires the development of 
bedside assays, for instant identification of patients that might potentially profit from 
additional, experimental therapies. Additionally, functional studies of allelic variants 
may provide better understanding of pathophysiologic processes. This currently 
appears to be the major contribution of genetic association studies. Speculations on 
individualized medicine, testing each individual, arise. But without better understanding 
of the magnitude of these genetic variations, which is likely small of individual 
variants but might become substantial upon combining them, and the current lack 
of therapeutic intervention, adequate screening programs are not to be expected in 
the near future, even though extensive progress is being made. Scientific evidence 
is insufficient for useful assessment of genetic risk for most common diseases or 
for providing lifestyle recommendations using the predictive genomic profiling tests 
commercially available at the moment.(51) Currently in complex diseases, only 2-3% 
and in some maybe 5% of the estimated genetic variance, which is the proportion 
of differences between individuals explained by genetic differences, is explained by 
genes actually found to be associated with this disease.
To complicate matters, infectious diseases are not only determined by host 
susceptibility, but also by exposure, and microbe diversity and microbe genetic 
heterogeneity. As an increasing number of bacterial genomes is becoming available, 
assessing the role of microbial genes in virulence and pathogenesis provides a great 
opportunity.(52, 53)
In summary one can conclude that despite the marked progress that has been made in 
revealing genotype-phenotype associations in complex diseases, there are still several 
barriers, such as incoherent disease definition, unrecognized clinical subpopulations, 
insufficient population size, multiple testing, and non replication. Recently, guidelines 
for genetic association studies for both candidate gene and genome-wide approaches 
have been published.(54, 55) In addition, a network of investigator networks is being 
formed between researchers and together with the Human Genome Epidemiology 
Network (HuGENet™) they serve to facilitate replication possibilities, exchange of 
information and standardization of analyses (http://www.cdc.gov/genomics/hugenet/).
(56, 57) These initiatives stress the need for good quality data and sample collection, 
development of adequate statistical packages, public availability of both positive and 
negative data, and replicating findings in other ethnic populations, and thereby will 
contribute to the improvement of the quality of genetic association studies.
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Inleiding
Dit proefschrift is het resultaat van een samenwerking tussen diverse klinische en 
preklinische afdelingen van het Erasmus MC, en enkele Nederlandse en buitenlandse 
centra. Het project werd geïnitieerd vanwege een gemeenschappelijke interesse 
in de rol van genetische variaties bij de gevoeligheid voor en de pathogenese 
van inflammatoire ziekten. Van de gekozen ziektebeelden werd verwacht dat er 
tenminste een gedeeltelijke overlap was in de pathogenese. Alle geïncludeerde 
ziektebeelden hebben inflammatoire componenten, die veroorzaakt worden door een 
gemeenschappelijke innate immuunrespons. Deze immuunrespons kan geïnitieerd 
worden door infectie of kolonisatie met bacteriën of virussen, of kan een gevolg 
zijn van een auto-immuun reactie. De beschikbaarheid van goed gedefinieerde, 
homogene patiëntencohorten was een voorwaarde voor inclusie in de studie, om de 
introductie van bias door slecht gedefinieerde heterogene cohorten te voorkomen. 
In dit hoofdstuk zijn de resultaten uit dit proefschrift samengevat. Genetische 
polymorfismen werden geanalyseerd in patiënt cohorten met inflammatoire ziekten: 
meningokokken infecties, chronische hepatitis C virus (HCV) infectie en recidiverende 
acute middenoor ontsteking (AOM) als infectie ziekten; reumatoïde artritis (RA) uit 
de groep van auto-immuun ziekten; en Guillain Barré syndroom (GBS) en Barrett 
oesophagus als intermediair tussen infectie ziekten en auto-immuun ziekten. 
Daarnaast werden nasale dragerschap van S. aureus als risicofactor voor infectie, 
en sepsis na ernstig multitrauma als een inflammatoire aandoening bestudeerd. 
In Tabel 1 worden de resultaten van de studies samengevat. Polymorfismen in IL4, 
PAI1, TNFA, IL6, IL10 and C1INH waren geassocieerd met meer dan een van de 
bestudeerde ziektebeelden. Dit betekent dat de strategie, waarbij op basis van 
de literatuur bij aanvang van de studies werd gehypothetiseerd welke factoren 
gemeenschappelijk zijn in inflammatoire ziekten, correct is gebleken. Aangetekend 
moet worden dat sommige polymorfismen alleen werden bestudeerd in een of twee, 
maar niet alle patiënt cohorten (CRP, CFH, MBL, CD14, IL1RN, TAFI, and MMP9). 
Dit werd veroorzaakt door de specifieke interesse in bepaalde genen bij de betrokken 
afdelingen en centra. 
IL4 -542 C/T polymorfisme in meningokokken infectie en nasale 
kolonisatie door S. aureus
Het IL4 -524 C allel werd vaker door ouders aan patiënten met meningokokken 
infectie doorgegeven dan verwacht onder Mendeliaanse overerving (Hoofdstuk 2.4). 
In oudere individuen met het IL4 -524 C/C genotype werd, ook na correctie voor 
confounders, vaker persisterend S. aureus dragerschap gevonden dan in individuen 
met het IL4 -524 T allel (Hoofdstuk 5.3). De IL4 hoge productie variant is geassocieerd 
met atopie, astma en ernstige respiratoire infecties.(1-3) Het IL4 -524 C/C genotype 
is geassocieerd met lage IL4 expressie, en lage IL-4 serum concentraties zijn 
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Tabel 1. Associaties tussen SNP en ziekten beschreven in dit proefschrift
NB, niet beschikbaar.
1Het DEFB1 polymorfisme werd alleen gegenotypeerd voor meningokokken infectie en voor S. aureus 
dragerschap.
2TAFI polymorfismen werden alleen bepaald in patiënten met meningokokken sepsis DIC, gedissemineerde 
intravasculaire coagulatie; tdt, transmission disequilibrium test.
3MMP9 werd alleen gegenotypeerd in patiënten met Guillain Barré syndroom en controles.
4IL1RN and CD14 polymorfismen werden alleen gegenotypeerd in Barrett oesophagus patiënten en 
controles.
5ETR, ‘end of treatment’ respons.
6MBL, CFH and CRP polymorfismen werden alleen bepaald voor S. aureus dragerschap analyses.
geassocieerd met lage mucine productie.(4-6) Dit zou kunnen betekenen dat zowel 
een verhoogde gevoeligheid voor infectie met meningokokken als kolonisatie met S. 
aureus mede veroorzaakt worden door een verminderde mucociliaire klaring. 
Niet zozeer lang bestaande, maar vooral recente kolonisatie met bacteriën geeft 
een verhoogd risico op infectie. Kolonisatie met micro-organismen genereert een 
13
Tabel 1. A iaties tussen SNP en ziekten b schreven in dit proefschrift
Ziektebeeld Gevoeligheid Ernst Effect van behandeling
Meningokokken infectie DEFB1
1
 G/G > UK
IL4 -542 C >, tdt
C1INH 480 Val >, tdt
DEFB1 G/G > DIC, UK
1
DEFB1 C/C > mortaliteit,
UK
1
IL4 -524 T/T > mortaliteit,
NL
TAFI 325Ile/Ile > DIC, NL
2
NB
Sepsis in trauma patiënten PAI1 4G/4G > - NB
Guillain Barré syndroom - MMP9 -1562 T > ernstig
3
TNFA -863 A/A > ernstig
NB
Reumatoïde artritis IL6 -174 G/G >
IL8 781C/C >
PAI1 5G/5G >
TNFA -308 G/G > ernstig
TNFA -238 A/A > ernstig
NB
Barrett oesophagus IL1RN 2018C >
4
CD14 -260 T/T <
 4
CD14 -260 T/T en TLR4
+896 A/A gecombineerd <
IL1B -511 C/C + IL1RN
2081 T/T + CD14 -260T/C
+ TLR4 896 A/G
gecombineerd <
NB NB
Chronische HCV infectie IL6 -174 G/G >
TNFA -857 T >
- IL10 -819 T
IL10 -1082A;-819T > virale
respons
PAI1 5G/5G SVR
PARP 762 A < ETR
5
Recidiverende acute otitis
media
IL6 -174 G/G > PAI1 4G/4G >
TNFA -238 G/G >
TNFA -376 G/G >
TLR4 299 A/A >
TNFA -238 G/G
TNFA -863 A lagere
specifieke antistof respons
na vaccinatie
IL10 -1082 A/A: beschermt
tegen toename AOM na
complete vaccinatie
Staphylococcus aureus
nasale kolonisatie
Staphylococcus aureus
infectie: steenpuisten
C1INH 480 Val >
MBL haplotype A >
6
IL4 -524 C/C >
CRP haplotype 1184C;
2042C; 2911C <
CFH Tyr402 >
CRP 2911 C/C >
- NB
NB, niet beschikbaar.
1
Het DEFB1 polymorfisme werd alleen gegenotypeerd voor meningokokken infectie en voor S. aureus dragerschap.
2
TAFI polymorfismen werden alleen bepaald in patiënten met meningokokken sepsis DIC, gedissemineerde
intravasculaire coagulatie; tdt, transmission disequilibrium test.
3
MMP9 werd alleen gegenotypeerd in patiënten met Guillain Barré syndroom en controles.
4
IL1RN and CD14 polymorfismen werden alleen gegenotypeerd in Barrett oesophagus patiënten en controles.
5
ETR, ‘end of treatment’ resp ns.
6
MBL, CFH and CRP orfismen werd n alleen bepaald voor S. aur us dragerschap analyses.
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specifieke antistof productie; dit neemt echter enige tijd in beslag. Wanneer de 
kolonisatie pas recent heeft plaatsgevonden is er onvoldoende tijd geweest voor de 
gastheer om specifieke antistoffen te produceren, en gebrek aan deze specifieke 
antistoffen resulteert in een verhoogd risico op infectie.(7) De rol van IL-4 in 
systemische infecties is cruciaal, hetgeen gedemonstreerd wordt door de verhoogde 
gevoeligheid van IL-4 deficiënte muizen voor shock geïnduceerd door een combinatie 
van stafylokokken enterotoxine B en D-galactosamine.(8) IL-4, in combinatie met 
IL-10, beschermt muizen tegen een overactieve pro-inflammatoire immuunrespons 
tijdens infectie met S. aureus.(9) In volwassen sepsis patiënten zijn de IL-4 mRNA 
concentraties verlaagd in vergelijking met patiënten met bacteriemie of controles.
(10)
Gezien deze resultaten zou men kunnen verwachten dat co-kolonisatie met N. 
meningitidis en S. aureus voorkomt in daarvoor gevoelige individuen. Alhoewel 
voor kinderen een positieve correlatie werd vastgesteld tussen kolonisatie door N. 
meningitidis en S. pneumoniae kolonisatie, bestaat er geen correlatie tussen S. 
aureus en meningokokken dragerschap.(11) Mogelijk is er slechts een beperkte 
interactie tussen S. aureus en meningokokken die co-kolonisatie van deze twee 
microben mogelijk maakt, zonder dat kolonisatie van de ander positief of negatief 
beïnvloed wordt door de aanwezigheid van de eerste. De interactie van de microben 
en de gastheer in een bepaalde niche, bijvoorbeeld de nasopharynx, zal de uitkomst 
bepalen na blootstelling van de gastheer aan het micro-organisme: asymptomatische 
kolonisatie, infectie, ernst van infectie, en uitkomst van infectie.(12)
IL-4 is een typisch Th2 cytokine.(6) Individuen met lage IL-4 productie vertonen een 
verhoogde gevoeligheid voor microbiële kolonisatie en infectie, terwijl hoge IL-4 
productie genotypen geassocieerd zijn met astma en atopie. Dit onderstreept het 
belang van een adequate regulatie van zowel Th1 als Th2 respons, om beide ziekte-
fenotypen hierboven te voorkomen. 
PAI1 4G/5G polymorfisme is belangrijk in weefsel integriteit
PAI-1 inhibeert migratie en invasie van cellen, processen die essentieel zijn voor 
weefsel herstel bij inflammatoire ziekten.(13, 14) Hogere PAI-1 concentraties zouden 
kunnen resulteren in persisterende weefsel inflammatie, of abnormaal gerepareerd 
weefsel, dat gevoeliger is voor bacteriële kolonisatie en nieuwe infecties. Het -675 
4G/4G promoter genotype is geassocieerd met hoge PAI-1 expressie.(15, 16) Dit hoge 
productie genotype is geassocieerd met een slechte uitkomst van meningokokken 
infectie.(17)
Kinderen met het PAI1 4G/4G genotype hadden, ook na correctie voor co-factoren, 
een verhoogd risico op meer frequente AOM episodes vergeleken met kinderen 
die homozygoot zijn voor de 5G variant. Dit geldt voornamelijk voor kinderen onder 
de leeftijd van 4 jaar (Hoofdstuk 4.1). Daarnaast was het PAI1 4G/4G genotype 
in patiënten met HCV infectie geassocieerd met een niet-permanente respons na 
therapie (Hoofdstuk 3.4) Na een aanvankelijk goede response was later toch weer 
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virus detecteerbaar. In multitrauma patiënten is dit genotype geassocieerd met 
gevoeligheid voor steriele sepsis (Hoofdstuk 2.9). De PAI1 5G homozygote variant 
was bovendien geassocieerd met verhoogde gevoeligheid voor RA (Hoofdstuk 3.2).
Er zijn minstens twee mogelijke mechanismen voor PAI-1 interactie en inhibitie van 
weefselherstel. Ten eerste zou PAI-1 de proteolytische cascade aan het celoppervlak 
kunnen inhiberen, die normaal resulteert in matrixdestructie, waardoor migratie en 
invasie van cellen, nodig voor weefsel herstel, mogelijk is. Tijdens deze proteolytische 
cascade wordt oppervlakte-gebonden plasminogeen geactiveerd door urokinase 
plasminogen activator (uPA). PAI-1 kan binden aan uPA op het celoppervlak en 
inhibeert zo de proteolytische activiteit en dus weefselherstel.(18-20) Het tweede 
mechanisme betreft een competitieve binding van PAI-1 en integrine aan vitronectine. 
Beide maken gebruik van dezelfde bindingsplaats op vitronectine. Vitronectine/
integrine interactie is noodzakelijk voor cel migratie en adhesie. Het inhiberende effect 
van PAI-1 wordt ongedaan gemaakt wanneer een overmaat aan niet oppervlakte 
gebonden uPA een complex vormt met PAI-1 wat resulteert in dissociatie van PAI-1 
van vitronectine, dat dan beschikbaar komt voor interactie met integrine, waardoor 
celadhesie weer mogelijk is.(21)
Een mogelijke rol voor hoge PAI-1 concentraties is de versterkte inhibitie van 
herstel van ontstoken otolaryngeaal weefsel, wat kan resulteren in een verhoogde 
gevoeligheid voor otitis. Vijftien dagen na myringectomie is er een vertraagd herstel 
van het geperforeerde trommelvlies in plasminogeen-deficiënte muizen, vergeleken 
met het trommelvlies van wild type muizen.(22) Intraveneuze toediening van 
plasminogeen aan plasminogeen deficiënte muizen resulteerde zelfs tot 30 dagen na 
de perforatie in herstel. De verdeling van inflammatoire cellen in het geperforeerde 
trommelvlies verschilde significant tussen plasminogeen-deficiënte en wild type 
muizen. Plasminogeen-deficiënte muizen met aanvankelijk normale trommelvliezen 
ontwikkelden spontaan middenoor effusie. In een otitis media model in de rat is de 
expressie van uPA verhoogd tijdens infectie met Streptococcus pneumoniae.(23-26)
Interactie van PAI-1 met uPA voorkomt de katalytische activatie van plasminogeen 
naar plasmine. Hoge PAI-1 concentraties kunnen daarom resulteren in dezelfde 
klinische fenotypen als bij plasminogeen deficiëntie. Bovendien wordt bij weefsel 
herstel van de huid expressie van PAI-1, uPA en uPA-receptor gevonden ter plaatse 
van de regeneratieve epitheel uitgroei aan de rand van de wond.(27, 28) Plasminogeen 
deficiënte muizen hebben een verstoorde wondgenezing.(29)
Het pleiotrope PAI-1 molecuul is ook betrokken bij fibrose.(30) Bovendien beschermt 
PAI-1 deficiëntie tegen fibrosering in diverse diermodellen.(31) Plasminogeen 
deficiëntie interfereert met de klaring van debris na acuut letsel, en resulteert in de 
activatie van hepatische stellaire cellen die betrokken zijn bij progressie van fibrose.
(32, 33) Omdat verhoogde PAI-1 concentraties wondgenezing inhiberen en fibrose 
induceren, is het redelijk aan te nemen dat dit mechanisme bijdraagt aan de niet-
permanente respons op de behandeling met peg-interferon alfa-2a plus ribavirine in 
PAI1 4G homozygote HCV geïnfecteerde patiënten (Hoofdstuk 3.4). 
Of de rol van PAI-1 in pathofysiologische processen in otitis media en HCV infectie 
gelijk is aan die voor gevoeligheid voor sepsis in multitrauma patiënten is nog niet 
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duidelijk, maar wel aannemelijk. PAI-1 concentraties bij opname zijn verhoogd in 
multitrauma patiënten.(34) Dit resulteert in een verlaagde fibrinolyse, en de vorming 
van microthrombi in gedissemineerde coagulatie zoals in meningokokken sepsis. 
Het hoge productie PAI1 4G/4G promoter genotype is geassocieerd met verhoogde 
mortaliteit.(34) Dit laatste kon in de huidige studie niet bevestigd worden, mogelijk 
door een minder ernstig ziektebeeld en verbeterde behandelprotocollen in de huidige 
studiepopulatie. 
De rol voor PAI-1 in reumatoïde artritis lijkt te verschillen van de mechanismen 
zoals hierboven beschreven voor otitis media, HCV infectie and sepsis in trauma 
patiënten. De PAI1 5G homozygote variant, gerelateerd aan lage PAI-1 concentraties 
en dus verminderde inhibitie van plasminogeen activator was geassocieerd met 
RA in vergelijking met controles. Er was geen associatie met de ernst van RA. 
Plasminogeen deficiëntie is geassocieerd met verlaagde gevoeligheid voor en 
verminderde ernst van artritis in muismodellen.(35) PAI-1 deficiëntie is echter ook 
geassocieerd met verminderde ernst in antigeen-geïnduceerde artritis in muizen.(36) 
Over het algemeen is de rol van factoren betrokken bij weefselherstel en integriteit, 
zoals filaggrine en myosine, de laatste jaren duidelijker geworden, zoals geïllustreerd 
wordt in respectievelijk atopische dermatitis en coeliakie.(37-39) Twee genetische 
varianten resulterend in functie verlies van filaggrine, zijn sterk geassocieerd met 
atopische dermatitis.(38) Dit onderstreept het belang van weefselherstel en integriteit 
in de pathogenese van inflammatoire ziekten.
IL6 en verhoogde gevoeligheid voor inflammatoire ziekten
Het IL6 -174 G/G genotype was oververtegenwoordigd in reumatoïde artritis patiënten 
(Hoofstuk 3.2), en individuen met hepatitis C infectie (Hoofdstuk 3.4) vergeleken met 
gezonde controles. Bovendien werd het IL6 -174 G/G promoter genotype frequenter 
gevonden in AOM patiënten (Hoofdstuk 4.2). Dit ondersteunt de vondst van verhoogde 
expressie van IL-6 tijdens experimentele otitis media in dieren.(40, 41) Het IL6 G/G 
genotype is geassocieerd met verhoogde IL-6 concentraties vergeleken met het 
C/C genotype. Deze SNP draagt dus bij aan de complexe regulering van de IL-6 
productie, waarbij meerdere polymorfismen betrokken zijn.(42-45) Bovendien wordt 
de IL-6 expressie beïnvloed door TNF-α, en interactie van polymorfismen in deze en 
andere genen zal het fenotype mede bepalen.
De hoge productie variant komt meer voor in persisterende HCV infectie vergeleken 
met spontane virale klaring.(46) Patiënten met chronische hepatitis C hebben een 
verhoogde IL-6 expressie vergeleken met gezonde controles. Of dit secundair is aan 
de infectie, of een verhoogde gevoeligheid of verminderde klaring van infectie met 
HCV weerspiegelt, is nog niet duidelijk.(47) De substantiële verbetering van RA door 
behandeling met anti-IL-6 receptor antistof onderstreept het belang van dit pleiotrope 
cytokine in de pathogenese. (48) De exacte functionele rol van IL-6 in de toename 
van de gevoeligheid voor deze ziekten is nog niet bekend. Experimentele modellen 
die de vroege fase van ziekte analyseren in normale en IL-6 deficiënte dieren kan 
een beter inzicht opleveren over de rol van IL-6 in de gevoeligheid voor RA.
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IL10 lage productie varianten vergemakkelijken pro-inflammatoire 
responsen
IL-10 is een bekend anti-inflammatoir cytokine, dat samen met andere cytokinen zoals 
IL-4 zorgt voor een tegenbalans bij de pro-inflammatoire respons die veroorzaakt 
wordt door infectie. Het promoter -1082A;-819T haplotype is eerder geassocieerd 
met een verminderde expressie van IL-10.(49-51)
In de huidige studie was dragerschap van het IL10 -819T allel geassocieerd met 
een snelle virale respons (een vermindering of ondetecteerbaar worden van virale 
titers) in HCV patiënten na 6 weken behandeling met peg-interferon alfa-2a plus 
ribavirine (Hoofdstuk 3.4). Het lage productie haplotype van de IL10 promoter was 
geassocieerd met virale respons aan het eind van de behandeling en persisterende 
virale respons 24 weken na het beëindigen van de behandeling.
Bovendien was het IL10 -1082 A/A genotype geassocieerd met bescherming tegen 
AOM na vaccinatie (Hoofdstuk 4.2). Deze observaties wijzen op een verbeterde pro-
inflammatoire response in lage IL-10 producerende patiënten met recidiverende AOM 
gevaccineerd tegen pneumokokken en patiënten behandeld in verband met HCV 
infectie. Het eerste concept wordt ondersteund door observaties in proefdier studies. 
In IL-10 deficiënte muizen, geïmmuniseerd met een niet-virulente ongekapselde 
S. pneumoniae (stam R36A), werd een verhoogde inductie van pro-inflammatoire 
cytokinen geobserveerd, wat de hypothese ondersteunt dat individuen met lage 
IL-10 productie een betere respons hebben op vaccinatie. Antistof titers tegen 
pneumokokken eiwitten waren verhoogd in IL-10 deficiënte muizen vergeleken met 
wild type muizen.(52) De huidige resultaten impliceren dat het mogelijk is individuen 
te identificeren die meer waarschijnlijk dan anderen een matige respons hebben op 
vaccinatie. Deze individuen kunnen in de toekomst mogelijk geselecteerd worden 
voor aangepaste vaccinatie regimes, waardoor optimale vaccinatie voor meerdere 
individuen mogelijk is.
C1INH polymorfisme in meningokokken infectie en nasale 
kolonisatie met S. aureus
De C1INH 480 Val variant was geassocieerd verhoogde gevoeligheid voor 
meningokokken infectie en ook met nasale dragerschap van S. aureus (Hoofdstukken 
2.4 en 5.1).
Het complementsysteem is essentieel bij de afweer tegen bacteriële infecties. Dit 
wordt geïllustreerd door de verhoogde gevoeligheid voor meningokokken infectie van 
mensen met een complement deficiëntie, en door de mechanismen die S. aureus heeft 
ontwikkeld om het complement systeem te kunnen ontwijken.(53, 54) Overactivatie 
van de complement cascade wordt voorkomen door de serine protease C1 inhibitor 
(C1-Inh), dat een belangrijke regulator is. Dit multifunctionele eiwit inhibeert ook de 
activiteit van contactsysteem proteases, zoals kallikrein en stollingsfactor XII, en is 
betrokken bij het binden van leukocyten aan het endotheel bij de extravasatie.(55-57)
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Omdat de functionele relevantie van de V480M substitutie nog bepaald moet worden, 
is de rol van dit polymorfisme in stafylokokken kolonisatie en de pathogenese van 
meningokokken infectie onbekend.(58) Eerder werd geen verschil gevonden tussen 
de V480 C1-Inh en de M480 C1-Inh met betrekking tot structuur, eiwit stabiliteit, 
serum concentratie of inhibitie van C1.(59) Het is daarom onwaarschijnlijk dat er een 
verschil is in de directe interactie tussen microben en C1-Inh.(60) Het is mogelijk dat 
het polymorfisme een effect heeft op een van de andere functies van C1-Inh.(56, 59) 
Toekomstige opsonofagocytose experimenten of karakterisering van complement 
depositie op bacteriële cellen met behulp van serum monsters van donoren met 
verschillende C1INH genotypen zijn noodzakelijk om de moleculaire basis van 
(indirecte) microbe- C1-Inh interacties te bepalen.
TNFA expressie: te veel, of te weinig? 
De TNFA -863 A variant was geassocieerd met ernstiger beloop van GBS en 
een verminderde specifieke antistof respons na anti-pneumokokken vaccinatie 
(Hoofdstukken 3.1 en 4.2). Een eerdere studie toonde dat het A-allel op positie -863 
van TNFA geassocieerd was met hogere TNF-α concentraties door een inadequate 
inhibitie van de productie.(61) Eerdere publicaties toonden ook een associatie 
aan tussen hoge serum concentraties van TNF-α en de ernst van GBS.(62-66) Dit 
wordt mogelijk gemedieerd door de mate van macrofaag activatie, die onvoldoende 
gecontroleerd kan zijn, en dus sterk pro-inflammatoir.
Daarnaast was het TNFA -238 G/G genotype geassocieerd met frequenter 
recidiverende AOM, terwijl het -238 A/A genotype geassocieerd was met ernstiger 
RA (Hoofdstukken 3.2 en 4.2).
De interpretatie van deze bevindingen is complex. Zowel een te hoge als een 
insufficiënte TNFA expressie kan ernstiger ziekte bij AOM verklaren. Een overschot 
aan TNF-α kan resulteren in verhoogde weefselschade en gevoeligheid voor 
recidiverende infecties, terwijl een verlaagde TNF-α respons kan verhinderen dat een 
adequate klaring of inactivatie van microben optreedt, resulterend in persisterende 
infectie. Het effect van het TNFA -238 polymorfisme op TNF-α expressie is onduidelijk. 
In het recente verleden zijn diverse studies uitgevoerd naar de associatie tussen 
TNFA promoter polymorfismen en TNF-α levels in verschillende inflammatoire- en 
infectie ziekten, die tegenstrijdige resultaten rapporteerden.(67) TNF-α expressie 
wordt door een combinatie van meerdere polymorfismen in TNFA en -geassocieerde 
genen bepaald. Dit wordt nog eens gecompliceerd door de lage mutant allelfrequentie. 
Kleine veranderingen in de aantallen kunnen de resultaten substantieel wijzigen, wat 
het risico van vals-positieve en vals-negatieve resultaten vergroot. Bovendien kunnen 
verschillende pathogenen een variabele cytokine signatuur induceren. Omdat diverse 
pathogenen, zowel bacterieel als viraal, otitis kunnen veroorzaken, is het bepalen 
van de rol van de polymorfismen in TNF-α productie in de humane situatie erg 
moeilijk. Bovendien is timing van monstername een erg belangrijke determinant van 
de resultaten, omdat TNF-α concentraties zullen veranderen gedurende de infectie. 
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Verschil in expressie van TNF-α beïnvloedt waarschijnlijk de gevoeligheid en ernst 
van ziekte. TNF-α stimuleert bijvoorbeeld immunoglobuline en mucine productie. 
Lage TNF-α concentraties compromitteren deze afweermechanismen.(68) TNF-α 
concentraties in nasofaryngeaal secreet zijn verlaagd in kinderen met recidiverende 
otitis media vergeleken met gezonde kinderen.(69) 
De associaties tussen diverse TNFA polymorfismen en AOM, RA, en GBS beschreven 
in dit proefschrift tonen dat er waarschijnlijk een rol is voor deze polymorfismen in 
TNF-α productie in vivo. Analyse van TNF-α expressie in onze patiënt cohorten in 
relatie tot de TNFA haplotypen, zou het effect van de polymorfismen getypeerd in 
deze patiënten kunnen verhelderen.
Conclusie en perspectieven
Bovenstaande toont aan dat diverse polymorfismen beschreven in dit proefschrift 
inderdaad geassocieerd zijn met twee of meer van de bestudeerde fenotypen. Dit 
ondersteunt de hypothese dat soortgelijke pathogenetische processen betrokken 
zijn in verschillende ziekten. Terwijl de observaties consistent waren voor enkele 
polymorfismen, lijken er ook voor bijvoorbeeld SNPs in TNFA verschillen te bestaan 
tussen de diverse ziektebeelden. Een lage allelfrequentie, gevonden in relatief kleine 
patiënt populaties, met daardoor een verhoogd risico op zowel vals-positieve als vals-
negatieve resultaten kan hieraan bijgedragen hebben. Dit wordt verder geïllustreerd 
door het verlies van statistische significantie na correctie voor multiple testen. Men 
moet zich echter bedenken dat het effect van genetische polymorfismen beperkt is, 
en dat er meerdere SNPs en ook omgevingsfactoren betrokken zijn bij complexe 
ziekten. 
Observationele studies in samenhang met gecontroleerde (in vitro/proefdiermodellen) 
experimenten, naar eiwit concentraties te, zoals beschreven voor TAFI, ADAMTS13, 
VWF, and MIF in meningokokken infectie (Hoofdstukken 2.5 tot en met 2.7) zijn 
noodzakelijk om de relevantie van SNPs die geassocieerd zijn met ziekte te bepalen. 
Daarnaast kunnen RNA expressie profielen zoals beschreven in hoofdstuk 2.8 
een genetische associatie ondersteunen, en nieuwe gezichtspunten genereren en 
kandidaat genen alsmede biologische processen identificeren die betrokken zijn bij 
de gen regulatie in de pathogenese van inflammatoire ziekten.
De toenemende interesse en het belang van weefselintegriteit worden ondersteund 
door de observaties voor het PAI1 polymorfisme in AOM, HCV infectie, en mogelijk 
sepsis in multitrauma patiënten. Daarnaast verdient de rol van IL4 and C1INH in 
gevoeligheid voor nasale S. aureus dragerschap en gevoeligheid voor infectie met 
meningokokken verdere aandacht. Functionele studies die de bijdrage van deze 
moleculen aan de pathogenese bestuderen zijn derhalve noodzakelijk.
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soms kon vervloeken, maar waarvan ik ook besefte dat ze de manuscripten verder 
zouden verbeteren. Heren, nogmaals wil ik jullie bedanken voor jullie ontembare 
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opleiding Immunologie. Prof. Benner allereerst, dank voor de mogelijkheden die u 
me geboden heeft binnen de afdeling immunologie, en het mede mogelijk maken van 
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Beste Tar, dank voor al je hulp bij de layout van de figuren en de kaft. Je bent van 
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terug uit de States, benieuwd waar onze paden weer kruisen. Wouter, op het moment 
dat ik naar de gastheer overstapte kwam jij bij het pneumokokken clubje, succes 
met je verdere carrière. Peter A. dank voor alles wat je me tijdens mijn afstudeer 
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Breda, dank voor de mooie tijd, de leermomenten, en jullie oprechte interesse in een 
bewogen jaar.
Thijs en Aukje, op het moment dat ik dit schrijf nog met zijn tweeën, maar bij het 
verschijnen van dit proefschrift met drie. Dank voor jullie steun en liefde, jullie zijn 
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The persons who are a master in the art of living make little distinction 
 
between their work and their play, their labor and their leisure, 
their mind and their body, 
 
their education and their recreation, their love and their religion. 
They hardly know which is which. 
 
They simply pursue their vision of excellence and grace in whatever they do, 
 
leaving others to decide whether they are working or playing. 
 
To them, they are always doing both.
(Anonymous, Zen text)
